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For want of an ALK5 the TGFβ signal was lost.
For want of a TGFβ signal the pSmad3 was lost.
For want of a pSmad3 the chondrocyte was lost.
For want of a chondrocyte the matrix was lost.
For want of a matrix the cartilage was lost.
For want of a cartilage the joint was lost.
And all for the want of an ALK5.
after: “For want of a nail”, English proverb
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Introduction
Joint pathologies can greatly negatively impact the quality of life of patients. In this chapter 
we will discuss part of the biology behind the most common joint disease: osteoarthritis 
(OA). We will start by discussing the basic biology behind cartilage, the tissue OA affects most. 
Next, we describe cartilage pathophysiology in OA. Subsequently, we will discuss the role 
of the transforming growth factor β (TGFβ)-family in regulation of cartilage homeostasis by 
explaining how this family signals and how this signaling impacts cartilage. We end by listing 
several TGFβ-family members and describing their importance in cartilage biology.
Osteoarthritis
OA is the world’s most common joint disease, e.g. approximately 30% of all men and women 
older than 60 have radiographic knee OA [1]. Patients suffer from loss of joint function and 
pain, which can greatly reduce their quality of life. According to the Osteoarthritis research 
society international, OA is defined as follows:
“Osteoarthritis is a disorder involving movable joints characterized by cell stress and 
extracellular matrix degradation initiated by micro- and macro-injury that activates 
maladaptive repair responses including pro-inflammatory pathways of innate immunity. 
The disease manifests first as a molecular derangement (abnormal joint tissue metabolism) 
followed by anatomic, and/or physiologic derangements (characterized by cartilage 
degradation, bone remodeling, osteophyte formation, joint inflammation and loss of normal 
joint function), that can culminate in illness. (OARSI 2015)“
which illustrates both the multifactorial origins and multifactorial outcomes of OA; all (synovial) 
joint tissues can initiate and be affected by the disease. However, end stage disease is always 
characterized by cartilage degeneration. Unfortunately, cartilage has poor regenerative 
capacity, making loss almost always irreversible. Up till now, no disease modifying treatment 
or cure has been developed [2], leaving total joint replacement as the only option for severely 
affected patients. Risk factors of OA include genetic predisposition, race, sex, increased body 
mass, and age [3, 4]. In view of the expected rise in life expectancy and average body weight 
in western societies, the incidence of OA is expected to rise in the future [3, 4]. Because of 
this expected increase in OA incidence and the lack of a cure, it is of great importance to 
either develop such a cure or to learn how to prevent the onset of disease. Both aims can 
greatly benefit from a better understanding of joint homeostasis and OA pathophysiology. 
Because cartilage degeneration is the final and irreversible hallmark of OA pathology, a better 
understanding of this tissue may well be critical to combat this disease.
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Articular (Hyaline) Cartilage
Articular cartilage is a type of hyaline cartilage, and is the connective tissue that can be found on 
the long ends of bones in diarthrodial joints [5, 6]. It combines two of its main characteristics: 
(visco) elasticity and a lubricated smooth surface to facilitate diarthrodial joint function by 
working as a shock absorber and by lowering the joint’s friction coefficient. Articular cartilage 
is of mesodermal origin and, rather uniquely for a tissue, is not innervated nor does it contain 
blood vessels to supply oxygen or nutrients [5, 6]. Hyaline cartilage contains only one cell 
type: the chondrocyte. However, chondrocytes make up only a small part of hyaline cartilage 
(≤ 2% volume), most of this tissue consists of the extracellular matrix (ECM) (98% volume) 
and water (up to 80% of wet weight) [5, 7]. This ECM is a highly organized network of collagen 
proteins, hyaluronan molecules, and proteoglycans.
 Collagens are the most abundant proteins in the human body and provide it with 
its shape [8]. In cartilage, over 90% of all collagen is collagen type II [9]. Collagen type II is a 
fibrillar collagen which forms (long) fibrils consisting of multiple subunits of three collagen 
proteins arranged in a triple helix [8]. Notably, these fibrils are distributed throughout the 
ECM and provide (tensile) strength and shape. These fibrils can be formed in association with 
other collagens like collagen type IX and collagen type XI [8, 10]. This association regulates 
fibril diameter, strength, (thermo)stability, and the interaction with other (bio)molecules 
[8]. In addition to these collagens, also network-forming collagens like collagen type IV, VI 
and X can be found in cartilage (the latter only around hypertrophic-like chondrocytes, see: 
chondrocyte homeostasis)[9]. These collagens are found in close proximity to chondrocytes 
and form a network instead of fibers, which helps compartmentalize biomolecules and 
processes to the pericellular region.
 Hyaluronan is a glycosaminoglycan (GAG), which is a large unbranched polysaccharide 
consisting of repeating disaccharide units [11]. Unlike other GAGs, hyaluronan is not sulfated, 
nor is it covalently attached to a proteoglycan. A single hyaluronan molecule can contain as 
much as 25 000 disaccharide repeats and can weigh as much as 10 million Dalton [12]. Due to 
this size, production of hyaluronan does not occur inside the cell but trough the cell membrane 
by hyaluronan synthases [12]. Hyaluronan is very hydrophilic and forms spontaneously 
aggregating networks of randomly coiled molecules [13]. This network forms a scaffold to 
which other biomolecules such as proteoglycans can bind. Furthermore, this network helps 
to regulate the water content of cartilage by “trapping” water molecules. Hyaluronan is also 
a signalling molecule; for example, via the CD44 receptor high molecular mass hyaluronan 
is anti-angiogenic, whereas small hyaluronan fragments are pro-inflammatory and pro-
angiogenic [14, 15].
 Proteoglycans are proteins glycosylated with sulfated GAGs. Proteoglycans are 
classified based on their size in large proteoglycans and small leucine-rich proteoglycans 
(SLRPs) [16]. Examples of large proteoglycans in cartilage are perlecan, versican and aggrecan, 
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examples of small leucine-rich proteoglycans are biglycan, decorin, asporin and fibromodulin. 
Aggrecan is the most abundant large proteoglycan in cartilage and is responsible for 90% of 
all proteoglycan mass in this tissue [17]. Aggrecan is heavily glycosylated with sulfated GAGs 
and forms aggregates with hyaluronan via link protein. These aggregates carry a static charge 
density due to the negative charge of the GAG chains and therefore attract water, resulting 
in a high osmotic (swelling) pressure [17]. This swelling pressure is needed to counteract 
compressive forces and helps restore tissue shape after compression. Additionally, this 
swelling pressure is further increased by the electrostatic repulsion between the sulfated 
GAG chains, which makes these molecules occupy as much space as possible [17]. SLRPs are 
less important for generating this swelling pressure but are important for the stabilization 
and formation of collagen fibrils during growth [18]. Furthermore, SLRPs modulate growth 
factor signaling by regulating the bioavailability of these factors by binding them, for example 
biglycan and asporin bind BMP2, BMP4 and TGFβ [18].
 The organization and composition of cartilage ECM is not static but dynamic and 
subject to change based on external input like mechanical force. Chondrocytes, as the only 
cell type present in cartilage, are responsible for the biological non-physical aspects of 
this change. These cells can produce large amounts of the ECM building blocks and ECM-
strengthening enzymes such as collagen cross linking enzymes. Furthermore, chondrocytes 
can also produce matrix degrading enzymes like matrix metallopeptidases (MMP) or ADAM 
metallopeptidases with thrombospondin type 1 motif (ADAMTS), which are needed for 
remodeling of the existing matrix. Together, the anabolic and catabolic production of 
chondrocytes function in tandem to help maintain a healthy and functional cartilage ECM. 
The zones of articular cartilage
Cartilage is not a homogeneous tissue and its organization is a classic example of form fits 
function: its form differs throughout the different zones that characterize articular cartilage 
in order to fulfill the specific demands required for the function of each zone. The main 
determinants of cartilage organization are the forces to which this tissue is exposed to: 
osmotic swelling pressure from the tissue itself combined with sheer stresses and hydrostatic 
pressure generated by joint movement.
The uppermost zone of cartilage is the lamina splendens. This layer is only a few micrometer 
(± 4-8 µm) thick and contains no cells [19]. Its matrix is characterized by collagen fibrils 
oriented in parallel to the cartilage surface [19, 20] and by high levels of hyaluronan and 
of the lubricant proteoglycan 4 (PRG4) [21], but this zone contains relatively little other 
proteoglycans. These characteristics provide a very smooth surface with a low friction 
coefficient, which lowers shear stress on the cartilage surface during joint movement.
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Fig.1. Appearance and structure of adult (bovine) articular cartilage. Note that the orientation of collagen fibrils 
differs per zone, from parallel in the superficial zone to peripendicular in the deep zone. Scale bar = 100 µm.
Below the lamina splendens lies the superficial or tangential zone which represents 10 - 20% 
of articular cartilage [6]. This zone contains a relatively high amount of cells, which have a 
flattened morphology and are oriented in parallel to the cartilage surface [6]. These cells 
produce high levels of proteoglycan 4 and hyaluronan. The collagen fibrils in this layer are also 
oriented in parallel to the cartilage surface and are tightly packed to provide tensile strength 
[20]. This orientation helps counteract the swelling pressure of tissue below, and helps absorb 
compressive force and sheer stresses. The superficial zone contains relatively high levels 
(w/w) of the proteoglycans biglycan and decorin, but relatively low levels (w/w) of aggrecan 
compared to the lower zones of cartilage [22]. The high levels of hyaluronan in this zone help 
to retain water in the deeper zones below by limiting outflow. This helps retain water in the 
deeper cartilage layers, which provides better shock absorption capacity because enclosed 
fluids like water are (considered) almost physically incompressible. Therefore, cartilage with a 
higher water content will be more difficult to compress than dehydrated cartilage. 
 Beneath the superficial zone lies the middle zone, which represents 40-60% of the 
articular cartilage [6]. Chondrocytes are rounded but sparse. The collagen fibers are oriented 
isotropically to the cartilage surface [20], which allows for efficient collapse of the tissue upon 
compression to dissapate the energy of the impact. The collapse of this layer is accompanied 
by displacement and loss of water. The more this layer is compacted, the more resistance to 
further collapse is increased [5]. This resistance to further compression is due to an increase 
in electrostatic repulsion between the proteoglycans and also to an increase in hyaluronan 
viscosity because of an increase in concentration of this molecule [23]. 
 Underneath the middle zone lies the deep zone (± 30%). In the deep zone, 
chondrocytes are organized in columns placed between collagen fibrils oriented 
peripendicular to the cartilage surface [6, 20]. Furthermore, this zone contains relatively the 
highest levels of aggrecan of all zones [5]. The high levels of aggrecan restrict water flow and 
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thereby increase the compressive stiffness of cartilage. The collagen fibers are oriented to 
withstand the swelling pressure generated by these proteoglycans and to withstand sheer 
stresses generated by compression of the layers above. Part of the deep zone, below the 
tidemark, contains calcium salts in the matrix and is thus called the calcified zone [6]. The 
calcified zone forms the interface between bone and cartilage and anchors cartilage to the 
bone. This zone contains hypertrophic-like chondrocytes which resemble chondrocytes 
undergoing endochondral ossification (see: chondrocyte homeostasis) [24].
Osteoarthritic cartilage
During OA, cartilage homeostasis is disturbed, resulting in the degradation and loss of this 
tissue. This disturbed homeostasis is reflected in many changes on macroscopic, microscopic 
and molecular level.
 Macroscopically, cartilage thinning can be seen, often combined with loss of cartilage 
integrity: in early stage OA this loss of integrity is characterized by surface roughening, in late 
stage OA whole parts of the tissue can be lost. 
 Microscopically, fibrillations, fissures and ruptures (e.g. at the tidemark) can be 
observed. Furthermore, especially in the superficial zone, loss of chondrocytes by cell death 
occurs. However, sometimes proliferation of the remaining cells can be seen, resulting in 
very characteristic cell clusters not observed in healthy cartilage. Part of the chondrocytes, 
especially in the deep zone, become hypertrophic-like and are no longer able to maintain a 
healthy cartilage ECM [24]. In the deep zone also ingrowth of blood vessels occurs, facilitating 
cartilage resorption by chondro/osteoclasts and the formation of bone.
 On a molecular level, the ECM is severely impacted by OA. Collagen fiber organization 
is disrupted by enzymatic digestion of collagen fibrils [7]. This results in a loss of tensile stiffness 
and tissue ruptures due to loss of cartilage’s ability of to deal with shear stresses and swelling 
pressure [7]. The core protein of proteoglycans is also enzymatically degraded, resulting in 
e.g. smaller aggrecan aggregates and more free aggrecan not attached to hyaluronan. This 
degradation of proteoglycans results in a reduced GAG content for OA cartilage and therefore 
in a more water permeable ECM and a lower osmotic pressure. Together, these changes result 
in a reduced compressive stiffness of cartilage [7]. The degradation of aggrecan and collagen 
fibers is mediated in part by MMP and ADAMTS enzymes. Prime examples are MMP3, MMP9 
and MMP13 for collagen degradation [25] and MMP3, MMP13, ADAMTS4 and ADAMTS5 for 
aggrecan degradation [25, 26]. In the joint, these enzymes are produced in inactive form by 
both synoviocytes and chondrocytes, and both production and activation of these enzymes 
is increased under OA conditions, for example by cell stress and reactive oxygen species 
respectively [25]. Remarkably, in contrast to this increase in production of cartilage degrading 
enzymes, also the anabolic production of chondrocytes is increased in OA; up to 5 times more 
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proteins and sulfated GAGs are produced [27, 28]. However, this increased production is 
evidently not sufficient to maintain a healthy cartilage matrix, illustrating a severe imbalance 
in matrix maintenance in OA cartilage and indicating a disturbed chondrocyte homeostasis.
OsteoarthritisHealthy
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Figure 2. Deleterious changes in osteoarthritic cartilage. On the left healthy cartilage is depicted, on the right 
osteoarthritic cartilage with the deleterious changes that occur listed. The loss of proteoglycans is not depicted.
Chondrocyte homeostasis
Chondrocyte homeostasis is a key determinant of cartilage homeostasis. Without 
chondrocytes articular cartilage rapidly degrades. This is illustrated by the observation 
that induction of chondrocyte apoptosis in vivo by monosodium iodoacetate leads to rapid 
onset and development of cartilage degradation [29]. Exemplary for disturbed chondrocyte 
homeostasis in OA is the presence of proliferating chondrocytes and the appearance of 
hypertrophic-like chondrocytes throughout the cartilage, which are chondrocytes with a 
phenotype that resembles that of hypertrophic chondrocytes in the epiphyseal plate [24].
 In the epiphyseal plate endochondral ossification occurs in order to facilitate the 
growth of long bones. In this process, first cartilage is made which is then gradually replaced 
by bone [30]. During endochondral ossification, chondrocytes undergo a developmental 
program that goes from rest to proliferation to maturation to hypertrophy and finally either 
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into cell death via apoptosis (terminal differentiation) or (rarely) further differentiation into 
an osteoblast phenotype [30]. The role of the hypertrophic stage in this process is to prepare 
the replacement of cartilage by bone. To enable this replacement, hypertrophic chondrocytes 
modify their surrounding ECM and secrete factors that stimulate bone formation. The ECM 
is altered by hypertrophic chondrocytes via the production of MMP13 and collagen type 
X and via the stimulation of matrix calcification by secretion of matrix vesicles containing 
calcium salts [31]. Hypertrophic chondrocytes also produce alkaline phosphatase, an enzyme 
needed for this matrix calcification but also for the growth of hydroxyapatite crystals present 
in bone [32]. Bone formation is further stimulated by secretion of various growth factors, like 
vascular endothelial growth factor (VEGF), which stimulate angiogenesis and members of the 
Wnt family which stimulate osteoblasts formation [33]. Based on these previously mentioned 
characteristics hypertrophic chondrocytes can be distinguished from normal (articular) 
chondrocytes but this can also be done based on their size; hypertrophic chondrocytes 
are much larger than normal chondrocytes. During OA, chondrocytes resembling these 
hypertrophic chondrocytes, hence their name hypertrophic-like, start to appear in articular 
cartilage; large chondrocytes that produce MMP13, collagen type X, VEGF and alkaline 
phosphatase [24]. If they are truly hypertrophic and also induce matrix calcification and 
undergo further differentiation is unknown yet.
 Many factors regulate chondrocyte homeostasis. Chondrocytes are highly 
mechanosensitive cells, that recognize hydrostatic pressure (generated by joint movement) 
via integrins, their cell skeleton and mechanosensitive ion channels [34]. In a similar way 
these cells can recognize tensile strain. In response to these stimuli chondrocytes orientate 
their cell body to reduce (tensile) strain and modulate the cartilage ECM accordingly. Also 
pro-inflammatory mediators such as interleukin 1 (IL1) can greatly affect chondrocyte 
homeostasis, for example by induction of nitric oxide [35] and reactive oxygen species [36] 
which block proteoglycan synthesis and induce cell stress which can result in apoptosis. 
Furthermore, pro-inflammatory cytokines and alarmins like S100A8/A9 induce the production 
of cartilage degrading MMPs and ADAMTSs [37]. Another key regulator of chondrocyte 
homeostasis is signaling by growth factors. Growth factors modulate chondrocyte 
metabolism, differentiation, proliferation, survival and regulate ECM production and turnover. 
An important group of growth factors which modulate chondrocyte homeostasis on all these 
levels are those belonging to the transforming growth factor β (TGFβ)-family. For example, 
this family is crucial for the regulation of chondrocyte hypertrophy.
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The TGFβ-family
The TGFβ-family consists of over 30 members, including the TGFβ’s, activins, bone 
morphogenetic proteins (BMP’s) and growth/differentiation factors (GDF’s). Family members 
are produced as large pro-proteins which carry a cystine knot motif near their C-terminus 
[38, 39]. This cystine knot allows for the formation of disulfide bridges, essential for proper 
protein dimerization and folding, which are required for the characteristic quarternary dimer 
structure of family members [39].
 Signaling by TGFβ-family members is induced via formation of heteromeric 
complexes between two types of serine threonine-protein kinase receptors, conveniently 
called type I and type II receptors [40]. There are seven type I receptors (activin receptor-
like kinase (ALK) 1 to 7, also known as activin A receptor type II-like I (ACVRL1), activin A 
receptor type I (ACVR1), bone morphogenetic protein receptor type I A (BMPR1A), activin 
A receptor type I B (ACVR1B), transforming growth factor β receptor type I (TGFBR1), bone 
morphogenetic protein receptor type I B (BMPR1B), and activin A receptor, type I C (ACVR1C) 
respectively) and five type II receptors: transforming growth factor β receptor type II 
(TGFBR2), bone morphogenetic protein receptor type II (BMPR2), activin A receptor type II A 
(ACVR2A), activin A receptor type II B (ACVR2B) and anti-mullerian hormone type II receptor 
(AMHR2) (Table 1). In addition, multiple type III receptors have been characterized which 
facilitate the interaction between ligand and receptor and can stabilize receptor complexes. 
For example, betaglycan [41, 42] and endoglin [43] have been identified as co-receptors for 
TGFβ, and the repulsive guidance molecule (RGM) family members: RGM domain family 
member A (RGMA), dragon and hemojuvelin are co-receptors for BMP signaling [44]. Also 
inhibitory (pseudo) receptors have been identified; for example CD109  which mitigates TGFβ 
signaling [45] and BMP and activin membrane bound inhibitor (BAMBI) which mitigates BMP 
and activin signaling [46].
 Because every growth factor recruits a specific, but not necessarily unique, receptor 
complex, this choice in receptors allows for cell specific growth factor-sensitivity. To signal, a 
growth factor binds to a type II receptor and together this complex recruits the type I receptor 
(e.g. for activins and TGFβs) or the other way around in which first the type I receptors and 
then the type II receptors are recruited (e.g. for BMPs) [40]. After the receptor complex has 
been assembled, the auto-phosphorylated type II receptor trans-phosphorylates the type I 
receptor on multiple sites, activating the kinase domain of the type I receptor. The activated 
type I receptor subsequently transmits the signal to intracellular signaling proteins, which 
are recruited via the help of adaptor proteins. Although multiple signaling pathways can 
be activated, for example the mitogen-activated protein kinase (MAPK) pathway involving 
TGFβ-activated kinase 1 (TAK1 also known as MAP3K7), the unique and canonical pathway for 
TGFβ-family signaling is the receptor-SMAD (R-SMAD) pathway.
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Type I receptor Type II receptors R-Smads Typical ligands
Name Gene Interaction Partner(s)
ALK1 ACVRL1 ACVR2A ACVR2B BMPR2 SMAD1/5/9 BMP9, TGFβ1,  
TGFβ2,TGFβ3
ALK2 ACVR1 ACVR2A ACVR2B BMPR2 SMAD1/5/9 Activin A, BMP2, BMP4, 
BMP6, BMP9
ALK3 BMPR1A ACVR2A ACVR2B BMPR2 SMAD1/5/9 BMP2, BMP4, BMP6,
BMP7, GDF5
ALK4 ACVR1B ACVR2A ACVR2B SMAD2/3 Activin A, Nodal
ALK5 TGFBR1 TGFBR2 SMAD2/3 TGFβ1, TGFβ2, TGFβ3
ALK6 BMPR1B ACVR2A ACVR2B BMPR2 SMAD1/5/9 BMP2, BMP7, GDF5
ALK7 ACVR1C ACVR2A ACVR2B SMAD2/3 Activin AB, Nodal
Table 1. TGFβ-family receptors, their type II receptors and their typical ligands in cartilage. Note that AMHR2 is not listed 
because no role for this receptor or its ligand anti-müllerian hormone has been established in cartilage. Adapted from [47].
R-Smad-dependent signaling
R-SMADs are ±50 kDa sized proteins that upon activation by carboxy-terminal phosphorylation 
can migrate to the nucleus and function as transcription factors. Two groups of R-SMADs can 
be distinguished based upon structural and functional homology: one group consisting out of 
SMAD1, SMAD5 and SMAD9 (also known as SMAD8) and one group containing SMAD2 and 
SMAD3 [40]. Upon receptor type I activation, these R-SMADs are directly phosphorylated on 
two serines at their C-terminal SXS motif. Specific ALKs phosphorylate specific SMADs; ALK1, 
2, 3 and 6 phosphorylate SMAD1, 5 and 9, whereas ALK4, 5 and 7 phosphorylate SMAD2 and 
SMAD3. This phosphorylation facilitates complex formation of the R-SMADs with the common 
SMAD (co-SMAD), SMAD4. Two R-SMADs can associate with one co-SMAD and this complex 
is subsequently transported to the nucleus. Inside the nucleus, this SMAD complex directly 
binds DNA, although with low affinity, and recruits transcription factors for a high affinity 
interaction with DNA. The only exception to this rule is a common splice variant of SMAD2 that 
contains exon 3 which by itself cannot bind DNA and requires additional transcription factors 
to bind DNA. The location where SMAD complexes bind DNA is dependent on characteristic 
SMAD binding regions (SBR) present in the DNA sequence, and these differ for SMAD3/4 and 
SMAD1/5/9; e.g. GTCTAGAC for SMAD2/3/4 complexes [48] and GCCGnCGC for SMAD1/5/9/4 
complexes [49]. Furthermore, the interaction between SMADs and DNA is further regulated by 
the presence of master regulator transcription factors [50]. Master regulators vary per tissue, 
and an important master regulator of chondrocyte phenotype is SRY-box9 (Sox9), which for 
example closely interacts with SMAD3 on the collagen type II promotor [51]. It is important to 
note that because of this dependency on master regulatory proteins, R-SMADs can regulate 
expression of different genes in different tissues.
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Figure 3. TGFβ-family SMAD-dependent signaling. Ligand binding induces the formation of a receptor complex. This 
complex recruits R-SMAD2/3 via SMAD anchor for receptor activation (SARA) and/or R-SMAD1/5/9 via endofin. The 
R-SMADs are subsequently phosphorylated at their C-terminal SXS domain by the type I receptor and a complex is 
formed with the common SMAD4. This complex translocates to the nucleus where it can bind DNA at SMAD binding 
regions (SBR) and activate transcription. Important target genes are the inhibitory SMADs: SMAD6 and SMAD7, 
whose expression provides the cell with a negative feedback mechanism.
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Two important target genes of R-SMAD signaling are the inhibitory-SMADs (I-SMAD): SMAD6 
and SMAD7 [52, 53]. These I-SMADs function as inhibitors of R-SMAD signaling on multiple 
levels by inhibiting C-terminal R-SMAD phosphorylation, inhibiting R-SMAD DNA binding, 
inhibiting complex formation between SMAD4 and R-SMADs and by inducing receptor 
dephosphorylation and degradation via recruitment of Smurf ubiquitin ligases to the receptor. 
In this way, SMAD6 predominantly inhibits SMAD 1/5/9 and SMAD7 predominantly inhibits 
SMAD2/3 signaling, and both I-SMADs provide cells with an important negative feedback 
mechanism to inactivate R-SMAD signaling. 
 An (simplified) overview of the SMAD dependent signaling pathway is depicted in 
figure 3.
Smad-dependent signaling in chondrocyte and cartilage biology
SMAD signaling is essential for the formation and maintenance of healthy cartilage. Both in 
vivo and in vitro experiments point towards essential but distinct roles of SMAD2/3 versus 
SMAD1/5/9 signaling in chondrocyte biology.
 In humans, genetic variation in SMAD3 is associated with hip and knee OA and total 
burden of the disease [54, 55]. Dominant nonsense, missense or frameshift mutations in 
SMAD3 lead to aneurysms-OA syndrome, a severe condition characterized by cardiovascular 
anomalies and early onset of OA in multiple joints (mean age of diagnosis = 42 year) [56, 57]. 
Mice with a SMAD3 null mutation (SMAD3Δexon8/Δexon8) develop normal articular cartilage, but 
this cartilage starts to degrade rapidly one month after birth, resulting in severe OA [58]. This 
rapid degradation is linked to an increased amount of hypertrophic chondrocytes present in 
both articular and epiphyseal cartilage [58]. However, SMAD3 null mice also have a greatly 
diminished life span and suffer from severe systemic effects such as growth retardation, 
spontaneous tumorigenesis and impaired T-cell immunity which can affect cartilage biology 
indirectly [58-60]. To circumvent these systemic effects, chondrocyte specific SMAD3-null 
mice (SMAD3Δexon2+3/Δexon2+3) have been made using Col2-Cre and floxed SMAD3 [61, 62]. 
These mice also display increased chondrocyte hypertrophy and accelerated cartilage 
degeneration, confirming the direct role of SMAD3 in these processes [61]. Furthermore, 
in vitro studies with overexpression or knockout of SMAD3 also support a role for SMAD3 in 
inhibiting chondrocyte terminal differentiation by showing an inhibitory or stimulating effect 
on chondrocyte hypertrophy respectively [63-66]. The anti-hypertrophic effect of SMAD3 is 
attributed to its interaction with core-binding factor subunit α 1 (CBFA1), also known as runt-
related transcription factor 2 (RUNX2) [61, 67, 68]. RUNX2 is a potent regulator of chondrocyte 
maturation. For example, overexpression of RUNX2 in the murine teratoma-derived ATDC5 
chondrocyte-like cell line induces chondrocyte hypertrophy, whereas inhibition of RUNX2 
achieves the opposite [61, 68-70]. SMAD3 counteracts RUNX2 function by directly binding this 
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transcription factor and recruiting silencing histone class II deacetylases to RUNX2 responsive 
genes [67] such as MMP13, collagen type 10 a1 and alkaline phosphatase. The potency of 
SMAD3 in preventing chondrocyte hypertrophy is demonstrated in vivo by the observation 
that heterozygotic SMAD3 null mice (SMAD3wt/Δexon8) do not have (reported) accelerated 
cartilage degeneration, whereas e.g. T-cell biology is still negatively affected, indicating that 
having only one genetic copy of SMAD3 is enough to rescue the chondrocyte phenotype [58, 
60].
 The role of SMAD2 in cartilage biology is less clear than that of SMAD3. In humans, 
there is no known association between genetic variation in SMAD2 and OA. SMAD2 knockout 
animals or hypomorphs are not viable and die early during embryogenesis (≤ embryonic day 
(E) 9 [71-74]), before the formation of articular joints [75], and are thus not usable to study the 
role of SMAD2 in articular cartilage. Animals with only 1 genetic copy of SMAD2 (SMAD2+/-) can 
be viable [71, 76], but no cartilage phenotype has been reported. Cartilage-specific SMAD2 
knockout mice have recently been studied [77], and such mice have shortened growth plates 
during embryogenesis due to a shortened proliferative zone and elongated hypertrophic 
zone. This last observation indicates a similar anti-hypertrophic effect of SMAD2 as SMAD3. 
Unfortunately, the role of SMAD2 in mature cartilage was not studied in this model. An in 
vitro study seems to further support a role for SMAD2 similar to that of SMAD3, because 
overexpression of a dominant negative variant of SMAD2 enhances, whereas overexpression of 
wildtype SMAD2 protects against chondrocyte hypertrophy, although less potent than SMAD3 
[63].
 SMAD1 and SMAD5 seem to have an important but interchangeable role in 
cartilage biology. In contrast, SMAD9 seems to be of little importance for cartilage formation 
or maintenance. In humans, no association has been reported between genetic variation 
in SMAD1, SMAD5 or SMAD9 and OA, possibly due to redundant roles in cartilage. Like 
SMAD2 knockout mice, SMAD1 [78] or SMAD5 [79] knockout mice die before the formation 
of articular joints. Knockout of SMAD9 is not embryonically lethal yet does not seem to 
affect (epiphyseal) cartilage biology [80]. To study SMAD1 and SMAD5 in chondrogenesis, 
cartilage specific knockouts have been made using Col2-cre and floxed SMAD1 and SMAD5 
[80]. Cartilage specific removal of either SMAD1 or SMAD5 does not result in a phenotype. 
Furthermore, crossing these cartilage specific knockout mice with whole body SMAD9 
knockout mice does not result in a phenotype either. Only when both SMAD1 and SMAD5 
are ablated, severe chondrodysplasia can be observed [80]. Additional removal of SMAD9 
does not add much to this severe phenotype. Together, these observations indicate that 
SMAD1 and SMAD5 have an important, but redundant, role in cartilage formation whereas 
the role of SMAD9 seems limited [80]. The severe chondrodysplasia is in part due to a lack of 
hypertrophic chondrocytes in the growth plates, suggesting that SMAD1/5 signaling regulates 
chondrocyte maturation. Unfortunately, (inducible) SMAD1/5 knockout mice have not been 
used yet to study chondrocyte hypertrophy in mature articular cartilage or OA, but in vitro 
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studies support a stimulatory role of SMAD1/5 in chondrocyte maturation. For example, 
overexpression of SMAD6, an inhibitor of SMAD1/5/9, results in inhibited chondrogenesis in 
the ATDC5 cell line [81] and delayed chondrocyte hypertrophy [82]. The stimulatory effects of 
SMAD1/5 on chondrocyte maturation are most likely due to a stimulation of RUNX2 function. 
Such a stimulatory role of SMAD1/5 on RUNX2 function has been described to be essential 
for BMP2-induced osteoblast differentiation [83-86]. Furthermore, in pre-hypertrophic 
chondrocytes SMAD1/5-RUNX2 interaction induces the activation of a reporter construct 
based on the Col10a1 promoter, expression of which is an important phenotypic marker of 
hypertrophy [68, 87]. How exactly SMAD1 and 5 stimulate RUNX2 function is yet unclear, 
but possibly this stimulation occurs indirectly via induction of jumonji domain containing 3 
(JMJD3) expression. JMJD3 is a histone demethylase targeting H3K27me3, which enables 
transcription of otherwise silenced genes. Silencing of JMJD3 lowers RUNX2 dependent gene 
expression, and during osteoblast differentiation both SMAD1 and SMAD5 regulate JMJD3 
expression [88]. Therefore both SMAD1 and SMAD5 can regulate RUNX2 activity indirectly 
via JMJD3, but a more direct mechanism is not excluded.
Smad-independent signaling
TGFβ-family members can also activate other signaling pathways than the R-SMAD pathways. 
Prime examples are the MAPK pathways involving TAK1 or extracellular signal-regulated kinase 
1 and 2 (ERK1/2, also known as MAPK3/1), Phosphoinositide 3-kinase (PI3Ks)-dependent 
signaling and signaling via the GTPase ras homolog family member A (RhoA) [89]. The SMAD 
independent signaling pathways are depicted in figure 4. It is important to note that these 
pathways are not unique for TGFβ-family signaling but are also important signaling mediators 
of many other growth factors and cytokines as well.
 Activation of MAPKs by TGFβ-family members relies on adaptor proteins, e.g. SHC 
adaptor protein 1 (Shc1) for ERK [90] and tumor necrosis factor (TNF) receptor-associated 
factor 6 (TRAF6) for TAK1 [91, 92]. Shc1 binds, and is directly phosphorylated by, type I 
receptors [90]. This phosphorylation of Shc1 triggers a MAPK signaling pathway via Grb2/SOS, 
Ras, Raf, and MAP2K1 resulting in activation of ERK1/2 [90]. TRAF6 binds both TAK1 and type I 
and II receptors, and becomes activated upon receptor type I – type II complex formation via 
oligomerization and auto-ubiquitination but independently of type I receptor kinase activity 
[92]. TRAF6 subsequently poly-ubiquitinates TAK1, which recruits TGFβ activated kinase 1/
MAP3K7 binding protein 1 (TAB1), and together poly-ubiquitination and TAB1 allow TAK1 
to auto-phosphorylate and become active [92]. Ultimately, activation of MAPK signaling by 
TGFβ-family members results in activation of JNK and p38 kinases which directly regulate 
gene expression by modulating transcription factors such as: Jun proto-oncogene (c-JUN), 
MYC proto-oncogene (c-MYC), activating transcription factor 2 (ATF2), and CCAAT/enhancer-
binding protein β (C/EBP-β)[93].
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Figure 4. TGFβ-family SMAD-independent signaling. Ligand binding induces the formation of a receptor complex. 
This complex can initiate SMAD-independent signaling via activation of adaptor proteins e.g. SHC and TRAF6 or direct 
activation of signaling kinases (PI3K, RhoA). This activation results in initiation of signaling cascades, culminating in 
the activation of ERK, MTOR, ROCK, p38MAPKs, JNKs and NFκb. These pathways induce transcription and translation 
and regulate diverse cellular processes. Enzymes are indicated by a yellow star, transcription factors by a hexagonal 
shape. 4EBP1 = Eukaryotic translation initiation factor 4E-binding protein 1, AKT = RAC-alpha serine/threonine-
protein kinase, AP-1 = Activator protein 1,  ATF2 = Cyclic AMP-dependent transcription factor ATF-2, CEBPβ = CCAAT/
enhancer-binding protein β,  ERK = Mitogen-activated protein kinase 3, GRB2 = Growth factor receptor-bound protein 
2, GSK3β = Glycogen synthase kinase-3 β, HSP27 = Heat shock protein beta-1, IkBa = NF-kappa-B inhibitor alpha, IKK = 
Inhibitor of nuclear factor kappa-B kinase, JNK = c-Jun N-terminal kinase, MAP2K = Dual specificity mitogen-activated 
protein kinase kinase 1, MAPKAPK = MAP kinase-activated protein kinase, MEF2 = Myocyte-specific enhancer factor 
2A, MKK = Dual specificity mitogen-activated protein kinase kinase, MTOR = Serine/threonine-protein kinase mTOR, 
MTORC = MTOR complex, cMyc = Myc proto-oncogene protein, NEMO = NF-kappa-B essential modulator, NFKb = 
nuclear factor kappa-light-chain-enhancer of activated B cells, p38 MAPK = p38 mitogen-activated protein kinases, 
PI3K = Phosphatidylinositol 3-kinase, PIP3 = Phosphatidylinositol (3,4,5)-trisphosphate, Raf = RAF proto-oncogene 
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serine/threonine-protein kinase, RAS = GTPase HRas, RhoA = Transforming protein RhoA, ROCK = Rho-associated 
protein kinase 1, S6K1 = Ribosomal protein S6 kinase beta-1, SHC = SHC-transforming protein 1, SOS = Son of 
sevenless homolog 1, SP-1 = Sp1 transcription factor, TAB = TGF-beta-activated kinase 1 and MAP3K7-binding protein 
1, TAK1 = Mitogen-activated protein kinase kinase kinase 7, TCFs = ternary complex factors, TRAF6 = TNF receptor-
associated factor 6.
Both ERK and TAK1 contribute to TGFβ-family signaling in chondrocytes. Functional inhibition 
of ERK1 in ATDC5 cells via inhibition of its activating kinase MAP2K1 with the inhibitor 
U0126 reduces TGFβ-induced aggrecan expression [94]. Functional inhibition of ERK1 in 
rat chondrocytes with the use of the MAP2K1 inhibitor PD98059 reduces TGFβ-induced 
proliferation and aggrecan and collagen type II expression [95, 96]. Furthermore, in both 
human and bovine primary chondrocytes, use of PD98059 lowers TGFβ-induced mRNA and 
protein expression of the metallopeptidase inhibitor TIMP3 [97], indicating that ERK activity 
is a cartilage-protective component of TGFβ signaling in mature chondrocytes. In contrast, 
during TGFβ-induced chondrogenesis, use of PD98059 increases Col2a1 and Sox9 expression 
and proteoglycan synthesis in rat, chicken and human mesenchymal stem cells [98-100], 
indicating that ERK1/2 is an inhibitory component of TGFβ signaling during TGFβ-induced 
chondrogenesis.
 Functional inhibition of TAK1 using a dominant negative form of TAK1 greatly 
diminishes the ability of TGFβ and BMP2 to induce collagen type II expression in rabbit 
articular chondrocytes [101]. In Col2-Cre; TAK1fl/fl mice, TAK1 deletion in collagen type II 
expressing cells during embryogenesis results in runting and severe chondrodysplasia due to 
reduced chondrocyte proliferation and delayed maturation [102], and these mice die shortly 
before [102] or after birth [103]. This severe phenotype resembles the phenotype of mice 
lacking BMP receptor / SMAD1/5 signaling. Indeed these mice show impaired BMP-induced 
R-SMAD and p38 MAPK/JNK/ERK signaling [102, 103], confirming that TAK1 is an important 
component of BMP signaling in cartilage. Postnatal deletion of TAK1 using inducible Col2a1-
Cre ERT2;TAK1fl/fl mice also results in growth retardation and these mice have profoundly 
decreased proteoglycan and collagen type II production in their articular cartilage [104]. 
This last observation shows that the importance of TAK1 in cartilage biology is not limited to 
embryogenesis. 
 A possible role of TAK1 signaling in chondrocytes is the regulation of Sox9 expression. 
In chondrocytes, deletion of TAK1 inhibits endogenous and BMP2-induced Sox9 mRNA 
and protein expression, whereas overexpression of TAK1 enhances Sox9 levels [104]. This 
observation is reflected in vivo: both articular and epiphyseal chondrocytes from Col2a1-
Cre ERT2;TAK1fl/fl mice show lower Sox9 protein expression after deletion of TAK1 compared 
to control animals [104]. The induction of Sox9 expression by TAK1 involves binding of 
activating transcription factor 2 (ATF2), a downstream target of TAK1 via p38 MAPK, to the 
Sox9 promoter [104]. Furthermore, p38 MAPK signaling has also been shown to stabilize Sox9 
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mRNA in human chondrocytes, further strengthening the importance of this MAPK pathway 
in Sox9 regulation[105].
 In addition to MAPK signaling, both TGFβ and BMP signaling can also activate PI3K 
signaling but it is unclear how and to what extent this occurs in chondrocytes [106-109]. In 
case of TGFβ, this activation requires receptor type II presence and receptor type I kinase 
activity [107, 109]. Because PI3Ks activation kinetics closely resemble SMAD activation 
kinetics [107], it has been suggested that PI3Ks are a direct target of type I receptors [107, 
108]. Possibly this activation runs via Ras [110]. Activation of PI3Ks leads to phosphorylation 
and activation of AKT serine/threonine kinase 1/2/3 (AKT1/2/3). During endochondral 
ossification, AKT signaling is an inhibitor of chondrocyte hypertrophy. In forelimb explant 
cultures of mice expressing an inducible constitutively-active form of AKT1 (myrAKT1-MER, a 
fusion protein of myristoylated AKT with a modified estrogen receptor that becomes active 
upon presence of 4-hydroxytamoxifen), activation of myrAKT1-MER blocks Runx2 expression 
and chondrocyte hypertrophy, whereas inhibition of PI3K activity with LY294002 enhances 
Runx2 expression and hypertrophy [111]. Furthermore, mice overexpressing constitutively-
active AKT1 (myrAKT) have decreased chondrocyte hypertrophy and ECM calcification in their 
limbs, but show enhanced ECM deposition, resulting in enlarged bones [112]. In contrast, 
AKT1 -/- mice develop short limbs, but not because of excessive chondrocyte hypertrophy but 
because of a lack of growth plate calcification [113], showing that AKT1 signaling is essential 
for ECM calcification in cartilage.
 An important mediator of PI3K/AKT1 signaling in chondrocytes is mechanistic target 
of rapamycin (MTOR) [112]. In cartilage, MTOR is upregulated in OA [114] and is an inhibitor 
of protective autophagy [114-116]. In vivo, intra-articular or intra-peritoneal injection of 
rapamycin, i.e. an inhibitor of MTOR, increases autophagy and reduces cartilage damage 
in the DMM model of OA [115, 116]. Furthermore, cartilage specific MTOR knockout mice 
(Col2-rt-TA-Cre; MTORfl/fl) are protected against DMM induced OA [114] confirming that MTOR 
signaling is deleterious in OA conditions. However, the cartilage-beneficial effects of AKT1 
during endochondral ossification have also been attributed to MTOR [112], indicating that 
PI3K/AKT/MTOR signaling outcome is context, e.g. chondrocyte maturation state, dependent.
 TGFβ-family members can also signal via the GTPase RhoA [93], but also here it is 
unclear how and to what extent this occurs in chondrocytes. A well known role for RhoA 
signaling in various cell types is the formation of focal adhesions and actin stress fibers [117]. 
In primary chondrocytes, formation of such stress fibers via RhoA inhibits Sox9 expression, 
and this is possibly one of the reasons why chondrocytes dedifferentiate in vitro [118]. Loss 
of Sox9 expression is also observed in ATDC5 cells after overexpression of RhoA, but this can 
be blocked by inhibition of Rho Associated coiled-coil containing protein kinase 1 (ROCK1) 
downstream of RhoA [119, 120]. In primary human chondrocytes, ROCK inhibition induces 
Sox9, Col2a1 and Acan mRNA expression [105], while in primary murine chondrocytes, 
ROCK inhibition enhances the output of a Sox9-responsive luciferase assay along with Col2 
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and Acan mRNA expression [120]. Therefore, these studies also indicate a negative effect 
of RhoA/ROCK signaling on chondrocyte phenotype. However, in murine mesenchymal 
cells during chondrogenic differentiation, ROCK1 inhibition negatively affects Sox9 function 
[120], suggesting that cellular context has a large impact on RhoA/ROCK1 signaling outcome. 
Finaly, overexpression of RhoA has also been reported to block hypertrophic differentiation 
of ATDC5 cells [121, 122], but this observation could very well be due to less chondrogenesis 
overall, due to increased proliferation and loss of Sox9 expression.
Interaction between the Smad-dependent and Smad-independent 
signaling pathways
Despite their names, the SMAD-dependent and SMAD-independent pathways are not truly 
distinct signaling pathways; in the cell, signaling of both pathways is integrated, and their 
interaction can greatly affect TGFβ-family signaling outcome. SMAD-independent pathways 
can interact with SMAD dependent signaling by post translational modification of the linker 
region of SMAD proteins [123]. The linker region is a regulatory domain located in the middle 
of the SMAD protein, and post-translational modification of this region regulates nuclear 
entry, SMAD-protein interactions and SMAD turnover, and thus greatly affects SMAD function 
[123]. However, the relative importance of these SMAD linker modifications in cartilage 
biology is not well understood yet and warrants further research. 
 The reverse also holds true; SMAD signaling can inhibit above mentioned non-
canonical pathways either directly or indirectly. An example of direct inhibition is via 
competition for co-factors, e.g. SMAD3 and NFκB (a transcription factor downstream of 
TAK1) can compete for their common co-transcription factor CREB binding protein (CBP) in 
endothelial cells [124]. An example of indirect inhibition is via induction of negative regulators 
of transcription factors, e.g. SMAD3 is a potent inducer of JunB, a negative regulator of the 
transcription factor complex AP-1 (a transcription factor downstream of TAK1 which in turn 
can negatively regulate SMAD signaling) [125]. The outcome of TGFβ-family signaling is thus 
an integration of both SMAD-dependent and SMAD-independent signaling, and not the 
result of the activation of a single pathway.
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The TGFβ-family in cartilage maintenance 
Via these aforementioned pathways, the TGFβ-family members play key roles in the 
maintenance of articular cartilage. Prime examples of TGFβ-family member with such a role 
are TGFβ1, TGFβ2 and TGFβ3, BMP2 and BMP7.
TGFβ1, TGFβ2 and TGFβ3
In mammals, three TGFβ’s exist; TGFβ1, TGFβ2, and TGFβ3, encoded by three different genes: 
TGFB1, TGFB2 and TGFB3, and these homologs (and not isoforms) share a high percentage of 
amino acid identity (71-79%). All three TGFβ’s are produced in inactive form as homodimers 
(or more rarely as heterodimers [126]) bound by latency associated peptide (LAP) (forming 
small latency complex) and latent TGFβ binding protein (LTBP) (forming large latency 
associated complex) [127]. This production in inactive form separates secretion from activity, 
an important concept in TGFβ biology. 
 The importance of TGFβ in cartilage biology was first observed in 1985 when two 
proteins were extracted from bone that were capable of inducing chondrogenesis in rat 
embryonic mesenchymal cells, and therefore called cartilage inducing factor A and B [128]. 
Later research revealed that these proteins were identical to TGFβ1 and TGFβ2 [129, 130].
All three forms of TGFβ are produced by chondrocytes [131-133] and a large amount (60-
200 ng/ml) of inactive TGFβ is bound to the ECM of cartilage [134, 135]. Chondrocytes also 
express the TGFβ type I receptors ALK1 and ALK5, the type II receptor TGFBR2, and co-
receptors such as endoglin and betaglycan [136]. Genetic variation in neither TGFB1, TGFB2 
nor TGFB3 is (yet) associated with OA, nor is genetic variation in TGFBR1 (= ALK5), ACVRL1 
(= ALK1), TGFBR2, ENG (= endoglin) or TGFBR3 (= betaglycan). However a gain of function 
variation in asporin (ASPN), a protein which limits TGFβ bioavailability by sequestering it, is 
associated with OA development [137].
 Because TGFβ is produced in inactive form, activation is a crucial step in TGFβ 
signaling. For this, the non covalent bond between LAP and TGFβ has to be disrupted. This 
can occur enzymatically by degradation of LAP by e.g. MMP3 [138], or non enzymatically 
by a conformational change in LAPs tertiary structure. Shearing stress [139] or chemical 
modification of LAP by reactive oxygen species [140] can induce such a conformational 
change. Recently, compressive force was also shown to possibly be an important physiological 
activator of ECM-bound TGFβ because this activates SMAD2/3 signaling [141].
 In chondrocytes, TGFβ induces both SMAD2/3 and SMAD1/5/9-dependent signaling 
via ALK5 and ALK1 respectively and SMAD-independent signaling [142, 143]. Which pathway 
is activated by TGFβ depends on receptor level expression, co-receptor expression, i.e. 
endoglin enhances signaling via ALK1, and dose of TGFβ; in chondrocytes a low dose of TGFβ 
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predominantly signals via pSMAD2/3, whereas at high dosages pSMAD1/5 signaling becomes 
more pronounced. Importantly, both pathways have been described to antagonize each 
other in chondrocytes [142, 143].
 TGFβ signaling is associated with cartilage ECM production and maintenance. In 
mice, a single intra-articular injection of rhTGFβ1 or rhTGFβ2 increases proteoglycan synthesis 
twofold after four days as measured by 35S-sulfate incorporation in patellar articular cartilage 
[144, 145]. Also in vitro, TGFβ enhances proteoglycan production in both chondrocytes and 
cartilage explants on both mRNA and protein level [146-149], together with production of 
other ECM components like collagen type II a 1 (Col2a1) [149, 150], cartilage oligomeric matrix 
protein [151, 152], perlecan [153], fibronectin [154] and hyaluronan [155]. Furthermore, TGFβ 
is a potent inducer of lubricin (PRG4) in chondrocytes [156], a key lubricating component 
of synovial fluid. However, in contrast to the previously mentioned studies, also inhibitory 
effects of TGFβ on chondrocyte proliferation, proteoglycan synthesis and collagen type II 
production have been described both in vitro and in vivo, [150, 157-162]. Possibly, different 
receptor signaling plays a role in these apparently contradictory observations
 TGFβ signaling also has important anti-inflammatory effects in cartilage. TGFβ1 
counteracts pro-inflammatory IL-1 signaling in vivo [163-165] and in vitro [166] and helps 
cartilage proteoglycan content recover after inflammation induced depletion [131, 167]. 
How TGFβ exerts its anti-inflammatory effects is not fully elucidated yet, but in primary 
rabbit articular chondrocytes, both TGFβ1 and TGFβ3 down-regulate IL-1 receptor (IL1R1) 
expression approximately 50% on protein and mRNA level [166, 168]. In macrophages, TGFβ 
signaling can also stabilize NFκB inhibitor alpha (NFKBIA, also known as IκBα), which is a 
potent inhibitor of NFκB, but this mechanism has not been described for chondrocytes yet 
[169]. Another, already mentioned, possible mechanism is the competition between SMAD3 
and NFκB for co-activating transcription factors like CREB binding protein, as has been 
described in endothelial cells [124]. Additionally, many inflammatory genes counteracted by 
TGFβ contain both SMAD3 and NFκb binding sites, leaving room for epigenetic regulation as 
mechanism. Notably, the anti-inflammatory effect of TGFβ is lost with advancing age [164], 
possibly due to age-related loss of ALK5 expression [131].
 An especially important role for TGFβ signaling in chondrocytes lies in regulation of 
chondrocyte hypertrophy. TGFβ-induced pSMAD2/3 signaling via ALK5 blocks hypertrophy 
and terminal differentiation of chondrocytes [58, 63, 65, 143, 170]. In contrast, TGFβ-induced 
pSMAD1/5 via ALK1 is associated with inhibition of pSMAD2/3 signaling and chondrocyte 
hypertrophy [142, 143]. Both effects of TGFβ on hypertrophy can be observed in vivo. Removal 
of TGFβ signaling in cartilage of two weeks old Col2-CreER; Tgfbr2flox/flox mice results in an OA-
like phenotype within 6 months via Runx2 mediated MMP13 and ADAMTS5 expression [171, 
172]. Furthermore, expression of a kinase-deficient dominant negative form of Tgfbr2 in 
mice induces chondrocyte hypertrophy and osteoarthritis [172]. In contrast, removal of TGFβ 
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signaling in the hypertrophic chondrocytes of Col10a1-cre; Tgfbr2flox/flox mice delays terminal 
differentiation in the epiphyseal plate [173], and removal of TGFβ signaling in cartilage of eight 
weeks old AgcCreERT2+/−; Tgfbr2flox/flox mice results in less hypertrophic chondrocytes, after 12 
months [174]. Because in both the Col2-CreER; Tgfbr2flox/flox and AgcCreERT2+/−; Tgfbr2flox/flox 
models efficient removal of Tgfbr2 was demonstrated, their different outcome illustrates that 
age of model onset and (thus) chondrocyte maturation status greatly affect the outcome and 
impact of TGFβ signaling in chondrocytes. 
 In line with the observation that chondrocyte maturation affects TGFβ signaling, the 
ability of TGFβ to induce two such opposing pathways has been postulated as an important 
driver of age-related development of OA; an age-related change in receptor expression 
towards relatively more ALK1 expression would change protective signaling into deleterious 
signaling and lead to OA. Indeed, in ageing mice, the expression of TGFβ receptors changes 
towards relatively higher ALK1 expression, and this change in ratio correlates with MMP13 
expression and OA development [143]. Furthermore, a similar change can be observed in 
guinea pigs [175], in which an age-related loss of TGFβ-ALK5 signaling occurs while ALK1 
signaling remains stable. The importance of a changing ALK1/ALK5 ratio in ageing as cause for 
OA is supported by computational modeling; especially TGFβ signaling via ALK1 can explain 
MMP13 expression and cartilage damage in aged cartilage [176]. 
 Besides in ageing cartilage, also in OA cartilage TGFβ signaling can have detrimental 
effects. AgcCreERT2+/−; Tgfbr2flox/flox mice are protected against mild DMM-induced cartilage 
damage as measured 8 weeks after model induction. Also systemic use of the ALK4/5/7 
inhibitor SB-505124 lessens cartilage damage 2 months post surgery in ACLT [177]. Possibly 
the ability of TGFβ to induce proteases and protease activators plays a role in these deleterious 
effects. TGFβ can induce both MMP3 and HtrA serine peptidase 1 (HTRA1) expression in 
chondrocytes, both enzymes with the capacity to degrade the ECM [178]. HTRA1 is known 
to degrade the pericellular matrix which activates the discoidin domain receptor tyrosine 
kinase 2 (DDR2) receptor and deleterious signaling in the chondrocyte [179]. Of note, HTRA1 
can also modulate TGFβ-family signaling for example by cleaving the extracellular domain of 
TGFβ-family type II and type III receptors, but also by cleaving of LAP.
In conclusion, TGFβ signaling has a wide range of effects in cartilage, and its outcome, both 
good and bad, is context dependent. A better understanding of how chondrocyte context 
regulates TGFβ signaling would greatly help approaches that seek to separate the good from 
the bad in diseases like OA.
BMP2 and BMP7
Chondrocytes can produce several BMPs, including BMP2, BMP4, BMP6 and BMP7 (OP1) 
[136, 180], and chondrocytes express the BMP type I receptors ALK1, ALK2, ALK3 and ALK6, 
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and the type II receptors: BMPR2, ACVR2A and ACVR2B. Genetic variation in neither of 
these factors is (yet) associated with OA. Like the TGFβs, BMPs are produced as a dimer 
but not only as homodimers; heterodimers of BMP2/6, BMP2/7 and BMP4/7 have been 
described both in vitro and in vivo [181]. In contrast to TGFβ, BMP activity is not thought to 
be controlled via reassembly of a BMP with its prodomain to form a latency complex [181]; 
BMPs do reassemble with their prodomain to facilitate ECM binding, but this does not seem 
to confer latency because it does not impair receptor type I and II binding [127, 181, 182]. 
Instead, antagonistic scavenger proteins, e.g. gremlin, noggin and sclerostin, and decoy 
receptors like BAMBI, play an important role in modulating BMP activity, all of which are 
produced by chondrocytes. Additionally, BMPs can antagonize each other via competition for 
receptor type II binding [183].
 BMP2 mRNA expression can be detected in both healthy and arthritic cartilage and 
does not seem to be affected by ageing [184]. BMP2 protein can be detected in chondrocytes 
exposed to inflammatory conditions and near cartilage lesions [185, 186]. Matrix-bound 
BMP2 levels have not been reported, but BMP2 binds the proteoglycan perlecan, which 
would locate it to the pericellular matrix of chondrocytes. To signal, BMP2 can use ALK2, 
ALK3 and ALK6, and the type II receptors: BMPR2, ACVR2A and ACVR2B to induce SMAD1/5 
phosphorylation and SMAD-independent signaling [181].
 In cartilage, BMP2 signaling induces ECM production; ex vivo in juvenile cartilage, 
BMP2 induces proteoglycan content and col2a1 production [187], while in vivo intra-
articular injection of BMP2 in murine knee joints enhances proteoglycan synthesis 2.5-fold 
(i.e.35S-incorporation) in patellar cartilage within 2 days [145]. Furthermore, intra articular 
overexpression of BMP2 in the murine knee joint using adenoviruses also enhances cartilage 
proteoglycan content [188]. Although BMP2 expression is induced in inflammatory conditions 
[186, 189], it, in contrast to TGFβ, does not have an anti-inflammatory effect in chondrocytes, 
and BMP2 effects are inhibited by IL1 but not by TNFα [190, 191]. In spite of this, BMP2 
does facilitate proteoglycan recovery after inflammation-induced depletion [188]. However, 
prolonged exposure of cartilage to high levels of BMP2 does induce increased aggrecan 
turnover as measured by VIDPEN and NITEGE neoepitope staining, indicating that BMP2 can 
induce metalloproteinase and aggrecanase activity [188]. 
 In vitro in mesenchymal stromal cells and chondrocyte-like cell lines, and in vivo 
in epiphyseal chondrocytes, BMP2 is a well known inducer of chondrocyte maturation 
and hypertrophy [192]. However, in mice with cartilage specific, tamoxifen inducible, 
overexpression of BMP2 (Col2 rTA; TRE-BMP2) increased hypertrophy is not observed in 
articular cartilage after 6 weeks of prolonged exposure to tamoxifen [193]. Furthermore, in 
the DMM model of experimental OA, the presence of excessive BMP2 signaling does not 
affect cartilage damage but does induce very extensive osteophyte formation [193]. These 
observations might indicate that in vivo, articular cartilage is not very sensitive for BMP2 
signaling compared to osteophyte-forming tissues like periosteum. Possibly, signaling of 
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hyaluronan, an important structural component of cartilage, via CD44 plays a role in this, as 
it has been demonstrated that this inhibits BMP2-induced pSMAD1/5 signaling in the murine 
bone marrow-derived ST2 stromal cell line [194]. Alternatively, GDF5 has recently been 
shown to be a context-dependent inhibitor of BMP2 signaling via a yet unknown mechanism 
possibly involving receptor competition [195], and GDF5 is present in (im)mature cartilage 
[196-198].
 BMP7 mRNA and protein expression can be detected in both immature and mature 
articular cartilage, but its levels decline with advancing age [199, 200]. This loss in BMP7 
expression is linked to increased methylation of its promoter [201]. Immunohistochemically, 
mature BMP7 can predominantly be detected in chondrocytes of the superficial zone, 
whereas its pro-form is mainly detected in deep zone chondrocytes [199, 202]. The total 
amount of mature BMP7 present in the cartilage ECM is estimated at 50 ng/g dry weight, 
but this amount decreases approximately 5-fold in OA cartilage [199, 203]. Whether this 
loss of mature BMP7 is due to a loss in mRNA expression is unclear; both increased and 
decreased BMP7 mRNA expression have been reported for OA cartilage [199, 203]. 
Inflammatory conditions like IL1 have also been described to induce BMP7 mRNA expression 
in chondrocytes, and a high dose of IL1 leads to activation of pro-form BMP7 into active 
form [204]. To signal, BMP7 can use ALK2, ALK3 and ALK6, and the type II receptors: BMPR2, 
ACVR2A and ACVR2B to induce SMAD1/5 phosphorylation and SMAD-independent signaling 
[181]. In contrast to BMP2, a positive interaction of CD44 with BMP7 signaling has been 
described; Without CD44, chondrocytes are not able to induce pSMAD1/5 in response to 
BMP7 [205-207]. Notably, ageing lowers the BMP7 response of chondrocytes. This loss has 
been linked to oxidative stress [208], but also an age-related decrease in expression of its 
type2 receptor Bmpr2 can possibly explain this loss [136].
 In chondrocytes, BMP7 signaling induces ECM production. Both proteoglycan and 
Col2a1 production are induced in vitro in juvenile and adult human primary chondrocytes 
[209] and ex vivo in juvenile bovine explants [187]. Furthermore, inhibition of endogenous 
BMP7 production with antisense oligonucleotides in cartilage explants lowers aggrecan 
production [210]. In vitro, BMP7 also induces the expression of cartilage oligomeric matrix 
protein [152] and hyaluronan synthase 2, resulting in more hyaluronan production by 
chondrocytes, facilitating deposition of aggrecan in the ECM [211]. BMP7 can counteract an 
IL1- or LPS-induced inhibition of proteoglycan synthesis in chondrocytes [212-214], and partly 
inhibit IL1-induced MMP13 expression, especially in the presence of IGF1 [215]. However, 
one study also reports that BMP7 signaling is inhibited by IL1 via down regulation of ALK2, 
ALK3 and SMAD1 expression [216]. 
 The positive effects of BMP7 in vitro are reflected in vivo; conditional deletion of 
BMP7 from limb mesenchym in Prx-Cre; Bmp7flox/flox mice results in proteoglycan loss (at 8 
weeks old) and enhanced MMP13 expression (at 24 weeks old) [217]. Of note, joint and 
cartilage formation were not detectably affected in these mice but BMP7 deletion did result 
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in synovial inflammation, making it difficult to exclude indirect effects. Administration of 
BMP7 is beneficial for cartilage in OA [218, 219]; Osteoarthritic cartilage is still responsive 
to BMP7 [198], and weekly injections of BMP7 diminish cartilage damage in the rabbit ACLT 
model of OA [220]. Furthermore, BMP7 increases the quantity and quality of cartilage repair 
tissue in rabbits with a full thickness cartilage defect [221]. Remarkably, although BMP7 can 
induce ectopic bone formation [222], excessive osteophyte formation was not observed in 
these studies, nor was excessive osteophyte formation observed in humans after a single 
injection of BMP7 in a Phase 1 study done in symptomatic knee OA patients [223]
 Although BMP7 induces SMAD1/5 phosphorylation, its signaling is not associated 
with chondrocyte hypertrophy. Bovine articular chondrocytes do not undergo hypertrophy 
when cultured with BMP7 [224] and BMP7 blocks hypertrophy in the ATDC5 cell line [225]. 
In long bone formation ex vivo, BMP7 does stimulate the formation of pre-hypertrophic 
chondrocytes in the epiphyseal plate but blocks the transition towards hypertrophy [226]. 
This anti-hypertrophic effect of BMP7 has been contributed to its ability to induce the 
transcription factor BAPX-1/NKX-3.2, a potent modulator of chondrocyte hypertrophy [227]. 
However, BMP7 does induce alkaline phosphatase expression and osteogenesis in primary 
fetal chondrocytes [228], and chick sternum chondrocytes do undergo hypertrophy when 
cultured with BMP7 [229], indicating that BMP7 can induce chondrocyte hypertrophy, but 
like TGFβ in a context dependent manner.
Activin A, BMP9, BMP4, BMP6 and GDF5
Next to these well studied TGFβ-family members, several other family members have 
been ascribed a role in cartilage biology, but relatively little is known about their role and 
importance. This includes Activin A, BMP9, BMP4, BMP6 and GDF5
 Activin A signals via ACVR2A/ACVR2B and ALK4/ALK7 to induce SMAD2/3 [230]. 
Expression of the Activin A subunit Inhibin β A (Inhba) is upregulated in OA cartilage, and so 
is activin A [231, 232]. In OA conditions, activin A can possibly inhibit IL1 induced ADAMTS4/5 
activity [232], but expression of its inhibitor follistatin is also profoundly upregulated during 
OA [233, 234]. Furthermore, a lack of response of adult cartilage tissue to activin A has 
been observed in multiple studies [152, 209, 235]; for example, activin A slightly induces 
proteoglycan synthesis (i.e.35S-incorporation) in immature (1-3 months old) but not in mature 
(> 18 months old) bovine articular cartilage explants [235]. These observations indicate that 
activin A is not involved in the maintenance of mature healthy cartilage, but can possibly play 
a role during OA. 
 Regarding the role in cartilage of the inhibitory counterparts of the activins; the 
inhibins, very little is known; only one study reports that inhibin inhibits both proteoglycan 
synthesis (i.e.35S-incorporation) and DNA synthesis in bovine chondrocytes [235].
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BMP9, also known as GDF-2, signals via ACVR2A/ACVR2B and BMPR2 via ALK1 and ALK2 to 
induce SMAD1/5 and SMAD-independent signaling. BMP9 production could not be detected 
in chondrocytes [180] but BMP9 circulates in high levels in blood [236]. In juvenile bovine 
cartilage, BMP9 enhances the production of proteoglycans and does so more potently than 
BMP2 [187]. In bovine chondrocytes, BMP9 enhances proteoglycan and collagen type 2 
production [237]. However, BMP9 can also induce ECM mineralization when chondrocytes 
are seeded in biodegradable PGA scaffolds [237]. Additionally, also in mesenchymal 
progenitor cells, BMP9 is a potent inducer of chondrogenesis accompanied by hypertrophy 
[238]. Therefore, BMP9 possibly has a detrimental effect on chondrocyte homeostasis.
 BMP4 signals via ALK2 and ALK3 to induce pSMAD1/5 and SMAD-independent 
signaling. BMP4 is best known for its positive effect on chondrogenesis of stem cells and 
during embryogenesis. BMP4 has been used to enhance the repair of full thickness cartilage 
defects by chondroprogenitors like MSCs in vivo, and has been described to outperform BMP7 
in such a setting [239]. However, very little is known regarding its role in mature articular 
cartilage. BMP4 is expressed in mature articular chondrocytes, and its expression is possibly 
increased during OA near cartilage defects just like BMP2 [240]. In bovine chondrocytes and 
cartilage explants, BMP4 enhances proteoglycan synthesis, collagen type 2 production and 
proliferation [235], and BMP4 has similar effects in human chondrocytes cultured in alginate 
[213]. However, if BMP4 is of any importance for the homeostasis of mature articular cartilage 
cannot be concluded from this limited evidence.
 BMP6 also signals via ALK2 and ALK3 to induce pSMAD1/5. BMP6 is important for 
chondrogenesis during embryogenesis, and is required for adipose-derived stromal cells to 
differentiate towards chondrocytes, but, like BMP4, very little is known regarding its role in 
mature articular cartilage. In humans, BMP6 mRNA and protein are expressed in both healthy 
and OA articular cartilage and expression is not affected by OA [180]. In human chondrocytes, 
BMP6 induces proteoglycan synthesis and collagen type 2 production [213, 241], but with 
advancing age, chondrocyte response to BMP6 decreases [241]. However, in the epiphyseal 
plate, BMP6 is especially expressed in the hypertrophic zone [242] where it has a stimulatory 
role on chondrocyte maturation. Furthermore, a pro-hypertrophic effect of BMP6 has also 
been observed in ATDC5 cells [243]. These studies indicate that BMP6 signaling could be 
detrimental for articular cartilage like BMP9, 
 GDF5 is a very important initiator of joint formation and patterning. The importance 
of GDF5 in cartilage biology is illustrated by the observations that mutations in GDF5 can lead 
to chondrodysplasias and that genetic variation in GDF5, resulting in less GDF5 expression, 
is associated with OA development [244]. However, regarding the role of GDF5 in mature 
cartilage relatively little is known. In chondrocytes, GDF5 predominantly signals via ALK6 [228] 
but can also signal via ALK2 and ALK3 [195] to induce SMAD1/5 phosphorylation and SMAD-
independent signaling [245]. GDF5 is expressed in mature cartilage, and its expression is not 
affected by OA [180, 197, 198]. In cartilage, GDF5 induces proteoglycan synthesis [197, 228] 
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and COMP expression [152] but not collagen type 2 synthesis or chondrocyte proliferation 
[197, 198]. Notably, OA chondrocytes do not respond consistently to GDF5 [245], i.e. large 
variation can be observed between OA patients on gene expression of targets like Acan and 
Sox9 after addition of GDF5. Possibly, a yet undiscovered co-receptor plays a role in this; such 
a co-receptor has been postulated to explain how GDF5 can function as a downstream BMP2 
antagonist in ATDC5 cells even though it uses the same type I and type II receptors [195]. 
Identification of such a co-receptor would greatly help in understanding GDF5 signalling in 
chondrocytes and how it differs from BMP signaling using the same receptors.
Conclusion
In conclusion, members of the TGFβ-family are crucial for the homeostasis of chondrocytes, 
and thus of cartilage, via both SMAD-dependent and SMAD-independent signaling, although 
both pathways are more integrated than their names suggest. Cellular context plays a large 
role in TGFβ-family signaling, greatly affecting its outcome, which is illustrated by e.g. the 
differential effects of TGFβ and BMP7 in immature versus mature chondrocytes. A better 
understanding of how cellular context regulates TGFβ-family signaling would greatly help in 
separating the beneficial effects of family members from the detrimental effects, making 
more efficient cartilage repair approaches or OA treatment possible; a challenging but 
rewarding task for future research.
Aim and outline of this thesis
As mentioned, OA is the world’s most common joint disease, and currently no disease-
modifying anti-OA drugs are available. This lack fuels the search for a curative OA treatment. 
To aid in the development of such a treatment, a better understanding of the disease process 
is of great importance. In part, such comprehension comes from a good understanding of 
how tissue homeostasis is regulated. Another part of this understanding can be gained by 
investigating how risk factors affect tissue homeostasis and contribute to disease development. 
In view of its importance in cartilage biology, the TGFβ-family is a prime target for studies 
in both directions. Therefore, the aims of this thesis were to (1) further characterize the 
importance of TGFβ-family signaling in cartilage homeostasis and (2) to show how ageing, the 
main risk factor for OA, impacts this signaling. 
 To begin, in chapter two, we wanted to know the extent of TGFβ-family signaling 
in healthy cartilage, i.e. if normal healthy cartilage is continuously exposed to TGFβ-
family signaling. We approached this question by isolating cartilage explants from bovine 
metacarpophalangeal joints (MCP) and analyzing TGFβ-family signaling immediately after 
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isolation and at later time points by investigating pSmad2 levels and corresponding gene 
expression. Next we analyzed in this chapter if loading, a process to which cartilage is daily 
exposed, plays a role in TGFβ-family signaling. Therefore we repeatedly loaded and unloaded 
cartilage explants using unconfined, dynamic mechanical compression and studing the 
outcome on gene expression and pSMAD2 levels. These experiments taught us that loading 
is an important activator of SMAD2/3 signaling in cartilage, and therefore we sought to find 
its physiological role. For this, we regularly compressed cartilage explants for up to two weeks, 
and investigated the effect of this regular compression on GAG content and chondrocyte 
hypertrophy. 
 After we established the importance of loading in activation of pSmad2/3 signaling 
in cartilage, we realized that ageing might negatively affect this process, because in previous 
studies of our lab we identified age-related changes in expression of TGFβ-family receptors 
in mice [125,137]. However, in these studies, ageing and OA development occurred 
concurrently, making it difficult to separate cause and effect. Therefore we sought to study 
age-related changes in TGFβ-family receptors and members in a model in which both OA 
and ageing could be separated. Chapter three describes that with the use of bovine MCP 
joints we were able to separate these processes. Bovine MCP joints can be obtained from 
animals of different ages and osteoarthritic cartilage can be excluded from analysis by visual 
inspection, which allowed us to study only ageing. Of these joints we obtained a piece of 
cartilage of a standardized location and isolated mRNA to measure gene expression and 
made tissue sections to study histology. Furthermore, we also incubated cartilage explants of 
animals of different ages with TGFβ and BMP9 to study if cartilage of a different age responds 
differently to these growthfactors. 
 Together with this study we also investigated if ageing negatively affects loading-
induced pSMAD2/3 directly in chapter four. We did this by loading cartilage pieces of young 
and old animals and analyzing how age impacted the outcome. Because we noticed that old 
cartilage is stiffer and more difficult to compress we used two forces: normal (i.e. 3 MPa) 
and excessive (i.e. 12 MPa). First we analyzed if (excessive) loading affects cartilage integrity 
by looking for tears and fissures using histology. Next we analyzed mRNA and analyzed 
gene expression 2 and 6 h after compression. Furthermore, we also investigated Smad2 
phosphorylation and nuclear accumulation after compression by immunohistochemistry.
 Because the previous chapters established the importance of loading in SMAD2/3 
signaling in chondrocyte biology, we also wanted to further characterize the effects of 
ALK1 / Smad1/5/9 signaling on chondrocyte biology. To do this, we stimulated in chapter 
five primary bovine chondrocytes with BMP9, a high affinity ALK1 ligand, and investigated 
Smad1/5 phosphorylation and downstream gene expression. Furthermore, we cultured 
primary chondrocytes for a week with BMP9 and analyzed the effects hereof on chondrocyte 
hypertrophy using qPCR. Additionaly, we were interested in the interaction of BMP9 with 
TGFβ and therefore stimulated chondrocytes with a combination of both growth factors, and 
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investigated their resulting interaction on SMAD2/3 and SMAD1/5/9 phosphorylation, gene 
expression and chondrocyte hypertrophy.
 In view of the fact that TGFβ signaling has been linked to many pathophysiological 
aspects of OA but not yet to this disease’s main clinical outcome: pain, we investigated 
in chapter six if TGFβ signaling plays a role in induction of nerve growth factor (NGF), an 
important pain stimulus in OA. For this, we stimulated chondrocyte cell lines, primary 
chondrocytes and cartilage explants with various dosages of TGFβ and measured NGF gene 
expression. Furthermore, we also stimulated chondrocytes with IL1β, an inflammatory 
cytokine and well known inducer of NGF in cartilage, to compare the effects of TGFβ and IL1β.
Because TGFβ signaling in chondrocyte biology is seen as a double-edged sword, we tried in 
chapter seven, to modulate TGFβ signaling with the use of small molecule inhibitors to direct 
TGFβ signaling away from its for cartilage potentially deleterious pSMAD1/5 signaling towards 
beneficial pSMAD2/3 signaling. We approached this by using an ALK5 kinase inhibitor, i.e. 
SB-505124, an ALK1 kinase inhibitor, i.e. LDN-193189, and a TAK1 kinase inhibitor, (5Z)-7-
oxozeaenol, to inhibit both SMAD-dependent and SMAD-independent signaling. We added 
these inhibitors to both primary chondrocytes and cartilage explants and analyzed SMAD 
phosphorylation and gene expression. 
Finally, in chapter eight a summary of the results described in this thesis is provided, together 
with some considerations regarding the implications of the described findings for cartilage 
biology and osteoarthritis. 
CHAPTER 1
38
References 
1. Felson, D.T., et al., The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. 
Arthritis Rheum, 1987. 30(8): p. 914-8.
2. Tonge, D.P., M.J. Pearson, and S.W. Jones, The hallmarks of osteoarthritis and the potential to develop 
personalised disease-modifying pharmacological therapeutics. Osteoarthritis Cartilage, 2014. 22(5): p. 609-21.
3. Arden, N. and M.C. Nevitt, Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol, 2006. 20(1): p. 3-25.
4. Johnson, V.L. and D.J. Hunter, The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol, 2014. 28(1): p. 
5-15.
5. Sophia Fox, A.J., A. Bedi, and S.A. Rodeo, The basic science of articular cartilage: structure, composition, and 
function. Sports Health, 2009. 1(6): p. 461-8.
6. Mescher, A.L. and L.C.U.a.B.h. Junqueira, Junqueira’s basic histology : text and atlas. 12th ed. ed. 2010, New 
York ; London: McGraw-Hill Medical.
7. Pearle, A.D., R.F. Warren, and S.A. Rodeo, Basic science of articular cartilage and osteoarthritis. Clin Sports Med, 
2005. 24(1): p. 1-12.
8. Shoulders, M.D. and R.T. Raines, Collagen structure and stability. Annu Rev Biochem, 2009. 78: p. 929-58.
9. Bruckner, P. and M. van der Rest, Structure and function of cartilage collagens. Microsc Res Tech, 1994. 28(5): 
p. 378-84.
10. Holmes, D.F. and K.E. Kadler, The 10+4 microfibril structure of thin cartilage fibrils. Proc Natl Acad Sci U S A, 
2006. 103(46): p. 17249-54.
11. Fraser, J.R., T.C. Laurent, and U.B. Laurent, Hyaluronan: its nature, distribution, functions and turnover. J Intern 
Med, 1997. 242(1): p. 27-33.
12. Bastow, E.R., et al., Hyaluronan synthesis and degradation in cartilage and bone. Cell Mol Life Sci, 2008. 65(3): 
p. 395-413.
13. Scott, J.E., et al., Secondary and tertiary structures of hyaluronan in aqueous solution, investigated by rotary 
shadowing-electron microscopy and computer simulation. Hyaluronan is a very efficient network-forming 
polymer. Biochem J, 1991. 274 ( Pt 3): p. 699-705.
14. Vigetti, D., et al., Hyaluronan: biosynthesis and signaling. Biochim Biophys Acta, 2014. 1840(8): p. 2452-9.
15. Turley, E.A., P.W. Noble, and L.Y. Bourguignon, Signaling properties of hyaluronan receptors. J Biol Chem, 2002. 
277(7): p. 4589-92.
16. Iozzo, R.V. and A.D. Murdoch, Proteoglycans of the extracellular environment: clues from the gene and protein 
side offer novel perspectives in molecular diversity and function. FASEB J, 1996. 10(5): p. 598-614.
17. Kiani, C., et al., Structure and function of aggrecan. Cell Res, 2002. 12(1): p. 19-32.
18. Ni, G.X., Z. Li, and Y.Z. Zhou, The role of small leucine-rich proteoglycans in osteoarthritis pathogenesis. 
Osteoarthritis Cartilage, 2014. 22(7): p. 896-903.
19. Teshima, R., et al., Structure of the most superficial layer of articular cartilage. J Bone Joint Surg Br, 1995. 77(3): 
p. 460-4.
20. Jeffery, A.K., et al., Three-dimensional collagen architecture in bovine articular cartilage. J Bone Joint Surg Br, 
1991. 73(5): p. 795-801.
21. Rhee, D.K., et al., The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell 
overgrowth. J Clin Invest, 2005. 115(3): p. 622-31.
22. Poole, A.R., et al., Contents and distributions of the proteoglycans decorin and biglycan in normal and 
osteoarthritic human articular cartilage. J Orthop Res, 1996. 14(5): p. 681-9.
General introduction
39
1
23. Cowman, M.K., et al., Viscoelastic Properties of Hyaluronan in Physiological Conditions. F1000Res, 2015. 4: p. 
622.
24. van der Kraan, P.M. and W.B. van den Berg, Chondrocyte hypertrophy and osteoarthritis: role in initiation and 
progression of cartilage degeneration? Osteoarthritis Cartilage, 2012. 20(3): p. 223-32.
25. Troeberg, L. and H. Nagase, Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim 
Biophys Acta, 2012. 1824(1): p. 133-45.
26. Nagase, H. and M. Kashiwagi, Aggrecanases and cartilage matrix degradation. Arthritis Res Ther, 2003. 5(2): p. 
94-103.
27. Mitrovic, D., et al., Metabolism of human femoral head cartilage in osteoarthrosis and subcapital fracture. Ann 
Rheum Dis, 1981. 40(1): p. 18-26.
28. Aigner, T., K. Gluckert, and K. von der Mark, Activation of fibrillar collagen synthesis and phenotypic modulation 
of chondrocytes in early human osteoarthritic cartilage lesions. Osteoarthritis Cartilage, 1997. 5(3): p. 183-9.
29. Guzman, R.E., et al., Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage 
of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol, 2003. 31(6): p. 619-24.
30. Salazar, V.S., L.W. Gamer, and V. Rosen, BMP signalling in skeletal development, disease and repair. Nat Rev 
Endocrinol, 2016. 12(4): p. 203-21.
31. Kirsch, T., et al., Regulated production of mineralization-competent matrix vesicles in hypertrophic chondrocytes. 
J Cell Biol, 1997. 137(5): p. 1149-60.
32. Orimo, H., The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J 
Nippon Med Sch, 2010. 77(1): p. 4-12.
33. Krishnan, V., H.U. Bryant, and O.A. Macdougald, Regulation of bone mass by Wnt signaling. J Clin Invest, 2006. 
116(5): p. 1202-9.
34. Chen, C., et al., Biomechanical properties and mechanobiology of the articular chondrocyte. Am J Physiol Cell 
Physiol, 2013. 305(12): p. C1202-8.
35. Blanco, F.J. and M. Lotz, IL-1-induced nitric oxide inhibits chondrocyte proliferation via PGE2. Exp Cell Res, 1995. 
218(1): p. 319-25.
36. Lo, Y.Y., et al., Interleukin-1 beta induction of c-fos and collagenase expression in articular chondrocytes: 
involvement of reactive oxygen species. J Cell Biochem, 1998. 69(1): p. 19-29.
37. Schelbergen, R.F., et al., Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic 
chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum, 2012. 64(5): p. 1477-87.
38. Shi, M., et al., Latent TGF-beta structure and activation. Nature, 2011. 474(7351): p. 343-9.
39. Mueller, T.D. and J. Nickel, Promiscuity and specificity in BMP receptor activation. FEBS Lett, 2012. 586(14): p. 
1846-59.
40. Heldin, C.H., K. Miyazono, and P. ten Dijke, TGF-beta signalling from cell membrane to nucleus through SMAD 
proteins. Nature, 1997. 390(6659): p. 465-71.
41. Wang, X.F., et al., Expression cloning and characterization of the TGF-beta type III receptor. Cell, 1991. 67(4): p. 
797-805.
42. Lopez-Casillas, F., et al., Structure and expression of the membrane proteoglycan betaglycan, a component of 
the TGF-beta receptor system. Cell, 1991. 67(4): p. 785-95.
43. Cheifetz, S., et al., Endoglin is a component of the transforming growth factor-beta receptor system in human 
endothelial cells. J Biol Chem, 1992. 267(27): p. 19027-30.
44. Siebold, C., et al., RGMs: Structural Insights, Molecular Regulation, and Downstream Signaling. Trends Cell Biol, 
2017. 27(5): p. 365-378.
CHAPTER 1
40
45. Finnson, K.W., et al., Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. 
FASEB J, 2006. 20(9): p. 1525-7.
46. Onichtchouk, D., et al., Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature, 1999. 401(6752): 
p. 480-5.
47. Graham, H. and C. Peng, Activin receptor-like kinases: structure, function and clinical implications. Endocr 
Metab Immune Disord Drug Targets, 2006. 6(1): p. 45-58.
48. Zawel, L., et al., Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell, 1998. 1(4): 
p. 611-7.
49. Kusanagi, K., et al., Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol 
Biol Cell, 2000. 11(2): p. 555-65.
50. Gaarenstroom, T. and C.S. Hill, TGF-beta signaling to chromatin: how Smads regulate transcription during self-
renewal and differentiation. Semin Cell Dev Biol, 2014. 32: p. 107-18.
51. Furumatsu, T., et al., Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/
p300 recruitment. J Biol Chem, 2005. 280(9): p. 8343-50.
52. Nakao, A., et al., Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature, 1997. 
389(6651): p. 631-5.
53. Imamura, T., et al., Smad6 inhibits signalling by the TGF-beta superfamily. Nature, 1997. 389(6651): p. 622-6.
54. Valdes, A.M., et al., Genetic variation in the SMAD3 gene is associated with hip and knee osteoarthritis. Arthritis 
Rheum, 2010. 62(8): p. 2347-52.
55. Aref-Eshghi, E., et al., SMAD3 is associated with the total burden of radiographic osteoarthritis: the Chingford 
study. PLoS One, 2014. 9(5): p. e97786.
56. van de Laar, I.M., et al., Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med 
Genet, 2012. 49(1): p. 47-57.
57. van de Laar, I.M., et al., Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with 
early-onset osteoarthritis. Nat Genet, 2011. 43(2): p. 121-6.
58. Yang, X., et al., TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for 
maintaining articular cartilage. J Cell Biol, 2001. 153(1): p. 35-46.
59. Yang, X., et al., Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell 
responsiveness to TGF-beta. EMBO J, 1999. 18(5): p. 1280-91.
60. Wolfraim, L.A., et al., Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med, 2004. 351(6): p. 552-9.
61. Chen, C.G., et al., Chondrocyte-intrinsic Smad3 represses Runx2-inducible matrix metalloproteinase 13 
expression to maintain articular cartilage and prevent osteoarthritis. Arthritis Rheum, 2012. 64(10): p. 3278-89.
62. Li, Q., et al., Redundant roles of SMAD2 and SMAD3 in ovarian granulosa cells in vivo. Mol Cell Biol, 2008. 
28(23): p. 7001-11.
63. Ferguson, C.M., et al., Smad2 and 3 mediate transforming growth factor-beta1-induced inhibition of chondrocyte 
maturation. Endocrinology, 2000. 141(12): p. 4728-35.
64. Ionescu, A.M., et al., ATF-2 cooperates with Smad3 to mediate TGF-beta effects on chondrocyte maturation. Exp 
Cell Res, 2003. 288(1): p. 198-207.
65. Kim, K.O., et al., Ski inhibits TGF-beta/phospho-Smad3 signaling and accelerates hypertrophic differentiation in 
chondrocytes. J Cell Biochem, 2012. 113(6): p. 2156-66.
66. Li, T.F., et al., Aberrant hypertrophy in Smad3-deficient murine chondrocytes is rescued by restoring transforming 
growth factor beta-activated kinase 1/activating transcription factor 2 signaling: a potential clinical implication 
for osteoarthritis. Arthritis Rheum, 2010. 62(8): p. 2359-69.
General introduction
41
1
67. Kang, J.S., et al., Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases 
by Smad3. EMBO J, 2005. 24(14): p. 2543-55.
68. Leboy, P., et al., Smad-Runx interactions during chondrocyte maturation. J Bone Joint Surg Am, 2001. 83-A 
Suppl 1(Pt 1): p. S15-22.
69. Enomoto, H., et al., Cbfa1 is a positive regulatory factor in chondrocyte maturation. J Biol Chem, 2000. 275(12): 
p. 8695-702.
70. Inada, M., et al., Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn, 1999. 214(4): p. 
279-90.
71. Nomura, M. and E. Li, Smad2 role in mesoderm formation, left-right patterning and craniofacial development. 
Nature, 1998. 393(6687): p. 786-90.
72. Waldrip, W.R., et al., Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the 
early mouse embryo. Cell, 1998. 92(6): p. 797-808.
73. Weinstein, M., et al., Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the 
tumor suppressor smad2. Proc Natl Acad Sci U S A, 1998. 95(16): p. 9378-83.
74. Vivian, J.L., et al., An allelic series of mutations in Smad2 and Smad4 identified in a genotype-based screen of 
N-ethyl-N- nitrosourea-mutagenized mouse embryonic stem cells. Proc Natl Acad Sci U S A, 2002. 99(24): p. 
15542-7.
75. Decker, R.S., E. Koyama, and M. Pacifici, Genesis and morphogenesis of limb synovial joints and articular 
cartilage. Matrix Biol, 2014. 39: p. 5-10.
76. Hamamoto, T., et al., Compound disruption of smad2 accelerates malignant progression of intestinal tumors in 
apc knockout mice. Cancer Res, 2002. 62(20): p. 5955-61.
77. Wang, W., et al., Smad2 and Smad3 Regulate Chondrocyte Proliferation and Differentiation in the Growth Plate. 
PLoS Genet, 2016. 12(10): p. e1006352.
78. Lechleider, R.J., et al., Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. Dev 
Biol, 2001. 240(1): p. 157-67.
79. Chang, H., et al., Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic 
defects. Development, 1999. 126(8): p. 1631-42.
80. Retting, K.N., et al., BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral 
bone formation. Development, 2009. 136(7): p. 1093-104.
81. Fujii, M., et al., Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and 
chondroblast differentiation. Mol Biol Cell, 1999. 10(11): p. 3801-13.
82. Horiki, M., et al., Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes 
dwarfism with osteopenia. J Cell Biol, 2004. 165(3): p. 433-45.
83. Javed, A., et al., Specific residues of RUNX2 are obligatory for formation of BMP2-induced RUNX2-SMAD 
complex to promote osteoblast differentiation. Cells Tissues Organs, 2009. 189(1-4): p. 133-7.
84. Javed, A., et al., Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal. J Biol 
Chem, 2008. 283(13): p. 8412-22.
85. Phimphilai, M., et al., BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J 
Bone Miner Res, 2006. 21(4): p. 637-46.
86. Bae, J.S., et al., Reconstitution of Runx2/Cbfa1-null cells identifies a requirement for BMP2 signaling through a 
Runx2 functional domain during osteoblast differentiation. J Cell Biochem, 2007. 100(2): p. 434-49.
87. Kielty, C.M., et al., Type X collagen, a product of hypertrophic chondrocytes. Biochem J, 1985. 227(2): p. 545-54.
88. Yang, D., et al., Histone demethylase Jmjd3 regulates osteoblast differentiation via transcription factors Runx2 
and osterix. J Biol Chem, 2013. 288(47): p. 33530-41.
CHAPTER 1
42
89. Heldin, C.H. and A. Moustakas, Signaling Receptors for TGF-beta Family Members. Cold Spring Harb Perspect 
Biol, 2016. 8(8).
90. Lee, M.K., et al., TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J, 
2007. 26(17): p. 3957-67.
91. Yamashita, M., et al., TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell, 2008. 
31(6): p. 918-24.
92. Landstrom, M., The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol, 2010. 42(5): p. 585-9.
93. Derynck, R. and Y.E. Zhang, Smad-dependent and Smad-independent pathways in TGF-beta family signalling. 
Nature, 2003. 425(6958): p. 577-84.
94. Watanabe, H., M.P. de Caestecker, and Y. Yamada, Transcriptional cross-talk between Smad, ERK1/2, and p38 
mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene 
expression in chondrogenic ATDC5 cells. J Biol Chem, 2001. 276(17): p. 14466-73.
95. Zhu, Y., et al., Transforming growth factor-beta1 induces type II collagen and aggrecan expression via activation 
of extracellular signal-regulated kinase 1/2 and Smad2/3 signaling pathways. Mol Med Rep, 2015. 12(4): p. 
5573-9.
96. Miyazaki, Y., et al., Dexamethasone inhibition of TGF beta-induced cell growth and type II collagen mRNA 
expression through ERK-integrated AP-1 activity in cultured rat articular chondrocytes. Osteoarthritis Cartilage, 
2000. 8(5): p. 378-85.
97. Qureshi, H.Y., et al., TGF-beta-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes 
is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor. J Cell Physiol, 2005. 
203(2): p. 345-52.
98. Tuli, R., et al., Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor 
cells involves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk. J Biol Chem, 2003. 
278(42): p. 41227-36.
99. Li, J., et al., MEK/ERK and p38 MAPK regulate chondrogenesis of rat bone marrow mesenchymal stem cells 
through delicate interaction with TGF-beta1/Smads pathway. Cell Prolif, 2010. 43(4): p. 333-43.
100. Bobick, B.E. and W.M. Kulyk, The MEK-ERK signaling pathway is a negative regulator of cartilage-specific gene 
expression in embryonic limb mesenchyme. J Biol Chem, 2004. 279(6): p. 4588-95.
101. Qiao, B., S.R. Padilla, and P.D. Benya, Transforming growth factor (TGF)-beta-activated kinase 1 mimics and 
mediates TGF-beta-induced stimulation of type II collagen synthesis in chondrocytes independent of Col2a1 
transcription and Smad3 signaling. J Biol Chem, 2005. 280(17): p. 17562-71.
102. Gunnell, L.M., et al., TAK1 regulates cartilage and joint development via the MAPK and BMP signaling pathways. 
J Bone Miner Res, 2010. 25(8): p. 1784-97.
103. Shim, J.H., et al., TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J, 2009. 28(14): p. 2028-41.
104. Gao, L., et al., TAK1 regulates SOX9 expression in chondrocytes and is essential for postnatal development of the 
growth plate and articular cartilages. J Cell Sci, 2013. 126(Pt 24): p. 5704-13.
105. Tew, S.R. and T.E. Hardingham, Regulation of SOX9 mRNA in human articular chondrocytes involving p38 MAPK 
activation and mRNA stabilization. J Biol Chem, 2006. 281(51): p. 39471-9.
106. Fong, Y.C., et al., BMP-2 increases migration of human chondrosarcoma cells via PI3K/Akt pathway. J Cell 
Physiol, 2008. 217(3): p. 846-55.
107. Lamouille, S. and R. Derynck, Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is 
regulated by activation of the mTOR pathway. J Cell Biol, 2007. 178(3): p. 437-51.
108. Zhang, L., F. Zhou, and P. ten Dijke, Signaling interplay between transforming growth factor-beta receptor and 
PI3K/AKT pathways in cancer. Trends Biochem Sci, 2013. 38(12): p. 612-20.
General introduction
43
1
109. Li, C., Q. Wang, and J.F. Wang, Transforming growth factor-beta (TGF-beta) induces the expression of 
chondrogenesis-related genes through TGF-beta receptor II (TGFRII)-AKT-mTOR signaling in primary cultured 
mouse precartilaginous stem cells. Biochem Biophys Res Commun, 2014. 450(1): p. 646-51.
110. Mendoza, M.C., E.E. Er, and J. Blenis, The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. 
Trends Biochem Sci, 2011. 36(6): p. 320-8.
111. Kita, K., et al., PI3K/Akt signaling as a key regulatory pathway for chondrocyte terminal differentiation. Genes 
Cells, 2008. 13(8): p. 839-50.
112. Rokutanda, S., et al., Akt regulates skeletal development through GSK3, mTOR, and FoxOs. Dev Biol, 2009. 
328(1): p. 78-93.
113. Fukai, A., et al., Akt1 in murine chondrocytes controls cartilage calcification during endochondral ossification 
under physiologic and pathologic conditions. Arthritis Rheum, 2010. 62(3): p. 826-36.
114. Zhang, Y., et al., Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from 
osteoarthritis. Annals of the Rheumatic Diseases, 2015. 74(7): p. 1432-1440.
115. Takayama, K., et al., Local intra-articular injection of rapamycin delays articular cartilage degeneration in a 
murine model of osteoarthritis. Arthritis Res Ther, 2014. 16(6): p. 482.
116. Carames, B., et al., Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann 
Rheum Dis, 2012. 71(4): p. 575-81.
117. Ridley, A.J. and A. Hall, The small GTP-binding protein rho regulates the assembly of focal adhesions and actin 
stress fibers in response to growth factors. Cell, 1992. 70(3): p. 389-99.
118. Kumar, D. and A.B. Lassar, The transcriptional activity of Sox9 in chondrocytes is regulated by RhoA signaling and 
actin polymerization. Mol Cell Biol, 2009. 29(15): p. 4262-73.
119. Woods, A., G. Wang, and F. Beier, RhoA/ROCK signaling regulates Sox9 expression and actin organization during 
chondrogenesis. J Biol Chem, 2005. 280(12): p. 11626-34.
120. Woods, A. and F. Beier, RhoA/ROCK signaling regulates chondrogenesis in a context-dependent manner. J Biol 
Chem, 2006. 281(19): p. 13134-40.
121. Wang, G., et al., RhoA/ROCK signaling suppresses hypertrophic chondrocyte differentiation. J Biol Chem, 2004. 
279(13): p. 13205-14.
122. Wang, G. and F. Beier, Rac1/Cdc42 and RhoA GTPases antagonistically regulate chondrocyte proliferation, 
hypertrophy, and apoptosis. J Bone Miner Res, 2005. 20(6): p. 1022-31.
123. Matsuzaki, K., Smad phospho-isoforms direct context-dependent TGF-beta signaling. Cytokine Growth Factor 
Rev, 2013. 24(4): p. 385-99.
124. DiChiara, M.R., et al., Inhibition of E-selectin gene expression by transforming growth factor beta in endothelial 
cells involves coactivator integration of Smad and nuclear factor kappaB-mediated signals. J Exp Med, 2000. 
192(5): p. 695-704.
125. Jonk, L.J., et al., Identification and functional characterization of a Smad binding element (SBE) in the JunB 
promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible 
enhancer. J Biol Chem, 1998. 273(33): p. 21145-52.
126. Ogawa, Y., et al., Purification and characterization of transforming growth factor-beta 2.3 and -beta 1.2 
heterodimers from bovine bone. J Biol Chem, 1992. 267(4): p. 2325-8.
127. Sengle, G., et al., Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify 
different functions: extracellular matrix interactions and growth factor bioavailability. J Biol Chem, 2011. 
286(7): p. 5087-99.
128. Seyedin, S.M., et al., Purification and characterization of two cartilage-inducing factors from bovine 
demineralized bone. Proc Natl Acad Sci U S A, 1985. 82(8): p. 2267-71.
CHAPTER 1
44
129. Seyedin, S.M., et al., Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta. J Biol 
Chem, 1986. 261(13): p. 5693-5.
130. Segarini, P.R., et al., Membrane binding characteristics of two forms of transforming growth factor-beta. J Biol 
Chem, 1987. 262(30): p. 14655-62.
131. Blaney Davidson, E.N., et al., Reduced transforming growth factor-beta signaling in cartilage of old mice: role in 
impaired repair capacity. Arthritis Res Ther, 2005. 7(6): p. R1338-47.
132. Villiger, P.M. and M. Lotz, Differential expression of TGF beta isoforms by human articular chondrocytes in 
response to growth factors. J Cell Physiol, 1992. 151(2): p. 318-25.
133. Pombo-Suarez, M., et al., Differential upregulation of the three transforming growth factor beta isoforms in 
human osteoarthritic cartilage. Ann Rheum Dis, 2009. 68(4): p. 568-71.
134. Morales, T.I., et al., Transforming growth factor-beta in calf articular cartilage organ cultures: synthesis and 
distribution. Arch Biochem Biophys, 1991. 288(2): p. 397-405.
135. Albro, M.B., et al., Dynamic mechanical compression of devitalized articular cartilage does not activate latent 
TGF-beta. J Biomech, 2013. 46(8): p. 1433-9.
136. van Caam, A., et al., Expression of TGFbeta-family signalling components in ageing cartilage: age-related loss of 
TGFbeta and BMP receptors. Osteoarthritis Cartilage, 2016.
137. Kizawa, H., et al., An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases 
susceptibility to osteoarthritis. Nat Genet, 2005. 37(2): p. 138-44.
138. Maeda, S., et al., Activation of latent transforming growth factor beta1 by stromelysin 1 in extracts of growth 
plate chondrocyte-derived matrix vesicles. J Bone Miner Res, 2001. 16(7): p. 1281-90.
139. Albro, M.B., et al., Shearing of synovial fluid activates latent TGF-beta. Osteoarthritis Cartilage, 2012. 20(11): p. 
1374-82.
140. Jobling, M.F., et al., Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive 
oxygen species. Radiat Res, 2006. 166(6): p. 839-48.
141. Madej, W., et al., Physiological and excessive mechanical compression of articular cartilage activates Smad2/3P 
signaling. Osteoarthritis Cartilage, 2014. 22(7): p. 1018-25.
142. Finnson, K.W., et al., ALK1 opposes ALK5/Smad3 signaling and expression of extracellular matrix components in 
human chondrocytes. J Bone Miner Res, 2008. 23(6): p. 896-906.
143. Blaney Davidson, E.N., et al., Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in 
osteoarthritis in humans and mice. Journal of Immunology, 2009. 182(12): p. 7937-45.
144. van Beuningen, H.M., et al., Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan 
synthesis and induces osteophyte formation in the murine knee joint. Lab Invest, 1994. 71(2): p. 279-90.
145. van Beuningen, H.M., et al., Differential effects of local application of BMP-2 or TGF-beta 1 on both articular 
cartilage composition and osteophyte formation. Osteoarthritis Cartilage, 1998. 6(5): p. 306-17.
146. Morales, T.I. and A.B. Roberts, Transforming growth factor beta regulates the metabolism of proteoglycans in 
bovine cartilage organ cultures. J Biol Chem, 1988. 263(26): p. 12828-31.
147. Malemud, C.J., et al., Enhanced sulfated-proteoglycan core protein synthesis by incubation of rabbit 
chondrocytes with recombinant transforming growth factor-beta 1. J Cell Physiol, 1991. 149(1): p. 152-9.
148. van der Kraan, P., E. Vitters, and W. van den Berg, Differential effect of transforming growth factor beta on 
freshly isolated and cultured articular chondrocytes. J Rheumatol, 1992. 19(1): p. 140-5.
149. Redini, F., et al., Transforming growth factor beta stimulates collagen and glycosaminoglycan biosynthesis in 
cultured rabbit articular chondrocytes. FEBS Lett, 1988. 234(1): p. 172-6.
General introduction
45
1
150. Galera, P., et al., Transforming growth factor-beta 1 (TGF-beta 1) up-regulation of collagen type II in primary 
cultures of rabbit articular chondrocytes (RAC) involves increased mRNA levels without affecting mRNA stability 
and procollagen processing. J Cell Physiol, 1992. 153(3): p. 596-606.
151. Recklies, A.D., L. Baillargeon, and C. White, Regulation of cartilage oligomeric matrix protein synthesis in human 
synovial cells and articular chondrocytes. Arthritis Rheum, 1998. 41(6): p. 997-1006.
152. Motaung, S.C., P.E. Di Cesare, and A.H. Reddi, Differential response of cartilage oligomeric matrix protein 
(COMP) to morphogens of bone morphogenetic protein/transforming growth factor-beta family in the surface, 
middle and deep zones of articular cartilage. J Tissue Eng Regen Med, 2011. 5(6): p. e87-96.
153. Iozzo, R.V., et al., Structural and functional characterization of the human perlecan gene promoter. Transcriptional 
activation by transforming growth factor-beta via a nuclear factor 1-binding element. J Biol Chem, 1997. 272(8): 
p. 5219-28.
154. Burton-Wurster, N. and G. Lust, Fibronectin and proteoglycan synthesis in long term cultures of cartilage 
explants in Ham’s F12 supplemented with insulin and calcium: effects of the addition of TGF-beta. Arch Biochem 
Biophys, 1990. 283(1): p. 27-33.
155. Morales, T.I., Transforming growth factor-beta 1 stimulates synthesis of proteoglycan aggregates in calf 
articular cartilage organ cultures. Arch Biochem Biophys, 1991. 286(1): p. 99-106.
156. Niikura, T. and A.H. Reddi, Differential regulation of lubricin/superficial zone protein by transforming growth 
factor beta/bone morphogenetic protein superfamily members in articular chondrocytes and synoviocytes. 
Arthritis Rheum, 2007. 56(7): p. 2312-21.
157. van der Kraan, P.M., E.L. Vitters, and W.B. van den Berg, Inhibition of proteoglycan synthesis by transforming 
growth factor beta in anatomically intact articular cartilage of murine patellae. Ann Rheum Dis, 1992. 51(5): p. 
643-7.
158. Glansbeek, H.L., et al., Correlation of the size of type II transforming growth factor beta (TGF-beta) receptor with 
TGF-beta responses of isolated bovine articular chondrocytes. Ann Rheum Dis, 1993. 52(11): p. 812-6.
159. Chadjichristos, C., et al., Down-regulation of human type II collagen gene expression by transforming growth 
factor-beta 1 (TGF-beta 1) in articular chondrocytes involves SP3/SP1 ratio. J Biol Chem, 2002. 277(46): p. 
43903-17.
160. O’Keefe, R.J., et al., Effects of transforming growth factor-beta on matrix synthesis by chick growth plate 
chondrocytes. Endocrinology, 1988. 122(6): p. 2953-61.
161. Vivien, D., et al., Differential effects of transforming growth factor-beta and epidermal growth factor on the cell 
cycle of cultured rabbit articular chondrocytes. J Cell Physiol, 1990. 143(3): p. 534-45.
162. van Beuningen, H.M., et al., Osteoarthritis-like changes in the murine knee joint resulting from intra-articular 
transforming growth factor-beta injections. Osteoarthritis Cartilage, 2000. 8(1): p. 25-33.
163. van Beuningen, H.M., et al., Protection from interleukin 1 induced destruction of articular cartilage by 
transforming growth factor beta: studies in anatomically intact cartilage in vitro and in vivo. Ann Rheum Dis, 
1993. 52(3): p. 185-91.
164. van Beuningen, H.M., et al., In vivo protection against interleukin-1-induced articular cartilage damage by 
transforming growth factor-beta 1: age-related differences. Ann Rheum Dis, 1994. 53(9): p. 593-600.
165. Takahashi, N., et al., Elucidation of IL-1/TGF-beta interactions in mouse chondrocyte cell line by genome-wide 
gene expression. Osteoarthritis Cartilage, 2005. 13(5): p. 426-38.
166. Redini, F., et al., Transforming growth factor beta exerts opposite effects from interleukin-1 beta on cultured 
rabbit articular chondrocytes through reduction of interleukin-1 receptor expression. Arthritis Rheum, 1993. 
36(1): p. 44-50.
167. Glansbeek, H.L., et al., Stimulation of articular cartilage repair in established arthritis by local administration of 
transforming growth factor-beta into murine knee joints. Lab Invest, 1998. 78(2): p. 133-42.
CHAPTER 1
46
168. Pronost, S., et al., Modulation of interleukin-1 receptor expression by transforming growth factor-beta in cultured 
rabbit articular chondrocytes: analysis by reverse transcription-polymerase chain reaction. Osteoarthritis 
Cartilage, 1995. 3(3): p. 147-55.
169. Shiou, S.R., et al., Oral administration of transforming growth factor-beta1 (TGF-beta1) protects the immature 
gut from injury via Smad protein-dependent suppression of epithelial nuclear factor kappaB (NF-kappaB) 
signaling and proinflammatory cytokine production. J Biol Chem, 2013. 288(48): p. 34757-66.
170. Li, T.F., et al., Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation. J 
Bone Miner Res, 2006. 21(1): p. 4-16.
171. Shen, J., et al., Deletion of the transforming growth factor beta receptor type II gene in articular chondrocytes 
leads to a progressive osteoarthritis-like phenotype in mice. Arthritis Rheum, 2013. 65(12): p. 3107-19.
172. Serra, R., et al., Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue 
promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol, 1997. 139(2): p. 541-52.
173. Sueyoshi, T., K. Yamamoto, and H. Akiyama, Conditional deletion of Tgfbr2 in hypertrophic chondrocytes delays 
terminal chondrocyte differentiation. Matrix Biol, 2012. 31(6): p. 352-9.
174. Chen, R., et al., Attenuation of the progression of articular cartilage degeneration by inhibition of TGF-beta1 
signaling in a mouse model of osteoarthritis. Am J Pathol, 2015. 185(11): p. 2875-85.
175. Zhao, W., et al., Cartilage degeneration and excessive subchondral bone formation in spontaneous osteoarthritis 
involves altered TGF-beta signaling. J Orthop Res, 2016. 34(5): p. 763-70.
176. Hui, W., et al., Oxidative changes and signalling pathways are pivotal in initiating age-related changes in 
articular cartilage. Annals of the Rheumatic Diseases, 2016. 75(2): p. 449-458.
177. Zhen, G., et al., Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates 
osteoarthritis. Nat Med, 2013. 19(6): p. 704-12.
178. Xu, L., et al., Induction of high temperature requirement A1, a serine protease, by TGF-beta1 in articular 
chondrocytes of mouse models of OA. Histol Histopathol, 2014. 29(5): p. 609-18.
179. Holt, D.W., et al., Osteoarthritis-like changes in the heterozygous sedc mouse associated with the HtrA1-Ddr2-
Mmp-13 degradative pathway: a new model of osteoarthritis. Osteoarthritis Cartilage, 2012. 20(5): p. 430-9.
180. Chen, A.L., et al., Expression of bone morphogenetic proteins, receptors, and tissue inhibitors in human fetal, 
adult, and osteoarthritic articular cartilage. J Orthop Res, 2004. 22(6): p. 1188-92.
181. Bragdon, B., et al., Bone morphogenetic proteins: a critical review. Cell Signal, 2011. 23(4): p. 609-20.
182. Sengle, G., et al., A new model for growth factor activation: type II receptors compete with the prodomain for 
BMP-7. J Mol Biol, 2008. 381(4): p. 1025-39.
183. Aykul, S. and E. Martinez-Hackert, Transforming Growth Factor-beta Family Ligands Can Function as Antagonists 
by Competing for Type II Receptor Binding. J Biol Chem, 2016. 291(20): p. 10792-804.
184. Pregizer, S.K. and D.P. Mortlock, Dynamics and cellular localization of Bmp2, Bmp4, and Noggin transcription in 
the postnatal mouse skeleton. J Bone Miner Res, 2015. 30(1): p. 64-70.
185. van der Kraan, P.M., E.N. Blaney Davidson, and W.B. van den Berg, Bone morphogenetic proteins and articular 
cartilage: To serve and protect or a wolf in sheep clothing’s? Osteoarthritis Cartilage, 2010. 18(6): p. 735-41.
186. Fukui, N., et al., Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal 
and osteoarthritic chondrocytes. J Bone Joint Surg Am, 2003. 85-A Suppl 3: p. 59-66.
187. Hills, R.L., L.M. Belanger, and E.A. Morris, Bone morphogenetic protein 9 is a potent anabolic factor for juvenile 
bovine cartilage, but not adult cartilage. J Orthop Res, 2005. 23(3): p. 611-7.
188. Blaney Davidson, E.N., et al., Elevated extracellular matrix production and degradation upon bone morphogenetic 
protein-2 (BMP-2) stimulation point toward a role for BMP-2 in cartilage repair and remodeling. Arthritis Res 
Ther, 2007. 9(5): p. R102.
General introduction
47
1
189. Fukui, N., et al., Pro-inflammatory cytokine tumor necrosis factor-alpha induces bone morphogenetic protein-2 
in chondrocytes via mRNA stabilization and transcriptional up-regulation. J Biol Chem, 2006. 281(37): p. 27229-
41.
190. Glansbeek, H.L., et al., Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan synthesis in 
vivo but does not counteract interleukin-1alpha effects on proteoglycan synthesis and content. Arthritis Rheum, 
1997. 40(6): p. 1020-8.
191. van der Kraan, P.M., et al., Role of nitric oxide in the inhibition of BMP-2-mediated stimulation of proteoglycan 
synthesis in articular cartilage. Osteoarthritis Cartilage, 2000. 8(2): p. 82-6.
192. Zhou, N., et al., BMP2 induces chondrogenic differentiation, osteogenic differentiation and endochondral 
ossification in stem cells. Cell Tissue Res, 2016.
193. Blaney Davidson, E.N., et al., Inducible chondrocyte-specific overexpression of BMP2 in young mice results in 
severe aggravation of osteophyte formation in experimental OA without altering cartilage damage. Ann Rheum 
Dis, 2015. 74(6): p. 1257-64.
194. Kaneko, K., et al., Hyaluronan inhibits BMP-induced osteoblast differentiation. FEBS Lett, 2015. 589(4): p. 447-
54.
195. Klammert, U., et al., GDF-5 can act as a context-dependent BMP-2 antagonist. BMC Biol, 2015. 13: p. 77.
196. Chang, S.C., et al., Cartilage-derived morphogenetic proteins. New members of the transforming growth factor-
beta superfamily predominantly expressed in long bones during human embryonic development. J Biol Chem, 
1994. 269(45): p. 28227-34.
197. Erlacher, L., et al., Presence of cartilage-derived morphogenetic proteins in articular cartilage and enhancement 
of matrix replacement in vitro. Arthritis Rheum, 1998. 41(2): p. 263-73.
198. Bobacz, K., et al., Cartilage-derived morphogenetic protein-1 and -2 are endogenously expressed in healthy 
and osteoarthritic human articular chondrocytes and stimulate matrix synthesis. Osteoarthritis Cartilage, 2002. 
10(5): p. 394-401.
199. Chubinskaya, S., et al., Human articular chondrocytes express osteogenic protein-1. J Histochem Cytochem, 
2000. 48(2): p. 239-50.
200. Chubinskaya, S., et al., Age-related changes in cartilage endogenous osteogenic protein-1 (OP-1). Biochim 
Biophys Acta, 2002. 1588(2): p. 126-34.
201. Loeser, R.F., et al., Methylation of the OP-1 promoter: potential role in the age-related decline in OP-1 expression 
in cartilage. Osteoarthritis Cartilage, 2009. 17(4): p. 513-7.
202. Muehleman, C., et al., Immunohistochemical localization of osteogenetic protein (OP-1) and its receptors in 
rabbit articular cartilage. J Histochem Cytochem, 2002. 50(10): p. 1341-50.
203. Merrihew, C., et al., Alterations in endogenous osteogenic protein-1 with degeneration of human articular 
cartilage. J Orthop Res, 2003. 21(5): p. 899-907.
204. Merrihew, C., et al., Modulation of endogenous osteogenic protein-1 (OP-1) by interleukin-1 in adult human 
articular cartilage. J Bone Joint Surg Am, 2003. 85-A Suppl 3: p. 67-74.
205. Peterson, R.S., et al., CD44 modulates Smad1 activation in the BMP-7 signaling pathway. J Cell Biol, 2004. 
166(7): p. 1081-91.
206. Andhare, R.A., et al., Hyaluronan promotes the chondrocyte response to BMP-7. Osteoarthritis Cartilage, 2009. 
17(7): p. 906-16.
207. Luo, N., et al., CD44 and hyaluronan promote the bone morphogenetic protein 7 signaling response in murine 
chondrocytes. Arthritis Rheumatol, 2014. 66(6): p. 1547-58.
208. Loeser, R.F., et al., Aging and oxidative stress reduce the response of human articular chondrocytes to insulin-like 
growth factor 1 and osteogenic protein 1. Arthritis Rheumatol, 2014. 66(8): p. 2201-9.
CHAPTER 1
48
209. Flechtenmacher, J., et al., Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis 
of cartilage proteoglycans and collagens by human articular chondrocytes. Arthritis Rheum, 1996. 39(11): p. 
1896-904.
210. Soder, S., et al., Antisense inhibition of osteogenic protein 1 disturbs human articular cartilage integrity. Arthritis 
Rheum, 2005. 52(2): p. 468-78.
211. Nishida, Y., et al., Osteogenic protein 1 stimulates cells-associated matrix assembly by normal human articular 
chondrocytes: up-regulation of hyaluronan synthase, CD44, and aggrecan. Arthritis Rheum, 2000. 43(1): p. 206-
14.
212. Huch, K., et al., Effects of recombinant human osteogenic protein 1 on the production of proteoglycan, 
prostaglandin E2, and interleukin-1 receptor antagonist by human articular chondrocytes cultured in the 
presence of interleukin-1beta. Arthritis Rheum, 1997. 40(12): p. 2157-61.
213. Chubinskaya, S., et al., Effects induced by BMPS in cultures of human articular chondrocytes: comparative 
studies. Growth Factors, 2008. 26(5): p. 275-83.
214. Bobacz, K., et al., Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease in cartilage 
matrix synthesis is dependent on the presence of toll-like receptor 4 and antagonized by bone morphogenetic 
protein 7. Arthritis Rheum, 2007. 56(6): p. 1880-93.
215. Im, H.J., et al., Inhibitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment- 
and interleukin-1beta-stimulated matrix metalloproteinase-13 expression in human chondrocytes. J Biol Chem, 
2003. 278(28): p. 25386-94.
216. Elshaier, A.M., et al., Effect of interleukin-1beta on osteogenic protein 1-induced signaling in adult human 
articular chondrocytes. Arthritis Rheum, 2009. 60(1): p. 143-54.
217. Abula, K., et al., Elimination of BMP7 from the developing limb mesenchyme leads to articular cartilage 
degeneration and synovial inflammation with increased age. FEBS Lett, 2015. 589(11): p. 1240-8.
218. Hurtig, M., et al., BMP-7 protects against progression of cartilage degeneration after impact injury. J Orthop 
Res, 2009. 27(5): p. 602-11.
219. Badlani, N., et al., The protective effect of OP-1 on articular cartilage in the development of osteoarthritis. 
Osteoarthritis Cartilage, 2008. 16(5): p. 600-6.
220. Hayashi, M., et al., Weekly intra-articular injections of bone morphogenetic protein-7 inhibits osteoarthritis 
progression. Arthritis Res Ther, 2008. 10(5): p. R118.
221. Kuo, A.C., et al., Microfracture and bone morphogenetic protein 7 (BMP-7) synergistically stimulate articular 
cartilage repair. Osteoarthritis Cartilage, 2006. 14(11): p. 1126-35.
222. Spiro, A.S., et al., BMP-7-induced ectopic bone formation and fracture healing is impaired by systemic NSAID 
application in C57BL/6-mice. J Orthop Res, 2010. 28(6): p. 785-91.
223. Hunter, D.J., et al., Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC 
Musculoskelet Disord, 2010. 11: p. 232.
224. Chen, P., et al., Bovine articular chondrocytes do not undergo hypertrophy when cultured in the presence of 
serum and osteogenic protein-1. Biochem Biophys Res Commun, 1993. 197(3): p. 1253-9.
225. Caron, M.M., et al., Hypertrophic differentiation during chondrogenic differentiation of progenitor cells is 
stimulated by BMP-2 but suppressed by BMP-7. Osteoarthritis Cartilage, 2013. 21(4): p. 604-13.
226. Haaijman, A., et al., OP-1 (BMP-7) affects mRNA expression of type I, II, X collagen, and matrix Gla protein in 
ossifying long bones in vitro. J Bone Miner Res, 1997. 12(11): p. 1815-23.
227. Caron, M.M., et al., BAPX-1/NKX-3.2 acts as a chondrocyte hypertrophy molecular switch in osteoarthritis. 
Arthritis Rheumatol, 2015. 67(11): p. 2944-56.
228. Erlacher, L., et al., Cartilage-derived morphogenetic proteins and osteogenic protein-1 differentially regulate 
osteogenesis. J Bone Miner Res, 1998. 13(3): p. 383-92.
General introduction
49
1
229. Chen, P., et al., Osteogenic protein-1 promotes growth and maturation of chick sternal chondrocytes in serum-
free cultures. J Cell Sci, 1995. 108 ( Pt 1): p. 105-14.
230. Mitsugi, S., et al., Mechanisms involved in inhibition of chondrogenesis by activin-A. Biochem Biophys Res 
Commun, 2012. 420(2): p. 380-4.
231. Hermansson, M., et al., Proteomic analysis of articular cartilage shows increased type II collagen synthesis in 
osteoarthritis and expression of inhibin betaA (activin A), a regulatory molecule for chondrocytes. J Biol Chem, 
2004. 279(42): p. 43514-21.
232. Alexander, S., et al., Activin A is an anticatabolic autocrine cytokine in articular cartilage whose production is 
controlled by fibroblast growth factor 2 and NF-kappaB. Arthritis Rheum, 2007. 56(11): p. 3715-25.
233. Tardif, G., et al., Differential gene expression and regulation of the bone morphogenetic protein antagonists 
follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis 
Rheum, 2004. 50(8): p. 2521-30.
234. Tardif, G., et al., The BMP antagonists follistatin and gremlin in normal and early osteoarthritic cartilage: an 
immunohistochemical study. Osteoarthritis Cartilage, 2009. 17(2): p. 263-70.
235. Luyten, F.P., et al., Recombinant bone morphogenetic protein-4, transforming growth factor-beta 1, and activin 
A enhance the cartilage phenotype of articular chondrocytes in vitro. Exp Cell Res, 1994. 210(2): p. 224-9.
236. Bidart, M., et al., BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed 
to its prodomain. Cell Mol Life Sci, 2011.
237. Blunk, T., et al., Bone morphogenetic protein 9: A potent modulator of cartilage development in vitro. Growth 
Factors, 2003. 21(2): p. 71-77.
238. Luu, H.H., et al., Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal 
stem cells. J Orthop Res, 2007. 25(5): p. 665-77.
239. Jiang, Y., et al., The inductive effect of bone morphogenetic protein-4 on chondral-lineage differentiation and in 
situ cartilage repair. Tissue Eng Part A, 2010. 16(5): p. 1621-32.
240. Scharstuhl, A., et al., Adenoviral overexpression of Smad-7 and Smad-6 differentially regulates TGF-beta-
mediated chondrocyte proliferation and proteoglycan synthesis. Osteoarthritis Cartilage, 2003. 11(11): p. 773-
82.
241. Bobacz, K., et al., Expression of bone morphogenetic protein 6 in healthy and osteoarthritic human articular 
chondrocytes and stimulation of matrix synthesis in vitro. Arthritis Rheum, 2003. 48(9): p. 2501-8.
242. Nilsson, O., et al., Gradients in bone morphogenetic protein-related gene expression across the growth plate. J 
Endocrinol, 2007. 193(1): p. 75-84.
243. Ito, H., et al., Bone morphogenetic protein-6 and parathyroid hormone-related protein coordinately regulate the 
hypertrophic conversion in mouse clonal chondrogenic EC cells, ATDC5. Biochim Biophys Acta, 1999. 1451(2-3): 
p. 263-70.
244. Miyamoto, Y., et al., A functional polymorphism in the 5’ UTR of GDF5 is associated with susceptibility to 
osteoarthritis. Nat Genet, 2007. 39(4): p. 529-33.
245. Ratnayake, M., et al., Human chondrocytes respond discordantly to the protein encoded by the osteoarthritis 
susceptibility gene GDF5. PLoS One, 2014. 9(1): p. e86590.

2.
Unloading results in rapid loss of TGFβ signaling 
in articular cartilage: role of loading-induced TGFβ signaling in 
maintenance of articular chondrocyte phenotype?
Madej W & van Caam A, Blaney Davidson E, Buma P, van der Kraan PM.
Osteoarthritis Cartilage. 2016 Oct;24(10):1807-15
CHAPTER 2
52
Abstract
Objective
Recently it was shown that loading of articular cartilage explants activates TGFβ signaling. 
Here we investigated if in vivo chondrocytes express permanently high TGFβ signaling, and 
the consequence of the loss of compressive loading-mediated TGFβ signaling on chondrocyte 
function and phenotype.
Method
Bovine articular cartilage explants were collected within 10 min post mortem and stained 
immediately and after 30, 60 and 360 min for phosphorylated-Smad2, indicating active 
TGFβ signaling. Explants were unloaded for 48 h and subsequently repeatedly loaded with 
a compressive load of 3 MPa. In addition, explants were cultured unloaded for 2 weeks and 
the effect of loading or exogenous TGFβ on proteoglycan level and chondrocyte phenotype 
(Col10a1 mRNA expression) was analyzed.
Results
Unloading of articular cartilage results in rapid loss of TGFβ signaling while subsequent 
compressive loading swiftly restored this. Loading and exogenous TGFβ enhanced expression 
of TGFβ1 and ALK5. Unloading of explants for 2 weeks resulted in proteoglycan loss and 
increased Col10a1 expression. Both loading and exogenous TGFβ inhibited elevated Col10a1 
expression but not proteoglycan loss.
Conclusion
Our data might imply that in vivo regular physiological loading of articular cartilage leads 
to enduring TGFβ signaling and TGFβ-induced gene expression. We propose a hypothetical 
model in which loading activates a self-perpetuating system that prevents hypertrophic 
differentiation of chondrocytes and is crucial for cartilage homeostasis.
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Introduction
Loading of articular cartilage is absolutely essential for its maintenance. Reduced joint 
loading leads to cartilage atrophy and degeneration, both in humans and animal models 
[1–5]. Patients with spinal cord injuries show progressive loss of knee cartilage at a pace 
faster than osteoarthritis (OA) patients [6,7]. In dogs it has been shown that joint motion in 
the absence of normal loading is not sufficient to prevent this cartilage loss [8]. Moreover, 
articular chondrocytes are mechanosensitive cells which has been clearly described in a 
number of excellent recent reviews [9–11]. However, the exact mechanism how unloading 
negatively affects articular cartilage homeostasis has not been elucidated yet.
 Transforming growth factor-β (TGFβ) is stored in high amounts (up to∼300 ng/g of 
all isoforms) in the articular cartilage matrix but in a latent form [12]. TGFβ signaling has been 
shown to be essential for the preservation of articular cartilage. Loss of the intracellular TGFβ 
signaling molecule Smad3 or functional loss of the TGFβ type II receptor in chondrocytes 
results in loss of articular cartilage in mice [13–15]. In humans, an inactivating mutation of 
Smad3 results in early onset of OA while a Smad3 polymorphism is associated with the total 
burden of radiographic OA [16–18].
 It has been shown that mechanical stimulation can activate TGFβ signaling in 
chondrocyte-like cells [19,20]. Recently, we described that compressive in vitro loading 
of bovine articular cartilage explants rapidly induces TGFβ signaling [21]. Based on these 
observations we hypothesized that under normal in vivo conditions articular cartilage is 
always subject to active TGFβ signaling and that loss of in vivo loading will result in loss of 
signaling. Remarkably, this has never been investigated yet. In this study it was investigated 
if TGFβ signaling was lost when articular cartilage was taken out of its natural environment 
and if the changes in TGFβ signaling could be reversed by in vitro compressive loading. 
Moreover, we studied the effect of prolonged unloading in vitro on proteoglycan content and 
chondrocyte phenotype, as measured by expression of Col10a1, and if induced changes could 
be prevented by loading or exogenously added TGFβ. Our data indicate that unloading results 
in rapid loss of TGFβ signaling and this might lead to changes in chondrocyte phenotype. 
Based on our observations a self-regulatory loading-driven model is proposed that keeps 
articular cartilage healthy, connecting compressive loading to cartilage homeostasis via TGFβ.
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Material and methods
For all performed experiments full cartilage thickness explants were harvested from bovine 
metacarpophalangeal joints (MCP) of skeletally mature cows (age- 4-5 years old) obtained 
from the local abattoir. 0.7 ± 0.12 mm thick explants were isolated with a 4 mm Ø biopsy 
punch (Kai-medical, Japan). All explants (if cultured) were cultured in standard culture 
conditions (37°C, 5% CO2 and 95% humidity) in DMEM/F-12 medium (Gibco®, UK) containing 
Antibiotic-Antimycotic (contains 10,000 units/mL of penicillin, 10,000 μg/mL of streptomycin, 
and 25 μg/mL of Fungizone®) (Gibco®, USA) unless stated differently. No serum was added to 
the medium unless stated differently.
Effect of unloading on TGFβ signaling in articular cartilage (Fig. 1A)
Bovine articular cartilage explants were harvested from the MCP joint of skeletally mature 
cows (age 3–5 years old). Joints were processed within 10 min post mortem (joint loading 
stopped). For immunohistochemical (IHC) analysis, explants (4 mm Ø) were fixed in 4% 
phosphate buffered formalin (pH 7.0) directly after isolation or first cultured for 30 min, 2 h, 
6 h or 24 h at standard culture conditions in DMEM/F-12 medium (Gibco®, UK). No serum 
was added to the medium.
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Fig. 1.  Schematic representation of experiments conducted in this study. (A) The effect of unloading on TGFβ 
signaling in articular cartilage was investigated by measuring Smad2P and Smad2/3P responsive genes on indicated 
time points. (B) Effect of repeated physiological mechanical compression on TGFβ signaling in articular cartilage was 
investigated by measuring Smad2P and Smad2/3P responsive genes on indicated time points before and 2 h and 
48 h after compression for multiple compressions. (C) Effect of loading on GAG content and Col10a1 expression was 
measured by culturing cartilage explants for 2 weeks ex vivo. Explants were compressed every 48 h the first week and 
hereafter either cultured for 1 week in serum free medium for Col10a1 or compressed again for GAG measurement.
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For gene expression analysis, explants were isolated within 3 h post mortem. One group of 
explants was flash frozen in liquid nitrogen immediately after opening. The remaining groups 
were placed in medium with or without the ALK4/5/7 kinase blocker SB-505124 (Sigma–
Aldrich, St. Louis, MO, USA)22 (5 μM) or vehicle control (0.5 μl/ml Dimethyl sulfoxide (DMSO)) 
for 24 or 48 h. This experiment was repeated in seven animals.
Effect of repeated physiological mechanical compression on TGFβ signaling in articular 
cartilage (Fig. 1B)
Five groups were used in this experiment (see Fig. 1B). Explants were harvested within 3 h 
post mortem. After 48 h of equilibration, the first group of explants was frozen, whereas the 
other groups of explants were subjected to 3 MPa dynamic mechanical compression for 30 
min with a frequency of 1 Hz [21] (Fig. 1B). At 2 h after the first compression, a second group 
of explants was frozen. The remaining groups of explants were again cultured for 48 h after 
which the third group of explants was frozen. At the same day the last two groups of explants 
were subjected to mechanical compression. Two hours after the second compression, the 
fourth group of explants was frozen and the fifth group was further cultured for 48 h and 
then frozen.
 The same experimental set up was repeated in the presence of SB-505124 (5 μM) 
or DMSO. The specimens were pre-incubated with SB-505124 (or DMSO) for 1 h prior to the 
compression to ensure penetration of the agent [21]. SB-505124 or DMSO was also present 
in the medium during and after dynamic mechanical compression. These experiments were 
repeated four times.
 To immunohistochemically investigate the induction of pSmad2 by mechanical 
compression after 48 h of equilibration, explants were stimulated with 3 MPa for 30 min with 
1 Hz. Then explants were fixed in 4% phosphate buffered formalin (pH 7.0) at 1 h after the 
compression. For the staining details see section: IHC Analysis.
Effect of loading on glycosaminoglycan (GAG) content and Col10a1 expression (Fig. 1C)
The first group of explants was isolated and flash frozen immediately after joint opening. After 
an equilibrium period of 48 h the medium of four other groups was changed for DMEM/F-12 
containing 10 % Fetal Bovine Serum, 20 ng/ml of rhIGF-1 (PeproTech, NJ, USA) or 10 ng/ml 
rhTGFβ1 (Biolegend, CA, USA) or combination of 20 ng/ml of rhIGF-1 + 10 ng/ml rhTGFβ1 
and refreshed every 72 h. An additional group of explants was subjected to mechanical 
compression every 48 h for 14 days. At day 14, explants from all groups were flash frozen and 
GAG content was measured using Dimethylmethylene Blue (DMB).
 To analyze if a lack of mechanical load on articular cartilage explants results in 
induction of Col10a1 a first group of explants was isolated and immediately frozen. Four 
other groups were cultured in unloaded condition for 14 days in DMEM/F-12 medium 
supplemented with 10 % FBS or 1 ng/ml rhTGFβ1 or 10 ng/ml rhTGFβ1 or 50 ng/ml of 
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Activin A (R&D Systems, MN, USA). To investigate if mechanical compression is able to 
inhibit non-loading induced induction of Col10a1 expression an extra group of explants was 
subjected to mechanical compression three times during the first week of the experiment 
(every 72 h). During the second week of the experiment, only medium was changed every 
72 h. This experiment was conducted 6 times.
Dynamic mechanical compression of articular cartilage explants
To compress cartilage, a BOSE® ElectroForce® BioDynamicTM bioreactor (5160 BioDynamic 
System) equipped with a 50 lbf load-cell was used (BOSE Bose Corp. ElectroForce Systems 
Group, MN, USA). First, a preset compression force of 5 N (0.3 MPa) was applied to guarantee 
contact between plates and specimen. Subsequently, explants were subjected to 3 MPa, force 
controlled, unconfined, dynamic mechanical compression using a 1 Hz sine wave and desired 
pressure for 30 min (1800 cycles). Unloaded controls were also placed in the bioreactor 
incubator but in a separate well.
Gene expression analysis
Samples were homogenized using a micro dismembrator (B. Braun Biotech International, 
Melsungen, Germany). Total RNA was isolated using RNeasy Fibrous tissue kits (Qiagen Inc., 
Valenzia, CA, USA) according to manufacturers protocol. Isolated RNA was transcribed into 
cDNA using M-MLV reverse transcriptase and single step RT-PCR: 5 min at 25°C, 60 min at 
39°C, and 5 min at 95°C. Gene expression was measured using 0.5 μM of validated primers 
(see Table I) (Biolegio, the Netherlands) in a quantitative real time polymerase chain reaction 
(qPCR) using SYBR green (Applied Biosystems, Darmstadt, Germany). A melting curve was 
made to verify gene specific amplification. Two reference genes were used: glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and ribosomal protein S14 (RPS14).
Immunohistochemical analysis
Samples were fixed overnight in phosphate buffered formalin, dehydrated and embedded in 
paraffin. Six μm thick sections were cut and mounted on Superfrost™ Plus Microscope Slides 
(Thermo Scientific, Waltham, USA). After deparaffinization, citrate buffer (0.1 M sodium citrate 
and 0.1 M citric acid) was used for 2 h at RT for antigen unmasking. Hydrogen peroxide 1% 
v/v in methanol was used for 30 min to block endogenous peroxidase. Afterwards, sections 
were incubated overnight at 4°C with specific primary antibodies against C-terminally 
phosphorylated Smad2P (rabbit pAb anti Phospho-Smad2 (Ser465/467) (1:100) (Cell 
Signalling Technology, Danvers, Massachusetts, USA). Biotin-labelled secondary antibodies 
were used (Dako, Glostrup, Denmark). Together with a biotin-streptavidin detection system 
used according to the manufacturers’ protocol (Vector Laboratories, Baiklin Game, California, 
USA). Staining was visualized using dimethylaminoazobenzene (DAB) reagent23.
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Gene symbol Ref seq P (bp) E (%) Forward 5′ → 3′ Reverse 5′ → 3′
bAcan NM_173981.2 144 97.3 TGAAACCACCTCCACCTTCCATGA TCAAAGGCAGTGGTTGACTCTCCA
bAlk1 NM_001083479.1 109 99.5 ACAACACAGTGCTGCTCAGACA TGCTCGTGGTAGTGCGTGAT
bAlk5 NM_174621.2 75 94.1 CAGGACCACTGCAATAAAATAGAACTT TGCCAGTTCAACAGGACCAA
bCol10a1 NM_174634.1 74 92.2 CCATCCAACACCAAGACACAGT TGCTCTCCTCTCAGTGATACACCTT
bGapdh NM_001034034.2 90 100.5 CACCCACGGCAAGTTCAAC TCTCGCTCCTGGAAGATGGT
bPai1 NM_174137.2 55 99.1 CGAGCCAGGCGGACTTC TGCGACACGTACAGAAACTCTTGA
bRps14 NM_001077830.2 125 104.9 CATCACTGCCCTCCACATCA TTCCAATCCGCCCAATCTTCA
bSmad3 XM_010808930.1 88 103.8 CATCGAGCCCCAGAGCAATA GTGGTTCATCTGGTGGTCACT
bSmad7 NM_001192865.1 72 105.4 GGGCTTTCAGATTCCCAACTT CTCCCAGTATGCCACCACG
bTgfb1 NM_001166068.1 80 106.8 GGTGGAATACGGCAACAAAATCT GCTCGGACGTGTTGAAGAAC
bBmp2 NM_001099141.1 73 104.0 CGCAGCTTCCATCACGAA AGAAGAATCGCCGGGTTGTT
Table I. Template, efficiency and sequence of the primers used in this study. P is product size in basepairs (bp) and 
E is efficiency in percentage (%).
Spectrophotometric analysis
Cartilage explants were weighed and digested overnight at 60°C using papain (1 mg/ml papain, 
0.1 M sodium acetate, 10 mM l-cysteine hydrochloride and 50 mM ethylenediaminetetraacetic 
acid sodium salt, pH 6.0). After digestion, samples were centrifuged for 15 min at 15,000 RPM 
and supernatant was diluted 20 times in ultra pure water. 200 μl of the DMB solution was 
added to 40 μl of diluted digest, and absorbance at λ = 595 nm was measured immediately 
using a 96-well plate reader (Biorad, CA, USA).
Statistical analysis
All quantitative data analysis were expressed as a Tukey box blot with mean showed as “+” 
and outliers showed as “•”. All datasets were checked for normality using the Shapiro–Wilk’s 
test and then for equality of variances by Levene’s test.
 Linear mixed models with Bonferroni multiple comparison post tests were used 
to estimate the effect of time and treatment (+DMSO or + SB-505124) on gene expression 
levels. One way ANOVA with Fisher’s LSD post-test was used to estimate the effect of 
compression or the effect of lack of the compression on gene expression (LSD does not 
correct for multiple comparisons, however we compared only the effect of the compression 
on induction of the gene expression or the effect of lack of the compression on gene drop, no 
multiple comparisons were required). The same approach was used to estimate the effect of 
compression or lack of the compression and treatment (+DMSO or +SB-505124) on Smad7 
expression levels. One way ANOVA with Tukey’s post-test was used to estimate the effect of 
treatments on GAG content. The same approach was used to estimate the effect of treatments 
on bCol10a1 gene expression. Unpaired one tailed t-test was used to estimate the effect of 
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time on Pai1 expression levels. One way ANOVA with Tukey’s post-test was used to estimate 
the effect of addition of TGFβ1 or Activin A on Smad7, Pai1 and Tgfb1 expression levels. The 
same approach was used to estimate the effect of dynamic mechanical compression on the 
expression levels of Alk1.
All the analyses were performed with the statistical software packages: SPSS 20.0 (SPSS, 
Chicago, USA).
Results
Unloading results in loss of TGFβ signaling
To investigate if unloading results in loss of TGFβ signaling, articular cartilage was obtained 
within 10 min post mortem from the MCP joint of mature cows and fixed immediately or after 
in vitro incubation. At the earliest time points, the majority of chondrocytes clearly stained 
positive for active TGFβ signaling (phosphorylated-Smad2, Smad2P) throughout all zones 
of the articular cartilage (Fig. 2A). However, already after 2 h of unloaded culture, cells in 
middle zone of the cartilage had lost staining which was even more pronounced after 6 h. At 
6 and 24 h only very few cells stained positive for Smad2P. To ensure that this loss in Smad2P 
staining was not a cutting artifact we left intact MCP joints unopened for 6 h or overnight 
and thereafter isolated the cartilage. After 6 h, cartilage had highly reduced Smad2P staining. 
Moreover, cartilage stored overnight showed significantly reduced Pai1 (a marker for active 
TGFβ signaling) expression when compared to fresh tissue (Supplementary Fig. 2). 
To determine whether this rapid drop in Smad2/3 signaling was reflected in TGFβ signaling-
dependent gene expression, expression of the known ALK5/Smad3 responsive genes Smad7 
[24], Pai1 [25] and Alk5 (also known as Tgfbr1)[26] was assessed. Expression of all three 
genes was significantly reduced after 24 h and further lowered after 48 h (Fig. 2B). Addition 
of the ALK4/5/7 blocker SB-505124 which blocks TGFβ signaling did not result in a more 
severe loss of gene expression, indicating that no residual TGFβ signaling was present in 
the unloaded, cultured cartilage and that absence of loading has similar effects as actively 
blocking Smad2/3 signaling (Fig. 2C). Notably, a decrease in gene expression is not a general 
phenomenon in unloaded cartilage, as the expression levels of for example Acan (aggrecan) 
and Smad3 were maintained (Fig. 2D).
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Fig. 2. Loss of active Smad2/3 signaling in unloaded cartilage. (A) Phosphorylated Smad2 levels in adult cartilage 
after unloading, as detected by IHC. Representative individual shown. (B) Relative gene expression of the TGFβ-
responsive genes: Alk5, Smad7 and Pai1 24 h and 48 h after unloading compared to fresh samples. Tukey box plot, 
+ = mean, N = 7, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (C) The effect of the ALK4/5/7 blocker SB-505124 on relative 
gene expression of Alk5, Smad7 and Pai1 24 h and 48 h after unloading, compared to fresh samples. DMSO was 
used as vehicle control. Tukey box plot, + = mean, N = 7, N.S. = not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
(D) Relative gene expression of Aggrecan or Smad3 24 h and 48 h after unloading. Tukey box plot, + = mean, N = 7.
Reloading repeatedly induces TGFβ signaling
Next, we evaluated if compressive reloading could restore Smad2P signaling and TGFβ-
dependent gene expression and if this was a repeatable process. Therefore explants were 
loaded 48 h after isolation and again 48 h after the first in vitro loading. Compressive loading 
rapidly induced Smad2P staining in cartilage explants (Fig. 3A).
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Fig. 3. Repeatable restoration of active Smad2/3 signaling by dynamic mechanical compression. (A) Induction of 
Smad2 phosphorylation by dynamic mechanical compression (3 MPa) of adult articular cartilage, as detected by IHC. 
(B) Relative gene expression of the TGFβ-responsive genes: Alk5, Smad7 and Pai in response to repeated dynamic 
mechanical compression and unloading. Tukey box plot, + = mean, N = 4, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n.d. = 
not detected. (C) Relative gene expression of Smad7 in response to repeated dynamic mechanical compression and 
unloading in the presence of the ALK4/5/7 inhibitor; SB-505124. DMSO was used as vehicle control. Tukey box plot, 
N = 4, + = mean, N.S. = not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (D) Scheme reflecting the effects of 
dynamic compression on TGFβ-signaling in the absence or presence of SB-505124. (E) Relative gene expression 
of Alk1 in (repeatedly) dynamically compressed (3 MPa) cartilage compared to unloaded controls 48 h after 
compression. Tukey box plot, + = mean, N = 8, ***P ≤ 0.001.
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Two hours after the first 30 min of loading, gene expression of Alk5, Smad7 and Pai1 was 
significantly induced, indicating that loading restores TGFβ signaling (Fig. 3B). Strikingly, 48 h 
after the first in vitro loading gene expression had dropped again to unloaded levels. Two 
hours after a second loading for 30 min, again gene expression of Smad7 and Pai1 was 
strongly elevated. We could confirm our earlier observations [21] that the loading-induced 
expression of Smad7 can be fully blocked by the ALK4/5/7 inhibitor SB-505124 (Fig. 3C), 
indicating that compression-induced Smad7 expression indeed runs via active Smad2/3P.
 Notably, SB-505124 did not inhibit all compression-induced gene expression. For 
example, a loading-induced ∼4-fold increase in Bmp2 expression (Supplementary Fig. 3) was 
unaffected. Because Bmp2 expression was also not responsive to exogenously added TGFβ, 
regulation of this gene is most likely TGFβ-independent. This observation thus shows that SB-
505124 does not affect compression-induced gene expression that is induced independently 
of TGFβ. In Fig. 2D a schematic representation of the effects of loading and unloading is 
depicted showing the repeated mechano-responsiveness of TGFβ signaling in cartilage. 
Finally, we were also able to confirm our earlier observations that loading reduces ALK1 
expression (Fig. 2E) [21].
 As a possible source for the observed induction of Smad2/3P we investigated two 
ligands capable of inducing these Smads: TGFβ and Activin-A. Incubation of bovine explants 
with exogenously added TGFβ resulted in comparable up-regulation of gene expression as 
induced by compressive loading, in contrast to Activin-A, which did not induce expression of 
either Alk5, Smad7 or Pai1 although it was bioactive (Supplementary Fig. 4).
Loading-induced TGFβ signaling blocks chondrocyte hypertrophy
Subsequently, the potential physiological relevance of the loading-induced TGFβ signaling was 
investigated. We postulated that TGFβ signaling either sustains the proteoglycan (aggrecan) 
content of cartilage or blocks hypertrophic differentiation of chondrocytes or both. Culturing 
bovine explants for 2 weeks resulted in a significant loss of glycosaminoglycans (GAGs) 
(nearly 60%) from the extracellular matrix (ECM). Compressive loading was totally ineffective 
to prevent this loss (Fig. 4A). In contrast, this GAG loss could be prevented by addition of 10% 
fetal calf serum or 20 ng/ml Insulin-like Growth Factor-1 (IGF1) to the medium. However, 
addition of 10 ng/ml TGFβ was completely ineffective and even lowered IGF1 effects on GAG 
content (Fig. 4B). We conclude that it is unlikely that TGFβ plays a direct role in maintenance 
of GAG content in articular cartilage.
 Apart from GAG loss, culturing of bovine explants in the absence of loading resulted 
in strongly increased expression of Col10a1, an accepted marker for early hypertrophic 
differentiation of chondrocytes [27]. The increase in Col10a1 expression was not affected 
by addition of 10% fetal calf serum, underling that serum factors are not able to inhibit 
hypertrophic differentiation of articular chondrocytes (Fig. 4C). In contrast, addition of 1 ng/ml 
TGFβ fully blocked induction of Col10a1 gene expression. Of note, addition of 10 ng/ml Activin 
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did not affect the increase in Col10a1 expression. When we investigated whether compressive 
loading inhibited the up-regulation of Col10a1 expression, loading for 30 min at time point 
48, 96 and 144 h after isolation significantly prevented the up-regulation of Col10a1 in bovine 
explants measured after 2 weeks (Fig. 4D). Unfortunately, in this experimental setting, a 14 
day culture period, we were unable to include the inhibitor SB-505124 because addition 
of this compound for such a long period resulted in significantly decreased cell viability in 
the cartilage explants (Supplementary Fig. 5), making us unable to show the importance of 
Smad2/3P in this process.
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Fig. 4. Dynamic mechanical compression protects against chondrocyte hypertrophy. (A) The sulfated GAG content 
(w/w) of adult articular cartilage, cultured for 2 weeks ex vivo either with or without 10% FCS, 10 ng/ml TGFβ1 or 
subjected to dynamic mechanical compression (3 MPa). Tukey box plot, + = mean, N = 8, ***P ≤ 0.001. (B) GAG 
content (w/w) of articular cartilage cultured for 2 weeks ex vivo in serum free medium, or in the presence of either: 
10% FCS, 20 ng/ml IGF1, 10 ng/ml TGFβ1, or a combination of IGF1 and TGFβ1. Tukey box plot, N = 9, *P ≤ 0.05, 
***P ≤ 0.001. (C) Expression of the hypertrophy marker Col10a1 after 2 weeks ex vivo culture in serum free medium 
or in the presence of 10% FCS, 1 or 10 ng/ml TGFβ1, or 50 ng/ml Activin A. Tukey box plot, + = mean, N = 4 (for Activin 
A, N = 2), ***P ≤ 0.001. (D) The effect of repeated dynamic mechanical compression (3 MPa) on Col10a1 expression 
after 2 weeks ex vivo culture. Tukey box plot, + = mean, N = 6. **P ≤ 0.01, ***P ≤ 0.001.
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Discussion
This study is the first to demonstrate that removal of articular cartilage from in its in vivo 
situation results in rapid loss of TGFβ signaling and that subsequent compressive loading can 
repeatedly restore this signaling. This suggests that the absence of loading will result in the 
loss of TGFβ signaling in articular cartilage. The consequence of this is reduced expression 
of TGFβ1 and the TGFβ type 1 receptor ALK5, together with increased expression of ALK1 
[21]. Moreover, prolonged unloading leads to proteoglycan loss and change in chondrocyte 
phenotype, as determined by increased Col10a1 expression. However, compressive loading 
or addition of exogenous TGFβ prevent the increase in Col10a1 expression but not of 
proteoglycan loss.
 Our data demonstrate the repeated mechano-responsiveness of TGFβ signaling in 
cartilage, which shows rapid activation upon compression and inactivation upon unloading, 
we propose the following hypothetical model for this loss and activation of TGFβ signaling 
by compressive mechanical loading: Articular cartilage contains high amounts of TGFβ (up to 
300 ng/g [12]), but inactive and bound to the latency-associated peptide (LAP) and ECM. LAP 
forms a so-called straitjacket that keeps the mature form of TGFβ1 associated with LAP, but 
unfolding of LAP by mechanical force (40 pN) can release active TGFβ [28,29]. Mechanical 
force (compressive loading) is thus able to release active TGFβ, and this has been shown 
in multiple systems [30,31]. However, upon unloading, all active TGFβ is sequestered again 
to the abundant binding places in the ECM [32], inactivating it again. Although no tools are 
available yet to investigate this mechanism in situ in intact articular cartilage, we propose that 
such a mechanism explains the repeated mechanosensitivity of TGFβ in cartilage. 
 We hypothesize that this loading-released TGFβ will bind to its receptors, but will 
also rapidly bind the ECM becoming unavailable again [32]. In the absence of mechanical 
force TGFβ signaling will rapidly diminish. The loading-induced TGFβ signaling will induce 
synthesis of TGFβ1 [33], but in an inactive form that will be bound to the ECM. Moreover, 
expression of ALK5 will be up-regulated whereas expression of ALK1 will be down-regulated, 
favoring TGFβ-dependent Smad2/3 signaling and decreasing Smad1/5/8 signaling (Fig. 5). 
Chondrocyte terminal differentiation is stimulated by Smad1/5/8 activation and inhibited by 
Smad2/3 [34]. This is in line with our current observation that regular loading appears to 
prevent early hypertrophic differentiation of chondrocytes. 
 Other factors than TGFβ will undoubtedly play a role in the mechanical regulation of 
articular cartilage and several mechanosensitive actors have been identified in chondrocytes 
[9]. For instance, compressive loading can induce BMP2 expression in cartilage [23]. Our 
current study shows that loading and exogenous TGFβ can block hypertrophic differentiation 
of chondrocytes, as measured by Col10a1 mRNA expression, but is not able to block 
proteoglycan loss in vitro. In vivo, proteoglycan synthesis will be maintained by systemic levels 
of IGF-I and BMP9 and by (load-induced) factors such as BMP2 [35–37]. The observation that 
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the biological consequence of the loading/TGFβ driven process is not the direct maintenance 
of proteoglycan content might appear to be in contrast with the study of Morales et al.. 
However, in that study cartilage of 6 months old calves was used, where growth still takes 
place, while cartilage from skeletally mature cows was used in our study [38]. Both TGFβ and 
compressive loading inhibited the up-regulation of the early hypertrophy marker Col10a1, 
suggesting that loading-induced TGFβ signaling blocks hypertrophic differentiation of 
chondrocytes in articular cartilage. Unfortunately we were not able to use SB-505124 in our 
long term cultures but in our short term cultures we could show that loading-induced TGFβ 
signaling can be blocked by this inhibitor, in line with our previous work [21]. Our results 
are in line with earlier observations that TGFβ, via the Smad2/3 signaling route, is a potent 
inhibitor of chondrocyte hypertrophy [13,39,40]. Importantly, our results seem to indicate 
that loading and cartilage homeostasis are interconnected via TGFβ signaling.
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Fig. 5. Proposed hypothetical model for compression-mediated protection of articular cartilage integrity. Compression 
of articular cartilage leads to release of active TGFβ from the ECM. This active TGFβ signals via ALK5, resulting 
in phosphorylation of Smad2/3. Subsequently, phosphorylated Smad2/3 inhibits hypertrophic differentiation of 
articular chondrocytes, as characterized by Col10a1. Additionally, phosphorylated Smad2/3 activates a positive 
feedback loop by not only inducing expression of ALK5 and lowering expression of ALK1, but also by inducing the 
expression of inactive TGFβ1, which after production will bind to the ECM, returning the system to its original state.
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Our study has a number of limitations. We used expression of Col10a1 as a marker for 
changes in chondrocyte phenotype in the direction of hypertrophy. Because we had to 
perform our cultures without fetal calf serum, to prevent continuous presence of TGFβ, we 
were not able to perform our in vitro cartilage cultures endlessly. This made it impossible to 
demonstrate the induction of late hypertrophic markers, such as MMP13. However, although 
we only demonstrated elevated mRNA expression in the time span studied, we still think that 
our results indicate a phenotypic shift towards hypertrophy since this is supported by other 
studies that show that loss of TGFβ signaling results in chondrocyte hypertrophy [13,15,17].
 Another limitation is our loading regime. We use simple compressive loading as a 
simplified model for the mechanical forces acting in vivo on articular cartilage. The loading 
protocol we used results in a permanent deformation during the 30 min loading cycle of 
approximately 10% [23]. The force we used is in a physiological range (3 Mpa) but the loading 
itself will be quite different from in vivo loading. In addition, there are regions in articular 
cartilage which are considered non-load bearing in vivo. In our concept, it should be expected 
that these areas deteriorate. However, it can be argued if truly non-load bearing articular 
cartilage exists in joints. Furthermore, these locations might experience high shear stress, 
which has also been shown to be able to activate TGFβ [31]. Moreover, our data indicate that 
short physiological compressive loading once every day will be sufficient to maintain TGFβ-
induced gene expression. Infrequent compressive loading might be experienced by this so-
called “non-loaded” cartilage but still be sufficient to maintain homeostasis.
 Finally, a considerable limitation is the lack of absolute proof that the observed 
processes run via TGFβ. SB-505124 gives an indication that an ALK4/5/7 ligand is important, 
but we were limited in its use due to its toxic long term effects. Unfortunately, no tools are 
currently available to investigate our proposed hypothesis more deeply in situ. Ideally we 
would knock out the TGFβ type II receptor TGFBR2 [41] to show the importance of TGFβ 
in our proposed model, but we have been unable to target chondrocytes in situ with the 
currently available tools to manipulate gene expression.
 Absence of loading results in cartilage loss. Chondrocyte hypertrophy is associated 
with cartilage degradation and proteoglycan loss [42]. Our finding of early hypertrophic 
differentiation of chondrocytes in the absence of loading-induced TGFβ signaling might 
provide an explanation for the loss of articular cartilage that is observed after long term 
cartilage unloading. Increased numbers of hypertrophic chondrocytes and expression of matrix 
degrading enzymes have been described in articular cartilage of rats after immobilization 
[4,5], which is in line with our hypothetical model. This model, in the light of our observation 
that mechanically-induced activation of TGFβ signaling is impaired in aged cartilage [23], 
could be involved in the age-dependency of OA. If the hypothetical model we propose is 
valid, age-related loss of this loading-induced mechanism will make articular cartilage more 
prone to hypertrophic changes of articular chondrocytes and OA development. Furthermore, 
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this suggests that unraveling the exact molecular mechanism underlying this system could 
provide tools to interfere with OA development and or progression.
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Supplementary figure 1
Fresh 30 min 2 h 6 h 24 h
100 μm
H
em
at
ox
yl
in
Supplementary figure 2
A
-12
-10
-8
-6
-4
-2
R
el
at
iv
e 
P
ai
1 
ex
pr
es
si
on
 (-
Δ
C
t)B
Fresh O/N
6 h after unloading
pSmad2 Hematoxylin
Supplementary figure 3
N.S.N.S.
Static Compressed TGFβ
5 ng/ml
-8
-6
-4
-2
DMSO
SB-505124
Re
la
tiv
e 
B
m
p2
 e
xp
re
ss
io
n 
(-
∆
C
t)
N.S.
N.S.
***
**p = 0.005
p < 0.001
***
p < 0.001
Supplementary Figure 1: Counterstaining of bovine cartilage explants. Hematoxylin staining of bovine cartilage 
explants as used in Fig. 1.
 i    
 
H
em
at
ox
yl
in
R
el
at
iv
e 
P
ai
1 
ex
pr
es
si
on
 (-
Δ
C
t)
/
  ft  l i
t li
. .. .
t ti
 / l
Re
la
tiv
e 
B
m
p2
 e
xp
re
ss
io
n 
(-
∆
C
t)
. .
. .
  .
  .   .
Supplementary Figure 2: Active TGFβ-signaling is lost in articular cartilage of intact MCP joints. (A) Phosphorylated 
Smad2 (left) and Hematoxylin (right) staining of cartilage explants isolated 6 h after unloading of the MCP joint. The 
MCP joint was left intact for the whole duration of this experiment. Arrows depict cells without pSmad2 staining. (B) 
Gene expression of Pai1 relative to the average expression of the reference genes: Gapdh and Rps14, in cartilage 
explants isolated rapidly after unloading or after an overnight (O/N) period. Tukey box plot, + = mean, N = 8, **P ≤ 0.01.
Supplementary Figure 3. Compression induces Bmp2 
expression but this is not affected by SB-505124. 
Relative gene expression of Bmp2 in dynamically 
compressed cartilage compared to unloaded controls 
2 h after compression in the presence of SB-505124 
(gray) or vehicle/DMSO (white). Additionally, explants 
were stimulated with 5 ng/ml TGFβ for 2 h but this did 
not significantly induce Bmp2 expression. Tukey box 
plot, + = mean, N = 5, ***P ≤ 0.001, n.s. = not significant.
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Supplementary Figure 4: rhActivin A does not induce Smad7, Pai1 or Tgfb1 expression in bovine cartilage explants. 
(A) Relative gene expression of Smad7, Pai1 and Tgfb1 in cartilage explants 24 h after stimulation with rhTGFβ1 or 
rhActivin A compared to unstimulated samples. Tukey box plot, + = mean, N = 4, ***P ≤ 0.001. (B) Relative gene 
expression of Smad7 and Pai1 5 h after stimulation of primary bovine chondrocytes with various doses of rhActivin A 
showing that the used rhActivin A is bioactive and compatible with bovine cells. Experimental duplo shown.
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Supplementary Figure 5: SB-505124 negatively affects chondrocyte viability in long term explants culture. Relative 
viability of cartilage explants after 2 weeks ex vivo culture in the presence of DMSO or 5 μM SB-505124 as measured 
by XTT assay according to manufacturers protocol (Roche Diagnostics GmbH, Germany). Tukey box plot, + = mean, 
N = 5, *P ≤ 0.05.
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Supplementary Materials and Methods
Dynamic mechanical compression of articular cartilage explants
Cartilage samples that were to be mechanically stimulated were placed into bioreactor 
chamber of a BOSE® ElectroForce® BioDynamicTM bioreactor (5160 BioDynamic System) 
equipped with a 50lbf load-cell (BOSE Bose Corp. ElectroForce Systems Group, MN, USA). 
The chamber was filled with 70 ml of DMEM/F12 medium. First, a preset compression force 
of 5 N (0.3 MPa) was applied which guaranteed contact between plates and specimen. 
Subsequently, explants were subjected to 3 MPa, force controlled, unconfined, dynamic 
mechanical compression using a 1 Hz sine wave and desired pressure. All compressions 
were performed for 30 min (1800 cycles). The compression procedure was performed in an 
incubator under standard culture conditions (37°C, 5% CO2 and 95% humidity). All explants 
that served as unloaded controls were also placed in the bioreactor incubator but in a separate 
well. After the compression procedure all the samples were placed back into a regular culture 
incubator. At desired time intervals samples were flash frozen in liquid nitrogen and stored 
at -80°C.
Gene expression analysis
First deep frozen articular cartilage samples were homogenized using a micro dismembrator 
(B. Braun Biotech International, Melsungen, Germany) at 1500 RPM for 1 minute. Total RNA 
was isolated from the homogenate using an RNeasy Mini Kit (Qiagen Inc., Valenzia, CA, USA). 
The homogenate was dissolved in RLT buffer containing 1 % (v/v) of 2-mercaptoethanol 
solution and transferred to 1.5 ml tubes. Subsequently, the capsules of microdismembrator 
were rinsed with 650 µl of ultra pure H2O. 10 µl of proteinase K (Qiagen Inc., Valenzia, CA, 
USA) was added and samples were incubated at 55°C for 10 min. Afterwards tubes were 
centrifuged for 3 min with 12 000 RPM and supernatant was transferred to a new tube. 
Thereafter, 450 µl of 100 % ethanol was added and samples were mixed. Samples were 
brought on RNAesy column and centrifuged for 1 min with 10 000 RPM. Flow was drained 
and column was washed first with RW1 buffer and then twice with RPE buffer, each time by 
centrifugation for 1 min with 10 000 RPM. Finally, RNA was eluted with 30 µl of ultra pure 
RNAse free H2O by centrifugation for 1 min with 10 000 RPM. Isolated mRNA was transcribed 
into cDNA using M-MLV reverse transcriptase. To perform the reverse transcriptase (RT) 
reaction; 1.9 μl ultra pure water, 2.4 μl 10 x DNAse buffer, 2.0 μl 0.1 M DTT, 0.8 μl 25 mM 
dNTP, 0.4 μg oligo dT primer, 1 μl 200 U/μl M-MLV reverse transcriptase (all Life Technologies, 
USA) and 0.5 μl 40 U/μl RNAsin (Promega, the Netherlands) was added, and samples were 
incubated for 5 min at 25 °C, 60 min at 39 °C, and 5 min at 95 °C using a thermocycler. 
The obtained cDNA was diluted 10x in ultra pure water, and gene expression was measured 
using 0.25 µM of validated cDNA-specific primers (see Table 1) (Biolegio, the Netherlands) 
in a quantitative real time polymerase chain reaction (qPCR) using SYBR green master mix 
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(Applied Biosystems, Darmstadt, Germany). The following protocol was used: after 10 min 
at 95 °C, 40 cycles of 15 sec 95 °C and 1 min 60 °C each were run. Hereafter a melting curve 
was made to verify gene specific amplification. For calculations of the -ΔCt, 2 reference genes 
were used: glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and ribosomal protein S14 
(RPS14).
All used primers are listed in Table 1.
Immunohistochemical analysis 
All samples for immunohistochemical staining were fixed overnight in 4% phosphate buffered 
formalin (pH 7.0) at 4° C. First the specimens were dehydrated in a tissue processing apparatus 
(Pathos, Milestone Medical Inc.) and embedded in paraffin. Later 6 µm thick sections were 
cut and mounted on SuperfrostTM Plus Microscope Slides (Thermo Scientific, Waltham, 
USA). Sections were deparaffinised and washed with phosphate-buffered saline (pH 7.0). 
For antigen unmasking, sections were incubated in citrate buffer (0.1 M sodium citrate and 
0.1 M citric acid) for 2 h at RT. Endogenous peroxidase was inhibited by incubation for 30 min 
in solution of 1% hydrogen peroxidase in methanol. Then, sections were blocked with 5% 
normal goat serum. Afterwards, sections and incubated overnight at 4°C with specific primary 
antibodies against C-terminally phosphorylated SMAD2P (rabbit pAb anti Phospho-Smad2 
(Ser465/467) (1:100) (Cell Signalling Technology, Danvers, Massachusetts, USA) [39, 40]. 
After washing with phosphate-buffered saline, sections were incubated for 30 min at room 
temperature with the biotin-labeled secondary antibody (Dako, Glostrup, Denmark). This 
was followed by a biotin–streptavidin detection system used according to the manufacturers’ 
protocol (Vector Laboratories, Baiklin Game, California, USA). Staining was visualized using 
dimethylaminoazobenzene (DAB) reagent, dehydrated and mounted with Permount (Fisher 
Chemicals, New Jersey, USA).
Spectrophotometric analysis of cartilage glycosaminoglycan content
First explants were thawed and any excessive liquid was removed. Then cartilage explants 
were weighed and subsequently digested overnight at 60°C with papain mixture (consisting 
of 1 mg/ml papain, 0.1 M sodium acetate, 10 mM L-cysteine hydrochloride and 50 mM 
ethylenediaminetetraacetic acid sodium salt, pH 6.0). After digestion, samples were 
centrifuged for 15 min at 15 000 RPM to get rid of residue. Next, the digest was diluted 
20 times in ultra pure water. Subsequently, 200 µl of the DMB solution (40 mM glycine, 
40 mM NaCl, 0.012 N HCl, 45 µM 1,9 dimethylmethylene blue, pH 3.0) was added to 40 µl 
of diluted digest, and sulphated glycosaminoglycan content was immediately determined by 
spectrophotometric analysis by measuring absorbance at λ = 595 nm using a 96-well plate 
reader (Biorad, CA, USA). Chondroitin sulfate type A (Sigma–Aldrich, St. Louis, MO, USA) from 
shark cartilage was used to create a standard curve [41].
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Cell viability analysis (XTT assay) 
Immediately before use, the XTT labeling reagent and electron-coupling reagent (both 
from Roche Diagnostics GmbH, Germany) were thawed in a waterbath (37°C). Later each 
component was mixed carefully to obtain clear solutions. Subsequently XTT labeling and 
electron coupling reagents were mixed in ratio 50:1 respectively. Afterwards, 100 µl of XTT 
labeling mixture was added to 96 well plate with articular cartilage explants (one 4 mm Ø 
explant per well) in 100 µl of non-phenol red DMEM/F12 medium (Gibco®, UK). Explants were 
incubated with XTT labeling mixture for up to 5 hours. At the 2 hours time point, a 100 µl of XTT 
mixture was aspirated and transferred to a separate 96 well plate. The spectrofotometrical 
absorbance of samples was measured by microplate reader under 480 nm wave length. The 
reference wavelength was 750 nm. After this measurement, the 100 µl was added back to 
the explants. To obtain a reliable estimate of XTT mixture conversion by metabolically active 
cells, measurements were repeated after 3, 4 and 5 hours. After subtraction of background 
XTT conversion, the area under the curve was calculated for each explant. Next DNA content 
of samples was measured (see below), and measured XTT activity was corrected for DNA 
content. Obtained values were used for statistical analysis. 
DNA content analysis with Quant-iTTM PicoGreen® dsDNA Assay Kit
First, articular cartilage explants (4 mm Ø) were digested overnight (O/N) at 60°C with papain 
mixture (consisted of 1 mg/ml papain, 0.1 M sodium acetate, 10 mM L-cysteine hydrochloride 
and 50 mM ethylenediaminetetraacetic acid sodium salt (pH 6.0)). After digestion samples 
were centrifuged for 15 min at 15 000 RPM and supernatant was used for measurement. 
Subsequently, 1 X TE (Tris-EDTA buffer) (Invitrogen, OR, USA) buffer was prepared. dsDNA 
standards (Invitrogen, OR, USA) were diluted in TE buffer to obtain dilution series from 
2000 ng/ml to 31.25 ng/ml for standard curve. Afterwards, articular cartilage digests of 
experimental samples were diluted in TE buffer in proportion 1:10. After transferring of all 
standards and experimental samples to 96 well plate in duplos, 100 µl of Quant-iT PicoGreen® 
reagent (200 X diluted in TE buffer) (Invitrogen, OR, USA) was added to 100 µl of sample or 
standard. Samples were mixed well and incubated for 2 to 5 minutes at room temperature, 
protected from light. Samples fluorescence was measured with fluorescence microplate 
reader (excitation 480 nm and emission 520 nm). To minimize the photobleaching effect the 
measurement times were constant for all samples. 
Statistical analysis
All quantitative data analysis were expressed as a Tukey box blot with mean showed as”+” 
and outliers showed as “•”. The sample size was always mentioned in the figure legend. First 
all datasets were checked for normality using the Shapiro-Wilk’s test and then for equality of 
variances by Levene’s test. 
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Linear mixed models with Bonferroni multiple comparison post tests were used to estimate 
the effect of time and treatment (+DMSO or +SB-505124) on gene expression levels. One 
way ANOVA with Fisher’s LSD post test was used to estimate the effect of compression or 
the effect of lack of the compression on gene expression (LSD does not correct for multiple 
comparisons, however we compared only the effect of the compression on induction of the 
gene expression or the effect of lack of the compression on gene drop, no multiple comparisons 
were required). The same approach was used to estimate the effect of compression or lack 
of the compression and treatment (+DMSO or +SB-505124) on Smad7 expression levels. One 
way ANOVA with Tukey’s post test was used to estimate the effect of treatments on GAG 
content. The same approach was used to estimate the effect of treatments on bCol10a1 gene 
expression. 
 Unpaired one tailed t-test was used to estimate the effect of time on Pai1 expression 
levels. One way ANOVA with Tukey’s post test was used to estimate the effect of addition of 
TGFβ1 or Activin A on Smad7, Pai1 and Tgfb1 expression levels. The same approach was used 
to estimate the effect of dynamic mechanical compression on the expression levels of Alk1. 
All the analyses were performed with the statistical software packages: SPSS 20.0 (SPSS, 
Chicago, USA).
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Abstract
Objective
Ageing is the main risk factor for osteoarthritis (OA). We investigated if expression of 
transforming growth factor β (TGFβ)-family components, a family which is crucial for the 
maintenance of healthy articular cartilage, is altered during ageing in cartilage. Moreover, we 
investigated the functional significance of selected age-related changes.
Design
Age-related changes in expression of TGFβ-family members were analysed by quantitative 
PCR in healthy articular cartilage obtained from 42 cows (age: ¾–10 years). To obtain 
functional insight of selected changes, cartilage explants were stimulated with TGFβ1 or bone 
morphogenetic protein (BMP) 9, and TGFβ1 and BMP response genes were measured.
Results
Age-related cartilage thinning and loss of collagen type 2a1 expression (∼256-fold) was 
observed, validating our data set for studying ageing in cartilage. Expression of the TGFβ-
family type I receptors; bAlk2, bAlk3, bAlk4 and bAlk5 dropped significantly with advancing 
age, whereas bAlk1 expression did not. Of the type II receptors, expression of bBmpr2 
decreased significantly. Type III receptor expression was unaffected by ageing. Expression of 
the ligands bTgfb1 and bGdf5 also decreased with age. In explants, an age-related decrease 
in TGFβ1-response was observed for the pSmad3-dependent gene bSerpine1 (P = 0.016). In 
contrast, ageing did not affect BMP9 signalling, an Alk1 ligand, as measured by expression of 
the pSmad1/5 dependent gene bId1.
Conclusions
Ageing negatively affects both the TGFβ-ALK5 and BMP-BMPR signalling routes, and aged 
chondrocytes display a lowered pSmad3-dependent response to TGFβ1. Because pSmad3 
signalling is essential for cartilage homeostasis, we propose that this change contributes to 
OA development.
Ageing is associated with reduction of mechanically-induced activation of Smad2/3P signaling in articular cartilage.
79
3
Introduction
Osteoarthritis (OA) is the world’s most common joint disease, and cartilage degradation is its 
main hallmark [1]. Eventually, OA leads to pain and disability, greatly affecting quality of life of 
patients. Many risk factors have been identified for OA including: obesity, female gender, and 
occupational risks, but its main risk factor is (old) age [2, 3]. To better understand why ageing 
is a risk factor for OA, research has centred on age–related changes in cartilage, as this is the 
main tissue affected by this pathology.
 During ageing, many changes accumulate in cartilage. On a macroscopic level, 
progressive thinning of the cartilage occurs, most prominently at load-bearing areas [4, 5, 6, 
7]. On a more detailed level, in the extracellular matrix (ECM), structure, size and expression 
of the essential structural proteoglycan aggrecan change during ageing [8]. Furthermore, 
age-related accumulation of advanced glycation end products (AGEs) occurs in collagen fibres 
[9, 10]. Together, these changes adversely affect the mechanical properties of the cartilage 
matrix, as they lead to a loss of water retaining capacity and matrix stiffening respectively. 
On a cellular level, up to 40% of chondrocytes are lost during ageing [11]. Possibly, this 
loss occurs because ageing chondrocytes produce less of and/or respond less to essential 
anabolic growth factors like insulin-like growth factor 1 (IGF1), fibroblast growth factor 2 
(FGF2), transforming growth factor β (TGFβ) and bone morphogenetic protein 7 (BMP7) [12, 
13, 14, 15].
 Both TGFβ and BMP7 belong to the TGFβ-family. Canonical signalling by members 
of this family induces receptor-regulated Smad (R-Smad) activation via phosphorylation, 
which is crucial for chondrocyte homeostasis [16]. Phosphorylated Smad3 (pSmad3) is 
chondroprotective and inhibits many processes deleterious for cartilage, including matrix 
metalloprotease 13 (MMP13) production and cellular hypertrophy [17, 18]. Phosphorylated 
Smad1/5 (pSmad1/5) is associated with ECM production, e.g., glycosaminoglycans and 
collagen type II expression, but, in contrast to pSmad3, also with MMP13 production and 
deleterious chondrocyte hypertrophy [16, 19].
 Previously, we have demonstrated in murine cartilage that TGFβ-family signalling is 
affected by ageing [13, 20, 21]. However, in these experiments in mice, ageing and OA were 
concomitant. Because OA chondrocytes are profoundly different from ageing chondrocytes, 
e.g., in anabolic activity [22, 23], and both processes possibly interfere, we wanted to 
further study cartilage ageing in a system in which we could observe age-related changes 
independently of an OA process. To achieve this, we investigated ageing in non-OA cartilage 
of the bovine metacarpophalangeal (MCP) joint. Bovine material can be obtained in a wide 
age range, and examination of the cartilage allows for inclusion of only healthy joints with an 
intact cartilage surface.
 In this study we investigated the impact of ageing on expression of receptors and 
ligands of the TGFβ-family. We were predominantly interested in expression of TGFβ and 
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bone morphogenetic protein (BMP) receptors, as especially little is known of the latter in the 
context of ageing. We show that in old cartilage the Smad2/3-inducing receptors bAcvr1b and 
bTgfbr1 are profoundly lower expressed than in young cartilage, just as the BMP-receptors 
bBmpr1 and bBmpr2. Furthermore, we show that reduction of Tgfbr1 expression is reflected 
in a reduced response to TGFβ1. Overall, we conclude that changes in TGFβ-family signalling 
occur before onset of OA symptoms but could predispose cartilage to this disease.
Materials and methods
Sample collection
Bovine MCP joints were obtained from a local abattoir within 3 h post mortem. Joints were 
opened and the cartilage surface was examined for signs of OA. Only joints showing an intact 
cartilage surface were included in this study. Subsequently, a ∼0.5 cm2 full thickness cartilage 
slice was obtained from the middle of the medial condyle adjacent to the intertrochlear notch 
of the metacarpal bone. This cartilage sample was shortly rinsed in saline and flash frozen in 
liquid nitrogen for later use. In total 42 female cows were included with ages ranging from 9 
months old up to 10 years old (see Supplementary Fig. 1).
Detection of gene expression
A ∼0.5 cm2 cartilage slice was homogenized using a Mikro-dismembrator (B.Braun, Germany) 
for 1 min at 1.5 × 103 RPM. Subsequently, RNA was isolated with a Fibrous tissue kit (Qiagen) 
according to manufacturers protocol. Next, 8 μl of sample was treated with 1 μl DNAse (Life 
Technologies, USA) for 10 min at room temperature to remove DNA contamination. Hereafter, 
DNAse was inactivated at 65°C with 1 μl 25 mM EDTA (Life Technologies, USA) for 10 min. To 
perform reverse transcriptase (RT) reaction; 1.9 μl ultra pure water, 2.4 μl 10× DNAse buffer, 
2.0 μl 0.1 M DTT, 0.8 μl 25 mM dNTP, 0.4 μg oligo dT primer, 1 μl 200 U/μl M-MLV RT (all 
Life Technologies, USA) and 0.5 μl 40 U/μl RNAsin (Promega, the Netherlands) was added, 
and samples were incubated for 5 min at 25°C, 60 min at 39°C, and 5 min at 95°C using a 
thermocycler. The obtained cDNA was diluted 10× in ultra pure water, and gene expression 
was measured using 0.25 μM of validated cDNA-specific primers (see Table 1) (Biolegio, the 
Netherlands) in a quantitative real time polymerase chain reaction (qPCR) using SYBR green 
master mix (Applied Biosystems, USA). The following protocol was used: after 10 min at 95°C, 
40 cycles of 15 s 95°C and 1 min 60°C each were run. A melting curve was made to verify gene 
specific amplification. For calculations of the −ΔCt, the average of the following four reference 
genes was used: bovine (b) glyceraldehyde 3-phosphate dehydrogenase (bGapdh), ribosomal 
protein S14 (bRps14), ribosomal protein L22 (bRpl22) and beta glucuronidase (bGusb). These 
reference genes correlate highly in our samples, showing that ageing does not affect their 
interrelation (see Supplementary Fig. 2).
Ageing is associated with reduction of mechanically-induced activation of Smad2/3P signaling in articular cartilage.
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Name NCBI ref seq Efficiency Forward (5’→3’) Reverse (5’→3’)
bGapdh NM_001034034.2 100,5 CACCCACGGCAAGTTCAAC TCTCGCTCCTGGAAGATGGT
bRpl22 XM_002694113.3 96,5 GTTCGCTCACCTCCCTTTCTG GCAGCATCCATGATTCCATCT
bGusb NM_001083436.1 104,5 CGAGGGGTCAACAAGCATGA CTGCAGCACCTCCTCTGAAT
bRps14 NM_001077830.2 104,9 CATCACTGCCCTCCACATCA TTCCAATCCGCCCAATCTTCA
bCollagen Type 2a1 NM_001001135.2 97,2 TGATCGAGTACCGGTCACAGAA CCATGGGTGCAATGTCAATG
bAcan NM_173981.2 97,3 TGAAACCACCTCCACCTTCCATGA TCAAAGGCAGTGGTTGACTCTCCA
bMgp NM_174707.3 100 CACCACAACAGAGATGGAGAGC ATAGCGTTCGCAAAGTTTGAAGT
bAcvrl1 (ALK1) NM_001083479.1 99,5 ACAACACAGTGCTGCTCAGACA TGCTCGTGGTAGTGCGTGAT
bAcvr1 (ALK2) NM_176663.3 104,8 CGTTGGAGACAGCACTTTAGCA AGAGCCGCTTCCCGATGTA
bBmpr1a (ALK3) NM_001076800.1 96,1 GAGCAAGATGAAGCATTTATTCCA CAACCTGCCGAACCATCTG
bAcvr1b (ALK4) XM_002687257.3 103,6 CCCAGCGGTCACCTCAAG TAATGACGAGGAAAACAATGATGAT
bTgfbr1 (ALK5) NM_174621.2 94,1 CAGGACCACTGCAATAAAATAGAACTT TGCCAGTTCAACAGGACCAA
bBmpr2 XM_002685492.2 94,3 TTCCACCTCCAGACACAACAC CTTGTTTGCGGTCTCCTGTCA
bTgfbr2 NM_001159566.1 117,8 GGCTGTCTGGAGGAAGAATGA GTCTCTCCGGACCCCTTTCT
bEng NM_001076397.1 98,5 GTCAGTAACGAGGTGGTCATCA GAAGTGTGGGCTGAGGTAGAG
bTgfbr3 XM_002686233.2 110,1 TGCAGAAGGGTGTGTGATGT CTGGAAAGCACTGTAGGGGTTA
bTgfb1 NM_001166068.1 106,8 GGTGGAATACGGCAACAAAATCT GCTCGGACGTGTTGAAGAAC
bTgfb2 NM_001113252.1 103,4 CCACCATAAAGACAGGAACCT TGGTATAGGTAGAGGTGCCATCA
bTgfb3 NM_001101183.1 101,4 ACTGTGCGTGAATGGCTCTT ATCGCTGTCCACACCTTTGA
bGdf5 NM_001192273.1 101,1 TTATTGACAAAGGGCAAGATGAC CCCCTAGTAGCCCATCCTTCT
bBmp2 NM_001099141.1 104,0 CGCAGCTTCCATCACGAA AGAAGAATCGCCGGGTTGTT
bBmp7 NM_001206015.1 98,0 GGCTTTTCCTACCCCTACAAG TGTCATGTTCCACGAGATTGA
bSmad7 NM_001192865.1 105,0 GGGCTTTCAGATTCCCAACTT CTCCCAGTATGCCACCACG
bPAI NM_174137.2 99,1 CGAGCCAGGCGGACTTC TGCGACACGTACAGAAACTCTTGA
bID1 NM_001097568.2 107 GCTCCGCTCAGCACTCTCAA GATCGTCCGCTGGAACACA
Table I. Template, efficiency and sequence of the primers used in this study
Immunohistochemistry (IHC) 
Samples were fixed overnight in phosphate buffered formalin (10%). Four animals were used 
per age-group. Hereafter, the samples were dehydrated in a tissue processing apparatus 
(Pathos, Milestone Medical Inc.) and embedded in paraffin. Six μm thick sections were cut 
and deparaffinised. Subsequently, IHC was performed: first, sections were treated with citrate 
buffer (0.1 M sodium citrate and 0.1 M citric acid) for 2 h at room temperature for antigen 
unmasking. Next, endogenous peroxidase was inactivated by incubation with 1% hydrogen 
peroxidase in methanol for 30 min. Then, sections were blocked with 5% normal rabbit 
serum. Afterwards, sections were incubated overnight at 4°C with goat polyclonal TGFβ RI 
Antibody (V-22) 1:200 (v/v) (sc-398-G Santa Cruz Biotechnology, USA) or goat polyclonal 
ALK-1 Antibody (D-20) 1:200 (v/v) (sc-19546 Santa Cruz Biotechnology, USA) [20]. Hereafter, 
sections were washed with PBS (pH 7.0) and incubated for 30 min with a biotin-labelled 
rabbit anti goat antibody (Dako, Glostrup, Denmark). Next streptavidin-linked horseradish 
peroxidase was added (Vector Laboratories, Baiklin Game, California, USA), and staining 
was visualised using dimethylaminoazobenzene. To quantify IHC, a 0-3 scoring was used 
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(½ values allowed) by a scorer using blinded sections (as recommended by [24]). A value 
of three represented strongest staining in contrast to a value of 0, which represented the 
weakest staining (see Supplementary Fig. 3). Four animals were used per age group, and per 
animal four sections were scored for each of the three cartilage zones: surface, middle and 
deep.
Ex vivo stimulation of explants
MCP joints were obtained from 22 animals aged 0.5 up to 11 years old and opened under 
aseptic conditions. With the use of a biopsy punch, ∼7 mm2 explants were made. Subsequently, 
these explants were incubated for 24 h in standard cell culture conditions in DMEM/F12 1:1 
(Gibco, USA) containing penicillin/streptomycin and pyruvate but no FCS. After 24 h, explants 
were stimulated with 1 ng/ml rhTGFβ1 or 5 ng/ml rhBMP9 (both R&D systems, USA) for 24 h. 
Per condition, four pooled explants were used, except for the unstimulated control for which 
two times four pooled explants were used. After stimulation, mRNA was isolated using the 
aforementioned protocol.
Statistics
Gene expression of individual animals is plotted with a solid line depicting the best fit 
regression analysis and 95% confidence interval (CI) as dotted line. For every analysis, data 
was checked for normality using the Shapiro–Wilk test. A Kruskal–Wallis test with Dunn’s 
multiple comparison post hoc test was used to analyse the scoring of IHC. All statistics were 
conducted using GraphPad Prism v 5.0.
Results
Bovine cartilage as a valid model for age-related changes in cartilage
To validate our bovine model and chosen age range (¾-10 years old) as a model for ageing 
cartilage, we first characterized well known markers of ageing cartilage in our data set. 
Macroscopically, with advancing age, thinning of the cartilage was observed and cartilage 
colour changed from purple towards yellow. Microscopically, aged cartilage showed decreased 
cellularity compared to young cartilage (for quantification of cell number and thickness see 
[25]), and a clear tidemark could be detected in old cartilage using a hematoxilin staining 
(Fig. 1A). Closer examination showed that this tidemark actually consisted out of multiple 
tidemarks (Fig. 1B). Furthermore, in young cartilage the osteochondral junction was less 
well defined, as shown by the close interaction of bone marrow and blood vessels with the 
cartilage, and absence of a tidemark. Moreover, the superficial zone of old cartilage looks 
irregular when looking at the lamina splendens as visualized by Safranin O/Fast green staining 
(Fig. 1A). On gene expression, a very profound ∼250-fold drop in bovine collagen type 2 
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alpha 1 (bCol2a1) expression was observed (P < 0.0001, R2 = 0.63) when comparing young vs 
old (Fig. 1C). In contrast, aggrecan (bAcan) expression did not drop extensively (∼2-fold) (P < 
0.01, R2 = 0.16), and expression of matrix gla protein (bMgp) was significantly (∼8 fold) higher 
in old cartilage vs young cartilage, showing that not of every gene expression decreases with 
ageing. Because these observations on macroscopic, microscopic and gene expression level 
reflect well known markers of ageing cartilage [4, 5, 7, 11, 26, 27], we concluded that our data 
set is a valid model for studying ageing processes in articular cartilage.Figure 1
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Fig. 1. Age-related changes in bovine cartilage. (A) Safranin O/Fast green and Hematoxilin/Eosin staining of articular 
cartilage obtained from a 2 years old (left) or 10 years old cow (right). Pictures are representative of three animals 
each. 100× Magnification, scale bar = 100 μm. Thickness and cellularity are reduced and a clear tidemark is visible 
(arrow) in 10 year old cartilage. Note that the surface is intact. (B) 800× Magnification, scale bar = 12.5 μm. Multiple 
tidemarks (stars) in healthy 10 year old cartilage. No tidemark is visible between non-calcified and calcified cartilage 
in 2 year old cartilage. (C) Relative gene expression of bovine collagen type 2 alpha 1 (bCol2a1), aggrecan (bAcan) 
and matrix Gla protein (bMgp) in ageing cartilage as determined by qPCR. Regression analysis (solid line) with 95% 
CI (dotted line) depicted. Expression of bCol2a1 decreases whereas expression of bMgp increases during ageing.
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Fig. 2. Age-related drop in TGFβ-family receptor expression in healthy cartilage. (A) Relative gene expression of the 
Smad1/5 phosphorylating receptors: activin A receptor like type 1 (bAcvrl1), activin A receptor type I(bAcvr1) and 
bone morphogenetic protein receptor type IA (bBmpr1a), in ageing cartilage as determined by qPCR. Regression 
analysis (solid line) with 95% CI (dotted line) depicted. Expression of bBmpr1a clearly decreases with advancing age. 
(B) Relative gene expression of the Smad2/3 phosphorylating receptors: transforming growth factor beta receptor I 
(bTgfbr1) and activin A receptor type IB (bAcvr1b) in ageing cartilage as determined by qPCR. Regression analysis 
(solid line) with 95% CI (dotted line) depicted. Expression of bTgfbr1 and bAcvr1b clearly decreases with age. (C) IHC 
of bAcvrl1 (left) and bTgfbr1 (right) in 1 year and 5 years old animals in the three zones of articular cartilage. Pictures 
are representative of four animals each. 1000× Magnification, scale bar = 10 μm. During ageing, bTgfbr1 expression 
decreases below the detection threshold and unstained cells start to appear (arrows). (D) Scoring of Acvrl1 and 
Tgfbr1 staining in the superficial, middle and deep zone of 1 and 5 year old bovine cartilage using a 0–3 scale (see 
Supplementary Fig. 3). Four animals were scored in quadruple for each group for each zone. Error bars represent 
95% CI. Statistics were calculated using a Kruskal–Wallis test; * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001.
Expression of TGFβ-family type I receptors during ageing
Previously we demonstrated decreased levels of phosphorylated Smad2 in aged murine 
cartilage compared to young [13] and linked this observation to altered expression of TGFβ-
family-type I receptors; the activin receptor-like kinase (ALK) receptors [13, 20]. Therefore, 
we first measured gene expression of the four Smad1/5 phosphorylating receptors: bAcvrl1 
(=ALK1), bAcvr1 (=ALK2), bBmpr1 (=ALK3) and bBmpr1b (=ALK6) (Fig. 2A). bAcvrl1 expression 
was unaffected by ageing. bAcvr1 expression did drop ∼3-fold but, in view of the relatively 
high p-value (P = 0.02, R2 = 0.13), not very convincingly. In contrast bBmpr1 expression 
clearly diminished ∼4-fold during ageing (P = 0.001, R2 = 0.24). bBmpr1b expression was 
not reliably detected, despite the use of multiple primer sets. Subsequently, we measured 
the three Smad2/3 phoshorylating receptors: bAcvr1b (=ALK4), bTgfbr1(=ALK5) and bAcvr1c 
(=ALK7) (Fig. 2B). Of these three receptors, expression of bAcvr1b and bTgfbr1 was readily 
detected. In contrast, we were unable to reliably detect bAcvr1c expression, again despite 
the use of multiple primer sets. Expression of both bAcvr1b and bTgfbr1 decreased ∼8-
fold and ∼4-fold respectively (P = 0.0009, R2 = 0.30 for bAcvr1b and P = 0.0004 R2 = 0.29 
for bTgfbr1) with advancing age. Next we validated part of this gene expression data by 
immunohistochemically staining the corresponding proteins (Fig. 2C) and quantifying this 
(Fig. 2D). bAcvrl1 and bTgfbr1 were selected to relate this study to our previous results 
obtained in mice [20]. Staining for bTgfbr1 clearly showed abundant positive cells in young 
animals, but with advancing age Tgfbr1 staining decreased in the superficial, middle and deep 
zone of the cartilage. This was in contrast with the bAcvrl1 staining, which was only reduced 
in the deep zone. Taken together, our data show a profound decrease in expression of the 
Smad2/3 phosphorylating receptors bAcvr1b and bTgfbr1 with advancing age, whereas of the 
Smad1/5 phosphorylating receptors bBmpr1 expression was clearly diminished but bAcvrl1 
expression was not. 
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Expression of TGFβ-family type II and type III receptors in ageing cartilage
Next to receptor type I expression, the presence of type II receptors is necessary for TGFβ-
family signalling and therefore we measured expression of these receptors [28]. Furthermore, 
because several ligands of the TGFβ-family can use multiple type I receptors (e.g., TGFβ1), 
we measured expression of the type III receptors Endoglin (bEng) and Betaglycan (bTgfrbr3) 
because these receptors can direct receptor choice of such a ligand (Fig. 3). With advancing 
age, gene expression of the type II receptor bBmpr2 clearly decreased ∼6-fold (P < 0.0001, 
R2 = 0.38) (Fig. 3). In contrast, bTgfbr2 expression was not significantly decreased with age (P 
= 0.0517, R2 = 0.10) (Fig. 3). Expression of both bEndoglin and bTgfbr3 did not change during 
ageing. Figur  3
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Fig. 3. Age-related changes in TGFβ-family type II and type III receptors in healthy cartilage. Relative 
gene expression of bone morphogenetic protein receptor type II (bBmpr2), transforming growth factor 
beta receptor II (bTgfbr2), endoglin (bEng), and transforming growth factor beta receptor III (bTgfbr3) 
in ageing cartilage as determined by qPCR. Regression analysis (solid line) with 95% CI (dotted line) 
depicted. Only expression of bBmpr2 clearly decreases with advancing age.
Decreased expression of TGFβ1 and GDF5 in ageing cartilage
In addition to the changes we observed on receptor expression, we also looked into the 
expression of ligands. As TGFβ is crucial for healthy articular cartilage, we investigated 
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expression of the three TGFβ isotypes: TGFβ1, TGFβ2 and TGFβ3. Of these three TGFβ 
isoforms, only expression of bTgfb1 was significantly ∼3-fold (P = 0.0002, R2 = 0.32) less 
expressed in old cartilage compared to young cartilage (Fig. 4). In contrast, expression of both Figure 4
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Fig. 4. Age-related drop in TGFβ-family ligands. Relative gene expression of transforming growth 
factor beta 1 (bTgfb1), transforming growth factor beta 2 (bTgfb2), transforming growth factor beta 
3 (bTgfb3), growth differentiation factor 5 (bGdf5), bone morphogenetic protein 2 (bBmp2) and bone 
morphogenetic protein 7 (bBmp7) in ageing cartilage as determined by qPCR. Regression analysis (solid 
line) with 95% CI (dotted line) depicted. Expression of both bTgfb1 and bGdf5 clearly decreases with 
advancing age.
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Tgfb2 and Tgfb3 was not lowered with advancing age. Next, we measured bGdf5 expression, 
because reduced expression of this growth factor has been identified as a risk factor for OA 
[29]. bGdf5 expression significantly (P = 0.0090, R2 = 0.10) decreased ∼2-fold with advancing 
age. Additionally, we measured bBmp2and bBmp7 expression in view of their importance 
for cartilage biology. bBmp2 expression was not affected by age, whereas bBmp7 expression 
was remarkably low (undetected) in most samples, This made it difficult to draw a clear 
conclusion regarding bBmp7 expression. Taken together our data shows that expression of at 
least two important growth factors for cartilage homeostasis decreases with advancing age.
Functional implications of altered receptor expression in ageing cartilage
 In view of the changes we observed in receptor expression, we wanted to investigate the 
functional implications of these changes. We focused on the TGFβ receptors Acvrl1 (ALK1) 
and Tgfbr1 (ALK5) because of TGFβ’s importance in cartilage biology. First, we analysed our 
data set for clues of decreased TGFβ signalling. Previously, we have identified expression of 
bSmad7 as an indicator of TGFβ signalling in bovine explants [30]. When analysing bSmad7, 
we observed a clear ∼4-fold reduction in expression with advancing age (P = 0.0089, R2 = 
0.17) (Fig. 5A). To prove that aged cartilage indeed is less responsive to TGFβ, we stimulated 
cartilage explants of 22 animals (aged 0.5–11 years old) ex vivo with TGFβ1 for 24 h and 
measured bSmad7 expression. However, TGFβ-induced bSmad7 expression was not 
significantly different between young and old animals (Fig. 5C). A possible reason for this is 
that TGFβ1 can induce bSmad7 expression via both bTgfbr1 and bAcvrl1 [31,32] and bAcvrl1 
expression was unaffected by ageing. Therefore, we subsequently measured bSerpine1 
expression, a gene which is induced by TGFβ in a specifically pSmad3-dependent way [33], 
and thus a good indicator of only bTgfbr1 signalling. Although bSerpine1 expression did not 
change with age (Fig. 5B), old cartilage clearly responded less to TGFβ1 than young cartilage, 
because age-dependent bSerpine1 expression in response to TGFβ1 is characterized by a 
negative regression coefficient (P = 0.0157) (Fig. 5D). This negative coefficient reflects a ∼3-
fold lower response to TGFβ1 of 10 year old cartilage compared to 6 months old cartilage. 
Finally, we wanted to investigate if Acvrl1 functionality did not decrease with age. Therefore 
we stimulated explants with BMP9, a high affinity Acvrl1 ligand [34]. BMP9 stimulation 
induced bId1 expression to a similar extent (∼4-fold) in both young and old animals showing 
that Acvrl1 (ALK1) function was not diminished (Fig. 5E). Taken together, these results indicate 
that, in ageing chondrocytes, loss of bTgfbr1 expression indeed has functional consequences 
for cellular response to TGFβ1. 
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Discussion
Ageing affects cartilage on multiple levels, including chondrocyte homeostasis. In this paper 
we investigated the impact of ageing on the expression of TGFβ-family signalling components 
in healthy articular cartilage. With the use of bovine cartilage we were able to separate 
ageing from OA, two processes that are often concomitant and interfering. We report that 
ageing decreases Smad2/3 phosphorylating receptors and that this is reflected in a lowered 
Smad3-dependent TGFβ1 response.
 In chondrocyte biology, ageing and (early) OA can have diametrically opposed 
effects. For example, ageing negatively affects production of essential matrix components 
like glycosaminoglycans and collagen type 2a1, whereas in early OA expression of both matrix 
components is markedly upregulated [22, 23]. Another example is that while cell division 
is as good as absent in (mature) ageing cartilage, proliferation and clonal expansion of 
chondrocytes are common during OA [35, 36]. These opposite effects of ageing and OA on 
chondrocyte biology are most likely a reflection of antagonistic regulation of gene expression. 
Therefore, it is difficult to study the effects of ageing on chondrocyte gene expression in 
joints with concurrent OA, and ideally both processes should be studied separately. In 
mice, we found this separation difficult to do, as e.g., in our hands the widely used C57BL/6 
strain spontaneously developed OA as young as 8 months old, leaving little room to study 
ageing separately. However, in the bovine MCP joint we were able to study ageing without 
concomitant OA.
 Ageing affects cartilage on a macroscopic, microscopic and cellular level. We were 
able to identify many previously defined features of ageing cartilage in our bovine data set, 
including progressive thinning of the cartilage, loss of superficial zone organization, tidemark 
duplications and profound loss of Col2a1 expression [4, 5,7, 11, 26, 27]. Therefore using 
bovine cartilage to study ageing is a valuable tool to replace healthy human cartilage, which 
is often very difficult to obtain reliably.
 Phosphorylated Smad3 (pSmad3) is an essential transcription factor for the 
maintenance of healthy cartilage. Mice lacking Smad3 show rapid and profound degeneration 
of their articular cartilage, a process in which chondrocyte hypertrophy plays a major role 
[17]. Chondrocyte hypertrophy is characterized by elevated production of matrix degrading 
enzymes like MMP13, and eventually loss of cell viability [37, 38]. Phosphorylated Smad3 
effectively inhibits chondrocyte hypertrophy via its interaction with, and subsequent inhibition 
of, the transcription factor runt-related transcription factor 2 (RUNX2) [16, 39]. RUNX2 is 
regarded as the master regulator of chondrocyte maturation, as chondrocyte hypertrophy 
is blocked in cells lacking RUNX2 [40]. We show that, compared to young chondrocytes, 
aged chondrocytes express less of the Smad2/3 phosphorylating receptors bAcvr1b and 
bTgfbr1. Furthermore, this decreased bTgfbr1 expression is coupled to diminished pSmad3-
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dependent TGFβ1 signalling (bSerpine1 expression). The direct dependency of TGFβ-induced 
Serpine1 expression on pSmad3 has been well established [33, 41, 42], but a dependency 
of Serpine1 on pSmad2 has not clearly been established. Therefore, and because we did 
not measure pSmad2 levels directly, we cannot conclude from our experiments if pSmad2 
signalling was also diminished. However, we do think this is likely [31, 32, 43]. Overall, taken 
the importance of pSmad3 in cartilage biology into account, our observations suggest that 
ageing chondrocytes are more prone to become hypertrophic, and give a possible reason for 
age as the main risk factor of OA.
 A diminished response to TGFβ1 with advancing age was suggested by our previous 
studies showing age-related loss of TGFβ type I and type II receptors in vivo in murine cartilage 
[13, 20]. Here we actually confirm that a reduced response is indeed the case. Previously, the 
effects of TGFβ on chondrocytes of different ages have been studied using chondrocytes 
cultured in monolayer, but this has yielded variable results on a common parameter as 
proteoglycan production [14, 44, 45]. With increasing age, both increased and decreased 
proteoglycan production have been described in response to TGFβ [14, 44, 45], highlighting 
the difficulty of studying cellular response of aged cells in vitro. Because the outcome of 
TGFβ signalling is very dependent on cellular context, e.g., which phase of the cell cycle 
cells are in or ECM composition [46], we think that using explants with cells in their native 
environment is a more suitable approach to study TGFβ signalling in aged cells compared 
to the use of matrix deprived monolayer chondrocytes. Of note, we have previously also 
shown that compared to young cartilage, aged bovine cartilage has a diminished capacity to 
induce Smad2/3 signalling in response to mechanical stimulation [25]. This indicates that the 
receptor changes we observe also have functional consequences when cells are not directly 
stimulated with an exogenous ligand.
 Although we chose to focus on age-related changes in TGFβ signalling, BMP signalling 
is also relevant for cartilage homeostasis, for example in regulation of proteoglycan content. 
Locally produced BMP2 and BMP7 have been shown to be important for maintenance of 
cartilage GAG content [47, 48]. Both BMP2 and BMP7 use Bmpr2 as type II receptor and 
share Bmpr1 as type I receptor. Remarkably, we observed profound downregulation of both 
receptors ((∼4-fold) in bBmpr1 expression, ∼6-fold bBmpr2) with advancing age, and are 
the first to report so. Possibly this decrease results in lower BMP2 and BMP7 signalling in 
elder cartilage, resulting in less proteoglycan maintenance. However, although we did 
observe age-related downregulation of BMP receptors, we only observed a ∼2 fold drop 
in aggrecan expression. This indicates that the relative importance of BMP signalling in 
aggrecan production is maybe limited. Additionally, Bmpr1 is also the receptor used by GDF5. 
Notably we also observed that GDF5 expression itself decreases with ageing. Reduced GDF5 
expression is associated with OA, because a SNP lowering expression of this growth factor 
was the first genetic risk factor to be identified for OA [29]. Our results indicate that the 
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GDF5/BMP7/BMPR1 axis is profoundly impacted by ageing, and warrants further study into 
this signalling route.
 However, BMP signalling can also be detrimental for cartilage [19]. Both 
phosphorylated Smad1 or Smad5 have been shown to enhance RUNX2 function, and can 
via this way induce chondrocyte hypertrophy [49, 50, 51]. In view of this, it is relevant that 
we did not observe an age-related decrease in Acvrl1 expression or function. Previously we 
have suggested that a shift in balance between Acvrl1 and Tgfbr1 receptors could be a cause 
of OA, and that Acvrl1 is involved in chondrocyte Mmp13 expression [20]. In our samples we 
also observed this shift, because Acvrl1 expression remained stable over time whereas Tgfbr1 
expression diminished. Therefore we can confirm this shift as a robust age-related effect in 
cartilage that occurs across species. In contrast to previous papers, which studied cartilage 
ageing in mice, we did not observe a loss of Tgfb2, Tgfb3, or Tgfbr2 expression [13, 20]. 
Possibly, this difference is due to a species-specific effect, or interference of an OA-related 
effect like inflammation. Additionally, it could imply an additional level of regulation of these 
factors on protein level, as we did not study this.
 Our study does have limitations. First of all, we did not use human material and 
therefore species specific observations cannot be excluded. However, we observed many 
changes documented for human cartilage in bovine cartilage [4, 5, 7, 11, 26, 27], indicating 
that similar processes happen in both species. Secondly, in all cases we predominantly 
analysed mRNA expression and did not study the translation of this signal into protein. 
Nonetheless, with the use of mRNA we were able to detect many age-related changes in 
TGFβ-family signalling that have been confirmed on protein level in other species, like the 
change in Acvrl1/Tgfbr1 ratio [20]. Finally, we macroscopically selected healthy cartilage. This 
doesn’t fully exclude microscopic changes, thus making it possible that very early OA samples 
entered our sample pool.
 In conclusion, ageing bovine cartilage displays many characteristics of ageing human 
cartilage, making it a valuable tool to supplement rare human material. The separation of 
ageing and OA allowed us to study ageing independently of OA, which revealed that expression 
of TGFβ and BMP receptors decreases with advancing age. The decrease in expression of the 
TGFβ-receptor Tgfbr1 resulted in a lowered phosphorylated Smad3-dependent response of 
older cartilage to TGFβ1. Due to the importance of phosphorylated Smad3 in cartilage biology, 
reduction of Smad3 activation during ageing could explain the close relation between ageing 
and OA development, highlighting ageing as the main risk factor for the development of this 
disease.
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Supplementary Figure 3. Scoring system used to quantify Acvrl1 (ALK1) and Tgfbr1 (ALK5)  expression in bovine 
cartilage.
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Abstract
Objective
Mechanical signals control key cellular processes in articular cartilage. Previously we 
have shown that mechanical compression is an important ALK5/Smad2/3P activator in 
cartilage explants. However, age-related changes in the cartilage are known to affect tissue 
mechanosensitivity and also ALK5/Smad2/3P signaling. We have investigated whether ageing 
of cartilage is associated with an altered response to mechanical compression.
Design
Articular cartilage explants of two different age groups (young-6–36 months old, aged-6 – 13 
years old) were subjected to dynamic mechanical compression with 3 MPa (physiological) 
or 12 MPa (excessive) load. Subsequently, essential cartilage extracellular matrix (ECM) 
components and tissue growth factors gene expression was measured in young and aged 
cartilage by QPCR. Furthermore, the ability of young and aged cartilage, to activate the 
Smad2/3P signaling in response to compression was analyzed and compared. This was done 
by immunohistochemical (IH) Smad2P detection and Smad3-responsive gene expression 
analysis.
Results
Aged cartilage showed a highly reduced capacity for mechanically-mediated activation of 
Smad2/3P signaling when compared to young cartilage. Compression of aged cartilage, 
induced collagen type II (Col2a1) and fibronectin (Fn1) expression to a far lesser extent than 
in young cartilage. Additionally, in aged cartilage no mechanically mediated up-regulation 
of bone morphogenetic protein 2 (Bmp2) and connective tissue growth factor (Ctgf) was 
observed.
Conclusions
We identified age-related changes in cellular responses to mechanical stimulation of articular 
cartilage. We propose that these changes might be associated with age-related alterations in 
cartilage functioning and can underlie mechanisms for development of age-related cartilage 
diseases like osteoarthritis (OA).
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Introduction
Mechanical signals have been shown to play a crucial role in cartilage formation as well 
as in tissue maintenance [1]. One of the major consequences of mechanical stimulation 
on cartilage is regulation of cartilage tissue matrix proteins expression, including aggrecan 
[2], collagen type II3 [3], fibronectin [4] and perlecan [5]. Furthermore in chondrocytes, the 
expression of many growth factors crucial for cartilage maintenance like transforming growth 
factor beta 1-Tgfb1 [6] connective tissue growth factor-Ctgf [7] and bone morphogenetic 
protein 2-Bmp2 [8] is modulated by mechanical signals. Additionally various of intracellular 
signaling cascades are also mechanosensitive, including Smad2/3P [6], FAK [9] and ERK [10].
 Age-related changes in cartilage affect the extracellular matrix (ECM) as well as the 
chondrocytes. In articular cartilage the size, structure and sulfation characteristics of aggrecan 
in the ECM change during ageing [11,12]. Because aggrecan is the main determinant of the 
water content in cartilage ECM, changes in aggrecan result in reduction of tissue resiliency, 
hydratation and finally volume. Furthermore, age-related glycation of collagens has been 
shown, causing increase in stiffness of the cartilage ECM [13,14]. In addition, chondrocytes 
are susceptible to senescence during ageing [15]. Importantly, many studies have shown 
an age-related declined responsiveness and/or disrupted signaling of key cartilage growth 
factors, including IGF1 [16], BMP7 [17] and TGFβ [18,19].
 Particularly TGFβ is an essential anabolic growth factor in articular cartilage as it 
prevents deleterious chondrocyte terminal differentiation [20]. Importantly, TGFβ can signal 
via two different type I receptors, i.e. ALK5 and ALK1, in chondrocytes, being able to induce 
opposing effects in cartilage. There is evidence that TGFβ action in restriction of cartilage 
terminal differentiation is limited to TGFβ signaling via the type I receptor-TGFBR1 (ALK-5), 
followed by Smad2 and Smad3 phosphorylation [18,20]. Recently we showed that mechanical 
compression potently activates Smad2/3P signaling in young mature articular cartilage 
which was apparently TGFBR1 (ALK5) controlled [6]. Independently, in vivo studies in mice 
demonstrated a strong reduction in ALK5 expression in ageing articular cartilage [18,21].
 Considering the fact that current understanding of mechanotransduction events is 
based on the studies of tissues from young experimental models, there is a need to investigate 
how age-related changes, in the cartilage ECM and cells, influence cellular response in situ 
to mechanical stimulation. Evidence for altered mechanosensitivity of articular cartilage in 
many aspects could provide more insight into understanding age-related articular cartilage 
disease like osteoarthritis (OA).
The purpose of this study was to investigate if aged articular cartilage, responds differently to 
dynamic mechanical compression than young cartilage. To investigate this, we analyzed the 
effect of physiological (3 MPa) and excessive (12 MPa) mechanical compression on the gross 
structural changes, expression of ECM components together with essential cartilage growth 
factors and activation of Smad2/3P signaling in young and aged articular cartilage.
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Materials and methods
Articular cartilage explants culture
Bovine articular cartilage explants were harvested from metacarpophalangeal joints (MCP) 
of two different age groups (exact ages, established on original abattoir documentation 
are provided in figure legends of each experiment and in Supplementary Tables 1 and 2). 
Joints were obtained from the local abattoir within 3 h post mortem. Full cartilage thickness 
(young-986 ± 34 μm, aged-725 ± 42 μm thick) explants (without sub-chondral bone) were 
isolated with a 4 mm biopsy punch (Kai-medical, Japan). After isolation, all specimens 
were equilibrated for 48 h in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F-12) (Gibco®, UK) (1 ml medium per one 4 mm Ø explant) with addition of Antibiotic-
Antimycotic (contains 10,000 units/mL of penicillin, 10,000 μg/mL of streptomycin, and 25 
μg/mL of Fungizone®) (Gibco®, USA) in standard culture conditions (37°C, 5% CO2 and 95% 
humidity). No serum was added to the medium.
Histological analysis
Full thickness osteochondral biopsies were isolated from MCP, with a diamond coated blade 
saw. Biopsies were fixed overnight at 4°C in 10% phosphate buffered formalin (pH 7) and 
decalcified for 1 week in 10% formic acid at room temperature. Specimens were dehydrated 
with a tissue processing apparatus (Pathos, Milestone Medical Inc.). After embedding in 
paraffin, sections of 7 μm were cut, than stained with Mayer’s hematoxylin and visualized 
under a standard light microscope.
Dynamic mechanical compression of cartilage explants
Explant from stimulation groups were subjected to force controlled, sinusoidal, unconfined, 
dynamic mechanical compression with 3 or 12 MPa for 30 min, with 1 Hz, exactly like 
described before [6]. Full detailed description is included in Supplementary materials.
Articular cartilage strain monitoring during dynamic mechanical compression
The displacement of cartilage explants was monitored during the complete duration 
of dynamic, force controlled mechanical compression with 3 MPa or 12 MPa pressure. 
Compressions were performed as described before [6]. Data were recorded with WinTest® 
software (BOSE ElectroForce, USA). Displacement values were corrected for the thickness 
of the specimen (measured on histological section of unloaded controls) to calculate strain 
values.
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Total mRNA isolation and quantitative RT-PCR (Q-PCR)
mRNA isolation and Q-PCR were performed exactly like described before [6]. Full detailed 
description is included in Supplementary materials. Primers used are included in Table I.
Gene 
symbol
Full gene name Ref seq P (bp) E (%) Forward 5′ → 3′ Reverse 5′ → 3′
bGapdh
glyceraldehyde 
3-phosphate 
dehydrogenase
NM_001034034.2 90 100.92% CACCCACGGCAAGTTCAAC TCTCGCTCCTGGAAGATGGT
bAcan aggrecan NM_173981.2 144 96.84% TGAAACCACCTCCACCTTCCATGA TCAAAGGCAGTGGTTGACTCTCCA
bBmp2
bone morphogenetic 
protein 2
NM_001099141.1 73 105.35% CGCAGCTTCCATCACGAA AGAAGAATCGCCGGGTTGTT
bCol2a1 collagen, type II, alpha 1 NM_001001135.2 60 96.84% TGATCGAGTACCGGTCACAGAA CCATGGGTGCAATGTCAATG
bCtgf
connective tissue 
growth factor
NM_174030.2 86 105.35% GACTTCGGCTCCCCAACCAA TGGTACACAGTTCCTCCGAAAAT
bFn1 fibronectin 1 XM_005202786.1 95 96.84% GCACCACTCCCGACATTACT CTGATCGGCATGGACCACTT
bHspg2
heparan sulfate 
proteoglycan 2
XM_005197610.1 160 105.35% GGGACTTCCAGATGGTTTATTTC TGGTCTCCAGGGATCTTCA
bJunb jun B proto-oncogene NM_001075656.1 139 96.84% CCTTCTACCACGACGACTCA CCGGGTGCTTTGAGATTTCG
bSerpine1
plasminogen activator 
inhibitor type 1
NM_174137.2 55 100.92% CGAGCCAGGCGGACTTC TGCGACACGTACAGAAACTCTTGA
bSmad7 SMAD family member 7 NM_001192865.1 72 105.35% GGGCTTTCAGATTCCCAACTT CTCCCAGTATGCCACCACG
bTgfb1
transforming growth 
factor, beta 1
NM_001166068.1 80 105.35% GGTGGAATACGGCAACAAAATCT GCTCGGACGTGTTGAAGAAC
bTgfbr1
transforming growth 
factor, beta receptor 1
NM_174621.2 75 93.07% CAGGACCACTGCAATAAAATAGAACTT TGCCAGTTCAACAGGACCAA
Table I. Primers list. Only primers with efficiency between 93% and 105% were used
Immunohistochemical (IH) analysis
At 2 h after compression, samples were fixed over night at 4°C in 10% phosphate buffered 
formalin. Specimens were dehydrated and embedded in paraffin. 7 μm thick sections were 
cut and mounted on Superfrost™ Plus Microscope Slides (Thermo Scientific, USA). Then, the 
immunohistochemistry for c-terminally phosphorylated SMAD2P (rabbit mAb anti Phospho-
Smad2 (Ser465/467) (1:100) (Cell Signalling Technology, Danvers, Massachusetts, USA)) was 
performed as previously described [21].
Computational scoring of Smad2P IH
To score the load-induced Smad2P staining, first the detection threshold was set to detect only 
intense Smad2P staining. Obtained values of positive Smad2P staining were first corrected for 
ROI (region of interest). Then values of each experimental group were corrected for values of 
staining in unloaded controls (to show the load-induced Smad2P in each age). Finally, the load-
induced Smad2P staining was corrected to the average cell number in a certain age group.
To score the nuclear localization of Smad2P staining, first the threshold was set to detect only 
Smad2P nuclear staining. In each scored section it was verified that staining detected after 
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thresholding was always located in the cell nucleus but not in the cytoplasm. Obtained values 
were corrected for ROI (region of interest), and then corrected for average cell number in the 
certain age group.
 All scoring values were expressed as a % of young. Scoring was performed with LAS 
(Leica Application Suite, Leica Microsystems, Germany).
Statistical analysis
Quantitative data of gene expression analysis were expressed as a grouped column scatter 
of multiple repeats with displayed mean. All experiments were repeated 5 times on material 
isolated from different animals, N = 5 (experimental setups are included in Supplementary 
Tables 1 and 2). First all datasets were checked for normality using the Shapiro–Wilk test. 
Linear mixed models were used to estimate the effects of compression level and age on 
gene expression. Linear mixed models take into account the correlated nature of repeated 
measures on cartilage isolated from the same subject. All the analyses were performed with 
the statistical software packages: SPSS 20.0 (SPSS, Chicago, USA).
 Additionally, linear mixed models were used to fit the individual strain profiles of 
dynamically compressed cartilage explants of different ages (Supplementary Table 2). The 
dependent variable was strain. The independent variables were the loading condition and 
age. Interaction terms between loading condition and age were included in the model. 
The intercept and the regression coefficients of time were treated as random effects. The 
estimated regression parameters with standard errors were used to calculate the mean 
strain profiles with 95% confidence intervals for each loading/age condition. These statistical 
analyses were performed using R version 3.1.2 with package ‘nlme’ (R Development Core 
Team).
Results
Age-related changes in articular cartilage structure
Histological comparison of articular cartilage of 2 year and 13 year old revealed a very 
prominent age-related reduction in cartilage thickness (Fig. 1). In young cartilage an irregular 
transition of cartilage to bone, active remodeling and abundant vascularity was observed. In 
contrast, in aged cartilage the transition to the sub-chondral bone was straight and a clear tide 
mark was present (Fig. 1). Furthermore, a significantly reduced number of chondrocytes was 
present in aged when compared to young cartilage (P = 0.0002) (Fig. 1 and Supplementary 
Fig. 2).
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Articular cartilage of different ages responds differently to dynamic mechanical 
compression
Histological evaluation showed that 3 MPa mechanical compression did not cause any 
severe structural changes in 1 year or 10 years old cartilage (Fig. 2B and E, respectively) 
when compared to corresponding unloaded controls (Fig. 2A and D, respectively). In both 
cases, intact surfaces, normal matrix architecture, no enlargement/distortion of chondrons 
were observed. However, the disappearance of the unstained superficial cartilage zone 
caused by 3 MPa compression was noticed. 12 MPa compression did not result in severe 
structural changes of 1 year old cartilage either (Fig. 2C). However, in 10 years old cartilage, 
12 MPa mechanical compression induced surface discontinuities in a form of vertical fissures 
(Fig. 2F). Examination of the sections under polarized light confirmed that no vertical fissures 
were present in the unloaded control (Fig. 2G) and 3 MPa (Fig. 2H) compressed cartilage but 
in 12 MPa compressed 10 years old cartilage vertical fissures penetrated the mid-zone (Fig. 2I).
Fig. 1. Age-related changes in articular cartilage structure. Representative full thickness cross section of bovine 
articular cartilage with subchondral bone of a 2 years old individual (A) and of 13 years old individual (B).
Cartilage deformation as a function of time can deliver information about mechanical 
properties and water content of the tissue [22]. We analyzed load-induced cartilage 
deformation to compare young and aged cartage mechanical properties. Individual strain 
(deformation) profiles showed typical patterns over time, starting with a steep increase in 
strain followed by a gradual increase and flattening of the strain profile (Fig. 2J). Analysis of 
strain profiles showed that young cartilage was able to deform significantly more, starting 
from 1550 second (P = 0.04) compared to aged cartilage when subjected to 3 MPa mechanical 
compression (Fig. 2J). Comparison of cartilage deformation during 12 MPa mechanical 
compression revealed no significant differences in the amount of the deformation between 
young and aged cartilage (Fig. 2J).
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Fig. 2. Effect of dynamic mechanical compression on young and old articular cartilage. (A–F) Representative cross 
sections of articular cartilage stained with Safranin O and Fast Green. Intact articular cartilage specimens were 
dynamically compressed with 3 MPa or 12 MPa. Compression was performed as a sine wave with frequency of 1 Hz for 
30 min (1800 cycles). (A, B, C) 1 year old cartilage: (A) unloaded, (B) 3 MPa compressed and (C) 12 MPa compressed 
cartilage, (D, E, F) 10 years old cartilage: (D) Unloaded, (E) 3 MPa compressed and (F) 12 MPa compressed cartilage. 
(G,H,I) Cross section of 10 years old cartilage stained with Picro Sirius Red and examined under the polarized light: 
(G) Unloaded, (H) 3 MPa compressed and (I) 12 MPa compressed cartilage. Arrows indicate the cartilage surface 
discontinuity. (J) Articular cartilage strain during dynamic mechanical compression with 3 or 12 MPa. Blue lines 
represent averaged strain of cartilage isolated from 1, 2 and 3 years old individuals. Red lines represent averaged 
strain of cartilage isolated from 6 and 10 years old individuals. Grey shadows represent the curve’s 95% CI.
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Ageing affects the influence of dynamic mechanical compression on the expression of 
articular cartilage ECM components
Expression of cartilage ECM components is highly sensitive to mechanical signals [3]. We 
measured the impact of compression on expression of ECM components in young and 
aged cartilage. Dynamic mechanical compression had no effect on the expression of bAcan 
(Aggrecan) (Fig. 3A). However, at 2 h after compression a significantly diverse (3.9-fold, 22.0Ct, 
P = 0.048) regulation of bCol2a1 expression with up-regulation in young and down-regulation 
in aged in cartilage by 12 MPa compression was found (Fig. 3B). Analysis of the bFn1 
expression at 6 h time point showed a significantly different regulation of bFn1 expression by 
12 MPa compression in cartilage of different age (Fig. 3C) (2.1-fold, 21.1Ct, P = 0.001), with up-
regulation in young cartilage and down-regulation in aged cartilage. Remarkably, at the 6 h 
time point, in both stimulation groups, a down-regulation of perlecan (bHspg2) was observed 
in aged cartilage whereas no changes in bHspg2 expression were observed in young cartilage 
(Fig. 3D). This resulted in significantly different changes in expression levels of bHspg2 in 
cartilage of different age (3.4-fold, 21.8Ct, P = 0.002 for 3 MPa and 2.3-fold, 21.2Ct, P = 0.025 for 
12 MPa compressed cartilage) (Fig. 3D).
Ageing affects mechanically mediated expression of essential cartilage growth factors
Expression of many key cartilage growth factors, same like ECM components, is also 
mechanosensitive [6–8]. We studied if aged articular cartilage has an altered mechanically-
mediated regulation of key tissue growth factors.
 At 2 h time point, a potent and significant (P = 0.001 for all cases) up-regulation 
of bTgfb1 expression was measured in both age and stimulation groups (Fig. 4A). At 6 h 
time point, in 12 MPa compressed cartilage up-regulation was significant for both age 
groups (P < 0.0001 for young cartilage and P = 0.001 for aged cartilage) (Fig. 4A). At 2 h after 
compression, a down-regulation of bCtgf in aged cartilage compressed with 12 MPa (P = 
0.027) was observed. This down-regulation was significant when compared to young cartilage 
compressed with 12 MPa (6.3-fold, 25.6Ct, P < 0.0001) (Fig. 4B). At 6 h time point, in both 
stimulation groups, an up-regulation of bCtgf was observed in young cartilage with down-
regulation in aged cartilage. At this time point, a significantly opposed effect of mechanical 
compression on bCtgf expression regulation (10-fold, 23.3Ct, P < 0.0001 for 3 MPa and 48.1-
fold, 25.6 Ct, P < 0.0001 for 12 MPa compressed group) was identified in cartilage of different 
age. At 2 h time point, a pronounced up-regulation of bBmp2 induced by both compression 
levels (P < 0.0001 for both stimulation groups) was seen, however only in young cartilage 
(Fig. 4C). Remarkably, in aged cartilage bBmp2 was not affected by any level of mechanical 
compression (Fig. 4C). This revealed significantly different regulation of bBmp2 expression by 
compression between young and aged cartilage compressed with 3 MPa (3.0-fold, 21.6Ct, P = 
0.045) and 12 MPa  (4.2-fold, 22.1Ct, P = 0.011) (Fig. 4C). 
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Fig. 3. Influence of dynamic mechanical compression on the expression of cartilage ECM components in cartilage of 
different age. Relative expression of bAcan (A), bCol2a1 (B), bFn1 (C) and bHspg2 (D) in young and aged cartilage. 12 
MPa dynamic mechanical compression induced significantly different regulation of bCol2a1 (B), and bFn1 (C) expression 
in cartilage of different age. Both levels of mechanical compression down-regulated bHspg2 only in aged cartilage 
(D). Data are expressed as a grouped column scatter of multiple repeats with displayed mean (each point represents 
individual experimental repeat on material isolated from different animal). Age of cartilage was as follows: Young: three 
7 months, and two 11 months old; aged: 12, 10, 8 and two 9 years old. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001.
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Fig. 4. Influence of dynamic mechanical compression on the expression of key tissue physiology mediators in 
cartilage of different age. The influence of 3 and 12 MPa dynamic mechanical compression on relative expression of 
(A) bTgfb1, (B) bCtgf and (C) bBmp2 in young and aged articular cartilage. Mechanical compression potently induced 
bTgfb1 expression in young and aged cartilage (A). However, mechanical compression had significantly different 
effect on bCtgf and bBmp2 expression regulation in cartilage of different age (B and C). Data are expressed as a 
grouped column scatter of multiple repeats with displayed mean (each point represents individual experimental 
repeat on material isolated from different animal). Age of cartilage was as follows: Young: three 7 months, and two 
11 months old, aged: 12, 10, 8 and two 9 years old.* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001. 
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The up-regulation of bBmp2 expression in young cartilage was still present at 6 h after 
the compression in both stimulation groups (P = 0.002 for 3 MPa and P < 0.0001 for 
12 MPa) whereas in aged cartilage still no regulation of bBmp2 was observed. Thus, 
significantly different regulation of bBmp2 in cartilage of different age was present 
in 3 MPa (2.2-fold, 21.1Ct, P = 0.048) and in 12 MPa group (5.2-fold, 22.4Ct, P < 0.0001).
Ageing reduces mechanically mediated phosphorylation of Smad2 in articular cartilage
Previously we showed that mechanical compression can act as a significant inducer of 
Smad2/3P signaling in mature articular cartilage [6]. Here, we analyzed if ageing affects 
mechanically-mediated phosphorylation of Smad2 in articular cartilage.
 A clear induction of Smad2P staining was observed in young cartilage compressed 
with 3 MPa (Fig. 5Ab, e, h) when compared to unloaded control (Fig. 5Aa, d, g). Evident 
induction of Smad2P staining was also observed in 12 MPa compressed young cartilage (Fig. 
5Ac, f, i) when compared to unloaded control (Fig. 5Aa, d, g). A reduced level of Smad2P 
staining in aged compressed cartilage was detected when compared to young cartilage. This 
was visible in 3 MPa (Fig. 5Ak, n) and 12 MPa (Fig. 5Al, o) compressed aged cartilage as well 
as in unloaded control (Fig. 5Aj, m). Computational scoring of Smad2P IH confirmed these 
observations (Fig. 5B). Aged cartilage showed highly reduced load-induced Smad2P staining 
when compared to young cartilage. This was the case for 3 MPa (P < 0.0001) as well as for 12 
MPa compressed cartilage (P < 0.0001) (Fig. 5B). 
 Furthermore, prominent differences between dynamically compressed young 
and aged cartilage were observed in the localization of Smad2P staining. In young cartilage 
compressed with 3 MPa as well as with 12 MPa, Smad2P staining was mainly localized in the 
cell nuclei (Fig. 5Ca, b) whereas in aged cartilage Smad2P staining was more predominantly 
present in the chondrocyte cytoplasm (Fig. 5Cc, d). Computational scoring of Smad2P nuclear 
staining showed that in aged cartilage there is a significant reduction of nuclear Smad2P 
localization when compared to young cartilage (P < 0.0001). This was the case for both 
loading conditions (Fig. 5D).
Ageing reduces mechanically-induced activation of Smad3P signaling reporter genes
To investigate if the reduction of mechanically-induced TGFβ signaling in aged cartilage, 
indicated by the reduced Smad2P, is reflected in gene expression, the expression of 
downstream reporter genes for Smad3P in compressed cartilage isolated from individuals of 
different age was examined. These included: Serpine1 (Pai1), JunB and Smad7. All of these 
genes contain a Smad Binding Element in their promoter [23–25].
 Because in cartilage TGFBR1 (ALK-5) is the main receptor activating Smad2/3 
signaling pathway, the influence of age on basal expression of bTgfbr1 (bAlk5) in bovine 
cartilage was analyzed. Comparison of bTgfbr1 expression levels between young and aged 
cartilage demonstrated significantly lower (2.4-fold, 21.3Ct, P = 0.002) bTgfbr1 expression levels 
in aged cartilage than in young cartilage (Fig. 6A).
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Fig. 5. Influence of dynamic mechanical compression on Smad2 activation in cartilage of different age. Clear induction 
of Smad2P staining was observed in young cartilage compressed with 3 and 12 MPa when compared to unloaded 
controls (Ab, e, h to Aa, d, g), (Ac, f, i to Aa, d, g). Clearly lower level of induction of Smad2P by compression was 
noticed in old cartilage compressed with 3 MPa and 12 MPa when compared to young cartilage (Ak, n to Ab, e, 
h) and (Al, o to Ac, f, i). Scoring of IH staining showed significantly lower load-induced Smad2P staining in aged 3 
MPa and 12 MPa compressed cartilage when compared to young cartilage compressed with the same pressure 
(B). Smad2P staining in young compressed cartilage was most likely restricted to the cell nuclei (Ca, b) whereas in 
old compressed cartilage staining was more predominantly present in the cell cytoplasm (Cc, d). Scoring of nuclear 
IH staining showed significant reduction in Smad2P nuclear staining in aged cartilage when compared to young 
cartilage (D). Arrows indicate the Smad2P staining detected by threshold used for computational scoring of IH. Young 
cartilage: 1 year old; aged cartilage: 10 years old.
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At 2 h after compression a profound up-regulation of bSerpine1 expression was observed, 
especially in young cartilage (Fig. 6B); 3 MPa mechanical compression of young cartilage up-
regulated bSerpine1 expression (32-fold, 25 Ct, P < 0.0001) whereas the same compression level 
in aged cartilage did not up-regulate bSerpine1 expression significantly (Fig. 6B). Therefore, 
bSerpine1 expression was significantly different up-regulated by 3 MPa compression in 
cartilage of different ages (6.1-fold, 22.6Ct, P = 0.002) (Fig. 6B). In 12 MPa compression group, 
a significantly higher bSerpine1 up-regulation was observed in young compared to aged 
cartilage (3.7-fold, 21.9Ct, P = 0.015) (Fig. 6B). At 6 h after compression significant bSerpine1 
up-regulation was observed in young cartilage (P = 0.003 in 3 MPa and P < 0.0001 for 
12 MPa compressed group) and in 12 MPa compressed aged cartilage (P = 0.006) (Fig. 6B). 
However, only in 12 MPa compressed cartilage, a significantly different levels of bSerpine1 up-
regulation levels between young and aged cartilage were observed (5.9-fold, 22.6Ct, P = 0.005) 
(Fig. 6B) with higher expression levels in young cartilage.
 Expression analysis of an alternative Smad3P responsive gene: bJunB confirmed the 
results of the bSerpine1 measurements. Only in young cartilage, bJunB was greatly induced 
at 2 h after both levels of mechanical compression (22-fold 24.5Ct, P < 0.0001 for 3 MPa and 
25-fold 24.7Ct, P < 0.0001 for 12 MPa) (Fig. 6C). At the same time in aged cartilage, bJunB 
expression showed no response to any level of compression (Fig. 6C). Therefore, bJunB 
expression responded significantly different to mechanical stimulus in young vs aged cartilage 
(17-fold, 24.1Ct, P < 0.0001 for 3 MPa and 10-fold, 23.3Ct, P < 0.0001 for 12 MPa stimulation 
group). At 6 h time point the age-related differences were not longer detectable.
 Expression levels of another Smad3P responsive gene: bSmad7 were analyzed but 
no age-related differences in regulation of bSmad7 expression by mechanical compression 
were detected (Fig. 6D).
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Fig. 6. Basal expression of Smad2/3 activating receptor (Tgfbr1) and influence of dynamic mechanical compression 
on relative expression of Smad3P reporter genes in cartilage of different age. (A) Basal expression of bTgfbr1 in 
cartilage of different age. The influence of 3 and 12 MPa dynamic mechanical compression on relative expression 
of (B) bSerpine1, (C) bJunB and (D) Smad7 in young and aged articular cartilage. Significantly higher bSerpine1 up-
regulations were observed in young compressed cartilage than in aged (B). Moreover, only in young compressed 
cartilage the up-regulation of bJunB was detected (C). In both age groups, bSmad7 up-regulation was observed (D). 
Data are expressed as a grouped column scatter of multiple repeats with displayed mean (each point represents 
individual experimental repeat on material isolated from different animal). Age of cartilage was as follows: Young: 
three 7 months, and two 11 months old, aged: 12, 10, 8 and two 9 years old.* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001.
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Discussion
Articular cartilage performs a very important biomechanical function being at the same time a 
highly mechanosensitive tissue. Cartilage experiences various forms of loads and these loads 
have been shown to play an important role in tissue formation, physiology and maintenance [1]. 
However, cartilage accumulates a number of age-related changes in the ECM as well as in 
its cells [26]. Notwithstanding growing interest in the role of mechanical signals in cartilage 
biology, the knowledge on how age-related changes influence tissue mechanosensitivity is 
scarce. That is why the response of young and aged cartilage to physiological and excessive 
mechanical compression was investigated and compared. We report a reduced or loss of 
ability for regulation of various ECM components and essential tissue growth factors in 
aged cartilage by mechanical signals. However, most importantly, we identified a diminished 
ability for activation of Smad2/3 signaling as a response to mechanical load in aged cartilage. 
This indicates that age-related changes in articular cartilage have significant impact on the 
characteristic of tissue response to mechanical signals.
 Previously our group has demonstrated that mature cartilage, when compressed, 
is activating Smad2/3 signaling which we hypothesized to be a consequence of latent TGFβ1 
activation and subsequent signaling via TGFBR1 (ALK5) receptor [6]. In the present study we 
show a highly reduced ability for mechanically mediated Smad2/3P signaling activation in 
aged cartilage. Moreover, we observed that Smad2P in young compressed cartilage is localized 
in cell nuclei whereas in aged cartilage is more predominantly present in the cytoplasm. 
This indicates that particularly in young dynamically compressed cartilage Smad2/3P was 
translocated to the nucleus to control transcription of genes. Not ruling out the role of other 
receptors known to be able to activate Smad2/3P signaling (ALK4 and ALK7) we think that 
this might be a consequence of age-related loss in bTGFBR1 (ALK5) expression in articular 
cartilage which was shown in this study and also previously in murine cartilage [18]. The loss 
of ALK5 receptor would disable the function of the mechanically activated TGFβ1 growth 
factor and subsequent Smad2/3P signaling activation. Moreover, a reduced synthesis of TGFβ 
ligands [21,27], could decrease the content of this ligands in aged cartilage ECM. This could 
negatively affect the extent of growth factor activation mediated by mechanical signals.
 As previously reported, cartilage shows an age-related decrease in tensile fracture 
stress what indicates an alteration in biomechanical properties of this tissue when aged [28]. 
We show that higher pressure had to be applied on aged cartilage to achieve the same 
amount of deformation as in young cartilage. This indicates an increase in stiffness together 
with loss of water content in aged cartilage ECM. It is known that cells from many tissues are 
able to sense and respond to changes in ECM elasticity [29]. Because cartilage ECM is the 
major transducer of mechanical signals to the chondrocytes, increase in ECM stiffness could 
result in lower mechanosensitivity of aged cartilage and negatively affect mechanical signal 
transduction.
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However, an alternative explanation for altered mechanically-mediated regulation of 
essential tissue growth factors and cartilage ECM components could be found in age-
related changes in the expression of integrins [30] which are the main cell surface receptors 
transducing mechanical signals from the ECM and translating it to cell signaling pathways [31]. 
Because it has been shown that numerous of chondrocyte mechanosensitive signaling 
pathways are integrin-dependent [31], it can be speculated that alterations in the expression 
of integrins could have a significant impact on the mechanical signal transduction and further 
downstream gene expression regulated by load.
 Numerous factors can control chondrocyte response to loads. Importantly, this also 
includes the cell’s epigenetic status. Additionally, many studies reveal an epigenetic drift 
with aging also in cartilage [32]. This could indicate that in our experiments genes which are 
not responding to mechanical compression in aged cartilage compared to young cartilage, 
like bBmp2, are epigenetically repressed or silenced. Indeed an age-related epigenetically 
silencing in a promoter of another growth factor from the same family (BMP7) was found in 
cartilage [33]. Moreover, according to the Encyclopedia of DNA Elements data (ENCODE, http://
genome.ucsc.edu/, release date of the genome assembly-20.01.2015), two CpG islands are 
present in the Bmp2 promoter. It is known that DNA methylation, resulting in gene silencing, 
occurs mostly in CpG islands. Furthermore, ENCODE shows that several chromatin modifiers 
bind to the Bmp2 promoter, including Histone-lysine N-methyltransferase (EZH2), which 
also in cartilage is involved in silencing of gene expression [34]. Independently, it has been 
reported that direct modulation of histone deacetylase (HDAC) activity, so the modulation 
of cell epigenetic status, can interfere with mechanically mediated gene expression [35]. 
Remarkably not all key growth factors genes were less responsive for mechanical signals in 
aged cartilage. The expression of bTgfb1 gene was as potently induced in aged cartilage as in 
young. This shows that aged cartilage is not less responsive in all studied aspects and there 
are pathways induced by mechanical signals which are not altered by ageing.
 There are some limitations of our study. First of all, as we showed, aged cartilage 
has highly reduced thickness when compared to young cartilage. By this, during unconfined 
compression of cartilage explant the force could possibly be differently distributed in samples 
with different thickness. However, our experiments were performed with force controlled set 
up, so there was always the same amount of force applied on the explant, not depending 
on specimen thickness. Moreover, age-related decrease of cartilage thickness appear also in 
vivo [26], but aged cartilage will in general experience a similar magnitude of loading like 
young. Secondly, our conclusions are based on a bovine animal model and might not be 
directly applicable to humans. However, as we demonstrated, bovine cartilage shows age-
related changes in tissue gross appearance similar to changes observed in humans [26].
 There are numerous studies showing the importance of mechanical signals in 
articular cartilage homeostasis. There are also many studies demonstrating age-related 
changes in the articular cartilage cells and ECM. Nevertheless, to our knowledge this is the 
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first report connecting these two aspects and showing that aged cartilage responds differently 
to mechanical load compared to young cartilage. Here we report a disruption in Smad2/3 
phosphorylation in aged articular cartilage, a pathway which is known to be protective 
for articular cartilage [20]. Our results demonstrate that the age of the articular cartilage 
greatly affects the response of tissue to mechanical signals. Age-related alteration in cartilage 
mechanotransduction can point to mechanisms of age-related articular cartilage diseases like 
OA.
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Supplementary Materials and methods
Number of individuals 5 5 
Specific ages of each 
individual (years)
1 1 0.6 0.6 0.6 8 9 9 10 12
Age group Young Old
Time point after 
compression
2 hours 6 hours 2 hours 6 hours
Compression level 3 MPa 12 MPa 3 MPa 12 MPa 3 MPa 12 MPa 3 MPa 12 MPa
Number of individuals 3 2
Specific ages of each 
individual (years)
1 2 3 6 12
Age group Young Old
Compression level 3 MPa 12 MPa 3 MPa 12 MPa
Supplementary Table 2. Experimental setup for the articular cartilage strain monitoring during dynamic mechanical 
compression
Dynamic mechanical compression of articular cartilage explants.
After 48 hours equilibration in standard culture conditions, cartilage explants were randomly 
distributed to two stimulation groups (3 MPa - physiological or 12 MPa- excessive compression) 
and corresponding unloaded control groups. Explant from stimulation groups were subjected 
to sinusoidal, unconfined, dynamic mechanical compression using BOSE® ElectroForce® 
BioDynamicTM bioreactor (5160 BioDynamic System) equipped with a 50 lbf load-cell (BOSE, 
Bose Corp. ElectroForce Systems Group, MN, USA) exactly like described before [6], however 
in 60 ml of (DMEM/F12) medium (for detals see the Supplementary Fig.1). The compression 
duration was 30 min (1800 cycles) with a frequency 1Hz and it was performed under standard 
culture conditions (37°C, 5% CO2 and 95% humidity). After the compression all the samples 
were placed back into the culture wells and back to the culture incubator for 2 or 6 h. At 
required time intervals samples were flash frozen in liquid nitrogen and stored at -80°C. 
Supplementary Table 1. Experimental setup for the gene expression analysis
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Total mRNA isolation and quantitative RT-PCR (Q-PCR). 
Deep frozen articular cartilage samples were homogenized with a micro-dismembrator (B. 
Braun Biotech International, Melsungen, Germany) at 1500 RPM for 1 minute. The homogenate 
of one 4 mm Ø cartilage explant was dissolved in 300 µl of RLT buffer containing 1 % (v/v) 
2-mercaptoethanol. Total RNA was isolated using an RNeasy Mini Kit (Qiagen Inc., Valenzia, CA, 
USA) according to the manufacturer’s protocol. Isolated mRNA was transcribed into cDNA using 
M-MLV reverse transcriptase. Obtained cDNA was used in quantitative PCR (qPCR) analysis, 
carried out with the StepOnePlus Real-Time PCR System (Applied Biosystems, Germany) using 
SYBR-green according to the manufacturer’s protocol. Validated primers were used and are 
listed in Table1. Thereafter, all Ct values for the genes of interest were first corrected for Ct 
values of glyceraldehyde 3-phosphate dehydrogenase (bovine Gapdh) to obtain ΔCt values. 
Finally, all the ΔCt values of the experimental groups (compressed cartilage) were corrected for 
the values of appropriate controls (unloaded cartilage) to obtain ΔΔCt values. 
Supplementary Fig. 1. Schematic representation of Bose 
Electroforce 5160 BioDynamic System set-up used for dynamic 
mechanical compression of cartilage explants. The load-cell on 
the top (above the specimen) and motor on the bottom.
Yo
un
g
Ag
ed
0
20
40
60
80
100
120
140
160
180
200
***
ce
ll 
nu
m
be
r (
%
 o
f y
ou
ng
)
Supplementary Fig. 2. Cellularity of articular cartilage in different 
age. Aged articular cartilage showed high reduction in cellularity 
when compared to young cartilage. Cartilage cellularity was 
scored on hematoxylin stained, full thickness (with sub-chondral 
bone) cartilage sections. This was done by computational system 
LAS (Leica Application Suite, Leica Microsystems, Germany). Age 
of cartilage was as follows: young-1, 2 and 3 years old, aged-two 
10 and one 13 years old. ***- P ≤ 0.001. Each dataset of certain 
age group consist of N = 18 measured values (6 different areas of 
the section measured in 3 different individuals).
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Supplementary Fig. 3. Articular cartilage stained with Rabbit isotope negative control immunoglobulin. No unspecific 
staining was noticed in Rabbit IgG (DakoCytomation, Denmark) control antibody stained articular cartilage.
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Abstract
Objective
In osteoarthritic cartilage, expression of the receptor ALK1 correlates with markers of 
deleterious chondrocyte hypertrophy. Recently, bone morphogenetic protein 9 (BMP9) was 
identified as a high affinity ligand for ALK1. Therefore, we studied if BMP9 signaling results 
in expression of hypertrophy markers in chondrocytes. Furthermore, because transforming 
growth factorß1 (TGFβ1) is a well known anti-hypertrophic factor, the interaction between 
BMP9 and TGFβ1 signaling was also studied.
Design
Primary chondrocytes were isolated from bovine cartilage and stimulated with BMP9 and/or 
TGFβ1 to measure intracellular signaling via pSmads with the use of Western blot. Expression 
of Smad-responsive genes or hypertrophy-marker genes was measured using qPCR. To 
confirm observations on TGFβ/Smad3 responsive genes, a Smad3-dependent CAGA12-luc 
transcriptional reporter assay was performed in the chondrocyte G6 cell line.
Results
In primary chondrocytes, BMP9 potently induced phosphorylation of Smad1/5 and Smad2 
to a lesser extent. BMP9-induced Smad1/5 phosphorylation was rapidly (2 h) reflected in 
gene expression, whereas Smad2 phosphorylation was not. Remarkably, BMP9 and TGFβ1 
dose-dependently synergized on Smad2 phosphorylation, and showed an additive effect 
on expression of Smad3-dependent genes like bSerpine1 after 24 h. The activation of the 
TGFβ/Smad3 signaling cascade was confirmed using the CAGA12-luc transcriptional reporter. 
BMP9 selectively induced bAlpl and bColX expression, which are considered early markers of 
cellular hypertrophy, but this was potently antagonized by addition of a low dose of TGFβ1.
Conclusions
This study shows that in vitro in chondrocytes, BMP9 potently induces pSmad1/5 and a 
chondrocyte hypertrophy-like state, which is potently blocked by TGFβ1. This observation 
underlines the importance of TGFβ1 in maintenance of chondrocyte phenotype.
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Introduction
Osteoarthritis (OA) is the most common joint disease, characterized by degeneration 
of articular cartilage. This loss of articular cartilage is the result of an imbalance between 
matrix synthesis and degradation. Chondrocytes play a crucial role in balancing both 
processes with their capacity to produce both matrix molecules, like collagens, and catabolic 
proteolytic enzymes such as Matrix Metalloproteases (MMPs). During OA, a subpopulation 
of chondrocytes differentiates towards a hypertrophy-like phenotype, characterized by 
increased production of catabolic enzymes such as MMP13 [1–3]. As a consequence, these 
chondrocytes actively break down their surrounding matrix, resulting in pathology.
 Signaling by members of the Transforming Growth Factor β (TGFβ)-superfamily, 
which include TGFβs, Activins and Bone morphogenetic proteins (BMPs), regulate matrix 
synthesis, matrix degradation and cellular differentiation in chondrocytes [4]. The TGFβ-
superfamily members signal via Activin receptor-Like Kinase (ALK) receptors [5]. There 
are seven ALKs, which phosphorylate specific sets of receptor-Smads: ALK1/2/3 and 6 
phosphorylate Smad1/5 (pSmad1/5), whereas ALK4/5 and 7 phosphorylate Smad2/3 
(pSmad2/3). Both pSmad2 and pSmad3, but predominantly pSmad3, have been shown to 
be essential for chondrogenesis and maintenance of chondrocyte phenotype by potently 
blocking hypertrophy [6–8], whereas pSmad1 and pSmad5 are required for chondrocyte 
hypertrophy and terminal differentiation [9–12].
 In human osteoarthritic cartilage, ALK1 expression is positively correlated with 
expression of MMP13, the main cartilage degrading enzyme, and of COL10A1, a marker of 
chondrocyte terminal differentiation [13]. Recently, BMP9 was identified as a high affinity 
ALK1 ligand [14,15]. BMP9 is produced in the liver and is present in human, bovine and murine 
serum in high amounts of up to 10 ng/ml [16–18], responsible for over 60% of all BMP activity 
found in serum [15]. In endothelial cells, BMP9 potently induces pSmad1/5 and downstream 
signaling [14,15]. Furthermore, in mesenchymal stem cells, BMP9 is a potent inducer of 
chondrocyte hypertrophy, and has been shown to induce osteogenic differentiation [19,20]. 
Combined, these observations suggest a pro-hypertrophic effect of BMP9 in chondrocytes. 
However, it has been reported that BMP9 is also able to induce pSmad2 and subsequent 
downstream effects in endothelial cells [21,22]. Furthermore, a synergistic action of BMP9 
with TGFβ has been described in endothelial cells, in which BMP9 enhances TGFβ induced 
Smad2 phosphorylation and Smad3-mediated transcriptional responses [23].
 In view of the opposing functions of pSmad1/5 and pSmad2/3 in chondrocyte 
differentiation, we wondered what the effect of BMP9 signaling on chondrocytes would be. 
Therefore, the aim of this study was to investigate BMP9 induced Smad phosphorylation 
and downstream gene expression, and to unravel if BMP9 signaling results in induction of a 
hypertrophy-like phenotype in chondrocytes. Furthermore, because of the reported synergy 
with TGFβ, we also studied the interaction of BMP9 with TGFβ.
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We show that in primary chondrocytes, BMP9 indeed induces both phosphorylation of 
Smad1/5 and Smad2. Additionally, we demonstrate that BMP9 can synergize with TGFβ 
on Smad2 phosphorylation and expression of certain Smad3-dependent target genes. 
Furthermore, we report that BMP9 induces a hypertrophy-like state in chondrocyte as 
characterized by Alkaline phosphatase (Alpl) and Collagen 10a1 (Col10a1) expression, 
which is potently counteracted by TGFβ1. Our results underline the idea that pSmad1/5 and 
pSmad2/3 have opposing roles in regulation of chondrocyte differentiation.
Materials and methods
Chondrocyte culture
Primary bovine chondrocytes were isolated from the metacarpophalangeal joint of cows 
post mortem. Cartilage slices were incubated overnight in 1.5 mg/ml Collagenase B (Roche 
Diagnostics, Germany) in DMEM/F12 (Gibco, UK) supplied with 50 mg/L gentamicin 
(Centrafarm Services, the Netherlands) and 100 mg/L pyruvate (Gibco UK) in a ratio of 1 g 
cartilage per 10 ml medium. Subsequently, chondrocyte suspension was spun down at 1500 
rpm for 10 min, washed three times using saline (Aguettant, France) and resuspended in 
DMEM/F12 containing 10% fetal calf serum (FCS) (Thermo Scientific UK). Chondrocytes were 
seeded at a density of 1 × 105 cells per cm2 in 6 wells plates (Greiner Bio-one International, the 
Netherlands) for protein studies, or in 24 wells plates (Bio-one International, the Netherlands) 
for mRNA experiments. Cells were cultured for 1 week at 37°C and 5% CO2 before start of 
experiments. Subsequently, cells were serum starved and stimulated with recombinant 
hBMP9, hBMP2, hBMP7 (R&D systems, USA), or hTGFβ1 (BioLegend, the Netherlands) or a 
combination for indicated time periods and dosages. Each experiment was conducted at least 
three times, each time with cells of a different animal. In each experiment, conditions were 
tested in duplicate.
Detection of pSmads using SDS-PAGE and western blot
Cells were placed on ice and washed twice using ice cold saline. Subsequently, cells were lysed 
using lysis buffer (Cell signaling, USA) containing protease inhibitor cocktail (complete, Roche 
Diagnostics, Germany). Cell lysates were sonicated on ice for 10 cycles, of 30 s sonication and 
30 s rest, using a Bioruptor (Diagenode, USA). Hereafter, samples were centrifugated at 4°C 
at 13,500 rpm for 15 min and pellets were discarded. With a BCA-assay (Thermo Scientific, 
USA), protein concentration was measured. An equal amount of protein was loaded on a 
7.5% Bisacrylamide gel, for SDS-PAGE. Next, proteins were transferred to a nitrocellulose 
membrane using wet transfer (Towbin buffer, 2.5 h 275 mA at 4°C). After overnight incubation 
at 4°C with 1:1000 polyclonal Rabbit anti P-Smad1/5 (S463/465)/Smad8 (S426/428) (Cell 
signaling, USA) or P-Smad2 (S465/467) (Cell signaling, USA), membranes were incubated with 
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1:1500 polyclonal Goat anti Rabbit labeled with Horseradish peroxidase (DAKO, Belgium) for 
1 h. Hereafter, enhanced chemiluminescence (ECL) using ECL plus kit (GE Healthcare, UK) was 
used to visualize the proteins. As loading control β-Actin rabbit mAb (13E5) (Cell signaling) or 
Gapdh mouse mAb (1G5) (Sigma Aldrich, Germany) was used, both 1:1500.
Detection of gene expression
RNA was isolated using TRI-reagent (Sigma–Aldrich, Germany) by following manufacturer’s 
protocol. After this procedure, RNA was dissolved in ultra pure water and RNA concentration 
was measured using a NanoDrop photospectrometer (Thermo Scientific, USA). Subsequently, 
1 μg of RNA dissolved in 8 μl water was treated with 1 μl DNAse (Life Technologies, USA) for 
10 min at room temperature, and incubated at 65°C with 1 μl 25 mM EDTA (Life Technologies, 
USA) for 10 min. To perform reverse transcriptase (RT) reaction; 1.9 μl ultra pure water, 2.4 μl 
10 × DNAse buffer, 2.0 μl 0.1 M DTT, 0.8 μl 25 mM dNTP, 0.4 μg oligo dT primer, 1 μl 200 U/μl 
M-MLV Reverse transcriptase (all Life Technologies, USA) and 0.5 μl 40 U/μl RNAsin (Promega, 
the Netherlands) was added, and samples were incubated for 5 min at 25°C, 60 min at 39°C, 
and 5 min at 95°C using a thermo cycler. Gene expression was measured using 0.5 μM of 
validated cDNA-specific primers (see Table I) (Biolegio, the Netherlands) in a quantitative real 
time polymerase chain reaction (qPCR) using SYBR green master mix (Applied Biosystems). 
The following protocol was used: after 10 min at 95°C, 40 cycles of 15 s 95°C and 1 min 60°C 
each were run. For calculations of the −ΔCt, two reference genes were used: glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and ribosomal protein S14 (RPS14). 
CAGA
12
-luciferase transcriptional reporter assay
The CAGA12-luciferase reporter construct produces luciferase in response to Smad3-Smad4 
activation [24]. For this assay a human chondrocyte derived cell line (G6) was used. Cells were 
transduced with an adenovirus containing the CAGA12-luciferase construct at a multiplicity of 
infection of 10. Two days after transduction, cells were serum starved for 8 h, and hereafter 
stimulated with the reported doses of rhTGFβ1 and rhBMP9 for 16 h. Subsequently, cells 
were lysed and luciferase activity was measured after adding Bright glo™ (Promega) on a 
luminometer according to manufacturer’s protocol.
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NCBI Reference Efficiency
Gene sequence (%) Forward sequence (5’ → 3’) Reverse sequence (5’→ 3’)
bRps14 NM_001077830.2 105 CATCACTGCCCTCCACATCA TTCCAATCCGCCCAATCTTCA
bGapdh NM_001034034.2 100 CACCCACGGCAAGTTCAAC TCTCGCTCCTGGAAGATGGT
bAlk1 NM_001083479.1 99,5 ACAACACAGTGCTGCTCAGACA TGCTCGTGGTAGTGCGTGAT
bAlk2 NM_176663.3 104.8 CGTTGGAGACAGCACTTTAGCA AGAGCCGCTTCCCGATGTA
bSerpine1 NM_174137.2 99 CGAGCCAGGCGGACTTC TGCGACACGTACAGAAACTCTTGA
bSmad7 NM_001192865.1 103 GGGCTTTCAGATTCCCAACTT CTCCCAGTATGCCACCACG
bTgfb1 NM_001166068.1 107 GGTGGAATACGGCAACAAAATCT GCTCGGACGTGTTGAAGAAC
bJunb NM_001075656.1 97,2 CCTTCTACCACGACGACTCA CCGGGTGCTTTGAGATTTCG
bId1 NM_001097568.2 107 GCTCCGCTCAGCACTCTCAA GATCGTCCGCTGGAACACA
bCol10a1 NM_174634.1 92 CCATCCAACACCAAGACACAGT TGCTCTCCTCTCAGTGATACACCTT
bAlpl NM_176858.2 92 CTTTCCCTCCTGGACCAAATTA CCTGGGTCCTTGGAGTGGT
bMmp13 NM_174389.2 92 CTTTCCCTCCTGGACCAAATTA CCTGGGTCCTTGGAGTGGT
bSPP1 NM_174187.2 104.1 ACCCATCTCAGAAGCAGACT TGGGAGGGTATTTTGTTTGTTGT
bCol2a1 NM_001001135.2 97.2 TGATCGAGTACCGGTCACAGAA CCATGGGTGCAATGTCAATG
Table I. Primer sequences used in this study
Statistics
All quantitative data are expressed as a mean of multiple repeats ± SD. For every analysis data 
was checked for normality using the Shapiro-Wilk test. One-way analysis of variance (ANOVA) 
with Tukey’s multiple comparison post test was used to determine the significance. The statistical 
analyses were performed with the SPSS 20.0 (IBM, Chicago, USA) statistical software package.
Results 
In primary chondrocytes, BMP9 potently induces pSmad1/5 phosphorylation, and 
Smad2 phosphorylation to a lesser extent
First, expression of the two receptors BMP9 can use; ALK1 and ALK2 [15,25] was measured using 
qPCR, and detected at 0.11 and 0.23 fold of reference gene value respectively. Subsequently, 
chondrocytes were stimulated with a dose range of rhBMP9 to investigate its potency in inducing 
Smad phosphorylation. Concentrations reported [16–18] as physiological (50 pg, 250 pg, 1 ng, and 
2.5 ng/ml) as well as excessive (25 ng/ml) were tested. In this range, rhBMP9 dose-dependently 
induced pSmad1/5 after 1 h, starting from a dose of 50 pg/ml (Fig. 1A). Furthermore, from a 
dose of 1 ng/ml or higher, BMP9 also induced pSmad2, but not in all donors. Both BMP9-induced 
Smad1/5 and Smad2 phosphorylation lasted up to at least 2 h after stimulation. Therefore we 
conclude that in primary chondrocytes, BMP9 can induce phosphorylation of both pSmad1/5 and 
pSmad2, but that the induction of pSmad2 requires a higher dose of BMP9.
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Fig. 1. BMP9 induces Smad phosphorylation and downstream gene expression in primary bovine chondrocytes. (A) 
Primary bovine chondrocytes were stimulated with a dose range of rhBMP9 for 1 and 2 h, and induction of Smad1/5 
and Smad2 phosphorylation was analyzed on Western blot using specific antibodies. pSmad1/5 is potently dose-
dependently induced by BMP9 from 50 pg/ml, whereas pSmad2 is induced from a dose of 1 ng/ml and higher. 
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(B) Chondrocytes of three donors were stimulated in duplo with 0.25, 1 and 2.5 ng/ml BMP9 for 2, 6 and 24 h, 
to study BMP9-induced gene expression downstream pSmad1/5 and pSmad2/3 using qPCR. BMP9 significantly 
induced expression of bId1 at all time points, but not of bSerpine1. For Western blot, a donor is shown in which 
BMP9-stimulation resulted in both Smad1/5 and Smad2 phosphorylation. For qPCR data, average ± s.e.m. was 
plotted, with each dot representing the average of one donor. Statistics were calculated using one-way ANOVA with 
a Tukey’s post-hoc test (* = P < 0.05, ** = P < 0.01 and *** = P < 0.001).
Physiological doses of BMP9 induce expression of bId1, a Smad1/5-dependent gene, but 
not of Smad3-dependent genes
To investigate if the observed Smad phosphorylation results in gene transcription, mRNA 
expression of Smad-dependent genes was measured 2, 6 and 24 h after stimulation with 
rhBMP9 using qPCR (Fig. 1B). The effect of three doses of BMP9 (0.25, 1 and 2.5 ng/ml) 
with varying induction of Smad phosphorylation, was measured. Expression of bId1, marker 
of pSmad1/5 signaling, was profoundly upregulated ∼32 fold (∼5 ΔCt) at all time points 
compared to unstimulated samples, but with little difference between dosage. bSerpine1, a 
classical Smad3-dependent gene [24,26], was measured to study if BMP9 induced pSmad2 
was reflected in gene expression, because in adults not many Smad2-dependent genes have 
been identified [26,27], and pSmad2 and pSmad3 follow a very similar expression pattern, 
even when induced TGFβ independently [28,29]. In contrast to bId1, expression of bSerpine1 
was not induced by BMP9 at any time point. Two other Smad3-dependent genes; bTgfb1 
[26] and bAlk5 [30] were also not affected by BMP9. Expression of bSmad7 and bJunb, two 
genes that have been described as responsive to both pSmad1/5 and pSmad2/3 [31,32] were 
upregulated by BMP9, but remarkably only at 1 ng/ml or higher. In conclusion, BMP9 potently 
induced expression of Smad1/5-dependent genes, but not Smad3 specific genes.
BMP9 synergizes with TGFβ1 on induction of Smad2 phosphorylation
Because previously a synergistic effect of BMP9 and TGFβ1 on Smad2/3 phosphorylation has 
been reported [23], we investigated if this synergy also occurs in chondrocytes. To investigate 
a possible dose-dependency, two doses of rhTGFβ1, 0.1 and 1 ng/ml, and three doses of 
BMP9, 0.5, 5 and, based on the previously mentioned study [23], 50 ng/ml were used (Fig. 
2A). As expected, stimulation of chondrocytes with TGFβ1 led to phosphorylation of Smad2 
and Smad1/5. Furthermore, BMP9 strongly induced pSmad1/5 but not pSmad2 in this donor. 
Most remarkably, BMP9 dose-dependently enhanced TGFβ1-induced Smad2 phosphorylation 
of both TGFβ1 doses. In addition, inhibition of BMP9-induced pSmad1/5 was observed in the 
presence of 0.1 ng/ml TGFβ1, but not in the presence of 1 ng/ml TGFβ1. These data suggest 
that TGFβ1 and BMP9 synergize on the induction of pSmad2 in chondrocytes.
The high affinity ALK1-ligand BMP9 induces a hypertrophy-like state in chondrocytes that is antagonized by TGFβ1.
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Fig. 2. BMP9 synergizes with TGFβ1 on pSmad2 induction resulting in enhanced expression of pSmad2/3 responsive 
genes. (A) Chondrocytes were treated for 1 h with either 0.1 or 1 ng/ml of rhTGFβ1, 0.5, 5 or 50 ng/ml of rhBMP9 
or a combination of both growth factors and subsequently pSmad2 and pSmad1/5 were visualized on Western blot 
using specific antibodies. An inhibitory effect of 0.1 ng/ml on BMP9-induced pSmad1/5 was observed. Furthermore, 
a synergistic effect of BMP9 on TGFβ1 induced pSmad2 was observed, as signal intensity was increased for co-
stimulated samples compared to samples only stimulated with TGFβ1. (B) and (C) Co-stimulation of chondrocytes 
with BMP9 and TGFβ1 was also investigated on gene expression of Smad-dependent genes 2 h (B) or 24 h (C) after 
stimulation, by stimulating four donors in duplo. At 2 h after stimulation, no effect on bSerpine1 expression could 
be detected. bSmad7 and bJunB expression was upregulated more strongly in samples treated with both growth 
factors compared to single treatment, however not in a synergistic manner. At 24 h after stimulation, combination 
treatment induced more bSerpine1, bTgfb1 and bSmad7 expression compared to single treatment. (D) To study 
if co stimulation of chondrocytes with BMP9 and TGFβ1 results in enhanced Smad responsive biologic activity, 
the chondrocyte G6 cell line was transduced with the pSmad3-responsive CAGA12-luc construct, and treated with 
either 1 ng/ml TGFβ1, 5 or 50 ng/ml BMP9 and a combination of both for 16 h. Both growth factors synergized, 
as co-stimulation enhanced luciferase production significantly compared to TGFβ1 stimulation alone. For Western 
blot, a representative donor is shown. For qPCR data, average ± s.e.m. was plotted with each dot representing the 
average of one donor. Statistics were calculated using one-way ANOVA with a Tukey’s post-hoc test (* = P < 0.05, 
** = P < 0.01 and *** = P < 0.001).
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Co-stimulation of chondrocytes with BMP9 and TGFβ1 results in an additive effect on 
expression of Smad3-dependent genes
To investigate the observed synergy between BMP9 and TGFβ1 further downstream, mRNA 
levels of Smad3-dependent genes were measured after 2 and 24 h. A low dose of TGFβ1, 0.1 
ng/ml, and high dose of BMP9, 50 ng/ml were used, because these two conditions showed 
profound synergy on pSmad2 in the previous experiment. Two hour after stimulation, both 
TGFβ1 and BMP9 induced expression of bId1, ∼2.8-fold (∼1.5 ΔCt) and ∼16-fold (∼4 ΔCt) 
respectively, but no additive, synergistic of inhibitory effect, was observed between both 
growth factors (Fig. 2B). Expression of the Smad3-dependent genes bSerpine1, bTgfb1, bAlk5 
was not yet induced by either growth factor alone or in combination. Single stimulation with 
TGFβ1 or BMP9 both induced bSmad7 expression ∼2.5-fold (∼1.3 ΔCt), and co-stimulation 
increased the expression ∼6-fold (∼2.5 ΔCt). Furthermore, bJunb levels were only significantly 
upregulated ∼4-fold (∼2 ΔCt) after co-stimulation with TGFβ1 and BMP9.
 Twenty-four hour after stimulation, bId1 expression was still upregulated ∼2.8-fold 
(∼1.5 ΔCt) by BMP9 but no longer by TGFβ1. Again, no additive, synergistic of inhibitory effect 
was observed on this pSmad1/5 dependent gene (Fig. 2C). In contrast to the 2 h timepoint, 
Smad3-dependent genes were upregulated after 24 h. Only co-stimulation with TGFβ1 and 
BMP9 significantly upregulated bSerpine1 expression 2-fold (∼1 ΔCt), suggesting enhanced 
pSmad2/3 signaling. Enhanced pSmad2/3 signaling is further indicated by bTgfb1 expression 
levels, as co-stimulation induced significantly higher expression of this gene compared 
to single stimulations; ∼3-fold (∼1.6 ΔCt) vs ∼2-fold (∼1 ΔCt) respectively. Similar to 2 h 
stimulation, an additive effect of TGFβ1 and BMP9 was observed on bSmad7; both TGFβ1 
and BMP9 induced expression ∼2.5-fold (∼1.3 ΔCt), but co-stimulation induced expression 
4.6-fold (∼2.2 ΔCt). Therefore, these data show that co-stimulation with TGFβ1 and BMP9 
results in an additive effect on pSmad2/3-responsive gene expression, but not on pSmad1/5-
responsive genes.
Synergy between BMP9 and TGFβ1 on CAGA
12
-luc activity
To further confirm the synergy between BMP9 and TGFβ1 on Smad2/3 phosphorylation, we 
made use of a Smad3/Smad4-reporter construct: CAGA12-luc. Due to low transfection rates 
we were not able to use primary cells and used the human chondrocyte-like G6 cell line. 
Stimulation with 1 ng/ml TGFβ1 strongly induced luciferase activity ∼7-fold, whereas BMP9 
in doses of 5 and 50 ng/ml did not (Fig. 2D). Although co-stimulation of TGFβ1 with 5 ng/ml 
BMP9 only shows a trend towards enhanced pSmad3 signaling, co-stimulation with 50 ng/ml 
BMP9 strikingly and significantly enhanced luciferase activity up to ∼10-fold, displaying clear 
synergy between TGFβ1 and BMP9, and therefore this dose was used in our next experiments.
CHAPTER 5
134
A high dose of BMP2 and BMP7 does not synergize with TGFβ1 on pSmad2 
phosphorylation
Now that the synergy between BMP9 and TGFβ1 on pSmad2/3 was confirmed in chondrocytes, 
we investigated if this is a common BMP characteristic. We compared BMP9 to BMP2 and 
BMP7 due to their importance in chondrocyte biology [33], and their use of the same type 
II receptors but different type I receptors as BMP9 [15,34]. Because the synergy between 
BMP9 and TGFβ1 is best observed at a high dose of BMP9, we chose to use a high dose 
(250 ng/ml) of BMP2 and BMP7 as well. Both BMPs induced pSmad1/5 comparable to BMP9 
(Fig. 3), but in contrast to BMP9, both BMPs lacked a synergistic interaction with TGFβ1 on 
pSmad2 phosphorylation. This indicates that the synergy with TGFβ1 on pSmad2 is a unique 
characteristic of BMP9.
bId1
FIGURE3
β β
β
FIGURE2
Fig. 3. BMP2 and BMP7 do not synergize with TGFβ1 on pSmad2. Chondrocytes were treated for 1 h with 250 ng/ml 
of BMP2 or 250 ng/ml BMP7, 50 ng/ml BMP9 and 0.1 ng/ml TGFβ, and pSmad1/5 and pSmad2 induction was 
analyzed on Western blot using specific antibodies. Although both BMPs induced similar pSmad1/5 compared to 
BMP9, BMP2 and BMP7, unlike BMP9, did not synergize with TGFβ1 on induction of Smad2 phosphorylation. This 
Western blot depicts a representative experiment.
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Fig. 4. BMP9 induces expression of early hypertrophy-like marker genes, which is potently blocked by a low dose of 
TGFβ1. Chondrocytes of three donors were treated in duplo with 0.1 ng/ml of rhTGFβ1, 5 or 50 ng/ml of rhBMP9 or 
a combination of both growth factors for 7 days, and gene expression of markers of chondrocyte hypertrophy and 
terminal differentiation were measured using qPCR. Stimulation medium was refreshed every 3 days. After 7 days 
of treatment, expression of both Col10a1 and bAlpl was significantly increased in samples stimulated with 50 ng/ml 
rhBMP9, but not in samples treated with 50 ng/ml rhBMP9 and 0.1 ng/ml TGFβ1, indicating an inhibitory effect 
of TGFβ1. This inhibitory effect of TGFβ1 on BMP9 induced signaling is reflected in bId1 expression, as addition of 
TGFβ1 inhibited BMP9 induced bId1 expression significantly. For qPCR data, average ± s.e.m. was plotted with each 
dot representing the average of one donor. Statistics were calculated using one-way ANOVA with a Tukey’s post-hoc 
test.
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High dose of BMP9 induces expression of chondrocyte hypertrophy marker genes which 
is blocked by TGFβ1
Overexpression of BMP9’s constitutively active receptor ALK1 induces expression of 
chondrocyte hypertrophy markers [13]. Therefore, we analyzed the effect of BMP9 signaling on 
expression of hypertrophy markers after 1 week. Considering that pSmad3 is a potent blocker 
of chondrocyte hypertrophy, co-stimulation with TGFβ1 was included (Fig. 4). After 1 week, 
bId1 expression was highly upregulated ∼49-fold (∼5.6 ΔCt) by 25 ng/ml BMP9. Remarkably, 
co-stimulation with 0.1 ng/ml TGFβ1 significantly lowered this induction to ∼21-fold (∼4.4 
ΔCt). Of the four markers of chondrocyte hypertrophy that were measured, expression of 
bMMP13 or bSPP1 was not significantly regulated by BMP9, TGFβ1, or the combination of 
both. In contrast, expression of both bAlpl and bCol10a1, was highly upregulated by 25 ng/
ml BMP9; ∼10.6-fold (∼3.4 ΔCt) and ∼4.6-fold (∼2.2 ΔCt) respectively. Strikingly, 0.1 ng/ml 
TGFβ1 could block BMP9-induced expression of these hypertrophy markers. Notably, matrix 
mineralization could not yet be observed by either alcian blue or alizarin red staining in our 
experiments. However, also after addition of two known inducers of matrix mineralization; 
β-glycerophosphate and ascorbic acid, no mineralization could be observed either. Apart from 
the inhibition of hypertrophy marker genes, co-stimulation also significantly induced bCol2a1 
expression ∼2.1-fold (∼1.1 ΔCt), showing a beneficial effect of simultaneous stimulation with 
TGFβ1 and BMP9 on matrix production. Based upon these results we conclude that BMP9 
induces the expression of certain hypertrophy-like marker genes, which is counteracted by a 
low dose of TGFβ1.
Discussion
Increasing evidence suggests pivotal, but opposing, roles for pSmad2/3 and pSmad1/5 in 
chondrocyte differentiation, with a hypertrophy-inducing role for the latter [35–37]. We 
investigated in vitro in primary chondrocytes the effects of BMP9, a potent pSmad1/5 inducing 
ligand that circulates in blood. We report that, in primary chondrocytes, BMP9 induces 
pSmad1/5 and expression of the chondrocyte hypertrophy markers bCol10a1 and bAlpl, but 
that this effect is potently counteracted by TGFβ1. Possibly, this inhibition is facilitated by the 
synergy we observed between BMP9 and TGFβ1 on Smad2/3 phosphorylation, a synergy 
which is unique for BMP9 compared to BMP2 or BMP7.
 Previous reports have characterized BMP9 as a potent inducer of pSmad1/5 
in a variety of endothelial cell lines [21,22]. We were able to show that also in primary 
chondrocytes, BMP9 potently induces pSmad1/5. Surprisingly, in some donors, we not only 
observed Smad1/5 but also Smad2 phosphorylation after stimulation with BMP9. In some, 
but not all, endothelial cell lines, BMP9-induced pSmad2 has been reported as well [21,22]. 
BMP9-induced pSmad2 is remarkable, as both type I receptors that BMP9 can bind; ALK1 
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and ALK2, are not known to directly phosphorylate Smad2. Therefore, how BMP9 induces 
pSmad2 is yet unclear.
 After phosphorylation, Smad1/5 and Smad2/3 form complexes with Smad4, the 
common-Smad, and translocate to the nucleus where these complexes bind DNA and 
regulate gene transcription [5]. When analyzing BMP9-induced gene expression in primary 
chondrocytes, we observed rapid and robust up regulation of the pSmad1/5-dependent gene 
bId1, but not of pSmad3-dependent genes like bSerpine1. This lack of Smad3-dependent 
gene expression is apparently in contradiction with our observations on Western blot, which 
suggest pSmad2/3 signaling. However, in both endothelial cells and chondrocytes, inhibition 
of pSmad3 signaling by ALK1 signaling has previously been reported. In both cell types, 
over-expression of constitutively active ALK1 reduced pSmad3-dependent transcriptional 
activity, while not affecting Smad phosphorylation itself [38–40]. Possibly, the rapid induction 
of Smad7 we found in this study can explain the observed lack of pSmad2/3-responsive 
gene expression. Smad7 is an inhibitor of receptor-Smad signaling (inhibitory-Smad) with 
a multitude of actions, including the ability to prevent binding of the pSmad2/3-Smad4 
complex to DNA [41,42]. Expression of this inhibitory-Smad was rapidly induced ∼3.2-fold 
within 2 h of BMP9 stimulation. Additionally, in chondrocytes, adenoviral over-expression of 
Smad7 has previously been reported to inhibit mSerpine1 transcription [43]. Therefore, in 
primary chondrocytes, Smad7 might be an important regulator of the crosstalk between the 
BMP9-induced pSmad1/5 and pSmad2/3 signaling pathways.
 The crosstalk between pSmad1/5 and pSmad2/3 signaling controls chondrocyte 
differentiation (reviewed in [37]). Via an interaction with the Runx2, a transcription factor 
regarded as the key regulator of endochondral ossification, pSmad1 and 5 can directly enhance 
terminal differentiation by inducing expression of genes like Col10a1 and Mmp13 [35,44,45]. 
Prolonged stimulation with BMP9 indeed induced expression of the early hypertrophy marker 
genes bCol10a1 and bAlpl, but increased bMmp13 expression was not observed. However, 
bMmp13 expression mainly occurs in late stage hypertrophic chondrocytes [46], a cellular 
state most likely not achieved in our experimental setting, also indicated by the lack of 
mineralization in our experiments. Compared to pSmad1/5, pSmad2/3 has an opposite effect 
on Runx2 activity; it silences Runx2-responsive genes via recruitment of histone deacetylases 
[36]. In our experiments, BMP9-induced expression of hypertrophy markers was indeed 
antagonized by a low dose of TGFβ1, a well known inducer of Smad2 and 3 phosphorylation. 
Possibly, this antagonism is facilitated by the synergy we observed between BMP9 and 
TGFβ1 on Smad2/3 phosphorylation. In addition to Smad signaling, Smad-independent BMP-
signaling via e.g., ERK and TAK1 can play a role in chondrocyte hypertrophy [47,48]. A limitation 
of our study is that we did not investigate these pathways. However, the Smad-dependent 
and Smad-independent pathways are closely interwoven by regulation of the former by the 
latter [49], and we think that Smad signaling is the key effector in BMP-induced chondrocyte 
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hypertrophy. Nonetheless, additional experiments are needed to reveal whether this actually 
holds true.
 In cartilage, the inhibition of BMP9 induced hypertrophy is possibly an important 
physiological role of TGFβ1. TGFβ1 itself is produced by chondrocytes, and present in cartilage 
in high amounts [50]. Although we were unable to detect BMP9 mRNA in chondrocytes, 
BMP9 is most likely readily available in cartilage in vivo. The liver produces large amounts 
of BMP9, and BMP9 circulates in levels as high as ∼10 ng/ml in bovine and ∼12 ng/ml in 
human serum and plasma [16–18]. Furthermore, BMP9 is responsible for over 60% of all 
BMP activity in serum, indicating BMP9’s relative abundance [15]. Because synovial fluid 
partly consists of plasma filtrate [51], it is likely that chondrocytes are constantly exposed to 
BMP9 via synovial fluid, but this still has to be confirmed. Considering that BMP9 signaling 
can induce hypertrophy, inhibition of this signal would be of crucial importance for the 
maintenance of articular cartilage, and therefore an important role of TGFβ1. Additional in 
vivo experiments are needed to test this hypothesis. In a pilot study, we tried to investigate 
to ability of BMP9 to induce cartilage hypertrophy in vivo by intra-articular injection of BMP9, 
but severe osteophyte formation, resulting in disrupted joint homeostasis, in response to 
BMP9 made it very difficult to draw conclusions on BMP9’s direct effect on cartilage.
 BMP9 levels are not known to correlate with OA, but its serum level doesn’t decrease 
during aging in mice [18]. We think that this stable level of BMP9 becomes a problem for 
cartilage during aging, in view of age-related loss of TGFβ signaling [11,13]. From cartilage-
specific TGFβ-receptor type 2 knockout mice it is known that mice lacking TGFβ-signaling 
develop increased cartilage degradation and expression of hypertrophy markers [52]. It 
would be very interesting to see if BMP9 is the driving force behind this process by crossing 
these mice with BMP9 knockout mice.
 How BMP9 and TGFβ1 can synergize on pSmad2/3 phosphorylation and downstream 
gene expression is yet unknown. However, the synergy between both growth factors can 
be observed rapidly, which suggests a mechanism upstream in the signaling pathway. TGFβ-
superfamily signaling requires formation of a heterotetrameric receptor complex containing 
two type II and two type I receptors, in which receptor-Smads are phosphorylated by the type I 
receptors [5]. TGFβ1 can bind two type I receptors, ALK1 and ALK5, and form complexes 
containing both. Furthermore, complex formation between ALK1 and ALK5 induces both 
pSmad1/5 and pSmad2/3 [39]. Putatively, a receptor-complex containing both ALK1 and ALK5 
can phosphorylate less Smad2/3 compared to a complex containing ALK5 twice because ALK1 
cannot phosphorylate pSmad2/3. Using radiolabeled ligands, it has been shown that BMP9 
has a far greater affinity for ALK1 than TGFβ1 [15]. Possibly, BMP9 affects TGFβ1-induced 
receptor complex formation by sequestering ALK1, forcing TGFβ1 to signal via receptor 
complexes containing solely ALK5, thus resulting in more pSmad2. This idea is supported 
by the observation that two other BMPs, BMP2 and BMP7, do not synergize with TGFβ1 
on pSmad2 even at a very high dosage. These BMPs share the induction of pSmad1/5 and 
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the use of type II receptors like BMPR2 with BMP9, but do not use ALK1, making it more 
likely that ALK1 is involved in the synergy between BMP9 and TGFβ1. Moreover, the synergy 
between TGFβ1 and BMP9 is most obvious at high levels of BMP9, which would sequester 
ALK1 more efficiently.
 In summary, this study shows that in chondrocytes, the ALK1-ligand BMP9 induces 
pSmad1/5 and downstream gene expression, leading within a week to a hypertrophy-like 
state in chondrocytes characterized by bAlpl and bColX expression. However, we also show 
that this can potently be inhibited by addition of a low dose of TGFβ1. Possibly, the observed 
synergy between BMP9 and TGFβ1 on Smad2 phosphorylation plays a role in this inhibitory 
effect. Although we only investigated this interaction in vitro, we propose that the interaction 
of BMP9 with TGFβ1 underlines the importance of TGFβ1 in maintenance of chondrocyte 
phenotype and furthermore that our observations support the idea that pSmad1/5 and 
pSmad2/3 have opposing roles in regulation of chondrocyte differentiation.
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Abstract
Objective
Pain is the main problem for patients with osteoarthritis (OA). Pain is linked to inflammation, 
but in OA a subset of patients suffers from pain without inflammation, indicating an alternative 
source of pain. Nerve Growth Factor (NGF) inhibition is very efficient in blocking pain during 
OA, but the source of NGF is unclear. We hypothesize that damaged cartilage in OA releases 
Transforming Growth Factorβ (TGFβ), which in turn stimulates chondrocytes to produce NGF.
Design
Murine and human chondrocyte cell lines, primary bovine and human chondrocytes, and 
cartilage explants from bovine metacarpal joints and human OA joints were stimulated with 
TGFβ1 and/or Interleukin 1 (IL1)β. We analyzed NGF expression on mRNA level with QPCR 
and stained human OA cartilage for NGF immunohistochemically. Cultures were additionally 
pre-incubated with inhibitors for TAK1, Smad2/3 or Smad1/5/8 signaling to identify the TGFβ 
pathway inducing NGF.
Results
NGF expression was consistently induced in higher levels by TGFβ than IL1 in all of our 
experiments: murine, bovine and human origin, in cell lines, primary chondrocytes and 
explants cultures. TAK1 inhibition consistently reduced TGF-β-induced NGF whereas it fully 
blocked IL1β-induced NGF expression. In contrast, ALK5-Smad2/3 inhibition fully blocked 
TGFβ-induced NGF expression. Despite the large variation in basal NGF in human OA samples 
(mRNA and histology), TGFβ exposure led to a consistent high level of NGF induction.
Conclusion
We show for the first time that TGFβ induces NGF expression in chondrocytes, in a ALK5-
Smad2/3 dependent manner. This reveals a potential alternative non-inflammatory source 
of pain in OA.
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Introduction
The main symptom of osteoarthritis (OA) is joint pain. However, what part of the joint is actually 
causing pain is somewhat obscure. Pain is usually linked to inflammation [1], but in early OA 
patients, 45% of patients report pain without any detectible inflammatory component like 
synovitis that could be driving their pain [2]. This suggests a non-inflammatory cause for joint 
pain in at least a part of OA patients.
 In recent years, blocking Nerve Growth Factor (NGF) has surfaced as an efficient way 
to inhibit pain, also in OA [3–8].
 NGF was elevated in an animal model of OA with cartilage damage without joint 
inflammation, indicating a non-inflammatory source of NGF in OA [9,10]. McNamee et al. 
investigated NGF expression in a DMM model in whole knee joints and found that tumour 
necrosis factor alpha (TNFα) induced NGF in the post-operative phase, but TNFα was not 
responsible for later phases of OA pain as anti-TNFα only abrogated pain in the post-operative 
phase, not in late OA [9]. In contrast, NGF was key in both OA phases as soluble NGF receptor 
TrkAD5 prevented pain in both phases [9]. Iannone et al. showed that chondrocytes produced 
NGF. NGF was low in normal chondrocytes, increased in minor damaged cartilage, and 
further enhanced in severely damaged human articular cartilage [10]. Pecchi et al. found that 
Interleukin 1 (IL1) dose-dependently increased NGF expression in OA articular chondrocytes 
up to 5.7 fold at 10 ng/ml, paralleled by NGF protein release [11]. However, IL1 still suggests 
an inflammatory component, but does not explain a non-inflammatory source.
 We were intrigued by the fact that chondrocytes produced NGF and that levels were 
higher in damaged cartilage. In cartilage, Transforming Growth Factorβ (TGFβ1) is stored in 
high amounts [12]. Upon damage, TGFβ1 is released from the cartilage extracellular matrix 
[13]. During OA, TGFβ is upregulated in cartilage [14]. In addition, high levels of TGFβ1 were 
found in serum of OA patients with a strong correlation to a higher Kellgren–Lawrence grade 
and WOMAC scale [15]. Clearly, TGFβ1 levels are linked to cartilage damage and pain. By 
genome-wide gene expression analysis in murine chondrocytes, we showed that only six 
genes were enhanced by both IL1β and TGFβ1: one of these genes was NGF [16]. TGFβ1, like 
IL1β can signal through TAK1 [17,18]. This led to the hypothesis that TGFβ1 could be a driving 
factor in NGF expression in articular chondrocytes in a TAK1-dependent manner.
 We showed, for the first time, that TGFβ1 induced NGF expression in articular 
chondrocytes of murine, bovine and human origin and that TGFβ1-induced NGF levels were 
higher than those induced by IL1β. We identified that TAK1 inhibition blocked NGF expression 
by IL1β, but only reduced TGFβ1-induced NGF expression, thereby suggesting another 
major driving pathway for NGF induction. Further investigation revealed that blocking ALK5-
Smad2/3 signaling could fully prevent TGFβ1 induced NGF expression.
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Materials and methods
Chondrocyte cell lines
The murine chondrocyte cell line H4 [19] and human G6 chondrocyte cell line were used 
in monolayer [20]. The G6 cell line proliferates at 32°C and stops proliferating at 37°C. 
H4 chondrocytes were cultured in DMEM/F12 (Gibco, UK) with 50 mg/L gentamycin 
(Centrafarm Services, the Netherlands) and 100 mg/L pyruvate (Gibco, UK) with 5% FCS until 
use. G6 chondrocytes were cultured in a 1:1 mixture of DMEM/F12 10% serum and Lonza 
Mesenchymal Stem Cell Growth Medium (Lonza).
Bovine primary chondrocytes and cartilage explants
Primary bovine chondrocytes were isolated from cartilage of the metacarpal joint, obtained 
from the local slaughterhouse within 3 h post-mortem. Cartilage was removed with a scalpel, 
obtaining the non-calcified cartilage layers. We used 3 mm punches to generate equal size 
explants, which were randomly distributed over the different conditions, four explants per 
condition per cow. Cartilage explants were left untreated in DMEM/F12 0% FCS for 24 h prior 
to performing experiments. Alternatively for chondrocyte isolation, cartilage was treated 
with 1.5 mg/ml Collagenase B (Roche Diagnostics, Germany) in DMEM/F12 with 50 mg/L 
gentamycin and 100 mg/L pyrovate (1 g cartilage per 10 ml medium) overnight. Chondrocyte 
suspension was filtered (70 μm cell strainer (Beckton Dickenson Biosciences), pelleted, 
washed in saline, and seeded in a density of 1 × 105 cells per cm2. Cells were cultured for 1 
week to allow adherence prior to experiments.
Human OA primary chondrocytes or cartilage explants
Human OA cartilage was obtained from anonimized patients undergoing joint-replacement 
surgery. Cartilage explants were used, or chondrocytes were isolated as described for 
the bovine material, with the exception of the 1 week adherence prior to use, as human 
chondrocytes were cultured in monolayer overnight prior to stimulation.
Experiments
Cells or explants were serum starved overnight prior to stimulation. Cultures were 
supplemented with recombinant human or murine IL1β (1 or 10 ng/ml) (R&D) for human 
or murine cells, respectively, or recombinant human TGFβ1 (0.1, 1 or 10 ng/ml) (Biolegend). 
In experiments with inhibitors, DMSO was used as vehicle control. To block TAK1 activity, we 
used (5Z)-7-oxozeaenol [21] (oxozeanol in text, or oxo in figures) (Tocris Bioscience) either 
0.5 μM or 1 μM in the first experiment, but thereafter 0.5 μM. To inhibit TGFβ signaling via 
ALK5-Smad2/3, 5 μM of the ALK5 inhibitor SB-505124 [22] (SB in figures) (Sigma Aldrich) was 
used. For inhibition of the Smad1/5/8 pathway 0.05 μM LDN-193189 [23] was used (Axon 
Medchem). Cultures were pre-incubated with inhibitors for 1 h prior to addition of IL1β and/
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or TGF-β1. Twenty-four hours after addition of IL1β and/or TGF-β1, medium was removed 
and TRI-reagent was added for RNA isolation. Unless otherwise indicated a standard dose of 
10 ng/ml of TGFβ1 and/or 10 ng/ml IL1β was used for 24 h.
RNA isolation and Q-PCR
RNA isolation from explants was performed as previously described in Ref. [24] using the 
RNeasy Fibrous tissue Mini Kit (Qiagen) according to manufacturers protocol. RNA isolation 
from chondrocytes was performed using TRI-reagent (Sigma–Aldrich, Germany) as previously 
described in Ref. [25]. RNA concentration was measured using a Nanodrop photospectrometer 
(Thermo Scientific, USA), followed by cDNA preparation as previously described in Ref. [25].
The cDNA was diluted 10× in ultra pure water, and gene expression was measured using 1 μM 
of validated cDNA-specific primers (Table I) (Biolegio, the Netherlands) in a quantitative real 
time polymerase chain reaction (qPCR) using SYBRgreen master mix (Applied Biosystems). 
The protocol was: after 10 min at 95°C, 40 cycles of 15 s 95°C and 1 min 60°C each were run. 
A melting curve was made to verify gene-specific amplification. Data was expressed as ΔΔCt 
values corrected for GAPDH and controls, or when multiple controls were used a –Δct value 
was depicted. Besides NGF, we used MMP3 (for bovine) or MMP13 (for mouse and human) 
as a control for IL1 responsiveness.
Gene Forward 5’→3′ Reverse 5’→3′
mGAPDH GGCAAATTCAACGGCACA GTTAGTGGGGTCTCGCTCCTG
bGAPDH CACCCACGGCAAGTTCAAC TCTCGCTCCTGGAAGATGGT
hGAPDH ATCTTCTTTTGCGTCGCCAG TTCCCCATGGTGTCTGAGC
mNGF TGCGGCCAGTATAGAAAGCT GGGGAGCGCATCGAGTTTT
bNGF/hNGF CAGCTCTTTTGATCGGCATACA TGTGTCAAGGGAATGCTGAAGT
bMMP3 GAATCTGTGCCTCCCGAACC TCCTGAAAGATTTCCGCCAA
hMMP13 ATTAAGGAGCATGGCGACTTCT CCCAGGAGGAAAAGCATGAG
Table I. Primers used for QPCR
Immunohistochemistry
Cartilage explants were fixed for 24 h in 4% paraformaldehyde. Tissue was dehydrated with 
an automated tissue processing apparatus (Miles Scientific Tissue-Tek VIP tissue processor; 
Miles Scientific, now part of Bayer Corp., Emeryville, CA, USA) and embedded in paraffin. 
Seven μm sections were stained immunohistochemically as previously described in 
Ref. [26]. Primary antibody was anti-NGF (sc-33602, FL-241, Santa Cruz). A biotin–streptavidin 
detection system was used according to manufacturers protocol (Vector Laboratories, Inc.). 
Bound complexes were visualized via reaction with 3’,3’diaminobenzidine (Sigma Chemicals 
Co., Zwijndrecht, the Netherlands) and H2O2 resulting in a brown precipitate. Sections were 
counterstained with heamatoxylin and mounted with Permount.
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Statistical analysis
There are experiments within this paper that were not suitable for statistical analysis because 
we considered repetition of important scientifically relevant groups in separate experiments 
and different species of higher importance than repeating the same experiments. For human 
OA chondrocytes we included many patients, but given the variation in basal NGF expression 
in human OA patients we considered it would only be fair to the readers to display their −ΔCt 
values individually rather than pooling data and calculating ΔΔCt values. For the remainder of 
the experiments statistical analysis was performed using Graphpad Prism software. Gaussian 
distribution was tested using D’Agostino & Pearson omnibus normality test followed by either 
a one-way ANOVA with post-hoc Bonferroni comparison in case of a normal distribution, or 
by a Kruskall–Wallis test followed by Dunn’s comparison (see figure legends).
Results
TGFβ1 induces NGF in chondrocytes in an ALK5-Smad2/3 and TAK-1 dependent manner
To investigate whether TGFβ1 induced NGF in chondrocytes, we exposed the murine articular 
chondrocyte cell line H4 to 10 ng/ml TGFβ1 for 24 h. This led to a 2.8 fold increase (1.5 Ct) in 
NGF mRNA levels compared to non-treated controls (Fig. 1A). This increase was fully blocked 
by inhibiting TGFβ1 signaling via ALK5-Smad2/3 with SB-505124 (Fig. 1A). To investigate 
potential TAK1 dependency we exposed H4 chondrocytes to 10 ng/ml TGFβ1 with or 
without oxozeaenol (0.5 or 1 μM). TGFβ1 again increased NGF mRNA expression by 2.6 fold 
(1.4 Ct) (Fig. 1B). When adding appropriate DMSO dose to match the DMSO content of the 
oxozeaenol 0.5 or 1 μM, TGFβ1-induced NGF expression increased by 3.2 and 4 fold (1.7 and 
2.0 Ct), respectively. Preventing TGFβ1 signaling via TAK1 with oxozeaenol prevented TGFβ1- 
induced NGF-expression in both 0.5 and 1.0 μM oxozeaenol (Fig. 1B). Our data clearly show 
for the first time that TGFβ1 is capable of elevating NGF mRNA expression in chondrocytes 
using ALK5-Smad2/3 and TAK1 dependent.
TGFβ1 induces higher NGF expression than IL1β in human chondrocytes
To investigate whether TGFβ1 induced NGF in human cells, we stimulated human G6 
chondrocytes with 10 ng/ml of IL1β and compared that to a series of dosages of TGFβ1 (0.1, 1 
and 10 ng/ml) in (Fig. 2A). As expected, 10 ng/ml of IL-1 led to an increase in NGF mRNA levels 
of 2.3 fold (1.2 Ct). Surprisingly, TGFβ1 exposure increased NGF mRNA even higher by 10.6 fold 
(3.4 Ct) and 6.1 fold (2.6 Ct) in dosages of 1 and 10 ng/ml, respectively (Fig. 2A). This shows that 
1 ng/ml of TGFβ1 induced NGF expression that was 4.6 fold (2.2 Ct) higher compared to a high 
dose of IL1β (10 ng/ml) (Fig. 2A). Increasing the TGFβ1 dose from 1 to 10 ng/ml did not result in 
higher NGF levels, which might suggest a maximum level of NGF induction was already reached 
at 1 ng/ml of TGF-β1. These data show that TGFβ1 is more potent in inducing NGF than IL1β.
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Fig. 1. TGFβ1 induces NGF in murine articular chondrocytes in an ALK5-Smad2/3 and TAK1 dependent manner. 
Murine H4 chondrocytes were stimulated with 10 ng/ml TGFβ1 for 24 h in the presence or absence of ALK5-Smad2/3 
signaling inhibitor SB-505124 and compared to controls. RNA was isolated and QPCR was performed for NGF mRNA 
expression. TGFβ1 stimulation upregulated NGF expression compared to controls, which could be prevented by 
inhibiting ALK5-Smad2/3 signaling. Statistical analysis was performed using Krusskall–Wallis and Dunn’s comparison 
(A). Murine H2 chondrocytes were stimulated with 10 ng/ml of TGFβ1 for 24 h in the presence or absence of 0.5 μM 
or 1 μM oxozeaenol to prevent TAK1 signaling. TGFβ1 exposure resulted in an upregulation of NGF, which could be 
prevented by blocking TAK1 (B).
Fig. 2. TGFβ1 induces NGF expression in human chondrocytes in higher levels than IL1β; TGFβ1 and IL1β do not have 
an additive effect on NGF expression. Human G6 chondrocytes were stimulated with TGFβ1 or IL1β for 24 h, followed 
by RNA isolation and QPCR for NGF expression. Clearly, TGFβ1 induced higher levels of NGF compared to IL1β already 
at a dose of 1 ng/ml TGFβ1 (A). When TGFβ1 and IL1β were combined, NGF levels were not enhanced, showing a 
lack of additive effect of TGFβ1 and IL1β (B).
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IL1β and TGFβ1 are not additive in inducing NGF expression
To reveal whether or not TGFβ1 and IL1β could have an additive effect on NGF-expression 
in human G6 chondrocytes we combined IL1β and TGFβ1 in 1 and 10 ng/ml combinations. 
Again, TGFβ1 1 and 10 ng/ml had equal effects in upregulating NGF mRNA levels of 17.7 
fold (4.1 Ct) and 24.3 fold (4.6 Ct), respectively. Again, IL1β exposure yielded lower NGF 
expression compared to TGFβ1 of 4.6 fold (2.2 Ct) and 6.1 fold (2.6 Ct) by 1 ng/ml and 10 ng/
ml of IL1β, respectively. Combining TGFβ1 (either 1 ng/ml or 10 ng/ml) with IL1β (10 ng/ml) 
revealed no additive effect on NGF expression in any combination, but rather NGF levels 
were similar to the corresponding TGFβ1 levels without IL1β (Fig. 2B). Given the consistently 
lower IL1β responses compared to TGFβ1 and lack of additive effect, we wanted to confirm 
IL1β responsiveness and therefore additionally measured MMP13 mRNA expression. TGFβ1 
stimulation alone upregulated MMP13 by 3.26 Ct and 1.99 Ct in 1 ng/ml and 10 ng/ml, 
respectively, whereas IL1β stimulation resulted in an increase of 6.87 Ct and 6.77 Ct in 1 ng/ml 
and 10 ng/ml, respectively. IL1β 1 ng with TGFβ1 1 ng/ml or 10 ng/ml resulted in a mean 
increase in MMP13 expression of 8.57 Ct and 7.81 Ct, respectively and using IL1β 10 ng/ml 
with TGFβ1 1 ng/ml or 10 ng/ml increased MMP13 expression with 8.63 Ct and 8.15 Ct. Thus 
IL1β increased MMP13 expression thereby confirming IL1β responsiveness.
In primary bovine chondrocytes, TGFβ1 more potently induces NGF expression than IL1β
So far, we used chondrocyte cell lines. To confirm our findings in primary chondrocytes, 
we freshly isolated chondrocytes from bovine metacarpal joints and stimulated those with 
TGFβ1 (1 and 10 ng/ml), IL1β (1 or 10 ng/ml) or a combination of TGFβ1 1 ng/ml with IL1β 
10 ng/ml (Fig. 3A). This again showed that TGFβ1-induced NGF mRNA expression was 
comparable between 1 and 10 ng/ml leading to a 16 fold (4.0 Ct) and 19.7 fold (4.3 Ct) 
increase, respectively. This was again higher than NGF levels induced by IL1β, which were 2.6 
fold (1.4 Ct) and 3.7 fold (1.9 Ct) for 1 and 10 ng/ml, respectively. Combining TGFβ1 with IL1β 
did not further enhance NGF expression beyond TGFβ1-induced levels. Pre-incubation with 
TAK1-inhibitor oxozeaenol reduced NGF expression in all groups (Fig. 3A). However, TGFβ1 
stimulated groups with oxozeanol all still had elevated levels of NGF compared to baseline. 
Overall these data indicate that TGFβ1-stimulated NGF expression is only partially TAK1-
dependent, whereas IL1β fully relies on TAK1 signaling.
TGFβ1 increases NGF expression in bovine articular cartilage explants
From experience we know that isolated chondrocytes can respond differently from intact 
cartilage. To more closely mimic in vivo articular cartilage, we freshly isolated cartilage 
explants from healthy bovine metacarpal joints, and exposed these to TGFβ1 and IL1β. 
Isolated explants were left untreated for 24 h to reach a state of equilibrium. When comparing 
values of control samples 30 h after isolation to snap frozen samples, we found that NGF 
levels were increased. The NGF levels had restored to baseline after 48 h (24 h equilibrium + 
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24 h in experiment). Therefore, we used the 24 h stimulation after 24 h equilibrium for the 
remainder of our explants experiments. Upon TGFβ1 exposure, we again found a significant 
increase in NGF mRNA expression of 26 fold (4.7 Ct) on average compared to controls, 
whereas IL1β stimulation resulted in an average increase of 2.1 fold (1.1 Ct), which was not 
significantly different from controls (Fig. 3B). Combining TGFβ1 with IL1β again showed no 
additional effect on NGF expression levels. These data confirm that also in intact articular 
cartilage, TGFβ1 induces NGF mRNA expression levels that are higher than those induced 
by IL1β (Fig. 3B). We again wanted to confirm IL1β responsiveness in these samples and 
therefore measured MMP3 expression as MMP13 expression is below detection limit in 
bovine cartilage explants. This showed a significant increase in MMP3 expression in samples 
containing IL1β, thereby confirming IL1β responsiveness (Fig. 3C).
TGFβ1-induced NGF in bovine articular cartilage runs via ALK5-Smad2/3
As oxozeaenol could partially reduce TGFβ1-induced NGF expression we wanted to investigate 
if TGFβ1 signaling induces NGF in cartilage in a similar way (Fig. 3C). Therefore, we stimulated 
cartilage explants of four different cows to TGFβ1 with or without inhibitors for TGFβ1 signaling 
via ALK5-Smad2/3 (SB-505124), TGFβ1 signaling via Smad1/5/8 (LDN) or TAK1 (oxozeaenol).
TGFβ1 induced a 58.9 fold increase (5.9 Ct) compared to control. When comparing TGFβ1 + 
DMSO to TGFβ1 with inhibitors, TAK1 inhibition reduced TGFβ1-induced NGF expression by 
3.4 fold (1.8 Ct), but this was not significant. Blocking Smad1/5/8 signaling could not inhibit 
TGFβ1-induced NGF expression at all. In contrast, only blocking ALK5-Smad2/3 signaling 
was capable of significantly reducing TGFβ1-induced NGF expression (reduction of 55.6 fold 
(5.8 Ct). This shows that in intact articular cartilage, TGFβ1 signaling via ALK5-Smad2/3 
induces NGF and that there might be a small role for TAK1 in TGFβ1-induced NGF expression, 
whereas Smad1/5/8 signaling is not involved.
TGFβ1 and IL1β induce NGF expression in human OA cartilage
Until now we investigated the effect of TGFβ1 on healthy articular chondrocytes and intact 
cartilage. However, people experience pain during OA. We wanted to investigate whether 
human OA chondrocytes were also capable of upregulating NGF in response to TGFβ1 and 
IL1β. We freshly isolated chondrocytes from human OA cartilage and treated those with TGFβ1 
or IL1β. Similar to prior results, IL1β induced an increase in NGF mRNA expression of 6.1 fold 
(2.6 Ct) on average whereas TGFβ1 induced an increase of 18.4 fold (4.2 Ct) on average (Fig. 4A). 
We included MMP13 expression to confirm IL1β responsiveness in these samples (Fig. 4B). The 
most striking observation in these human OA samples was not so much the induced levels, but 
rather the massive variation in NGF mRNA expression in controls. We re-ordered the patients 
in the graph to clarify the large spread in basal NGF levels between OA patients, which clearly 
showed that upon induction with IL1β or TGFβ1 the levels of NGF mRNA seem to level out to a 
certain threshold, irrespective of the background levels. We isolated intact 
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Fig. 3. TGFβ1 induces higher levels of NGF than IL1β in bovine chondrocytes and bovine articular cartilage in a 
ALK5-Smad2/3 and partially TAK1 dependent manner. Primary bovine chondrocytes isolated from the bovine 
metacarpophelangeal joint were stimulated with TGFβ1 or IL1β or both with or without oxozeaenol. Both TGFβ1 
and IL1β induced NGF, but TGFβ1 induced NGF levels were much higher. Co-incubation with oxozeaenol, thereby 
preventing TAK1 signaling, could reduce TGF-β1-induced NGF expression, and fully reverse IL1β induced NGF 
expression (A). Bovine articular cartilage explants were stimulated with TGFβ1 or IL1β or a combination of both for 
24 h after which mRNA was isolated to measure NGF expression. This shows that TGFβ1 induced NGF expression is 
higher than IL1β induced NGF expression (B). Bovine articular cartilage was stimulated with TGFβ1 with or without 
inhibitors for ALK5-Smad2/3 signaling (SB-505124) 5 μM, Smad 1/5/8 signaling (LDN) 0.05 μM or TAK1 signaling 
(oxozeaenol) 0.5 μM for 24 h after which RNA was isolated to measure NGF expression. This showed that TGFβ1 
induced NGF expression could only be fully blocked in the presence of SB-505124, could not be blocked by LDN and 
slightly reduced by oxozeaenol (C). Statistical analysis was performed using Krusskall–Wallis and Dunn’s comparison.
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cartilage from three random OA patients and stained these for NGF with immunohistochemistry 
which illustrated that the staining patterns of NGF protein expression were very different for 
each patient (Fig. 4C). Whereas the first sample showed a light positive, but diffuse staining 
throughout the entire cell, sample 2 showed very intense nuclear staining, but not all cells 
were positive. The third showed a combination of both types of staining and some negative 
cells as well. Areas that had less damage seemed to contain less NGF positive cells, but since 
these were only three patients we cannot draw hard conclusions on this. However, our data 
underlines the diversity in NGF expression in human OA. Moreover, our stimulation data 
suggests that irrespective of the basal levels of NGF, upon stimulation with IL1β or TGFβ1 
the chondrocytes will produce a relative maximum level of NGF mRNA compared to GAPDH, 
which again generally seems to be higher for TGFβ1 stimulation than IL1β stimulation.
In human OA intact cartilage TGFβ1 induction of NGF is ALK5-Smad2/3 dependent
We identified that TGFβ1-induced NGF was ALK5-Smad2/3 dependent in bovine and murine 
chondrocytes. We wanted to investigate whether this holds true for OA. Therefore, we 
exposed human OA cartilage explants to TGFβ1 and combined this with ALK5-Smad2/3 
inhibition (SB-505124). We found that TGFβ1 induced a 6.5 fold increase of NGF (2.7 Ct) and 
that this was fully blocked when ALK5-Smad2/3 signaling was prevented in all but one patient 
(Fig. 4D). This shows that even in OA cartilage, TGFβ1 can induce NGF via ALK5-Smad2/3. 
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Fig. 4. TGFβ1 induces higher NGF expression than IL1β in human primary OA chondrocytes, but basal NGF levels show 
very high variation. Human primary OA chondrocytes were isolated from patients undergoing total joint replacement 
surgery after informed consent. After isolation, chondrocytes were stimulated with TGFβ1 or IL1β for 24 h followed 
by RNA isolation and Q-PCR for NGF. Clearly, TGFβ1-stimulated samples reached higher levels of NGF than IL1β- 
stimulated samples. However, a striking observation was that the basal levels of NGF in human OA chondrocytes 
showed a very large variation (A). In these samples MMP13 was measured to ensure IL1β responsiveness which 
showed that IL1β indeed induced MMP13 whereas TGFβ1 inhibited MMP13. Statistical analysis was performed using 
Krusskall–Wallis and Dunn’s comparison (B). Immunohistochemistry for NGF was performed on articular cartilage 
of three random OA patients showing diversity in NGF protein expression (C). Human OA cartilage explants were 
stimulated with TGFβ1 with or without an inhibitor for ALK5-Smad2/3 signaling (SB-505124) 5 μM for 24 h after 
which RNA was isolated to measure NGF expression. Co-incubation with SB-505124 resulted in a clear blockage of 
TGFβ1-induced NGF expression. After normality test, statistical analysis was performed with a one-way ANOVA and 
Bonferroni for comparison (D).
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Discussion
NGF has been identified as a potential target for pain therapy in OA. Iannone et al. showed 
that chondrocytes produce NGF and that levels of NGF were linked to cartilage damage [10]. 
In articular cartilage, TGFβ1 is stored in high amounts and is released upon damage [12]. Since 
there are patients with pain without any inflammatory component [27], we hypothesized 
that the source of NGF might be TGFβ released from the cartilage. We showed that TGFβ1 
induced NGF in articular cartilage via ALK5-Smad2/3 and these levels of NGF were much 
higher than those achieved by IL1β. This indicates that the non-inflammatory induction of 
NGF might have an even higher impact than presumed until now.
 As NGF was originally considered driven by inflammatory mediators, IL1β and TNFα 
have been in focus as inducing factors. In synovial OA fibroblasts, IL1β and TNFα were capable 
of inducing NGF [27]. However, the same authors identified that in experimental arthritis, IL1β, 
but not TNFα increased NGF and that TNFα even lowered constitutive NGF amounts in murine 
knee joints [28]. TNFα, however, enhanced IL1β-induced NGF indicating an indirect effect of 
TNFα and IL1β on NGF. The tissue of origin was unknown as whole knee joints were used. We 
compared IL1β to TGFβ1 as a reference for the extent of NGF induction. In all our experiments 
IL1β induced NGF, but TGFβ1 was far more potent, even when using a low dose of 1 ng/ml 
TGFβ1 compared to IL1β 10 ng/ml. This dose of IL1β is the same as used by Pecchi et al. [11]. 
They showed a basal value of NGF protein of approximately 15 pg/ml. We show that inhibiting 
ALK5-Smad2/3 signaling with SB-505124 reduced values to lower than controls (not significant). 
This could indicate that endogenous basal NGF levels rely on TGFβ as well.
 Pecchi et al. showed that mouse and human chondrocytes dose-dependently 
increased NGF expression, on mRNA level and protein, when exposed to IL1β [11]. Mechanical 
stimulation also induced NGF, but this could not be enhanced by IL1β. In fact, their finding 
could rely on TGFβ1 as a source of NGF induction, as we recently published that Smad2/3 
signaling was enhanced by mechanical stimulation [29]. Moreover, we found that IL1β 
could not enhance TGFβ1-induced NGF expression, which could explain why IL1β could not 
enhance NGF when combined with mechanical stimulation in Pecchi’s experiments.
 As both IL1β and TGFβ1 can signal via TAK1, we initially thought this could be the 
common pathway driving NGF. Moreover, our prior finding of NGF being one out of only six 
genes that were not counteracted, but rather enhanced by TGFβ1 and IL1β, strengthened our 
idea [16]. Indeed we found that TAK1 inhibition decreased TGFβ1-induced NGF expression, but 
not to the extent that we had originally expected. In contrast, IL1β-induced NGF expression 
was fully blocked by inhibition of TAK1, thereby confirming TAK1 dependency. This indicated 
involvement of another pathway in TGFβ1-induced NGF expression. By blocking different 
pathways activated by TGFβ1, we identified that TGFβ1-induced NGF in chondrocytes and 
cartilage explants was fully ALK5-Smad2/3 dependent.
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In pancreatic cells it was shown that TGFβ1 induced NGF via ALK5 [30]. This fully matches 
our data in chondrocytes, where we show that TGFβ1 relies on ALK5-Smad2/3 signaling for 
induction of NGF. In line with that, Braunger et al. showed in retinal progenitor cells of TGFβ1 
receptor II deficient mice, Smad3 phosphorylation was decreased, which led to lower levels 
of NGF mRNA. Similarly, mice deficient in Smad7, which is a TGFβ1 signaling inhibitor, had 
higher Smad3 phosphorylation and higher levels of NGF mRNA [31]. In rat hippocampus, 
TGFβ1 increased NGF mRNA expression in vivo [32]. Interestingly, Yu et al. showed four 
different transcripts of NGF that were differentially expressed comparing mouse and rat 
spinal cord and brain cells. This potentially relies on multiple TGFβ1 responsive elements 
in the NGF promoters located upstream of exons 1 and 3 [33]. TGFβ1 could induce NGF in 
astrocytes and glioma cells, but not in neuronal cells, whereas all cells expressed the same 
TGFβ1 receptors. It was concluded that differences were on a transcriptional level. They 
showed that in different cell types different combinations of NGF transcripts were induced 
by TGFβ1. We did not find species differences, but clearly IL1β and TGFβ1 showed different 
levels of NGF expression, which could correspond to different transcripts being expressed.
 In human OA cartilage, we found that basal levels of NGF were highly different 
between patients, which was reflected by differences in immunohistochemical NGF staining. 
The finding of nuclear NGF staining could point towards a nuclear translocation as previously 
found by Yanker et al. [34]. We observed that intact cartilage areas showed less NGF staining 
compared to damaged areas, but given the limited number of patients we are reluctant 
to conclude on that. However, it does fit the data of Iannone et al. who also found that 
damaged cartilage expressed more NGF [10]. Strikingly, despite the vast differences in basal 
NGF levels, stimulating these highly variable samples with either TGFβ1 or IL1β, resulted 
in similar levels of NGF expression for which the height of expression was dependent on 
the stimulus. TGFβ1-induced NGF was overall higher than the IL1β-induced NGF. This again 
points towards a potential different regulatory mechanism: ALK5-Smad2/3 vs TAK1 for TGFβ1 
and IL1β, respectively.
 In this study we included multiple species and monolayer vs tissue explants culture 
to ensure NGF-induction was not limited by method or species selected. However, this 
introduced a limitation where for some experiments a low number of individual samples 
were used in which case statistical analysis was not possible. Therefore it is not possible to 
extrapolate beyond current experiments when sample number was low.
 In conclusion, we show that TGFβ1 is a very potent inducer of NGF expression in 
chondrocytes and cartilage and its induction of NGF can be higher than IL1β. Moreover, we 
show that TGFβ1-induced NGF expression relies on ALK5-Smad2/3 signaling, even in human 
OA cartilage. In addition, we show that TGFβ1-induced NGF expression can be reduced by 
TAK1 inhibition. In contrast, IL1β induced NGF expression is fully TAK1 dependent. Overall 
our data strongly suggest that NGF-induced by TGFβ1 in chondrocytes could be a prominent 
alternative, non-inflammatory source of pain in OA.
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are both ALK5-kinase-dependent in primary chondrocytes 
and mediated by TAK1 kinase activity
van Caam A, Madej W, Garcia de Vinuesa A, Goumans MJ, Ten Dijke P,
 Blaney Davidson E, van der Kraan P.
Arthritis Res Ther. 2017 May 31;19(1):112
CHAPTER 7
164
Abstract
Objective
Dysregulated transforming growth factor β (TGFβ) signaling is implicated in osteoarthritis 
development, making normalizing TGFβ signaling a possible therapy. Theoretically, this can 
be achieved with small molecule inhibitors specifically targeting the various TGFβ receptors 
and downstream mediators. In this study we explore in primary chondrocytes the use of small 
molecule inhibitors to target TGFβ-induced pSmad1/5/9-, pSmad2/3- and TGFβ-activated 
kinase 1 (TAK1)-dependent signaling.
Design
Primary bovine chondrocytes and explants were isolated from metacarpophalangeal joints. 
To modulate TGFβ signaling the activin receptor-like kinase (ALK)1/2/3/6 inhibitor LDN-
193189, the ALK4/5/7 inhibitor SB-505124 and the TAK1 inhibitor (5Z)-7-Oxozeaenol were 
used. pSmad1/5 and pSmad2 were measured using western blot analysis and TGFβ1-induced 
gene expression was measured using quantitative real time PCR (qPCR).
Results
In chondrocytes, TGFβ1 strongly induced both pSmad1/5 and pSmad2. Remarkably, LDN-
193189 did not inhibit TGFβ-induced pSmad1/5. In contrast, SB-505124 did inhibit both 
TGFβ-induced Smad2 and Smad1/5 phosphorylation. Furthermore, (5Z)-7-Oxozeaenol also 
profoundly inhibited TGFβ-induced pSmad2 and pSmad1/5. Importantly, both SB-505124 
and (5Z)-7-Oxozeaenol did not significantly inhibit constitutively active ALK1, making an 
off-target effect unlikely. Additionally, LDN-193189 was able to potently inhibit BMP2/7/9-
induced pSmad1/5, showing its functionality. On gene expression, LDN-193189 did not affect 
TGFβ1-induced regulation, whereas both SB-505124 and (5Z)-7-Oxozeaenol did. Similar 
results were obtained in cartilage explants, although pSmad1/5 was not strongly induced by 
addition of TGFβ1.
Conclusion
Our data suggest that ALK5 kinase activity plays a central role in both TGFβ-induced Smad1/5 
and Smad2/3 phosphorylation, making it difficult to separate both pathways with the use 
of currently available small molecule inhibitors. Furthermore, our data regarding (5Z)-7-
Oxozeaenol suggest that TAK1 facilitates Smad-dependent signaling.
TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary 
chondrocytes and mediated by TAK1 kinase activity.
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Introduction
Transforming growth factor β (TGFβ) plays a crucial role in regulation of tissue homeostasis 
via its control over diverse cellular processes such as proliferation, differentiation and matrix 
formation. By binding to different receptors of the activin-receptor like kinase (ALK) family, 
TGFβ induces intracellular carboxy-terminal (C-terminal) phosphorylation of receptor-
regulated Smad (R-Smad) proteins. Phosphorylated R-Smads form complexes with the 
common-mediator Smad; Smad4, and these complexes translocate to the nucleus where 
they bind DNA to regulate gene transcription via recruitment of transcription factors [1, 
2]. Use of different ALKs can result in activation of different R-Smads; activation of ALK5 
(TGFβR1) induces phosphorylation of Smad2 and Smad3, whereas activation of an ALK1 (or 2 
or 3) complex mediates phosphorylation of Smad1, Smad5 and Smad9 [3, 4]. However, TGFβ 
signaling is not limited to R-Smads as Smad-independent signaling can occur by activation 
of e.g. TGFβ-activated kinase 1 (TAK1 or MAP3K7). Smad-independent signaling results in 
activation of various downstream signaling pathways, including the JUN N-terminal kinase 
(JNK) and p38 mitogen-activated protein kinase (MAPK) pathways [5].
 In many tissues, e.g. in cartilage, phosphorylated Smad2/3 and Smad1/5 have 
opposing functions [6, 7]. In cartilage, phosphorylated Smad3 guards chondrocyte 
phenotype against deleterious hypertrophy and production of catabolic enzymes like 
matrix metalloproteinases (MMPs) [8, 9, 10]. In contrast, phosphorylated Smad1/5 is 
essential for chondrocyte hypertrophy [11, 12], and is associated with expression of matrix 
metalloproteinase 13 (MMP13), the main cartilage-degrading enzyme [13]. Therefore, 
balancing TGFβ signaling via Smad2/3 or Smad1/5 is important for chondrocytes to maintain 
cellular homeostasis and deregulation of this balance has been proposed as a cause of 
disease, e.g. osteoarthritis (OA) [4, 13]. It would be of great benefit if cellular responses to 
TGFβ could be directed towards either the Smad1/5 or Smad2/3 pathway; this would enable 
blockade of deleterious pathways while maintaining beneficial signaling.
 Inhibiting Smad phosphorylation can be achieved by blocking the kinase domain 
of ALK receptors. Small molecules have been developed that specifically inhibit the kinase 
activity of ALK4, ALK5 and ALK7, the receptors that phosphorylate Smad2 and Smad3, or 
ALK1, ALK2, ALK3 and ALK6, the receptors that phosphorylate Smad1, Smad5 and Smad9 
[14, 15]. In this study we investigated in chondrocytes and cartilage explants the use of SB-
505124 [15, 16], an inhibitor of ALK4/5/7 kinase activity and LDN-193189, an inhibitor of 
the ALK1/2/3/6 kinase activity [14, 16] to study their ability to direct R-Smad signaling and 
downstream effects. Furthermore, we used (5Z)-7-Oxozeaenol as a selective inhibitor of TAK1 
kinase activity to evaluate the importance of TAK1 in TGFβ signaling in chondrocytes [17, 
18], because of the ability of TAK1 to induce the JNK and p38 MAPK pathways and MMP 
production in cartilage [19, 20].
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In this study we show that inhibition of ALK4/5/7 kinase activity prevented TGFβ1-induced 
C-terminal phosphorylation of both Smad2 and Smad1/5. Furthermore, treatment with (5Z)-
7-Oxozeaenol, a selective TAK1 kinase inhibitor, attenuated phosphorylation of both Smad2/3 
and Smad1/5 and expression of Smad target genes. Use of the ALK1/2/3 inhibitor LDN-193189 
did not affect TGFβ1-induced R-Smad phosphorylation or gene expression. In conclusion, 
our data show that in cartilage the activity of the ALK5 kinase domain is essential for TGFβ1 
signaling, whereas ALK1 kinase activity is not. Furthermore, our results obtained with (5Z)-
7-Oxozeaenol underline that TAK1 kinase activity is facilitating R-Smad phosphorylation. 
Our study indicates that TGFβ1-induced Smad1/5 and Smad2/3 phosphorylation cannot be 
selectively targeted by using the small molecule inhibitors SB-505124 and LDN-193189.
Materials and methods
Chondrocyte culture
Primary bovine chondrocytes were isolated from the metacarpophalangeal joint of cows 
(2–5 years old) obtained from a slaughterhouse within 3 hours post mortem. Chondrocytes 
were obtained by incubating cartilage slices overnight in Collagenase B (for details see [21]). 
Chondrocytes were seeded in DMEM/F12 1:1 containing 10% fetal calf serum (Thermo Scientific 
UK) at a density of 0.5 × 105 cells per cm2 in 6-well plates (Greiner Bio-one International, the 
Netherlands) for protein studies, or in 24-well plates (Bio-one International, the Netherlands) 
for mRNA experiments. Cells were cultured for 1 week at 37 °C and 5% CO2 before the start of 
the experiments. For explant studies, four 7 mm2 explants per condition were pooled in 1 ml 
of medium. Both monolayer and explant studies were repeated in different donors.
Adenoviral transfection of primary chondrocytes
Adenoviruses were used to induce expression of constitutively active (ca)ALK1 [4], constitutively 
active ALK5 [4] and the CAGA12-luciferace reporter construct [22] in primary chondrocytes. 
Cells were rinsed twice with saline, and adenoviruses were added in a multiplicity of infection 
of 200 for 3 h at 37 °C in a minimal volume of DMEM/F12 1:1. Hereafter, cells were washed 
twice with saline, and DMEM/F12 1:1 was added. Cells were used 48 h after transfection.
Inhibition of TGFβ1 signaling
Before stimulation, cells were deprived of serum for 24 h and thereafter stimulated with 1 
ng/ml recombinant human TGFβ1 (Biolegend, the Netherlands) for 2 or 24 h. In experiments 
where inhibitors were used, DMSO was used as vehicle control. To block TAK1 activity, we 
used (5Z)-7-Oxozeaenol [17] (Tocris Bioscience) in a concentration of 0.5 μM. To inhibit ALK5 
kinase, we used SB-505124 [15] (Sigma Aldrich) in a concentration of 5 μM. For inhibition 
of ALK1 kinase, LDN-193189 [14] (Axon Medchem) was used in a concentration of 0.05 
TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary 
chondrocytes and mediated by TAK1 kinase activity.
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μM. This concentration of LDN-193189 is well above its reported half maximal inhibitory 
concentration (IC
50
), 0.8 nM for ALK1, but far below its IC
50
 for ALK5 of 350 nM [16, 23]. Cells 
were pre-incubated with the inhibitors for 1 h prior to addition of TGF-β1. Either 2 or 24 h 
after addition TGFβ1, medium was removed and TRI-reagent was added for RNA isolation.
Protein isolation
To isolate proteins from monolayer cultures, cells were lysed on ice using lysis buffer (Cell 
signaling, USA) containing a protease inhibitor cocktail (complete, Roche Diagnostics, 
Germany) and subsequently sonicated on ice using a Bioruptor (Diagenode, USA). With a 
BCA-assay (Thermo Scientific, USA) protein concentration was measured and after addition 
of Laemmli sample buffer, samples were boiled for 5 minutes at 99 °C.
 To isolate proteins from explants, four 7-mm2 explants were homogenized 
using a Mikro-dismembrator (B. Braun, Germany) and dissolved in 1 ml ice cold 
radioimmunoprecipitation assay (RIPA) buffer with added 1 mM Na3VO4 and protease inhibitor 
cocktail (Roche Diagnostics, Germany). After 1 h incubation on a roller bench at 4 °C, samples 
were spun down for 3 minutes at 104 × g and the pellet was discarded. Cetylpyridinium 
chloride was added up to a concentration of 1% (m/v) and samples were incubated on a 
roller bench for 1 h at 4 °C. Hereafter, samples were spun down twice for 15 minutes at 104 × g 
at 4 °C and the pellet was discarded. Using 10 kDa centrifugal filter units (Millipore, USA) the 
supernatant was concentrated to a volume of 50 μl. Subsequently, proteins were precipitated 
by addition of 950 μl of 20% m/v trichloroacetic acid and 0.1% m/v dithiothreitol in aceton at 
-20 °C and spinning samples down for 15 minutes at 6700 × g at 4 °C. Next, the pellets were 
washed three times with 0.1% m/v dithiothreitol in aceton at -20 °C. Finally, the pellets were 
dried under vacuum for 20 minutes and dissolved in 100 μl 1% m/v sodium dodecyl sulfate in 
100 mM tris(hydroxymethyl)aminomethane in H2O pH 9.0.
Detection of proteins using SDS-PAGE and western blot
Proteins were seperated on a 7.5% Bisacrylamide gel, and transferred to a nitrocellulose 
membrane using wet transfer (Towbin buffer, 2.5 h 275 mA at 4 °C). After overnight incubation 
at 4 °C with 1:1000 polyclonal Rabbit anti P-Smad1/5 (S463/465)/Smad8 (S426/428) (Cell 
signaling, USA) or anti P-Smad2 (S465/467) (Cell signaling, USA), membranes were incubated 
with 1:1500 polyclonal Goat anti Rabbit labeled with horseradish peroxidase (HRP) (DAKO, 
Belgium) for 1 h. Hereafter, enhanced chemiluminescence using ECL plus (GE Healthcare, 
UK) was used to visualize the proteins. To visualize overexpression of constitutively active 
ALKs, a rabbit polyclonal antibody directed against their internal HA tag was used: HA-probe 
Antibody (Y-11) (Santa Cruz, USA) (1:1000). As loading control either Gapdh was stained with 
an anti-Gapdh mouse mAb (1G5) (Sigma Aldrich, Germany) (1:10 000) in combination with 
IRDye 680RD Donkey anti mouse (1:10 000) (Licor, USA) using the Odyssey detection system 
(Licor, USA) or Vinculin with a rabbit pAb (H300) (Santa Cruz, USA) (1:1000) in combination 
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with HRP-labeled Goat-anti Rabbit (1:2000) (DAKO, Denmark) using ECL. Finally, blots were 
quantified using ImageJ.
Detection of gene expression
TRI-reagent (Sigma-Aldrich, Germany) was used for RNA isolation according to the 
manufacturer’s protocol (for details see [21]). RNA concentration was measured using a 
Nanodrop photospectrometer (Thermo Scientific, USA). Per sample, 1 μg of RNA was treated 
with DNAse (Life Technologies, USA), which was subsequently inactivated at 65 ° C with 1 
μl 25 mM EDTA (Life Technologies, USA). To perform reverse transcriptase reaction, 1.9 μl 
ultra pure water, 2.4 μl 10 × DNAse buffer, 2.0 μl 0.1 M DTT, 0.8 μl 25 mM dNTP, 0.4 μg oligo 
dT primer, 1 μl 200 U/μl M-MLV Reverse transcriptase (all Life Technologies, USA) and 0.5 
μl 40 U/μl RNAsin (Promega, the Netherlands) was added, and samples were incubated for 
5 minutes at 25 °C, 60 minutes at 39 °C, and 5 minutes at 95 °C using a thermo cycler. The 
obtained cDNA was diluted 10 times in ultra pure water, and gene expression was measured 
using 1 μM of validated cDNA-specific primers (Biolegio, the Netherlands; see Table 1) in 
a quantitative real-time polymerase chain reaction (qPCR) using SYBR green master mix 
(Applied Biosystems). The following protocol was used: after 10 minutes at 95 °C, 40 cycles 
of 15 sec at 95 °C and 1 minute at 60 °C each were run. Hereafter a melting curve was made 
to verify gene-specific amplification. For calculations of the -ΔCt, two reference genes were 
used: glyceraldehyde 3-phosphate dehydrogenase and ribosomal protein S14.
Statistics
All quantitative data are expressed as a mean of multiple repeats ± SD. For every analysis data 
were checked for normality using the Shapiro-Wilk test. One-way analysis of variance (ANOVA) 
with Tukey multiple comparison post-hoc test was used to determine the significance. The 
statistical analyses were performed using Graphpad Prism 5.0 software.
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chondrocytes and mediated by TAK1 kinase activity.
169
7
Gene NCBI reference 
sequence
P (bp) E (%) Forward primer Reverse primer
bGapdh NM_001034034.2 90 101 CACCCACGGCAAGTTCAAC TCTCGCTCCTGGAAGATGGT
bRps14 NM_001077830.2 125 105 CATCACTGCCCTCCACATCA TTCCAATCCGCCCAATCTTCA
bAlk1 NM_001083479.1 109 100 ACAACACAGTGCTGCTCAGACA TGCTCGTGGTAGTGCGTGAT
bAlk2 NM_176663.3 61 105 CGTTGGAGACAGCACTTTAGCA AGAGCCGCTTCCCGATGTA
bAlk3 NM_001076800.1 142 96 GAGCAAGATGAAGCATTTATTCCA CAACCTGCCGAACCATCTG
bAlk5 NM_174621.2 75 94 CAGGACCACTGCAATAAAATAGAACTT TGCCAGTTCAACAGGACCAA
bSerpine1 NM_174137.2 55 99 CGAGCCAGGCGGACTTC TGCGACACGTACAGAAACTCTTGA
bId1 NM_001097568.2 73 107 GCTCCGCTCAGCACTCTCAA GATCGTCCGCTGGAACACA
bMmp3 NM_001206637.1 130 106 GAATCTGTGCCTCCCGAACC TCCTGAAAGATTTCCGCCAA
bSmad7 NM_001192865.1 72 98 GGGCTTTCAGATTCCCAACTT CTCCCAGTATGCCACCACG
bTgfb1 NM_001166068.1 80 107 GGTGGAATACGGCAACAAAATCT GCTCGGACGTGTTGAAGAAC
bJunb NM_001075656.1 139 97 CCTTCTACCACGACGACTCA CCGGGTGCTTTGAGATTTCG
bNgf NM_001099362.1 110 85 CAGCTCTTTTGATCGGCATACA TGTGTCAAGGGAATGCTGAAGT
bFn1 NM_001163778.1 95 96 GCACCACTCCCGACATTACT CTGATCGGCATGGACCACTT
bCol2a1 NM_001001135.2 60 97 TGATCGAGTACCGGTCACAGAA CCATGGGTGCAATGTCAATG
Table 1: Sequence and efficiency of the primers used in this study P is product length in base pairs, E is efficiency in 
percentage. Alk1 is also known as Acvrl1, Alk2 as Acvr1, Alk3 as Bmpr1a and Alk5 as Tgfbr1
Results
SB-505124 and (5Z)-7-Oxozeaenol both inhibit TGFβ1-induced Smad1/5 and Smad2/3 
phosphorylation whereas LDN-193189 does not
To begin, we confirmed in primary bovine chondrocytes the expression of the receptors that 
TGFβ can use to induce Smad2/3 phosphorylation i.e. ALK5 or Smad1/5 phosphorylation, i.e. 
ALK1, ALK2 and ALK3 [3, 4]. All four receptors were readily detected using qPCR (Additional 
file 1: Figure S1), and indeed confirmed that stimulation of chondrocytes with TGFβ1 results 
in both Smad2 and Smad1/5 phosphorylation (Fig. 1A).
 Subsequently, we analyzed the effects of the ALK4/5/7-kinase inhibitor SB-505124, 
the ALK1/2/3-kinase inhibitor LDN-193189 and the TAK1-kinase inhibitor (5Z)-7-Oxozeaenol 
on TGFβ1-induced R-Smad phosphorylation (Fig. 1A, B and C). Strikingly, addition of 5 μM 
SB-505124 not only inhibited Smad2 phosphorylation but also pSmad1/5 phosphorylation. 
Remarkably, treatment with 0.5 μM (5Z)-7-Oxozeaenol also resulted in inhibition of TGFβ1-
induced Smad1/5 and Smad2 phosphorylation. Noteworthy, addition of 0.05 μM LDN-193189 
did not affect TGFβ1-induced Smad1/5 phosphorylation but did significantly enhance TGFβ-
induced pSmad2.
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Fig. 1. SB-505124 and (5Z)-7-Oxozeaenol inhibit both transforming growth factor β1 (TGFβ1)-induced Smad1/5 and 
Smad2/3 phosphorylation whereas LDN-193189 does not. (A) Primary bovine chondrocytes were pre-incubated 
with either 5 μM SB-505124, 0.5 μM (5Z)-7-Oxozeaenol or 0.05 μM LDN-193189 for 1 h, and subsequently 
stimulated with 1 ng/ml TGFβ1 for 1 h, after which phosphorylated Smads were visualized using western blot by 
specific antibodies. kDa, kilodalton. (B) Quantification of the pSmad1/5 signal (as shown in (A)) in four experiments. 
pSmad1/5 levels were normalized to vinculin levels and plotted as a relative amount in arbitrary units (AU) compared 
to the control group: #p ≤ 0.001 compared to unstimulated; ***p ≤ 0.001. (C) Quantification of the pSmad2 signal (as 
shown in (A)) in four experiments. pSmad2 levels were normalized to vinculin levels and plotted as a relative amount 
in AU compared to the control group: # p ≤ 0.001 compared to unstimulated; ***p ≤ 0.001. (D) Dose-response effect 
of SB-505124 on TGFβ1 signaling in primary chondrocytes. (E) Quantification of pSmad levels (shown in (D)); levels 
were normalized to vinculin levels and plotted as a relative amount in percentage compared to the control group.
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Fig. 2. SB-505124 and (5Z)-7-Oxozeaenol do not affect constitutively active activin receptor-like kinase 1 (ALK1) 
whereas LDN-193189 does. (A) Primary bovine chondrocytes were transfected with either constitutively active ALK1 
(caALK1) or caALK5 and 2 days later treated with inhibitors for 1 h. A virus overexpressing LacZ was used as control. 
Efficiency of overexpression was visualized on western blot by staining for the HA-tag attached to the caALKs. kDa 
kilodalton. (B) Quantification of the pSmad1/5 and pSmad2 signal (as shown in (A)) in three experiments; # p ≤ 0.001 
compared to unstimulated. pSmad levels were normalized to vinculin levels and plotted as a relative amount in 
arbitrary units (AU) compared to the control group; § p ≤ 0.01 compared to unstimulated; **p ≤ 0.01; ***p ≤ 0.001. C 
Dose-response effect of LDN-193189 on transforming growth factor β1 (TGFβ1) signaling in primary chondrocytes. 
pSmad levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh) levels and indicated as a 
relative amount in AU compared to the control group. (D) Primary chondrocytes were incubated for 1 h with LDN-
193189 and subsequently stimulated for 1 h with 1 ng/ml (78 pM) TGFβ1, 25 ng/ml (1.94 nM) recombinant human 
bone morphogenic protein 2 (rhBMP2), 25 ng/ml (3.06 nM) bone morphogenic protein 7 (BMP7) or 1 ng/ml (83 
pM) bone morphogenic protein 9 (BMP9). pSmad levels were normalized to Gapdh levels and indicated as a relative 
amount in AU compared to the control group.
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To investigate if the striking effect of SB-505124 on Smad1/5 phosphorylation was a dose-
dependent effect, we performed a dose-response experiment (Fig. 1D and E). This experiment 
showed that at all tested doses (0.1, 0.5, 1, 5, 10 and 25 μM), SB-505124 inhibited TGFβ1-
induced Smad1/5 phosphorylation, and that Smad1/5 phosphorylation was inhibited more 
potently than that of Smad2. Therefore, to address if ALK1 inhibition was a possible off-
target effect of SB-505124, this compound was added to cells over-expressing constitutively 
active (ca)ALK1 or caALK5. This experiment showed that SB-505124 did not affect caALK1-
induced Smad1/5 phosphorylation (Fig. 2A and B), but did inhibit caALK5-induced Smad2 
phosphorylation (Fig. 2A and B). Therefore, SB-505124 is specific for ALK5 kinase and does 
not inhibit ALK1 kinase. The same experimental setup was used to address the specificity of 
(5Z)-7-Oxozeaenol, and no significant inhibitory effect of this compound on either caALK1 or 
caALK5 function was detected, making it unlikely that either the ALK1 or ALK5 kinase domain 
is an off-target of (5Z)-7-Oxozeaenol. 
 To investigate if the lack of effect of LDN-193189 on TGFβ1-induced Smad1/5 was 
maybe dose-dependent, we added a 10 times higher dose of LDN-193189 (0.5 μM) to the 
cells, but were still unable to inhibit TGFβ1-induced Smad1/5 phosphorylation (Fig. 2C). 
Therefore we sought to validate the function of LDN-193189. To do this, we added 0.05 
μM LDN-193189 to chondrocytes over-expressing caALK1 and observed that this blocked 
caALK1-induced Smad1/5 phosphorylation (Fig. 2A and B), Furthermore, the effect of 
0.05 μM LDN-193189 on bone morphogenic protein (BMP) signaling was also investigated 
(Fig. 2D) by stimulating primary chondrocytes for 1 h with either the ALK2/3 ligands BMP2 
or BMP7 [24] or the ALK1/2 ligand BMP9 [25, 26]. We observed that BMP-induced Smad1/5 
phosphorylation was clearly inhibited by 0.05 μM LDN-193189. Together, these experiments 
strongly confirm the function of 0.05 μM LDN-193189 in primary chondrocytes.
 In conclusion, in primary chondrocytes, TGFβ1-induced Smad1/5 phosphorylation 
is unaffected by LDN-193189, whereas both Smad2/3 and Smad1/5 phosphorylation are 
inhibited by SB-505124 and (5Z)-7-Oxozeaenol.
Fig. 3. SB-505124 fully and (5Z)-7-Oxozeaenol partly inhibits transforming growth factor β1 (TGFβ1)-induced Smad-
dependent gene expression whereas LDN-193189 does not. (A) Primary bovine chondrocytes were pre-incubated 
with 5 μM SB-505124, 0.5 μM (5Z)-7-Oxozeaenol or 0.05 μM LDN-193189 for 1 h, and subsequently stimulated 
with 1 ng/ml TGFβ1 for 2 h and 24 h. With the use of quantitative (q)PCR, expression of bSerpine1 was measured as 
response gene for pSmad3 signaling after 2 h, and bId1 for pSmad1/5 signaling after 2 h. (B) The pSmad3 responsive 
CAGA12-luciferase (CAGA 12 -luc) construct was placed in primary chondrocytes with the use of an adenovirus, and 
cells were stimulated with 1 ng/ml TGFβ1 for 8 h with or without inhibitors after 2 days. (C) Primary chondrocytes 
were stimulated with 1 ng/ml TGFβ1 for 24 h and gene expression was measured using validated cDNA-specific 
primers and qPCR. MMP matrix metalloproteinase, NGF nerve growth factor, ALK5 activin receptor-like kinase 5. (D) 
Gene expression was measured after pre-incubation of chondrocytes for 1 h with inhibitors followed by stimulation 
with 1 ng/ml TGFβ1 for 24 h. For qPCR data, average ± sd (mean ± sd) was plotted, with each dot representing the 
average of one donor (A) or four donors (C and D). Analysis was performed using one-way analysis of variance with 
Tukey’s post-hoc test: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. A change of 1 ΔΔC t equals twofold upregulation.
TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary 
chondrocytes and mediated by TAK1 kinase activity.
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SB-505124 fully and (5Z)-7-Oxozeaenol partly inhibit TGFβ1-induced Smad-dependent 
gene expression whereas LDN-193189 does not
Next, we analyzed the effects of TGFβ1 signaling inhibitors on TGFβ1-induced Smad-
dependent gene expression. For this, bId1 and bSerpine1 were used as markers of pSmad1/5 
and Smad3 signaling, respectively [4, 27] [22, 28]. Expression of bId1 was profoundly 
upregulated by stimulation with 1 ng/ml of TGFβ1 (Fig. 3A). In accordance with our western 
blot data on pSmad1/5, expression of bId1 was inhibited by both SB-505124 and (5Z)-7-
Oxozeaenol, and was unaffected by LDN-193189. Expression of bSerpine1 was upregulated 
by 1 ng/ml of TGFβ1 and fully inhibited by SB-505124, but was only partly inibited by (5Z)-7-
Oxozeaenol (Fig. 3B). To confirm these effects on pSmad3-dependent gene expression, we 
used the CAGA12-luc construct, which produces luciferase specifically in response to pSmad3. 
After 8 h, TGFβ-induced CAGA12-luc activity was significantly inhibited by (5Z)-7-Oxozeaenol 
and SB-505124, showing that pSmad3-signaling is indeed lowered in these conditions. 
When the effect of the inhibitors on multiple TGFβ1-induced (Fig. 3C), genes like bSmad7, 
bMmp3, bCol2a1, bNgf, bAlk5, bJunb, bFN1 and bTgfb1 was measured, none of these 
genes was significantly downregulated by LDN-193189, unlike SB-505124, which profoundly 
downregulated bSmad, bNgf, bAlk5, bJunb, bFN1 and bTgfb1, or unlike treatment with (5Z)-
7-Oxozeaenol, which significantly lowered bNgf, bTgfb1 and bMmp3 expression (Fig. 3D). 
Because a role for pSmad1/5 in the regulation of e.g. Smad7, Junb and Col2a1 has been 
established [29, 30, 31], these data indicate that the ALK5 kinase inhibitor SB-505124 inhibits 
gene expression downstream of both pSmad2/3 and pSmad1/5, whereas (5Z)-7-Oxozeaenol 
does so to a lesser extent and in a more limited amount of genes. No effect of LDN-193189 
was observed on TGFβ1-induced gene expression.
Fig. 4. In cartilage, SB-505124 fully inhibits and (5Z)-7-Oxozeaenol partly inhibits transforming growth factor β1 
(TGFβ1)-induced Smad2/3 phosphorylation and gene expression, whereas LDN-193189 does not. (A) Bovine cartilage 
explants were pre-incubated ex vivo with 5 μM SB-505124, 0.5 μM (5Z)-7-Oxozeaenol or 0.05 μM LDN-193189 for 
1 h, and subsequently stimulated with 1 ng/ml TGFβ1 for 2 h, after which phosphorylated Smads were visualized 
by western blot using specific antibodies. kDa kilodalton. (B) With the use of quantitative (q)PCR, expression of 
bSerpine1 was measured as response gene for pSmad3 signaling after 24 h, and bId1 for pSmad1/5 signaling after 24 
h. (C) Gene expression was measured after pre-incubation of explants for 1 h with inhibitors followed by stimulation 
with 1 ng/ml TGFβ1 for 24 h. For qPCR data, average ± sd (mean ± sd) was plotted, with each dot representing the 
average of one donor (B) or four donors (C). Analysis was performed using one-way analysis of variance with Tukey’s 
post-hoc test: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). A change of 1 ΔΔC t equals twofold upregulation or downregulation. 
TGF transforming growth factor, COL2A1 = collagen type II alpha 1 chain MMP matrix metalloproteinase, NGF nerve 
growth factor, ALK5 activin receptor-like kinase, JUNB = JunB proto-oncogene, FN1 = fibronectin 1
TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary 
chondrocytes and mediated by TAK1 kinase activity.
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Inhibition of TGFβ1-induced gene expression in cartilage explants (24 h)
CHAPTER 7
176
In intact cartilage, SB-505124 and-Oxozeaenol inhibit TGFβ1-induced pSmad1/5 and pSmad2
As TGFβ1 signaling is known to be affected by cellular context, we sought to validate our observations 
in monolayer chondrocytes in intact cartilage ex vivo. Therefore we stimulated cartilage explants 
with 1 ng/ml TGFβ1 with or without inhibitors, and investigated Smad phosphorylation. Explants 
were stimulated for 2 h to allow for diffusion of TGFβ1 through the cartilage matrix. In explants, 
1 ng/ml TGFβ1 induced pSmad2, but Smad1/5 phosphorylation was more difficult to detect (Fig. 
4A), in contrast to in monolayer cultures. Therefore BMP9 was used as positive control, which, 
in comparison to TGFβ, resulted in far stronger induction of pSmad1/5 (for quantification see 
Additional file 2: Figure S3). A smaller amount of pSmad1/5 was detected in explants treated with 
TGFβ1 and SB-505124, (5Z)-7-Oxozeaenol or LDN-193189 compared to TGFβ1-treated samples 
alone. TGFβ-induced phosphorylation of Smad2 was clearly inhibited by SB-505124 and partly by 
(5Z)-7-Oxozeaenol (Fig. 4A), but on gene expression bSerpine1 was only significantly inhibited by 
SB-505124 and not by (5Z)-7-Oxozeaenol (Fig. 4B). In explants, expression of bId1 could not be used 
as a read-out for pSmad1/5 signaling, because TGFβ1 downregulated its expression, in contrast 
to its induction in monolayer experiments. This is a well-known Smad3-dependent cytostatic 
effect of TGFβ1 [32], and further indicates that TGFβ1 signaling differs between chondrocytes 
in monolayer and chondrocytes in intact cartilage. Notably, LDN-193189 did downregulate bId1 
expression,  even in absence of TGFβ1 (Additional file 3: Figure S2), demonstrating the bioactivity 
of this compound in cartilage explants. Again, when multiple, TGFβ1-induced, Smad-dependent, 
genes were measured (Fig. 4C) SB-505124 inhibited TGFβ1-induced expression of bSmad7, bNgf, 
bFn1 and bTgfb1, and (5Z)-7-Oxozeaenol inhibited TGFβ1-induced expression of bFn1, bTgfb1, 
whereas no effect of LDN-193189 was observed. Therefore, SB-505124 also inhibits both TGFβ1-
induced Smad1/5 and Smad2 phosphorylation and gene expression in intact cartilage, whereas 
LDN-193189 does not. Furthermore, (5Z)-7-Oxozeaenol partly inhibited both TGFβ1-induced 
Smad1/5 and Smad2 phosphorylation.
Discussion
TGFβ1 signaling is a crucial regulator of chondrocyte homeostasis. We investigated the impact 
of small molecule inhibitors on TGFβ1 signaling in primary chondrocytes both in vitro and ex 
vivo. We report that inhibition of ALK4/5/7 kinase with SB-505124 lowered both TGFβ1-induced 
Smad1/5 and Smad2/3 phosphorylation and downstream gene expression, whereas inhibition of 
ALK1/2/3/6 kinase with LDN-193189 did not affect TGFβ1-induced Smad1/5 phosphorylation or 
transcriptional activity. In addition, we showed that treatment with (5Z)-7-Oxozeaenol, a selective 
TAK1 kinase inhibitor, attenuated TGFβ1-induced R-Smad phosphorylation and downstream gene 
expression.
 In many tissues, including cartilage, TGFβ1 induces pSmad1/5 and pSmad2/3 [3, 4, 7]. 
ALK5 is essential for TGFβ1-induced Smad2/3 phosphorylation, whereas a role for ALK1 [4], ALK2 
and ALK3 [3] has been demonstrated in TGFβ-induced Smad1/5 phosphorylation (see Fig. 5). 
TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary 
chondrocytes and mediated by TAK1 kinase activity.
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Remarkably, we found that specific inhibition of ALK4/5/7 kinase with SB-505124 was sufficient to 
inhibit both TGFβ1-induced Smad2/3 and Smad1/5 phosphorylation and transcriptional activity. 
In contrast, we were unable to block TGFβ1-induced Smad1/5 phosphorylation with LDN-193189, 
even though we used a dose (0.05 μM) well above the reported IC
50
 of this inhibitor for ALK1 (0.8 
nM), ALK2 (0.8 nM) and ALK3 (5.3 nM) [23]. Additionally, even a 10 times higher dose of LDN-
193189 (0.5 μM) was unable to block TGFβ1-induced Smad1/5 phosphorylation. LDN-193189 has 
been established as an efficient inhibitor of BMP type I receptors, i.e. ALK1/2/3 and ALK6, both 
in vitro and in vivo [14, 23, 33]. We were able to confirm this inhibitory effect of LDN-193189 on 
BMP-induced Smad1/5 phosphorylation in primary chondrocytes by using BMPs that signal via 
ALK1, ALK2 and/or ALK3, i.e. BMP2, BMP7 and BMP9 [24, 25]. Furthermore, we were also able to 
block caALK1 activity with LDN-193189 in our primary cell cultures. Together, these experiments 
indicate that LDN-193189 is functional in primary bovine chondrocytes and blocks the ALK1, ALK2 
and ALK3 kinase activity at a dose of 0.05 μM. Therefore, our data indicate that ALK1, ALK2 or 
ALK3 kinase activity is not required for TGFβ1-induced Smad1/5 in primary chondrocytes and 
cartilage. Notably, various studies using the LDN-193189 precursor dorsomorphin also show that 
this BMP type I receptor blocker is unable to block TGFβ1-induced Smad1/5 phosphorylation, 
supporting our observations [34, 35].
Based on structural analyses of R-Smad-ALK interactions, the ability to phosphorylate Smad1/5 
is thought to be limited to BMP type I receptors [36, 37]. Our data indicate that ALK5 kinase 
activity is crucial, and possibly sufficient, for TGFβ1-induced Smad1/5 phosphorylation. In 
line with our data, it has previously been demonstrated that inhibition of ALK5-kinase with 
SB-431542 in endothelial cells [6] or with SB-505124 in synovial fibroblasts [34] attenuates 
TGFβ1-induced phosphorylation of Smad1/5. Furthermore, by knocking down ALK5, it 
has been shown by others that this receptor is necessary for TGFβ-induced Smad1/5 
phosphorylation [3, 6]. Possibly, ALK5 can directly phosphorylate Smad1/5 independently 
of BMP type I receptors in cartilage. Direct phosphorylation of Smad1 by caALK5 has been 
demonstrated by in vitro kinase assays [35, 38], and it has been shown that TGFβ1-induced 
Smad1 phosphorylation is inhibited in cells expressing a kinase defective ALK5 variant: ALK5KR 
[38]. Together, these studies indicate a direct induction of pSmad1/5 by ALK5, which would 
be blocked by SB-505124, but challenge the dogma that ALK5 cannot directly interact with 
Smad1 [36, 37]. In contrast, multiple studies show that in the absence of BMP type I receptors, 
TGFβ1-induced pSmad1/5 is reduced [3, 6] indicating at least a role for these receptors.
 Apart from R-Smad phosphorylation, TGFβ1 also induces TAK1 activation, a key 
component of Smad-independent TGFβ signaling [5]. Noteworthy, with the use of the 
specific TAK1 kinase inhibitor (5Z)-7-Oxozeaenol [17] at 0.5 μM, we showed that TAK1 
kinase activity facilitates canonical C-terminal R-Smad phosphorylation in chondrocytes and 
cartilage. Previous studies support a role for TAK1 in R-Smad-dependent signaling; with the 
use of cartilage-specific TAK1 knockout animals, it has been shown that loss of TAK1 greatly 
CHAPTER 7
178
TGFβ BMP
ALK5 ALK5
TGFBR2 TGFBR2
SB-505124
(5Z)-7-Oxozeaenol
Smad2/3 pSmad2/3
SB-505124
(5Z)-7-Oxozeaenol
Smad2/3 pSmad2/3
Smad1/5 pSmad1/5
ALK5 ALK2
ALK1
ALK3
?
BMPR2
ACVR2a
ACVR2b
ALK1 ALK1
ALK2 ALK2
ALK3 ALK3
ALK6 ALK6
LDN-193189
(5Z)-7-Oxozeaenol
Smad1/5 pSmad1/5
Type II receptors
Type I receptors
R-Smads
Ligand
Fig. 5. Schematic overview of transforming growth factor β (TGFβ)-induced Smad signaling versus bone morphogenic 
protein (BMP)-induced Smad signaling in cartilage and the effects of small molecule inhibitors. To signal, a TGFβ 
dimer binds and induces dimerization of its type II receptor: TGFBR2. This complex subsequently recruits a dimer of 
the type I receptors TGFβ can bind: activin receptor-like kinase (ALK)1, ALK2, ALK3 and ALK5. Signaling complexes 
containing ALK5 homodimers will induce Smad2/3 phosphorylation, whereas complexes containing ALK5 combined 
with ALK1, ALK2 or ALK3 will induce both Smad1/5 and Smad2/3 phosphorylation. However, our current study 
shows that the kinase domain of ALK1, ALK2 or ALK3 is not involved in TGFβ-induced pSmad1/5 because TGFβ-
induced pSmad1/5 is inhibited by SB-505124 but not by LDN-193189. Possibly, ALK1, ALK2 and ALK3 function to 
recruit Smad1/5 to TGFβ receptor complexes but are not activated by TGFBR2 themselves and are therefore not 
active. For BMP signaling a heterotetrameric complex is also formed from its different type II and type I receptors; 
BMPR2, ACVR2a and ACVR2b can be used as type II receptors, whereas ALK1, ALK2, ALK3 and ALK6 function as type I 
receptors. These complexes will induce pSmad1/5 but this is potently blocked by LDN-193189 (as shown in this 
article) or partially blocked by (5Z)-7-Oxozeaenol (evidence from the literature).
diminishes BMP-induced C-terminal Smad1/5 phosphorylation while not affecting total 
R-Smad levels [39, 40]. Furthermore, tissue specific knockout of TAK1 in mesenchymal cells 
of neural crest origin shows that also C-terminal Smad2/3 phosphorylation is inhibited in 
the absence of TAK1 [41]. The pronounced effects of TAK1 on canonical C-terminal Smad 
phosphorylation have been ascribed to TAK1-induced Smad-linker phosphorylation, a post-
translational Smad modification [41, 42].
 Linker modification of R-Smads is an essential aspect of TGFβ1-signaling (reviewed 
in [43, 44]). The linker region of R-Smads contains threonine and serine residues that can 
be phosphorylated by various intracellular kinases like extracellular signal-regulated kinases 
(ERK), cyclin-depdendent kinases (CDKs) and JNKs [43, 45]. Degradation, nuclear transport and 
interaction of R-Smads with other proteins are regulated by phosphorylation of this region, 
enabling context-dependent TGFβ signaling [43, 44]. TAK1 can directly interact with R-Smads 
via the R-Smad MH2 domain [42], and phosphorylate, e.g. Smad2 at threonine 220 (Thr-
TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary 
chondrocytes and mediated by TAK1 kinase activity.
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220). Phosphorylation of this threonine greatly affects cellular localization and transcriptional 
activity of this Smad [41, 42]. TAK1 kinase activity is essential for this interaction of TAK1 
with R-Smads [42]. As a consequence of this kinase dependency, it has been reported that 
the use of (5Z)-7-Oxozeaenol results in similar effects on C-terminal Smad1/5 and Smad2/3 
phosphorylation as knockout of TAK1 [41]. We did not have access to cartilage-specific 
TAK1 knockout animals, but with the use of (5Z)-7-Oxozeaenol, we show for the first time 
that this selective TAK1 kinase inhibitor greatly affects TGFβ1-induced C-terminal R-Smad 
phosphorylation both in vitro and ex vivo in articular cartilage.
 A limitation of our study is the possibly imperfect specificity of the used compounds, 
making it possible that off-target effects can explain our observations and interfere with our 
conclusions. However, in the experiments with the caALKs, we did not observe a significant 
effect of SB-505124 or (5Z)-7-Oxozeaenol on caALK1-induced pSmad1/5, or an effect of (5Z)-
7-Oxozeaenol on caALK5-induced pSmad2. Therefore we do not think that these compounds 
have off-target effects on ALK1. Furthermore, a dose-response curve showed that SB-
505124 inhibited TGFβ-induced Smad1/5 phosphorylation more potently than Smad2/3 
phosphorylation, demonstrating that this effect of SB-505124 on TGFβ signaling is not an 
off-target effect obtained at high dosage, and this compound therefore cannot be used to 
specifically inhibit TGFβ-induced Smad2 in chondrocytes.
 Another limitation of our study is that we did not include in vivo data. Unfortunately, 
the in vivo use of both SB-505124 and LDN-193189 is difficult because of their unfavorable 
pharmacokinetic properties, resulting in the need for daily re-administation via injection [33]. 
Up to now, only one study has used SB-505124 as a TGFβ blocker in vivo in a model of OA; i.e. 
in anterior cruciate ligament transection in mice [46]. In this study, inhibition of TGFβ signaling 
with 1 mg/kg/day of SB-505124 attenuated OA development, confirming that inhibition of 
TGFβ signaling with a small molecule inhibitor is a feasible and promising approach to treat 
OA. However, the use of a higher dose of SB-505124 (2.5 mg/kg/day) was detrimental for 
cartilage because this resulted in proteoglycan depletion, indicating that total TGFβ inhibition 
comes with a risk. Possibly, a small molecule inhibitor that prevents TGFβ-induced pSmad1/5 
but leaves pSmad2 unaffected will not have this risk. To our knowledge, both LDN-193189 
and (5Z)-7-Oxozeaenol have not been used in vivo to study their effects on OA development. 
They have been used in other applications, e.g. LDN-193189 in atherosclerosis research and 
(5Z)-7-Oxozeaenol in cancer studies; however, this was not to specifically modulate TGFβ 
signaling but to inhibit BMP and TAK1 signaling, respectively. Therefore it is as yet unknown 
how these inhibitors modulate TGFβ signaling in vivo or in OA.
 In conclusion, with the use of the small molecule inhibitors SB-505124 and LDN-
193189 we were unable to direct TGFβ1-signaling towards either Smad1/5 or Smad2/3 
phosphorylation in cartilage. Our data suggest that in cartilage, ALK5 plays a central role in 
both TGFβ-induced Smad1/5 and Smad2/3 phosphorylation, making it difficult to separate 
the Smad pathways with the use of currently available intracellular small molecule inhibitors 
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of the ALK receptors. Furthermore, we showed that treatment with the TAK1 inhibitor 
(5Z)-7-Oxozeaenol inhibits TGFβ-induced C-terminal phosphorylation of both Smad1/5 and 
Smad2/3, suggesting a link between the non-canonical and the canonical TGFβ pathway in 
cartilage.
TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary 
chondrocytes and mediated by TAK1 kinase activity.
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Figure S1. Expression of ALK1, ALK2, ALK3 and ALK5 mRNA in primary bovine cartilage and chondrocytes. With the 
use of qPCR, expression of ALK1, ALK2, ALK3 and ALK5 was measured in both freshly isolated cartilage explants and 
in primary chondrocytes after 1 week of cell culture in DMEM/F12 supplemented with 10% non-heat-inactivated FCS 
without passage. All four ALKs were readily detected in both groups, but expression of all the receptors was higher in 
freshly isolated tissue. For calculations of the -ΔCt, two reference genes were used: bGapdh and bRps14.
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Figure S2. LDN-193189 in a concentration of 0.05 μM inhibits basal ID1 expression in cartilage explants. Primary 
chondrocytes were incubated with LDN-193189 for 2 h in a dose of 0.05 μM and bId1 expression was measured 
using qPCR. LDN-193189 significantly inhibited bId1 expression showing the bioactivity of this compound in cartilage 
explants.
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Figure S3. Quantification of TGFβ-induced pSmad2 and pSmad1/5 in cartilage explants. Quantification of the western 
blot as shown in Fig. 4a. The experiment was repeated three times. Significance was not obtained due to variation 
between experiments. pSmad levels were normalized to vinculin levels and plotted as a relative amount in arbitrary 
units (AU) compared to the control group.
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TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary 
chondrocytes and mediated by TAK1 kinase activity.
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Aim of this thesis
TGFβ-family signaling regulates the homeostasis of many tissues, including cartilage [1]. Via 
induction of SMAD-dependent and SMAD-independent signaling, members of the TGFβ-
family regulate gene expression, protein expression, cell survival, cell growth and cell division 
[2, 3]. In view of these diverse functions, it is not surprising that disturbed TGFβ-family 
signaling is linked to the development of many pathologies, including osteoarthritis (OA), the 
world’s most common joint disease [1]. Currently, there is no disease modifying treatment 
available for OA yet, fueling the search for such a treatment. To aid in the development of 
such a treatment, a better understanding of the disease process is of great importance. 
In part, such comprehension comes from a good knowledge of how tissue homeostasis is 
regulated. Another part of this understanding can be gained by investigating how risk factors 
affect tissue homeostasis and contribute to disease development. Therefore, the aims of this 
thesis were to further characterize (1) the importance of TGFβ-family signaling in cartilage 
homeostasis and (2) how ageing, the main risk factor for OA, impacts this signaling. To achieve 
these aims we studied TGFβ-family signaling and its activation in ageing (healthy) cartilage 
and characterized its effects.
Role of loading-induced TGFβ signaling in maintenance of articular chondrocyte 
phenotype.
Loading has long been identified as an important contributor to cartilage health and 
homeostasis [4]. In this thesis we demonstrated in chapter 2 that a crucial role for loading 
lies in the activation of pSMAD2/3 signaling. We identified this crucial role by first observing 
that unloading of (bovine) articular cartilage led to a rapid decrease in pSMAD2 levels 
and pSMAD2/3-mediated gene expression. This decrease in pSMAD2/3-mediated gene 
expression was even so severe that addition of a functional pSMAD2/3 inhibitor (which 
works by inhibiting its activating kinases, i.e. the ALK4/5/7 inhibitor SB-505124), had no 
additional effect, indicating that there was no residual pSMAD2/3 signaling left. Hereafter, 
we observed that loading was able to rapidly and repeatedly induce both pSMAD2 levels and 
pSMAD2/3-mediated gene expression to great extent in cartilage explants, thus confirming 
the importance of loading in SMAD2/3 signaling in cartilage. 
 After having identified that loading is essential for pSMAD2/3 levels in cartilage, 
we sought to find its physiological role in cartilage homeostasis. We first investigated the 
importance of loading-mediated SMAD2/3 signaling in maintenance of cartilage proteoglycan 
content. We did this by comparing the sulfated glycosaminoglycan (GAG) content of cartilage 
which was regularly loaded for two weeks to the content of cartilage which was not loaded 
at all. During the course of these two weeks, the GAG content of unloaded cartilage greatly 
diminished by 80%, but regular loading did not counteract this decrease in the slightest. In 
contrast, the addition of fetal calf serum or IGF1 both resulted in maintenance of cartilage 
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GAG content. These observations show that loading-induced signaling is unable to maintain 
GAG content in cartilage, and GAG maintenance is thus not likely a physiological role for 
loading-mediated pSMAD2/3 signaling.
 Subsequently we investigated if loading-mediated pSMAD2/3 signaling has a role 
in the maintenance of chondrocyte phenotype. Again, we compared cartilage which was 
regularly loaded to cartilage which was not loaded at all. We observed that in the absence 
of loading chondrocyte hypertrophy, as measured by collagen type X expression, was greatly 
induced. Strikingly, loading, even for only a relatively short time interval, was able to potently 
inhibit this induction of chondrocyte hypertrophy. In contrast, addition of serum (or IGF1) 
was unable to inhibit or prevent chondrocyte hypertrophy. This led us to the conclusion 
that prevention of chondrocyte hypertrophy is an important physiological role of loading-
mediated SMAD2/3 signaling.
 As the explanation behind loading-induced pSMAD2/3 signaling in cartilage, we 
would like to argue that this is activation of matrix-bound inactive TGFβ. To begin with, we 
observed that loading-induced pSMAD2/3 signaling can be blocked with the ALK4/5/7 kinase 
inhibitor SB-505124. This indicates that activation of (one of) these receptors is responsible 
for loading-mediated pSMAD2/3 signaling. Next, we measured that both ALK4 and ALK5 
are well expressed in cartilage, but ALK7 is not, making it unlikely that ALK7 activation is 
responsible. Therefore we next tested if loading-induced effects can be mimicked by addition 
of the ALK4 ligand activin A, and/ or by the ALK5 ligand TGFβ1 [5]. This showed us that the 
addition of activin A had no effect but that the addition of TGFβ resulted in similar effects as 
loading, suggesting a role for TGFβ in loading-induced pSMAD2/3 signaling. Such a role for 
TGFβ is further supported by the observation that the cartilage matrix contains high levels of 
inactive TGFβ [6], and in various tissues mechanical force is a potent activator of TGFβ due to 
mechanical unwinding of the LAP inactivation domain associated with TGFβ [7]. Therefore, 
we think that loading activates pSMAD2/3 signaling via activation of inactive TGFβ. 
 Finally, we explored how loading further affects chondrocyte phenotype. We did 
this by measuring gene expression of chondrocytes shortly and one day after they were 
exposed to loading. In these experiments we observed that loading (rapidly) induced the 
expression of TGFβ1 and ALK5, while it inhibited the expression of ALK1. These observations 
indicate that upon compression a positive feedback loop is activated in chondrocytes which 
induces the production of TGFβ1 and helps direct TGFβ1 signaling to pSMAD2/3 by changing 
the TGFβ receptor ratio in favour of more ALK5 expression and less ALK1 expression. This 
positive feedback loop further strengthens the importance of loading in pSMAD2/3 signaling 
in cartilage.
Ageing negatively affects TGFβ signaling in cartilage
After we established the importance of loading in activation of pSMAD2/3 signaling in 
cartilage via activation of TGFβ , we realized that ageing might negatively affect this process. 
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In a previous study of our lab we had identified age-related changes in expression of the TGFβ 
receptors ALK1 and ALK5 that resulted in relatively higher ALK1 expression levels in old mice 
compared to young mice [8, 9]. These changes positively correlated with OA development in 
both the DMM model of OA and STR/ort mice. However, in mice, ageing and OA development 
go hand in hand and therefore it was unclear if this receptor change preceded or reflected 
OA development. Furthermore, it was also still unclear if and how such a change in receptor 
expression affected their function. Therefore we re-investigated age-related changes in 
TGFβ-family signaling components, but this time in a model organism in which ageing can 
be separated from OA development; the cow. Bovine cartilage can be obtained from a wide 
age-range of individuals, and OA affected cartilage can be visually detected and excluded 
from analysis.
 In chapter 3 we used this approach to study cartilage ageing on histology and 
gene and protein expression. The cartilage samples we studied were obtained from 
metacarpophalangeal joints of 42 animals ranging from 1 to 10 years old. In this age range, 
many aspects of ageing cartilage could be observed; cartilage thinning, loss of cellularity, 
profound (1000-fold) loss of collagen type 2 expression and tidemark duplication(s) [10, 
11]. Importantly, we also observed age-related loss of the ALK5 receptor but saw only 
minor changes in ALK1 expression levels. This observation supports the idea that changing 
receptor levels precede the development of OA, and can therefore be a cause for OA. To 
further support this idea, we also investigated if a change in ALK1 and ALK5 receptor levels 
affects TGFβ signaling. We did this by exposing bovine cartilage of different ages to TGFβ 
ex vivo and measuring the induction of Serpine1, a gene whose TGFβ-induced expression is 
SMAD3 dependent [12]. This experiment showed us that with advancing age less Serpine1 
expression is induced by TGFβ, indicating a loss of TGFβ potency in inducing pSMAD3 in old 
cartilage. To evaluate if ALK1 signaling was affected, we exposed cartilage explants in a similar 
setting to BMP9, a high affinity ALK1 ligand [13], and measured ID1, a SMAD1/5-dependent 
gene. Strikingly, ageing did not negatively affect BMP9 signaling, and BMP9 signaling was 
possibly even increased with advancing age. Together these observations indicate that ageing 
differentially affects the ALK1 and ALK5 receptors and their ability to signal. This implicates 
that ageing can alter the balance between TGFβ-induced SMAD2/3 and SMAD1/5 signaling 
and thus change the effects that TGFβ has on chondrocyte phenotype from protective to 
deleterious.
 Now that we confirmed that ageing indeed negatively impacts TGFβ signaling in old 
(bovine) cartilage, we investigated if ageing also negatively affects compression mediated 
pSMAD2/3 (TGFβ) signaling in chapter 4. We did this by exposing bovine explants of different 
ages ex vivo to loading and measured phosphorylated SMAD2 levels. The induction of 
pSMAD2 by compression was markedly decreased by up to 90% in old cartilage. Also Serpine1 
gene expression was significantly less increased in old cartilage compared to young cartilage 
upon compression. Together, these observations show that loading-induced pSMAD2/3 
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signaling is impaired in old cartilage. Because the loading we applied to the cartilage was force 
controlled, we noticed that older cartilage was more difficult to compress at a physiological 
force of 3MPa. However, the reduced activation of pSMAD2/3 is not due to this increased 
stiffness of old cartilage. We tested this by increasing the force from 3 MPa to 12 MPa and 
repeating the experiment. This increased force resulted in a similar amount of cartilage 
deformation between young and old, but did not affect the difference in pSMAD2/3 activation 
between these two age groups. In conclusion, age-related changes have a significant impact 
on the response of chondrocytes to mechanical stimuli, including their pSMAD2/3 levels. 
These observations indicate that the essential role of TGFβ in maintenance of cartilage we 
postulated in chapter 2 is negatively impacted by ageing.
New insights into the role of TGFβ signaling in cartilage
Now that it was clear that loading-induced TGFβ signaling is essential for cartilage homeostasis, 
and that ageing negatively affects this protective mechanism, we wanted to further explore 
the importance of TGFβ signaling in cartilage.
 In view of the observations we did in ageing cartilage, we began by further 
exploring the impact of ALK1 signaling on chondrocyte phenotype. We did this by stimulating 
chondrocytes with BMP9, a high affinity ALK1 ligand [13], and measured the effects thereof 
on SMAD activation, gene expression and chondrocyte phenotype. We chose to use BMP9 
instead of TGFβ to separate (putative) deleterious ALK1 signaling from (putative) protective 
ALK5 signaling which would both be activated simultaneously in case of TGFβ [14]. In 
chapter 5 we show that BMP9 potently induced SMAD1/5/8 phosphorylation and SMAD1/5-
dependent gene expression. In chondrocytes that were exposed to BMP9 for 1 week, BMP9 
signaling led to increased expression of collagen type X and alkaline phosphatase, two markers 
of chondrocyte hypertrophy [15]. This indicates that long term ALK1 signaling is detrimental 
to chondrocyte phenotype. 
 However, remarkably, BMP9 also induced some SMAD2 phosphorylation, and more 
importantly, synergized with TGFβ on induction of SMAD2 phosphorylation and SMAD3-
dependent [16] luciferase production in an CAGA12-luciferase reporter assay. Furthermore, 
TGFβ was able to potently inhibit BMP9-induced collagen type X and alkaline phosphatase 
expression, possibly facilitated by the synergy between these ligands. These results again 
demonstrate the importance of TGFβ signaling for maintenance of chondrocyte phenotype. 
Notably, the synergy between BMP9 and TGFβ was an unique aspect of BMP9 signaling 
compared to the signaling of two other BMPs, BMP2 and BMP7, showing that this synergy is 
not a generalized effect of BMPs. A possible explanation for the synergy between TGFβ and 
BMP9 is that BMP9 outcompetes TGFβ for ALK1 binding due to its higher affinity, forcing 
TGFβ to make use of ALK5-ALK5 signaling complexes which are assumed to produce twice 
as much pSMAD2/3 as ALK1-ALK5 complexes because ALK1 cannot phosphorylate SMAD2/3 
[17].
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We would like to argue that the inhibition of BMP9 induced hypertrophy is an important 
function of TGFβ in cartilage. To begin, BMP9 is circulating in large amount [18], making it likely 
that chondrocytes are (continuously) exposed to this growth factor. Because we observed 
that prolonged BMP9 signaling induces chondrocyte hypertrophy, we therefore think that 
chondrocytes are continuously exposed to a drive towards hypertrophy. An inhibitor of this 
would thus be required to maintain articular cartilage phenotype and in view of our results 
we propose that this is TGFβ. Importantly, in ex vivo cartilage explants, BMP9 strongly induces 
cartilage matrix production (i.e. collagen type 2 and proteoglycans) (literature [19] and own 
observations) but TGFβ does not negatively affect this positive aspect of BMP9 signaling 
(own observation). Therefore, TGFβ signaling can separate the good from the bad in BMP9 
signaling in cartilage.
 After having established that TGFβ inhibits BMP9-mediated chondrocyte 
hypertrophy, we wanted to further examine TGFβ-induced gene expression in chondrocytes 
and cartilage to gain more insights into its role in cartilage biology. One approach we took was 
by stimulating (primary) human, murine and bovine chondrocytes with TGFβ for both short 
and long time intervals and measuring changes in gene expression. 
 In chapter 6 the results of these experiments are shown that led us to conclude 
that TGFβ potently induces nerve growth factor (NGF), an important pain stimulus [20], via 
an ALK5-dependent mechanism. In human, murine and bovine chondrocytes, TGFβ induced 
NGF mRNA expression after 24 hours. Strikingly, TGFβ was very potent in inducing this 
NGF mRNA expression, it was even more potent than IL1β which we had used as positive 
control. Next we used the ALK1 inhibitor LDN-193189, the ALK5 inhibitor SB-505124 and 
the TAK1 kinase inhibitor 5Z-(7)-oxozeaenol to test which receptor was crucial for this TGFβ-
induced NGF mRNA expression and if SMAD-independent signaling was involved. In this 
experiment, we observed that SB-505124 fully inhibited TGFβ-induced NGF expression, 
whereas LDN-193189 had no effect. Therefore we concluded that this effect of TGFβ is ALK5 
dependent. Furthermore, The 5Z-(7)-oxozeaenol compound inhibited TGFβ-induced NGF 
expression by approximately 50%, indicating involvement of SMAD-independent signaling. 
These observations make it clear that TGFβ can potently induce NGF mRNA expression. This 
links TGFβ to pain in OA, because NGF is a key driver of OA pain, because clinical studies 
have shown that inhibiting it (fully) blocks OA related pain [20]. However, we did notice 
that in vitro it was very difficult to detect NGF protein production in either human, murine 
or bovine chondrocytes after stimulation with TGFβ, even though mRNA expression was 
abundantly present. Only in human OA cartilage we were able to detect NGF protein using 
immunohistochemistry. To us, this indicates that a second stimulus (which would be present 
in OA cartilage) is required to mediate the translation of NGF mRNA into protein. Such a 
mechanism would prevent the (unwanted) continuous production of NGF in healthy cartilage 
exposed to TGFβ signaling e.g. by loading, but would allow for rapid NGF production in case 
of tissue damage or inflammation.
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Modulation of TGFβ signaling using small molecule inhibitors
Based on our previous results we think it is clear that TGFβ-induced pSMAD2/3 via ALK5 
is chondroprotective and an especially potent inhibitor of chondrocyte hypertrophy. In 
contrast, ALK1 signaling via pSMAD1/5 was associated with chondrocyte hypertrophy, and 
many SMAD-independent pathways like TAK1 signaling are associated with cartilage damage 
in literature. Therefore TGFβ has both good and bad sides to its signaling with respect to 
cartilage homeostasis [1]. For this reason, we wanted to explore if we could separate the 
for cartilage deleterious signaling from the chondroprotective pSMAD2/3 signaling with 
the use of small molecule inhibitors. Our approach was to add either LDN-193189; i.e. an 
ALK1/2/3/6 kinase inhibitor, or SB-505124, i.e an ALK4/5/7 inhibitor, or (5Z)-7-oxozeaenol, 
i.e a TAK1 inhibitor, to primary bovine chondrocytes in combination with TGFβ, and 
investigate SMAD phosphorylation and TGFβ-induced gene expression. In chapter 7 the 
results hereof are shown. To our surprise, we observed that the SB-505124 compound fully 
inhibited not only TGFβ-induced SMAD2/3 phosphorylation and downstream signaling, 
but also SMAD1/5 phosphorylation and signaling. In contrast, we observed no effect of the 
LDN-193189 compound on TGFβ signaling. These results would indicate that ALK5 kinase 
activity is phosphorylating both SMAD2/3 and SMAD1/5, and that ALK1 kinase activity is not 
involved in TGFβ signaling. Because this challenges the dogma that ALK5 kinase is not able 
to phosphorylate SMAD1/5 due to steric hindrance between SMAD1/5 and the ALK5 kinase 
pocket [17], we sought to validate the specificity of SB-505124. We did this by overexpressing 
a constitutively active form of ALK1, a form of the receptor which continuously phosphorylates 
SMAD1/5 [14]. Importantly, the function of this receptor was not inhibited by SB-505124, 
showing that this compound does not affect ALK1 kinase activity. In contrast, constitutively 
active ALK1 was inhibited by the LDN-193189 compound. These results support the previous 
results that the ALK5 kinase activity is crucial for both TGFβ-induced SMAD2/3 and SMAD1/5 
phosphorylation. Furthermore, these show that with these compounds it is not possible to 
separate TGFβ-induced pSMAD1/5 from pSMAD2/3. However, we did observe that the IC
50
 
of SB-505124 for pSMAD1/5 is much lower than that for pSMAD2/3. This indicates that the 
phosphorylation of pSMAD1/5 by ALK5 is much more sensitive for ALK5 kinase inhibition, and 
that therefore a dose of this inhibitor might be found that already fully inhibits TGFβ-induced 
pSMAD1/5 but only marginally affects SMAD2/3 phosphorylation.
 When we studied the effects of (5Z)-7-oxozeaenol on TGFβ signaling, we noticed 
that this compound inhibited both TGFβ-induced SMAD2/3 and SMAD1/5 phosphorylation, 
but the latter more extensively. Because (5Z)-7-oxozeaenol is not known to inhibit ALK1 or 
ALK5 kinase activity, this indicates that SMAD-independent signaling at least partly regulates 
SMAD-dependent signaling. This inhibition of SMAD phosphorylation was also reflected in 
TGFβ-induced gene expression, further illustrating the importance of SMAD-independent 
signaling in transduction of TGFβ signaling. Possibly the SMAD-independent signaling interacts 
directly with SMAD proteins in order to facilitate their C-terminal phosphorylation. This 
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would also explain why SMAD activation by TGFβ-family members is relatively slow compared 
to the induction of SMAD-independent signaling, e.g. in primary chondrocytes it takes 
approximately 1 hour for SMAD dependent signaling to reach its maximum, whereas SMAD-
independent signaling takes only 15 minutes to reach its peak (own observation). Possibly, 
the SMAD linker role plays an important role in this aspect of TGFβ signaling [21]. This SMAD-
linker is a domain connecting the MH1 DNA binding domain of SMADs to their MH2 protein 
binding domain. The linker region can be extensively post-translationally modified, e.g. via 
ubiquitination, phosphorylation, acetylation etc, regulating the function of both the MH1 and 
MH2 domain and SMAD half-life [21]. These modifications are done by intracellular kinases, 
including those that are activated by SMAD-independent signaling like TAK1. This makes the 
SMAD-linker a bridge between SMAD-dependent and SMAD-independent signaling.
 SMAD linker modifications are dependent on cellular context [21]; this context 
regulates the kinases making the modifications. We think this can explain the results we 
also obtained in chapter 7 when studying TGFβ signaling in cartilage explants and compared 
the results hereof to those we obtained in chondrocytes in monolayer. Remarkably, we had 
problems detecting TGFβ-induced SMAD1/5 phosphorylation in healthy bovine cartilage 
explants; whereas in chondrocytes in monolayer this pathway is abundantly activated upon 
addition of TGFβ, in explants this was not the case. Furthermore, also regulation of ID1 
expression by TGFβ was totally opposite in explants compared to monolayer; from induction 
in monolayer to inhibition in explants. Both these observation nicely illustrate the importance 
of cellular context in TGFβ signaling; the cellular environment regulates TGFβ signaling and its 
outcome.
Final considerations
The goals of this thesis were to further characterize (1) the importance of TGFβ-family 
signaling in cartilage homeostasis and (2) how ageing, the main risk factor for OA, impacts 
this signaling. We succeeded in characterizing the importance of pSMAD2/3 signaling in 
loading-mediated regulation of cartilage homeostasis. Moreover, we identified that ageing 
negatively impacts this pSMAD2/3 signaling by lowering ALK5 expression. Furthermore, 
we established the importance of TGFβ signaling especially to protection of chondrocyte 
phenotype against hypertrophy inducing processes like BMP9 signaling. The observations we 
did on TGFβ-induced NGF expression help us link TGFβ signaling to OA pain, and we learned 
that separating TGFβ-induced pSMAD1/5 from pSMAD2/3 is more difficult than expected, 
due to the reliance of both processes on ALK5
 In conclusion, based upon these results we suggest a model for cartilage 
homeostasis in which TGFβ is the factor that keeps articular cartilage healthy and protects 
it from hypertrophy (figure 1). The cartilage ECM contains a large amount of (inactive) TGFβ 
which is activated upon loading of the cartilage. This subsequently activates a protective 
pathway that results in TGFβ and ALK5 expression, and inhibition of ALK1 and chondrocyte 
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hypertrophy. This inhibition of chondrocyte hypertrophy is important because articular 
cartilage is continuously exposed to hypertrophy inducing factors like BMP9 via the synovial 
fluid. Unfortunately, ageing negatively affects this protective mechanism by reducing ALK5 
expression, the receptor TGFβ uses to establish these protective effects. Because we observed 
that the reduction in ALK5 expression precedes OA development, we think this is a cause for 
OA; the protective, anti-hypertrophic, loading-mediated mechanism is becoming less and 
less effective with advancing age, eventually leading to failure of this protective system. This 
model underlines that osteoarthritis is a disease and not just “wear and tear”, and indicates 
that reverting or inhibiting this age-related decrease in ALK5 expression will be a challenge 
for the future to combat age-related development of OA. 
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Fig. 1. Proposed model for cartilage homeostasis. TGFβ keeps young articular cartilage healthy by counteracting 
hypertrophy-promoting signaling like that of BMP9. Mechanical stimulation of cartilage activates latent TGFβ, which 
induces pSMAD2/3 via ALK5. This pSMAD2/3 induces TGFβ and ALK5 expression, establishing a positive feedback 
loop, and lowers ALK1 expression and downstream effects of BMP9 like hypertophy. However, upon ageing, ALK5 
expression is gradually lowered, resulting in less activation of this cartilage protective mechanism, slowly leading to 
failure and the onset of cartilage damage
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De transforming growth factor β (TGFβ)–familie is een verzameling van groeifactoren die 
allen gebruik maken van activin-receptor like kinases (ALK1 t/m ALK7) om signalen door te 
geven aan cellen. ALKs activeren intracellulaire SMAD eiwitten door deze te fosforyleren, 
waarna de SMADs naar de kern van de cel migreren. In de kern binden de SMAD eiwitten 
aan het DNA en sturen ze genexpressie. Op deze manier reguleren leden van de TGFβ-familie 
de homeostase van vele weefsels in het lichaam, waaronder die van articulair kraakbeen. 
Articulair kraakbeen is het weefsel dat de botuiteinden in synoviale gewrichten bedekt, en dit 
weefsel is zeer belangrijk voor de absorptie van krachten die vrijkomen bij bewegen en maakt 
wrijvingsarme beweging van de gewrichtsvlakken mogelijk. Een verstoorde werking van 
leden van de TGFβ-familie is gekoppeld aan het ontstaan van artrose, de meest voorkomende 
gewrichtsziekte ter wereld. Artrose wordt gekenmerkt door afbraak van het kraakbeen, wat 
leidt tot functieverlies van het gewricht en pijn. Er is helaas nog geen afdoende behandeling 
voor artrose afgezien van vervanging van het aangedane gewricht door een kunstgewricht. 
Hierdoor is er een grote behoefte aan een therapie die het ziekteproces aanpakt. De 
ontwikkeling van zo’n behandeling heeft baat bij een goed begrip van hoe de homeostase van 
kraakbeen gereguleerd wordt en bij een goed begrip van hoe risicofactoren deze homeostase 
beïnvloeden. Daarom waren de doelen van dit proefschrift om in kaart te brengen (1) het 
belang van de TGFβ-familie, en dan met name van TGFβ, voor de homeostase van kraakbeen 
en (2) hoe veroudering, de belangrijkste risicofactor voor artrose hierop ingrijpt. 
Het belang van regelmatige belasting voor het behoud van het fenoype van de 
kraakbeencel
Het is al langere tijd bekend dat regelmatig belasten goed is voor articulair kraakbeen; zonder 
belasting gaat articulair kraakbeen snel kapot. In hoofdstuk 2 van dit proefschrift wordt 
aangetoond dat belasting SMAD2/3 signalering activeert (pSMAD2/3) in chondrocyten, de 
enige cellen in het kraakbeen en daarom verantwoordelijk zijn voor het onderhoud van dit 
weefsel. Het belang van belasting voor SMAD2/3 signalering in chondrocyten werd voor het 
eerst geobserveerd in onbelast kraakbeen waaraan een remmer van SMAD2/3 signalering was 
toegevoegd; deze remmer bleek, tegen de verwachting in, geen effect te hebben. Uit nadere 
analyse bleek dat dit onbelaste kraakbeen amper tot geen pSMAD2/3 bevatte waardoor deze 
remmer inderdaad geen effect kon hebben. Vervolgens bleek dat experimentele mechanische 
belasting van kraakbeen een sterke pSMAD2/3 activiteit tot gevolg had, die weer verdween 
na het weghalen van de belasting. Samen bevestigden deze experimenten dus het belang van 
belasting voor pSMAD2/3 activiteit in chondrocyten.
 Nadat zo het belang van belasting voor pSMAD2/3 activiteit in kraakbeen was 
aangetoond, is onderzocht wat het belang hiervan is voor kraakbeenhomeostase. Als 
eerste werd een mogelijke rol in het onderhoud van de hoeveelheid glycosaminoglycanen 
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in kraakbeen onderzocht. Deze glycosaminoglycanen zijn essentiële bouwstenen van 
het kraakbeen en belangrijk voor de schokabsorberende functie van kraakbeen. Van 
dwarslaesiepatiënten is bekend dat het niet gebruiken van kraakbeen leidt tot een verlies 
van deze bouwstenen. Ook in de gedane experimenten bleek onbelast kraakbeen over een 
tijdsbestek van 2 weken een zeer aanzienlijk deel (80%) van deze bouwstenen te verliezen. 
Dit verlies was echter tegen te gaan door toevoeging van serum of insulin-like growth factor 
1 (IGF1), een andere belangrijke signaalstof voor kraakbeen. Echter belasting noch TGFβ, een 
sterke pSMAD2/3 activator, hadden enig effect op de hoeveelheid glycosaminoglycanen in 
kraakbeen. Hierdoor is het onwaarschijnlijk dat belasting of TGFβ signalering de hoeveelheid 
glycosaminoglycanen in kraakbeen reguleert. Een ander aspect van de kraakbeenbiologie dat 
vervolgens onderzocht werd, is de handhaving van het chondrocytfenotype. Een belangrijk 
aspect van artrose is namelijk het verlies van dit fenotype en het ontstaan van zogenaamde 
hypertrofe chondrocyten, cellen die hun omgeving, en dus het kraakbeen, actief afbreken. 
Uit experimenten bleek dat ook het aantal hypertrofe chondrocyten aanzienlijk toeneemt 
als kraakbeen twee weken lang niet belast wordt. Zowel belasting als TGFβ bleken echter de 
vorming van deze cellen sterk te remmen, terwijl serum of IGF1 dit niet deden. Hieruit kan 
geconcludeerd worden dat het remmen van de vorming van hypertrofe chondrocyten een 
belangrijke rol is van belasting en TGFβ.
 Een mogelijke verklaring voor de pSMAD2/3 activiteit in kraakbeen na belasting is 
dan ook de activering van TGFβ, en wel op basis van de volgende argumenten: (1) de activering 
van pSMAD2/3 in kraakbeen is geheel te remmen met SB-505124, een remmer van ALK4/5/7. 
Dit laat zien dat (een van) deze receptoren essentieel zijn (is) voor dit proces. (2) Van deze 
receptoren zijn ALK4 en ALK5 te detecteren in kraakbeen maar ALK7 niet of nauwelijks. Dit 
maakt een rol van ALK7 of een ligand hiervan onwaarschijnlijk. (3) De effecten van belasting 
op chondrocyt hypertrofie kunnen geheel nagebootst worden met behulp van de ALK5 ligand 
TGFβ maar niet met de ALK4 ligand Activin A. (4) De extracellulaire matrix van kraakbeen 
bevat zeer veel TGFβ gebonden in inactieve vorm, en uit studies met fibroblasten is gebleken 
dat belasting deze inactieve TGFβ kan activeren. Samen ondersteunen deze argumenten dus 
de hypothese dat activering van TGFβ de verklaring is voor belasting-gerelateerde pSMAD2/3 
activering.
 Opvallend genoeg had belasting niet alleen een remmend effect op 
chondrocythypertrofie, maar verhoogde het ook de expressie van TGFβ1 en diens receptor 
ALK5, terwijl het de expressie van ALK1 verlaagde. Omdat ALK5 voor activering van pSMAD2/3 
zorgt, en ALK1 voor pSMAD1/5, duiden deze observaties erop dat belasting in kraakbeen 
een positieve terugkoppeling teweeg brengt; belasting activeert TGFβ, en de pSMAD2/3 
signalering hiervan zorgt voor nieuwe TGFβ en verhoogt de SMAD2/3 activerende receptor. 
Ook verlaagt belasting de SMAD1/5/9 activerende receptor waardoor TGFβ signalering eerder 
via pSMAD2/3 zal verlopen. Door dit terugkoppelingsmechanisme wordt dus pSMAD2/3 
signalering door zichzelf in stand gehouden. 
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De effecten van veroudering op TGFβ signalering in chondrocyten
Nadat het belang van belasting voor pSMAD2/3 activering en chondrocytfenotype was 
aangetoond, is vervolgens onderzocht hoe risicofactoren hierop ingrijpen. De belangrijkste 
risicofactor voor artrose is veroudering, en daarom is voornamelijk hieraan aandacht 
besteed. Om veroudering in kraakbeen te kunnen bestuderen is gebruik gemaakt van de 
koe als model. Koeienkraakbeen lijkt namelijk sterk op humaan kraakbeen en is verkrijgbaar 
in een leeftijdsreeks waarin alle veranderingen waargenomen kunnen worden die ook in 
verouderend menselijk kraakbeen gezien worden; zoals dunner worden, het toenemen van 
de gecalcificeerde zone, het ontstaan van meerdere tidemarks, het verlies van chondrocyten 
en het verlies van collageen type 2 expressie. Gezond menselijk kraakbeen zelf was niet te 
gebruiken vanwege schaarste. Het gebruik van koeienkraakbeen had verder als voordeel dat 
artrotisch kraakbeen visueel uitgesloten kon worden van verdere analyse, zodat artrose en 
veroudering goed van elkaar gescheiden konden worden. Veroudering en artrose kunnen 
namelijk heel tegengestelde effecten in kraakbeen teweeg brengen, zoals bijvoorbeeld 
chondrocyt-senescence versus proliferatie, waardoor de interpretatie van resultaten 
bemoeilijkt word indien beide processen niet gescheiden worden. 
 In hoofdstuk 3 wordt beschreven dat in koeienchondrocyten veroudering de 
hoeveelheid ALK5 verlaagt, terwijl het weinig effect heeft op ALK1 expressie. Deze verandering 
in receptorenniveaus heeft gevolgen voor de cellulaire gevoeligheid voor TGFβ; jong kraakbeen 
reageert potenter op TGFβ dan oud kraakbeen, met name als een pSMAD3-gevoelig gen 
(PAI1 of Serpine1) gemeten wordt. Voor ALK1 signalering via pSMAD1/5 werd geen verlaging 
geobserveerd tussen jong en oud: toevoeging van BMP9, een ligand met hoge affiniteit voor 
ALK1 resulteerde in oud kraakbeen in een expressie van het pSMAD1/5-gevoelige gen ID1 
die zeker zo hoog, zo niet hoger, was als in jong kraakbeen. Deze observaties laten zien dat 
veroudering de ALK1 en ALK5 receptoren en hun signalering verschillend beïnvloedt, en 
impliceren dat de signalering van een ligand die van beide receptoren gebruik kan maken, 
zoals TGFβ, dus kan verschuiven bij veroudering.
 Na zo te hebben vastgesteld dat veroudering ALK5 expressie en functie negatief 
beïnvloedt, is vervolgens in hoofdstuk 4 onderzocht of veroudering ook door belasting 
geïnduceerde pSMAD2/3 signalering negatief beïnvloedt. Dit is gedaan door koeienkraakbeen 
van verschillende leeftijden te belasten en de uitkomsten te vergelijken. Deze experimenten 
lieten zien dat leeftijd ook op door belasting geïnduceerde pSMAD2/3 grote nadelige effecten 
had: in oud kraakbeen kon slechts 10% van de pSMAD2/3 en bijbehorende genexpressie van 
jong kraakbeen gemeten worden. Om uit te sluiten dat dit kwam doordat ouder kraakbeen 
moeilijker samen te drukken is dan jong kraakbeen zijn de experimenten ook herhaald met 
een hogere druk; 12 MPa in plaats van 3 MPa. Bij deze grotere druk wordt zowel jong als oud 
kraakbeen vergelijkbaar samengedrukt, maar dit had geen effect op het verschil in pSMAD2/3 
activering dat gemeten werd tussen jong en oud. Veroudering verlaagt dus inderdaad de 
belasting-geïnduceerde pSMAD2/3 niveaus in chondrocyten.
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Nieuwe inzichten in de rol van TGFβ signalering in kraakbeen.
Nu het belang van TGFβ signalering voor kraakbeen en de nadelige effecten van veroudering 
hierop duidelijk waren geworden is vervolgens gekeken welke rollen TGFβ nog meer vervult 
in kraakbeen naast bescherming van het chondrocytfenotype.
 Vanwege de resultaten aangaande ALK1 expressie bij veroudering is in hoofdstuk 5 
eerst gekeken naar de effecten van BMP9, een ligand met hoge affiniteit voor deze receptor, 
op chondrocyten en de effecten van TGFβ hierop. BMP9 induceerde een krachtig pSMAD1/5 
signaal in kraakbeen met chondrocythypertrofie tot gevolg zoals bleek uit het meten van 
collageen type X en alkalische fosfatase. Deze observatie impliceert dat over langere duur ALK1 
signalering inderdaad schadelijk is voor kraakbeen. Echter, BMP9 induceerde ook pSMAD2 
en, zeer belangrijk, vertoonde ook synergie met TGFβ op de activering van pSMAD2/3. 
Mogelijk geholpen door deze synergie was TGFβ in staat om de door BMP9 geïnduceerde 
hypertrofie geheel te remmen. Deze resultaten onderstrepen nogmaals het belang van TGFβ 
voor het behoud van chondrocytfenotype. Opmerkelijk was ook dat deze synergie van BMP9 
met TGFβ uniek was in vergelijking met andere BMPs zoals BMP2 en BMP7. Een mogelijke 
verklaring voor de synergie kan competitie zijn tussen BMP9 en TGFβ zijn voor de ALK1 
receptor; vanwege diens hogere affiniteit zal BMP9 deze competitie winnen waardoor TGFβ 
gedwongen wordt via ALK5-ALK5 complexen te signaleren. Theoretisch geven deze ALK5-
ALK5 complexen twee keer zoveel pSMAD2/3 als ALK5-ALK1 complexen omdat ALK1 geen 
pSMAD2/3 kan activeren.
 De rol van TGFβ in het tegengaan van BMP9 geïnduceerde hypertrofie is waarschijnlijk 
een belangrijk mechanisme voor de handhaving van kraakbeenhomeostase in vivo. BMP9 is 
namelijk een groeifactor die in hoge concentratie gemeten kan worden in bloed, waardoor 
het waarschijnlijk is dat chondrocyten continu aan deze factor worden blootgesteld via 
de synoviale vloeistof in de gewrichtsholte. Omdat BMP9 signalering voor hypertrofie kan 
zorgen, is er dus continu een rem nodig om dit te voorkomen. TGFβ is bij uitstek geschikt 
om als deze rem te functioneren gezien de observaties uit hoofdstukken 1 en 5. Opmerkelijk 
is ook dat BMP9 in kraakbeen kan zorgen voor de aanmaak van glycosaminoglycanen en 
collagenen, maar dat TGFβ op deze positieve effecten van BMP9 geen remmende werking 
heeft. TGFβ kan dus het goede van het kwade scheiden in BMP9 signalering.
 In hoofdstuk 6 wordt een geheel nieuwe functie van TGFβ besproken; diens rol in 
de expressie van nerve growth factor (NGF), een zeer belangrijke pijnprikkel in artrose. Na 
stimulatie van chondrocyten en kraakbeen met verschillende concentraties TGFβ bleek dat 
TGFβ een potente stimulus is voor de transcriptie van NGF. Zowel in humaan-, als muizen- 
en koeienkraakbeen induceerde TGFβ hoge genexpressie van NGF (mRNA). De door TGFβ 
geïnduceerde expressie was zelfs hoger dan de NGF expressie die door IL1β, een krachtige 
ontstekingsprikkel, bereikt werd. Deze studie verbindt dus TGFβ aan pijn in artrose, omdat 
uit studies is gebleken dat NGF bestrijding de pijn in artrose volledig laat verdwijnen. Om te 
onderzoeken via welke intracellulaire signaleringsroute TGFβ dit effect teweeg bracht, zijn de 
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volgende remmers gebruikt: de ALK5 remmer SB-505124, de ALK1 remmer LDN-193189 en 
de TAK1 kinase remmer (5Z)-7-Oxozeaenol. Uit dit experiment bleek dat het effect van TGFβ 
volledig via ALK5 liep, en dat SMAD-onafhankelijke signalering via TAK1 hier ook een rol in 
speelde. Opmerkelijk was dat in de gedane experimenten het erg moeilijk was om NGF eiwit 
aan te tonen, ook al konden hoge levels mRNA makkelijk gedetecteerd worden. Alleen in 
humaan artrotisch kraakbeen kon NGF eiwit aangetoond worden. Dit detectieprobleem kan 
er op duiden dat een tweede signaal nodig is (dat aanwezig is in artrotisch kraakbeen) om het 
door TGFβ geïnduceerde NGF mRNA om te zetten in functioneel eiwit. Zo’n mechanisme zou 
continue ongewenste aanmaak van NGF door TGFβ voorkomen, maar wel acute pijn in geval 
van trauma of ontsteking veroorzaken.
Het redigeren van TGFβ signalering met small molecule inhibitors
Uit de voorgaande resultaten is gebleken dat ALK5 signalering via pSMAD2/3 beschermend 
is voor het fenotype van de chondrocyte, terwijl ALK1 signalering via pSMAD1/5 gekoppeld 
kon worden aan chondrocythypertrofie. Omdat TGFβ beide receptoren en signaleringsroutes 
kan activeren, kan TGFβ dus zowel goede als slechte effecten hebben op chondrocyten. 
Vanuit therapeutisch oogpunt is het interessant om te proberen beide routes te scheiden 
en wel zodanig dat alleen de positieve effecten behouden blijven. Daarom is in hoofdstuk 7 
geprobeerd om met behulp van zogenaamde “small molecule inhibitors” de TGFβ 
signaleringsroutes van elkaar te scheiden. Hiervoor hebben we wederom gebruik gemaakt 
van de ALK1 remmer LDN-193189, de ALK5 remmer SB-505124 en de TAK1 remmer 
(5Z)-7-Oxozeaenol. Onverwacht bleek dat SB-505124 niet alleen de TGFβ-geïnduceerde 
pSMAD2/3 remde, maar ook de TGFβ-geïnduceerde pSMAD1/5/8, en dat LDN-193189 
geen enkel effect had. Deze resultaten impliceren dat ALK5 zowel pSMAD2/3 als pSMAD1/5 
kan activeren.  Omdat deze gevolgtrekking in gaat tegen het dogma dat dit onmogelijk 
zou zijn vanwege sterische hindering van SMAD1/5 met het kinasedomein van ALK5, is de 
functie van SB-505124 extra gevalideerd. SB-505124 bleek echter naar behoren te werken 
en had geen enkel effect op ALK1, waardoor het niet uit te sluiten is dat ALK5 inderdaad 
ook pSMAD1/5 activeert. Deze onverwachte mogelijke dubbele rol van ALK5 bemoeilijkt 
dus het scheiden van beide signaleringsroutes. Een aanknopingspunt voor het scheiden 
van beide SMAD signaleringsroutes is echter wel dat er veel minder SB-505124 nodig was 
om TGFβ-geïnduceerde pSMAD1/5 volledig te remmen dan dat er nodig was om TGFβ-
geïnduceerde pSMAD2/3 te remmen. Door slimme dosiskeuze zou de gewenste scheiding 
van signaleringsroutes dan alsnog bereikt kunnen worden.
 Naast SB-505124 had ook (5Z)-7-Oxozeaenol een sterk effect op TGFβ-geïnduceerde 
pSMADs; zowel pSMAD2/3 als pSMAD1/5 werden geremd. Een rechtstreeks effect van (5Z)-
7-Oxozeaenol op de ALK receptoren was moeilijk aan te tonen waardoor een verklaring 
voor deze remming ook in een ander mechanisme gezocht kan worden. Mogelijk speelt 
een direct effect van TAK1 op de SMAD eiwitten een belangrijke rol. TAK1 kan zowel 
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SMAD2/3 als SMAD1/5 eiwitten modificeren door ze te fosforyleren in hun linker domein. 
Uit literatuur is bekend dat deze linker modificaties verstrekkende gevolgen kunnen hebben 
voor het functioneren van de SMADs. Mogelijk speelt zo’n door (5Z)-7-Oxozeaenol geremde 
modificatie een belangrijke rol bij activering van de SMADs, bijvoorbeeld als deze modificatie 
een vereiste is voor transport van de SMAD naar de receptor.
Conclusie
De doelen van dit proefschrift waren om in kaart te brengen (1) het belang van de TGFβ-familie, 
en dan met name van TGFβ, voor de homeostase van kraakbeen en (2) hoe veroudering, de 
belangrijkste risicofactor voor artrose hierop ingrijpt. De experimenten die gedaan zijn om 
deze doelen te bereiken hebben laten zien dat  belasting pSMAD2/3 activeert in kraakbeen, 
en dat dit een belangrijk mechanisme is voor het tegengaan van chondrocythypertrofie. 
Veroudering ontregelt dit systeem door expressie van de ALK5 receptor te verlagen, 
waardoor chondrocyten niet langer in staat zijn voldoende pSMAD2/3 te fosforyleren na 
blootstelling aan TGFβ. Hierdoor valt het beschermende mechanisme tegen hypertrofie 
weg bij veroudering. Het belang van TGFβ en SMAD2/3 signalering in het tegengaan van 
hypertrofie werd ook gevonden in chondrocyten die blootgesteld waren aan BMP9. In dit 
proefschrift is ook voor het eerst TGFβ gekoppeld aan pijn in artrose via NGF productie. Het 
scheiden van de intracellulaire signaleringsroutes van TGFβ om zo de goede effecten van de 
kwade los te kunnen koppellen bleek echter moeilijker dan gedacht door de centrale rol van 
ALK5 in alle SMAD-afhankelijke signaleringsroutes van TGFβ.
 Op basis van alle resultaten in dit proefschrift kan een hypothetisch model opgesteld 
worden over kraakbeenhomeostase waarin TGFβ de factor is die kraakbeen gezond houdt 
door het te beschermen tegen chondrocyt hypertrofie. In jong kraakbeen activeert belasting 
TGFβ waardoor via een positieve terugkoppeling nieuwe TGFβ gemaakt wordt en chondrocyt 
hypertrofie onderdrukt wordt. Dit beschermt het kraakbeen tegen de schadelijke effecten van 
BMP9 waaraan het continu is blootgesteld via de synoviale vloeistof in de gewrichtsholte,  maar 
laat wel de positieve effecten van BMP9 op glycosaminoglycan- en collageenproductie toe als 
onderhoud van de extracellulaire matrix. Veroudering verstoort echter dit beschermende 
mechanisme door verlaging van ALK5 waardoor de positieve terugkoppeling verstoord raakt 
met alle gevolgen van dien. Dit model onderstreept dus dat artrose een ziekte is en geen 
slijtage, en dat het voorkomen of bestrijden van leeftijdsgerelateerde ALK5 verlaging een 
uitdaging voor de toekomst is om leeftijdsgerelateerde artrose te voorkomen.
209
9
List of publications
van Caam A, Madej W, Garcia de Vinuesa A, Goumans MJ, Ten Dijke P, Blaney Davidson E, van 
der Kraan P. TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-
dependent in primary chondrocytes and mediated by TAK1 kinase activity. Arthritis Res Ther. 
2017 May 31;19(1):112. 
Blaney Davidson EN, van Caam AP, van der Kraan PM. Osteoarthritis year in review 2016: 
biology. Osteoarthritis Cartilage. 2017 Feb;25(2):175-180. 
van Geffen EW, van Caam AP, van Beuningen HM, Vitters EL, Schreurs W, van de Loo FA, van 
Lent PL, Koenders MI, Blaney Davidson EN, van der Kraan PM. IL37 dampens the IL1β-induced 
catabolic status of human OA chondrocytes. Rheumatology (Oxford). 2017 Mar 1;56(3):351-
361. 
Shanmugaapriya S, van Caam A, de Kroon L, Vitters EL, Walgreen B, van Beuningen H, 
Davidson EB, van der Kraan PM. Expression of TGF-β Signaling Regulator RBPMS (RNA-Binding 
Protein With Multiple Splicing) Is Regulated by IL-1β and TGF-β Superfamily Members, and 
Decreased in Aged and Osteoarthritic Cartilage. Cartilage. 2016 Oct;7(4):333-45. 
van Caam A & Madej W, Blaney Davidson E, Buma P, van der Kraan PM. Unloading results 
in rapid loss of TGFβ signaling in articular cartilage: role of loading-induced TGFβ signaling 
in maintenance of articular chondrocyte phenotype? Osteoarthritis Cartilage. 2016 
Oct;24(10):1807-15.
van Caam A, Madej W, Thijssen E, Garcia de Vinuesa A, van den Berg W, Goumans MJ, Ten Dijke P, 
Blaney Davidson E, van der Kraan PM. Expression of TGFβ-family signalling components in 
ageing cartilage: age-related loss of TGFβ and BMP receptors. Osteoarthritis Cartilage. 2016 
Jul;24(7):1235-45. 
Madej W, van Caam A, Davidson EN, Hannink G, Buma P, van der Kraan PM. Ageing 
is associated with reduction of mechanically-induced activation of Smad2/3P
signaling in articular cartilage. Osteoarthritis Cartilage. 2016
Jan;24(1):146-57. doi: 10.1016/j.joca.2015.07.018. Epub 2015 Aug 4. PubMed PMID: 
26247611.
List of publications
CHAPTER 9
210
Pieters BC, Arntz OJ, Bennink MB, Broeren MG, van Caam AP, Koenders MI, van Lent PL, van 
den Berg WB, de Vries M, van der Kraan PM, van de Loo FA. Commercial cow milk contains 
physically stable extracellular vesicles expressing immunoregulatory TGF-β. PLoS One. 2015 
Mar 30;10(3):e0121123.
van Caam A, Blaney Davidson E, Garcia de Vinuesa A, van Geffen E, van den Berg W, 
Goumans MJ, ten Dijke P, van der Kraan P. The high affinity ALK1-ligand BMP9 induces a 
hypertrophy-like state in chondrocytes that is antagonized by TGFβ1. Osteoarthritis Cartilage. 
2015 Jun;23(6):985-95. 
Blaney Davidson EN, van Caam AP, Vitters EL, Bennink MB, Thijssen E, van den Berg WB, 
Koenders MI, van Lent PL, van de Loo FA, van der Kraan PM. TGF-β is a potent inducer of 
Nerve Growth Factor in articular cartilage via the ALK5-Smad2/3 pathway. Potential role in 
OA related pain? Osteoarthritis Cartilage. 2015 Mar;23(3):478-86. 
Thijssen E, van Caam A, van der Kraan PM. Obesity and osteoarthritis, more than just wear 
and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced 
osteoarthritis. Rheumatology (Oxford). 2015 Apr;54(4):588-600. 
Madej W, van Caam A, Blaney Davidson EN, van der Kraan PM, Buma P. Physiological and 
excessive mechanical compression of articular cartilage activates Smad2/3P signaling. 
Osteoarthritis Cartilage. 2014 Jul;22(7):1018-25.
Blaney Davidson EN, Vitters EL, Bennink MB, van Lent PL, van Caam AP, Blom AB, van den 
Berg WB, van de Loo FA, van der Kraan PM. Inducible chondrocyte-specific overexpression of 
BMP2 in young mice results in severe aggravation of osteophyte formation in experimental 
OA without altering cartilage damage. Ann Rheum Dis. 2015 Jun;74(6):1257-64. 
Balemans MC, Ansar M, Oudakker AR, van Caam AP, Bakker B, Vitters EL, van der Kraan 
PM, de Bruijn DR, Janssen SM, Kuipers AJ, Huibers MM, Maliepaard EM, Walboomers XF, 
Benevento M, Nadif Kasri N, Kleefstra T, Zhou H, Van der Zee CE, van Bokhoven H. Reduced 
Euchromatin histone methyltransferase 1 causes developmental delay, hypotonia, and cranial 
abnormalities associated with increased bone gene expression in Kleefstra syndrome mice. 
Dev Biol. 2014 Feb 15;386(2):395-407. 
211
9
Portfolio
Awards
Pauline van Wachem award for best presentation, NVMB 2012 
A.van den Hooff award for best debater, NVMB 2016
Young investigator award, OARSI 2016 (shared with W.Madej) 
Attended (Inter)national congresses
NVMB 2011, Lunteren, Annual meeting of the Dutch society for matrix biology (Nederlandse 
vereniging voor matrix biologie). Podium presentation.
EORS 2012, Amsterdam, Annual meeting of the European Orthopaedic Research society. 
Podium presentation.
OARSI 2012, Barcelona, Annual meeting of the Osteoarthritis Research Society International. 
Poster presentation.
NVMB 2012, Lunteren, Annual meeting of the Dutch society for matrix biology (Nederlandse 
vereniging voor matrix biologie). Podium presentation.
ORS 2013, San Antonio USA, Annual meeting of the European Orthopaedic Research society. 
Podium presentation.
NVMB 2013, Lunteren, Annual meeting of the Dutch society for matrix biology (Nederlandse 
vereniging voor matrix biologie). Podium presentation.
OARSI 2014, Paris, Annual meeting of the Osteoarthritis Research Society International. 
Poster presentation.
MBE 2014, Rotterdam, Annual meeting of the Matrix Biology Europe society. Podium 
presentation.
OARSI 2015, Seattle USA, Annual meeting of the Osteoarthritis Research Society International. 
Poster presentation.
ORS 2016, Orlando USA, Annual meeting of the European Orthopaedic Research society. 
Podium presentation.
Portfolio
CHAPTER 9
212
NVMB 2015, , Lunteren, Annual meeting of the Dutch society for matrix biology (Nederlandse 
vereniging voor matrix biologie). Podium presentation.
OARSI 2016, Amsterdam, Annual meeting of the Osteoarthritis Research Society International. 
Poster presentation.
ICRS 2016, Sorrento, Annual meeting of the International Cartilage Repair society. Podium 
presentation.
NVMB 2016, Lunteren, Annual meeting of the Dutch society for matrix biology (Nederlandse 
vereniging voor matrix biologie). Podium presentation.
213
9
Research data management
Findable:
All (raw) data described in this thesis can be found at the departement of Experimental 
Rheumatology of the Radboud university medical center
Accessible:
All (raw) data described in this thesis can be obtained on request from the departement of 
Experimental Rheumatology of the Radboud university medical center. The same holds true 
for the protocols of the experiments described in this thesis.
Interoperable:
The (raw) data in this thesis is documented in a formal, accessible, shared, and broadly 
applicable language for knowledge representation.
Reusable:
The (raw) data shown in this thesis are sufficiently documented to be reusable
Research data management
CHAPTER 9
214
215
9
Curriculum Vitae
Adrianus Petrus Maria (Arjan) werd op 26 maart 1985 geboren te Roosendaal en Nispen. 
Na het behalen van zijn gymnasium diploma aan het Gertrudiscollege te Roosendaal is hij 
Medische Biologie gaan studeren aan wat toen nog de Katholieke Universiteit Nijmegen 
heette, maar nu de Radboud universiteit heet. Voor deze studie heeft hij achtereenvolgens 
stage gelopen bij de afdelingen: Experimentele dierfysiologie (FNWI) van prof. dr. G. Flik 
onder begeleiding van dr. E. J. Geven, de afdeling Celbiologie (FNWI) van prof. dr. E.J.J. van 
Zoelen onder begeleiding van dr. S.P. van der Woning, en de afdeling Fysiologie van prof. 
dr. R.J.M. Bindels onder begeleiding van dr. S. Boros. Ook volgde Arjan tijdens zijn studie 
met succes het honoursprogramma van de RU. Na het succesvol bene meritum afronden 
van zijn studie is hij in augustus 2010 begonnen als onderzoeker in opleiding werkzaam aan 
het ZonMw project: Age-related changes in TGFβ signaling as cause for osteoarthritis op de 
afdeling Experimentele Reumatologie van prof. dr. W.B. van den Berg onder begeleiding van 
(nu prof.) dr. P.M. van der Kraan en dr. E.N. Blaney Davidson. In het kader van dit project is 
er nauw samengewerkt met de afdeling Moleculaire Celbiologie van het Leids Universitair 
Medisch Centrum met prof. dr. P. ten Dijke en prof. dr. M.J.T.H. Goumans. Momenteel is Arjan 
nog steeds werkzaam op de afdeling Experimentele Reumatolgie als onderzoeker en doet 
hij onderzoek naar ontregelde TGFβ signalering in Systemische Sclerose, een ernstige auto-
immuunziekte.
Curriculum Vitae
CHAPTER 9
216
217
9
Dankwoord
Met dit dankwoord wil ik graag iedereen bedanken die een bijdrage geleverd heeft aan het 
tot stand komen van dit proefschrift. Zonder jullie steun zou het veel moeilijk zijn geweest om 
mijn promotietraject succesvol af te ronden. Om Elvis te citeren: “Thank you, thank you very 
much!”
In het bijzonder wil ik graag nog bedanken:
Peter (vd K), bedankt dat je mij de kans en het vertouwen hebt gegeven om in jouw werkgroep 
aan een promotietraject te werken. Je staat altijd open voor nieuwe ideeën en ik heb veel 
plezier beleefd aan onze discussies over de pathofysiologie van artrose en de rol van TGFβ 
daarin. Ik heb zeer veel van je geleerd over het doen van wetenschappelijk onderzoek (onder 
andere wanneer iets goed genoeg is voor publicatie), waarvoor mijn grote dank. Ik hoop 
dat we ooit nog een keer samen kunnen gaan pubquizzen om je fenomenale feitenkennis te 
testen.
Peter (ten D), bedankt dat je mijn promotietraject hebt willen ondersteunen vanuit Leiden 
met je kennis en kunde. Jouw bereidwilligheid om te delen heeft een aantal hoofdstukken 
mogelijk gemaakt en je kritische blik heeft ze daarna alleen maar verbeterd. Je hebt mij de 
enorme waarde van samenwerken (in de wetenschap) laten zien en dat neem ik voor altijd 
mee. Hier wil ik dan ook je collega’s uit Leiden: Marie-José en Amaya bedanken voor al hun 
hulp bij het ZonMw project.
Esmeralda, vanaf dag één ben jij mijn dagelijkse begeleidster op lab reuma geweest en ik 
heb altijd plezierig met je samen gewerkt. Van jou heb ik veel geleerd over het plannen 
en doen van experimenten en natuurlijk heb ik het een en ander opgestoken van je haast 
ongeëvenaarde kennis van histologie. Ook heb ik van onze (soms hoogoplopende) discussies 
geleerd om goed te argumenteren en voor mezelf op te komen. Ik hoop dat we elkaar scherp 
kunnen blijven houden en Ik ben erg benieuwd naar waar je pijnproject heen gaat!
Dear Wojtek, or shall I call you mister? Ain’t nobody got time for the amount of thanks I 
would like to give to you.  I greatly enjoyed working with you and also greatly enjoyed your 
company outside of work.  I am therefore honored that you agreed to be my paranymph. 
Your company is greatly missed now that you went back to Poland, but I wish you and Ola all 
the best. I will take good care of your fish tank (full of bad eel jokes) and one day you will get 
a new one from me!
Michel, onze vriendschap is ooit begonnen met een potje kaarten in de pauze van een college. 
Daarna hebben we menig uur doorgebracht op Vossenveld met een pot bier en diepgaande 
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discussies over het wel en wee van de wereld (en natuurlijk the A-team). Mijn kookkunsten 
en jouw afwasskills bleken een gouden combi om onze studententijd door te komen. Daarna 
hebben we allebei een promotietraject doorlopen waarbij je nog steeds om de hoek woonde 
en we elkaar konden steunen indien nodig. Helaas woon je nu niet meer om de hoek en loopt 
de afwas dus in de soep, maar het doet me goed om te zien dat je lekker bezig bent met je 
nieuwe baan in Duitsland! Mijn grote dank voor je steun en vriendschap door de jaren heen.
Als volgende wil ik graag de weledelzeergeleerde heren van de schaakclub “het kreupele 
paard” bedanken; Guus en Mathijs. Ontspanning na inspanning houdt het leven leuk, en onze 
memorabele schaakavonden dragen hier zeker aan bij. Al kennen we “Man of la Mancha” al 
helemaal van buiten, ik hoop dat Placido Domingo nog menig schaakavond zal opluisteren 
terwijl ik weer door de klok heenga en jullie genadeloos claimen want tja, dat mag van de 
bond.
Hierna wil ik graag alle huidige en voormalige collega’s van Werkgroep 3 bedanken. Met jullie 
heb ik altijd mijn ideeën of “nutteloze” feitjes kunnen delen die ik weer eens had opgedaan. 
Bedankt voor jullie luisterend oor en de gezelligheid. Elly, zonder jou zou de werkgroep een 
stuk minder goed draaien; naast je niet aflatende energie en werklust sta je ook altijd klaar 
als iemand het moeilijk heeft. Ik ben dan ook erg blij dat je me nu helpt met het sclerodermie 
onderzoek! Henk, ook jij bent altijd behulpzaam en staat klaar als iemand je nodig heeft. 
Zonder jou zou menig experiment beschreven in dit proefschrift in het honderd gelopen zijn, 
waarvoor dank. Arjen, ook al ben je geen echte TGFβ-man, ik waardeer zeer (jij misschien 
wat minder) onze discussies over uiteenlopende zaken zoals moderne kunst en haaien. 
Of kunst nu mooi moet zijn of niet, daar zijn we nog niet over uit, maar ik bewonder in 
ieder geval jouw expressieve kant. Ellen, ooit ben je binnen komen wandelen als verlegen 
bachelorstudente die aan BMP9 kwam werken. Al snel bleek je een fantastische studente te 
zijn en ik ben dan ook blij dat je voor een promotietraject gekozen hebt bij lab reuma. Je hebt 
een geweldige ontwikkeling doorgemaakt, en ik vind ik vind het een eer dat ik jouw dagelijkse 
begeleider mag zijn.  Eva, ook jij bent ooit binnen komen wandelen als (een ietwat minder 
verlegen) studente om aan BMP9 te werken. Ook jij was een fantastische studente en je werk 
heeft ons veel geleerd over BMP9 in kraakbeen. Promoveren was niet je ding, maar ik mis 
wel onze levendige discussies over de uitspraak van Rihanna en wat voor soort muziek Taylor 
Swift maakt. Dennis, ik heb altijd met veel plezier met je gewerkt, en ik vond het een eer dat 
ik je paranimf mocht zijn. Je bent iemand die eruit gehaald heeft wat er in zit en daarna toch 
heeft durven kiezen voor wat hij echt leuk vindt (ook al was dit in het begin moeilijk), en dit 
vind ik zeer bewonderenswaardig. Laurie, ook jij bent ooit begonnen als studente aan een 
project over BMP2 onder begeleiding van Es en mij wat zich voortzette in een promotietraject 
over ALK receptoren in stamcellen. Uiteindelijk ben je me zelfs te snel af geweest en ben je 
reeds gepromoveerd, waarvoor hulde! Priya, I hope all is well and I enjoyed your company 
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at the lab, I still cherish the memory that you once invited us to a Diwali festival to celebrate 
that important day with you. Brenda, jij bent misschien een van de weinigen die weet waar 
MOOOOO voor staat, en je enthousiasme was altijd aanstekelijk. Succes met het afronden 
van je promotietraject! Renkse en Nathalie, jullie zijn pas recent bij de werkgroep gekomen 
maar ik ben blij dat jullie vragen de boel scherp houden.
Ook wil ik graag de vaste kern van lab reuma bedanken; jullie zijn essentieel voor het goed 
functioneren van het lab en de goede sfeer. Als eerste de groepsleiders: Peter, Fons en Marije 
voor hun opbouwende kritiek op mijn experimenten en plannen. Ook bedank ik graag de 
analisten Annet, Birgitte, Monique, Miranda en Onno, voor hun niet aflatende inzet voor het 
reilen en zeilen van de afdeling en voor hun belangrijke bijdrage aan de prettige werksfeer op het 
lab. Hiernaast wil ik ook Marianne bedanken voor haar belangrijke, maar vaak onderbelichte, 
administratieve ondersteuning. Graag bedank ik ook oud prof. Wim voor opzetten van het lab 
zoals het nu is, en oud collega Liduine voor de gezellige avondjes pubquizzen. 
Naast de vaste kern zijn ook de aio’s en postdocs van wezenlijk belang voor het goed 
functioneren van het lab. Bij dezen bedank ik graag de (oud) collega’s Shahla, Edwin, Silke, 
Marieke, Niels, Eline, Rik, Bas, Ben, Wouter H, Wouter de M, Debbie, Rebecca, Stephanie, 
Irene, Guiliana, Claire, Joyce, Bartijn, Daphne en Menno voor de gezellige avondjes in de 
aesculaaf, op het lab of bij de pubquiz. 
Een bijzonder bedankje gaat uit naar Martijn, de drukste man van het lab. Je combineert 
een tomeloze inzet voor de wetenschap met een goed kritisch denkvermogen. Met jou op 
congres of in de kroeg is nooit een straf, maar ik wil je in het bijzonder ook bedanken voor die 
grote pot Mentos op je bureau.
Ook bedank ik graag alle (nog niet eerder genoemde) studenten die (indirect) een bijdrage 
geleverd hebben aan het werk dat beschreven is in dit boekje: Tim, Gabi, Tonke, en Daniel. 
Ik heb veel van jullie geleerd en jullie werk  heeft mede de basis gelegd voor hoe ik nu denk 
over artrose en TGFβ signalering.
Naast het werk zijn ook vrienden en familie zeer belangrijk. Om te beginnen wil ik graag 
de biologen van het allereerste uur bedanken Liene, Jeroen, Harriëtte, Natalie, Jacqueline, 
Erik, Bernard en Michel. Ooit zijn we samen begonnen aan de studie biologie en hebben we 
menig roerig practicum beleefd (o.a. iets met een zakpijp). Nu vormen we nog steeds een 
zeer gezellige vriendengroep, onder andere door de toevoeging van Jos en Theo, en onze 
jaarlijkse weekendjes weg zijn altijd weer een hoogtepunt. Jullie hebben mij altijd gesteund, 
zowel in werkgerelateerde als in persoonlijke zaken. Mijn grote dank voor jullie steun in 
moeilijke tijden en de gezelligheid bij weerzien. Op naar ons derde lustrum volgend jaar!
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Hierna wil ik graag mijn familie bedanken: Pa en Ma, Peter en Hilde, Carien en André, jullie 
hebben altijd interesse getoond in mijn werk en hopelijk is het met dit boekje iets duidelijker 
wat ik nu al die jaren gedaan heb. Bedankt voor jullie steun de afgelopen jaren! Ook familie 
van den Berg; Siem en Marijke, Simone en Paul, wil ik graag bedanken voor hun interesse in 
mijn werk en hun steun de afgelopen jaren.
Als laatste wil ik graag Willemijn bedanken. Willemijn, je hebt mij altijd gesteund en mij 
geholpen de persoon te worden die ik nu ben. Samen hebben we al veel beleefd en we gaan 
hopelijk nog veel meer mooie dingen beleven. Een daarvan is Inez, en onze kleine meid is 
papa’s trots. Thuis kan ik tot rust komen en kan ik de dagelijkse beslommeringen van mij 
afzetten. Zonder jouw steun zou ik nooit zijn waar ik nu ben.
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